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Introduction:
Dihydropyridines are the largest and most studied class of drugs cal-
cium channel blockers1. In addition to their proven clinical utilities in car-
diovascular medicine, dihydropyridines are employed extensively as bio-
logical tools for the study of voltage-activated calcium channel 2.
Many 1,4-dihydropyridine derivatives have been synthesized and
devloped as calcium channel antagonists which inhibit smooth and cardiac
muscle contractions by blocking the influx of Ca+2  through calcium chan-
nels and antihypertensive action3-11. Besides this, vasodialator12, coronary
vasodialator13, antitumor14, antiinflammatory15, antimyocardiac ischemic16,
antiarrhythmic activities17 and antiallergic18 are also associated with these
molecules.
1. Godfraind,T. Miller,R. Wibo, M. Pharmacol. Rev. , 38, 321,1986.
2. Bellemann,P. Innovative Approches in Drug Research.;Elsevier: amsterdam,
p 23-46,1986.
3. Loev, B., Good, M. M., Snader, K. M., Tedeschi, R. and  Macko, E.; J. Med.
Chem., 17, 956 1974.
4. Bossert,  V. F., Hortsmann, H., Meyer, H. and  Vater, W.;  Arzneim.-Forsch./
Drug Res., 29(I) 226 1979.
5. Iwanami, M., Shibanuma, T., Fujimato, M., Kawai, R., Tamazawa, K., Takenaka,
T., Takahashi, K. and Murakami, M.; Chem. Pharm. Bull. 27, 1426 1979.
6. Imai, H., Matsui, K., Ochi, S., Nakazawa, M., Nakagawa, Y. and  Imai, S.; Arzneim-
Forsch / Drug Res. 37(II), 12 1987.
7. Derk, K., Stopel, K., Leibowitz, D., Taylor, R. and Vanov, S.; In Nitredipine, E.
Scriabine, S. Vanov, K. Derk, (eds.), 397, Urban & Schwarzenberg, Balti more-
Munich 1984.
8. Triggle, D. J.;  Handbook of Experimental Pharmacology; Chalcium In Drug
Actions -The Chemistry of Calcium Channel Agonists and Antagonists,
G. V. R. Born (ed.), 115, Springer-Verlag.Heidelberg 1986.
9. Wehingner, E. and Gross, R.; Ann. Rep. Med. Chem., 21, 85 1986.
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10. Janis, R. A. and  Triggle, D. J.; J. Med. Chem., 26, 775, 1983.
11. Alker, D., Arrowsmith, J. E., Campbell, S. F. and Cross, P. E.; J. Med. Chem.,
26(9), 907-13, 1991.
12. Wehinger, W. E., Horst, M., Andres, K. and  Yoshiharu; Ger. Offen; C.A., 107,
217482, 1987.
13. Hachiro, S., Kunizo, H., Tadao, S., Hideyuki, A., Yoshihsru, D.; Eur. Patent
197,488, 1986; Japan Patent 68,649, 1985; C.A., 106, 328559, 1987.
14. Zidermane, A., Duburs, G. and Zilbere, A.; . PSR Zinat. Akad. Vestic 4, 77
1971; C.A., 75, 47266, 1991.
15. Johnson, R. C., Taylor, D. J., Hann Kenneth, V. and Sheng, S., U.S. Patent
4,758,669; C.A. 109, 149366, 1988.
16. Yan, Z. M., Dong, Y. M., Xuebao, Y.; Eur. Patent  220, 653 1987; Japan Patent
253,909, 1985; C.A., 116, 173968, 1992.
17. Masakatu, H., Kenichi, K., Yasuhiko, S., Masakazu, H., Osamu, K. and  Hiroyoshi,
H.; Eur. Patent  653, 1987; Japan Patent 235 909, 1985; C.A. 107,  134209,
1987.
18. Marco, F., Andrea, Z., Carmelo, G. and  Bermini, M.; Eur. Patent 272, 693; C.A.
109, 190259, 1988.
19. Hantzsch, A., Justus Liebigs Ann.Chem., 1, 215, 1882.
20. Hantzsch, A., Ber., 17, 1515(1884); Ber., 18, 1774, 2579, 1885.
21. Singer, T. P. and  Kearney, E. B.; Advan. Enzymol., 15, 79, 1964.
22. Knoevengel, E. and Rushhaupt, W.; Ber., 31, 1025, 1898.
In 1882,  1,4-dihydropyridine was introduced by Hantzsch19,20  in a
single step preparation, The work was limited to symmetric diester at po-
sition C3 and C5 involving the condensation of an aldehyde, ammonia and
acetoacetic ester. After  that the 1,3-dicarbonyl compound was utilized by
Beyer21 and later by Knoevenagel22 to modify the preparation of unsym-
metrical 1,4 dihydropyride by condensation of an alkylidene or arylidene
1,3-dicarbonyl compound with a  b-amino-a,b- unsaturated carbonyl com-
pound for getting pure product avoiding side products23.
As per the finding and talent, many scientists had encouraged the
studies to investigate the geometrical requirement at the dihydropyridine
binding site24-26. Changes in the substitution of C3, C4 and C5 position of the
first generation calcium antagonist Nifedipine27, alters potency28, tissue se-
lectivity29-35and the stability & conformational36,37aspects of the 1,4-
dihydropyridine ring.
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Thus 1,4-dihydropyridines  may have  tremendous application with
diffrent modification in its structure. A number of good reviews on the struc-
ture, synthesis , stereochemistry, biological potentiality and hydrogen trans-
fer mechanism of the pyridine nucleoside are well reported in literature38-43.
As it is very pertinent to work on these issues, more than 10,000 articles,
publications  & patents are published in the literature on the unsymmetrical
1,4-DHPs.
23. (a) Nakashima Yoshimoto and coworkers EP0168789, US4730052
(b) Dante Nardi and coworkers US4772621
(c) Muto Kenji and coworkers O063365(A1), EP82103166, US4448964.
(d) Masaru Iwanami and coworkers O063365(B1), O063365(B2),
24. Venter, J. C., Fraser, C. M., Schaber, J. S., Jung, C.Y., Bolger, G. and  Triggle,
D. J.; J. Bio. Chem., 258, 9344, 1983.
25. Murphy, K. M., Gould, R. J., Largent, B. L. and  Snyder, S.H.; Proc. Natl. Acad.
Sci. U.S.A., 80, 860, 1983.
26. Ferry, D. R. and  Glossmann, H., Naunyn.-Schmiedebers’s Arch. Pharmacol.
321, 80, 1982.
27. Bossert, V.,  U.S. 3485847, 1969; Arzneimttel-Forsch, 22, 330-388, 1972.
28. Venter, J. C., Fraser, C. M., Schaber, J. S., Jung, C.Y., Bolger, G. and  Triggle,
D. J.; J. Bio. Chem., 258, 9344, 1983.
29. Gross, G., Warltier, D. and  Hardmann, H.; J.Cardiovasc. Pharmacol. 6, 61,
1984.
30. Knorr, A. and Garthoff, B.;  Arch. Int. Pharmacodyn., 269, 316, 1984.
31. Advenier, C., Cerrina, J., Duroux, P.,  Floch, A. and  Renier, A.; Br. J. Pharmacol.
82, 727, 1984.
32. Itil, T., Michael, S., Hoffmeister, F., Kunitz, A. and  Erlap, E.; Curr. Ther. Res.
35, 405, 1984.
33. Antman, E., Horowitz, J. and  Stone, P. ; Stone, P., Antman,E., (eds.)
Future; New York, 177, 1983.
34. Heusch, G. and  Deussen,  A.; J. Cardiovas. Pharmacoal., 6, 378, 1984.
35. Triggle, A. M.,  Shefter,  E. and  Triggle, D.; J. Med. Chem., 23, 1442, 1980.
36. Fossheim, R.,  Svarteng, K.,  Mostad,  A.,  Romming. C., Shefter,  E. and Triggle,
D. J.;  J. Med. Chem., 25, 126, 1982.
37. Dagnino, L.,  LiKwong-Ken,  M. C., Wolowyk., M. W.,  Wynn. H.,  Triggle, C. R.
and Knaus,  E. E.;  J. Med. Chem., 29, 2524, 1986.
38. Singer, T. P. and  Kearney, E. B.; Advan. Enzymol., 15, 79, 1964.
39. Kaplan, N. O.; Rec. Chem. Progr., 16, 177, 1955.
40. Westhiemer, F. H., Advan. Enzymol., 24, 469, 1962.
41. Sund, H., Diekmann, K. and Wallenfels, K.; Advan. Enzymol., 26, 115, 1964.
42. Colowick, S. P., Van Eys, J. and Park, J. H.; Compr. Biochem., 14, 1, 1966.
43. Chaykin, S.; Ann. Rev. Biochem., 36, 149, 1967.
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The key characteristic of calcium channel blockers is their inhibition
of entry of calcium ions via a subset of channels, thereby leading to
impairment of contraction. There are three main groups of calcium channel
blockers, i.e. dihydropyridines, phenylalkylamines and benzothiazepines,
typical examples of which are nifedipine, verapamil and diltiazem,
respectively(44-45). Each has a specific receptor on the calcium channel and
a different profile of pharmacological activity. Dihydropyridines have a less
negative inotropic effect than phenylalkylamines and benzothiazepines.
There are several new generation of such DHPs drugs discovered,
patended and marketed and now already in current use they are
Nimodipine46, Nifedipine27, Nicardipine47, Nilvadipine48, Felodipine49,
Isradipine50,  Darodipine51,  Riodipine52,  Flordipine53,  Amlodipine54,
Nitrendipine55, Lacidipine56, Barnidipine57, Sagandipine58, Benidipine59,
Furnidipine60, Taludipine61, Iganidipine62, Manidipine63, Lemidipine64,
Efonidipine65 and Azelnidipine66.
Literature Survay:
44. Therapeut ic  gu ide l ines,  card iovascular ,  3rd ed.  Victor ia:  Therapeut ic
Guidel ines ;  1998.
45. Calcium channel blocking agents in USP DI. 22nd ed.: Micromedex;  p. 727–42,
2002.
46. Meyer, H.; Denmark Patent 2117571, 1972;  U.S. Patent 3799934, 1974;
Towart, R. and  Kazda, S.;  British Journal of Pharmcology. 67, 409, 1979.
47. Murakami, M.; Belgium Patent 811324, 1974; U.S. Patent 3985758, 1976;
Iwanami. M. et al; Chem. Pharm. Bull., 27 1426, 1979.
48. Sato, Y.; Belgium Patent  879263, 1980; U.S. Patent  4338322, 1982; Miyamae,
A.; Chem. Pharm. Bull., 34, 3071, 1986.
49. Berntsson, P. B., Carlsson, A. I., Gaarder, J. O. and Ljuga, B.R.; C.A., 106,
4878, 1987.
50. Neumann, P.; Eur. Patent 150, 1979; C.A., 92, 94404, 1980.
51. Heitzmann, M.; C.A., 107, 236717, 1987.
52. Kastron, V. V., Dubur, G. J., Sharts, V. D. and Yabupolsky, L.M.; Arzneim
Forsch,  35, 669, 1985.
53. Huang, F. C., Lin, G. J. and Jones, H.; Eur. Patent. Appl., 10949, 1984.
54. Camlbell, S. F., Cross, P. E. and  Stubbs, J. K.; U.S. Patent 4,512,909, 1986;
C.A., 105, 42661, 1986.
55. Mayer, H., et al;  Denmark Patent  2117571, 1972;  U.S. Patent  3799934,
1974; Arzneim Forsch, 31, 407, 1981.
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56. Safer, M., et al; Clin. Pharmacoal. Ther., 46, 94-8, 1989.
57. Satoh, H.; Cardiovasc. Drug. Rev., 9(4), 340, 1991.
58. Schilager, L. H., (Gerot Pharm Gmbh); Eur. Patent .Appl., 342182, 1989.
59. Muto, K., et al;  ET 63365, 1982; U.S. Patent  4448964, 1984.
60. Statkow, P., et al; Eur. J. Pharmacol, Abstr. Pwe., 173, 183(4), 1990.
61. Semeraro, C., Michelli, D., Pieraccioli, D., Gaviraghi, G. and Borthwich, A. D.;
C.A., 107, 236519, 1987.
62. Robinson, C . P., Robinson, K. A. and  Castaner,  J.; Drugs Fut., 22(1), 23,
1997.
63. Meguro, K. and Nagakoka, A.; Euro. Patent 138505; Japan Patent 85084269;
U.S. Patent 4603135.
64. Prous, J. and Castaner, J.; Drugs Fut., 14(4), 331; Japan Patent 84152373,
85139671, 1989.
65. Sakoda, R., Kamilkawaji, Y. and Seto, K.; Chem. Pharm. Bull., 40(9), 2362,
1992.
66. Prous, J. and Castaner, J.; Drugs Fut., 15(7), 1671, 1990.
Major  possibilities of unsymmetrical 1,4-Dihydropyridine can be sub di-
vided in to two class.
(1) Unsymmetrical with respect to position 2 & 6 of 1,4-DHPs
(2) Unsymmetrical with respect to position 3 & 5  of 1,4-DHPs
Different funtionality in the position at 3 & 5 are mentioned in the
literature. It is possible to have cyano, acetyl, carboxyalkyl, carboxyaryl,
carboxyheteroaryl,  benzoyl, phenylcarbamoyl, 5 or 6 membered heterocy-
clic group containing one or more nitrogen atom, which may be optionally
fused to benzene ring or to a further 6 membered aromatic heterocyclic
group which may be optionally substituted with one or more substituted
with one or more substituents from C1-C4alkyl,C1-C4 alkoxy halo, CF3 and
CN groups either on 3  or  in 5 position.
Unsymmetrical 1,4-dihydropyridine with respect to cyano group:
Unsymmetrical 3-cyano-5-carboxyester-1,4-dihydropyridines(I) were
prepared by many researchers67-70 by condensation of aldehyde, 3-amino
crotononitrile with alkyl-3-aminocrotonate.These 3-cyano-1,4-DHP deriva-
tives were useful as coronary and cerebral vasodilators.
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+
N
H
COOR1NC
R
CH3CH3
R= -CH3, CH2Cl, CH3-CH=CH
-CH3CH2CH2, CH3SCH2CH2, Ph
R1= -Me, Et, Pr, 
R
CHO
NH CH3
COOR1
CH3 NH2
HNC
Cozzi and co-workers71 have prepared unsymmetric 3-cyano-4-[3-
(imidazo-1-yl)phenyl or 3-(1,2,4-triazol-1-yl)phenyl]-1,4-DHP derivatives  and
they found the activity of such DHPs in the treatment of prevention of breast,
edometrial, ovarian or pancreatic cancers, gynecomastia, benign breast
disease, endometriosis, poltstic ovarian disease,  prostatic hyperplasia
and in the male fertility or for female fertility control. Thus cyclization of 3-
(1H-imidazol-1-yl)benzaldehyde with 3-amino crotononitrile in glacial AcOH
afforded 34%(III), which showed IC50 of 1.7nm against human plecental
aromatase.
R1= -COOEt
R2= -H, X= -CH, N
67. Eberhard H., Gerhard F., Edgar J., Roland B., Ehrenfried B., Gerhard E., Werner
F., Ger. (East) patent 122,524; C. A., 87, 23073m, 1977.
68. Carsten M., Hans B., S. African Patent 7707702; C. A., 90, 186810z, 1979.
69. Kastron V. V., Duburs G., Vitolins R., Skrastins I., Kimenis A., Khim-Farm. Zh.
19(5), 545-9, 1985; C. A., 104, 88392d, 1986.
70. Wehinger E., Bossert F., Franckowiak G., Meyer H., Ger. Offen. Patent 2,658,804,
1978; C. A., 89, 109133j, 1978.
71. (a) Cozzi P., Carganico G., Fusar D., Grossoni M., Menichincheri M., Pinciroli
V.,Tonani R., Vaghi F., Salvati P., J. Med. Chem., 36, 2964-2972, 1993.
(b). Cozzi P., Briatico G., Guidci D., Rossi A., Salle E. D., J. Med. Chem. Res.,
6(9), 611-17, 1996.
N
R1NC
N
X
N
R2
CH3 CH3
N
R1NC
R2
CH3 CH3
R [CH2]n-Het
(I)
(II) (III)
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Steinhardt and co workers72 have prepared  many compounds with
respect to heterocyclic implantation in the 4th position of 1,4-DHPs and
they found good results on the cancer. Callaghan has synthesized the
componds of tetrahydropyridine 3,5-dicarbonitriles on Hantzsch synthesis.
72. Steinhardt Richard and coworkers, Patent application US 94-273666 19940712.
CAN 125:293043 AN 1996:610307.
73. Dyachenko V. D., Krivokalysko S. G., Litvinov V. P., Russ. J. Org. Chem., 34(6),
876-881 (1998); C. A., 130, 296591g (1999).
74. Venkatesh, D., Madegowda, M., Shah, A., Prasad, J.S., Analytical Sciences;2004
20, x45
Dyachenko and co-workers73 prepared unsymmetric 3-cyano-5-
phenylcarbamoyl-1,4-dihydropyridine-N-methyl morpholinium salt.
N
H
X-Me
O R H
N
CN
H
N
O
CH3
+
R= -COOEt, X= -S, Se
Shah et al74 has recently reported a unsymmetrical 1,4 DHPs having
cyano and ester group in it’s 3 & 5 position respectively and the compounds
were synthesized adopting the Hantzsch synthesis. the crystal structures
aredetermined.
(IV) (V)
(VI)
N
H
NC
CH3
CN
COOEt
N
H
COOEtNC
CH3 ROH
X X
X
X= 2-NO2, 3-NO2, 4-Cl, 2-OCH3,etc...
R= Ph
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N
H
S
CH3
CH3 CH3
H3COOC
N
A representative compound from a series of heterocyclic substituted as
under. New Cardiovascular agent with positive inotropic activity that
increased the contractile force of the heart and influenced the tone of
vascular smooth muscles in the isolated perfused guinea pig heart model.
The compound may be used for treatment of the pathologically changed
blood pressure, cardiac insufficiency, heart rhythm disturbances and as a
coronary therapeutic75.
N
H
MeNH2
O
O
CN
CH3
N
N
FCE-29013
75. Drug Data Report; 14 (8), 697, 1992.
76. Drug Data Report; 17(1): 48, 1995.
A new positive inotropic agent with high cardioselectivity, found in
Bay-y-595976 with calcium channel-modulating activity and devoid of
vasoconstricting effects. Compound increased dP/dtmax by up to 300% at
30-1000 mcg/kg i.v. in dogs, and it increased coronary blood flow at all
doses was reported and currently undergoing phase II trials for the treatment
of congestive heart failure.
(VII)
(VIII)
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Unsym. 1,4-dihydropyridine with respect to ester group:
In 1882, First 1,4-DHP was introduced by Hantzsch19,20, a single step
preparation  and the work was limited to symmetric diester at position 3
and 5. As these types of molecules gain pharmacological importance in
late seventy’s of 20th century, molecules having different ester groups at 3
and 5 position were synthesized. It led to the development of second gen-
eration of 1,4-DHPs.  Structures of some of unsymmetric 1,4-DHPs having
different esters at 3 and 5 position or  an ester group either at 3 or 5 posi-
tion are given (Table-1.1& 1.2).
N
H
MeNH2
O
O
CN
N
CH3
CH3
Bay-y-5959 
Antineoplastic agent, (FCE-29013) an aromatase inhibitor (IC50 =
1.5 nM against human placental enzyme) found to be  potentially useful for
the treatment of estrogen-dependent tumors and prostatic hyperplasia77.
N
H
MeNH2
O
O
CN
CH3
N
N
FCE-29013
77. Drug Data Rep 1997, 19(6): 557
(IX)
(X)
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Table-1.1:  1 ,4-dihydropyridine drugs bearing 3-ni trophenyl
substitution on C4 position of 1,4-DHPs.
Table-1.1
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Table-1.2
Table-1.2: 1,4-dihydropyridine drugs bearing 3-nitrophenyl substi-
tution on C4 position of 1,4-DHPs.
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Table-1.3 : DHPs drugs other then NO2 Group on C4 phenyl group.
Table-1.3
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Nimodipine46 has profound effect as cerebral vasodilator among other
analogues. Nicardipine47 bearing a large ester substituent shows less
cardiodepressent effect than Nifedipine. Introduction of large ester sub-
stituents instead of lower alkyl ester at C3 or C5 position of DHP rings
accompained by a large duration of antihypertensive action which is  be-
lieved to result from increased lipophilicity. Felodipine markedly dilates
peripheral blood vessels, particularly those of the coronary vessels, with-
out a negative inotropic effect and Amlodipine54 represent a new Ca+2 an-
tagonist within the subgroup of the dihydropyridine. The major advantage
of this novel compound is its long duration of action, so it is  allowing once
a daily dosing.
Out of many hints(~10,000) of  Unsym. 1,4-DHP some of  the com-
pounds of our interest which bearing an ester groups at C3 and C5 position
or at one of the position of 1,4-DHPs were located in the search below.
Few examples are mentioned .
Sugimoto74synthesized 3,5-diacetyl-2,4,6-trimethyl-1,4-dihydro-
pyridines(XI). Phillips75  also prepared symmetric and unsymmetric 1,4-
dihydropyridines of type(XI).
N
H
CH3CH3
R
H
COR1H3COC R1 = CH3, OCH3
R = Alkyl or aryl
74. Sugimoto, N.; J. Pharm. Soc. Japan, 64, 192(1944); C. A.,45,2862(1951).
75. Phillips, A. P.; J. Am. Chem. Soc., 73, 2248(1951).
(XI)
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Dagnino76 reported the calcium chanel antagonist activities for dialkyl-
1,4-dihydro-2,6-dimethyl-4-(pyridinyl)-3,5-pyridinedicarboxylates (XIIa) fur-
ther to that they corrected out reduction of the 4-(pyridinyl) substitutent of
(XIIa) to  4-(dihydropyridinyl) ring system as 3,5-disubstituted 4-[dihydro-
1-[[ alkyl(or phenyl)oxy]carbonyl]pyridinyl]-1,4-dihydro-2,6-dimethyl-
pyridines(XIIb)(XIIIa)(XIIIb).
N
R
CO2R3
N
R
CO2R3N
H
CH3CH3
R2 - OOC
R
H
COO - R1
N
R
a =
N
R
76. Dagnino, L.,  LiKwong-Ken,  M. C., Wolowyk., M. W.,  Wynn. H.,  Triggle, C. R.
and Knaus,  E. E.;  J. Med. Chem., 30, 640-646, 1987.
77. Ortega Pilar M., Garcia Del Carmen M., Gijon M. A., Fau de Casa-Juana M.,
Priego J. G., Sanchez Crespo M., Sunkel C., J. Pharmacol. Exp. Ther., 255,
28-33, 1990.
78. Fernandez Gallardo S., Ortega Pilar M., Fau de Casa-Juana M., Priego J. G.,
Sanchez Crespo M., Sunkel C., J. Pharmacol. Exp. Ther., 255, 34-49, 1990.
Ortega et al.77 had shown that PCA-424 (XIV) has to be a potent antago-
nist in vitro while, Fernandez-Gallardo et al.78 studied in vivo and and found
the molecule devoid of calcium channel blocking activity.
N
H
CH3OOC O
S
O
CH3 CH3
(XII)
(XIV)
(XIII)
b=
a=
b=
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Alkaer  et al.79 converted Amlodipine into a derivative of the type
(XV) as potent vasodilator.
N
H
COOEt
O
CH3OOC
Cl
N N
CH3
CH3 CH3
CH3
79. Alker O., Campbell S. F., Cross P. E., Burges R. A., Carter A. J., Gardiner D. G.,
J. Med. Chem., 33, 1805-1811, 1990.
80. Tsuchida K., Yamazaki R., Kaneko K., Aihara H., Arzneim-Forsch./Drug Res.,
37, 1239-1243, 1987.
Tsuchida et al.80 has shown that CD-349 (XVI) can be appeared to
be a potent cerebrovasodilator in dogs and could be useful in the treatment
of cerebrovascular disorders in human.
Cozzi and co-workers19 studied imidazolyl-1-yl and pyridine-3-yl-1,4-
dihydropyridine derivatives for its potential as a calcium channel antago-
nist. In vitro, these derivatives displayed Thromboxane A2 synthase inhib-
iting properties similar to Dazoxiben.
N
H
O
O
ONO2
CH3
O
OO2NO
CH3 CH3
(XV)
(XVI)
 
16
Chapter-1
Study of some novel unsymmetrical...
Christiaans and Timmerman et al.81 studied new molecules like CV-159,
SM-6586 for possible variation at 3-position. CV-159 shows an increase
in coronary flow, aortic flow and heart rate and decrease in mean blood
pressure as Incardipine after intravenous administration in anaesthetized
open chest dogs.
N
H
O
OO
H3CO (CH2)6 O
N
N
H
NO2
CH3 CH3
CV-159
N
H
NO2
O N
N
NCH3
CH3 CH3
CH3
SM-6568
Berson  and Brown et al.82reported earlier for first time the synthesis
of a quinoline containing unsymmetrical compound, 4-(4-quinolyl)-2,6-dim-
ethyl-3-carbethoxy-5-acetyl-1,4-dihydropyridine (IV).
N
H
COCH3
N
C2H5OOC
CH3 CH3
81. Christiaans H., and Timmerman H., Ph. D. Thesis, LACDR, The Netherlands
95, 1130, 1994.
82. Berson J. A., and Brown E. J., J. Am. Chem. Soc., 77, 444, 1955.
(XVII)
(XVIII)
(XIX)
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Shah et al. 83 synthesized some newly unsymmetrical 1,4-DHP de-
rivatives (XX) as potent antitubercular agents.
N
H
OO
H3CO
NO2
R
CH3 CH3
Gaveria  and coworkers84 reported some  unsymmetrical  1,4-
dihydropyridine(XXI) and (XXII) derivaties as potent antitubercular agents.
N
H
H
CH3 CH3
H3COOC
NO2
N
N
R
R
R = COCH3, H, C6H5
N
H
H
CO-CH=CH-R
CH3 CH3
H3COOC
NO2
In last few years,  researchers of our laboratory synthesized and studied
1,4-dihydropyridine derivatives bearing pyrazoline, Isooxazole at C3 posi-
tion85. They reported these derivatives as bactericidal, fungicidal and sur-
prisingly antitubercular also86.
83. Gaveriya H., Desai B., Vora V., Shah A., Ind. J. Pharm. Sci., 64(1), 59-62 (2002).
84. Gaveria, H., Desai, B., Vora, V. and  Shah, A.; Heterocyclic Communication,
7(5), 481-482 (2001).
85. Varu, B.; Ph.D. Thesis, Saurashtra University, Rajkot (2001).
86. Loriya, R.; Ph.D. Thesis, Saurashtra University, Rajkot (2001).
(XX)
(XXI) (XXII)
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Another examples of hybrid molecule which combine 1,4-DHP and
piperazine are BMY 20064 (XXIIIa) and BMY 20014(XXIIIb). The compound
BMY 20064 has potent antihypertensive effects in both normotensive and
spontaneously hypotensive rats and is effective against myocardial is-
chemia, being more potent than Nifedipine. Further more BMY 20064 is a
selective a-adrenergic antagonist.
N
H
MeMe
X
OO
H3CO
NO2
N
N
OCH3
X=NH, BMY-20014 X=O, BMY-20064
Similarly Niguldipine(XXIIIc)87 consist a diphenylpiperidinyl moiety. It
displayed a1-adrenergic antagonist activity. It also significantly inhibits
thromboxane A2-induced coronary vasoconstruction. The stereoselective
ratio for 1,4-DHP receptor binding, inhibition of TxA2-induced coronary
vasoconstruction and antihypertensive activity for (S)-(+)/(R)-(-) Niguldipine
is also studied.
N
H
MeMe
O
OO
H3CO
NO2
N
Nigulidipine
87. Eltze M., Boer R., Sanders K. H., Ulrich W. R., Flockerzi d., Chirality, 2, 233-
40, 1990.
(XXIIIa)
(XXIIIc)
(XXIIIb)
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The compound resulted after modification in the structure of Amlodipine.
This compound is a potent vasodilator and also possessed potent platelet
activating factor (PAF) antagonistic activity. A synthetic program undertaken
to eliminate the calcium channel blocking activities of compound (II) resulted
in UK-74,505.It is highly selective as a PAF antagonist89, showing only weak
affinity for the dihydropyridine binding site. Sunkel et al.90 have also synthe-
sized another selective PAF antagonist PCA-4228 . It was derived from
DHP calcium channel blockers, which were structually modified in such a
way that the therapeutic profile was completely switched from calcium chan-
nel blockers to PAF antagonists.
A hybrid molecule which combines 1,4-DHP with benzodioxan moi-
ety have been synthesized by M arciniak et al.88 which also appeared as a1-
adrenergic blockers. The most potent hybrid molecule shown in figure (XXIV )
consists of four stereo isomers.
N
H
O
OO
H3CO
NO2
N
O
O
CH3 CH3
CH3
88. Marciniak G., Delgado A., Leclerc G., Velly J., Decker N., Schwartz J., J. Med.
Chem., 32, 1402-1407, 1989.
89. Cooper K., Fray M. J., Parry M. J., Richardson k., and steele J., J. Med. Chem.,
35, 3115-3129, 1992.
90. Sunkel C. E., Fau de Casa-Juana M., Cillero F. J., Priego J. G., Ortega P. M.,
J. Med. Chem., 31, 1886-1890, 1988.
(XXIV)
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UK-74, 505
N
H
O
Cl
N
N
H5C2OOC
N N
N
CH3
H
CH3 N
H
O
OO
H3CO
S
CH3
CH3 CH3
PCA-4248
Thus,  large number of pharmacologically active 1,4-DHPs molecules
which are promising leads for development of  specific cardiovascular dis-
orders,  a1-adrenergic antagonist, anti-TB, TxA2 inhibitors, antitumor have
been reported14. It has opened up new gates for 1,4-DHPs derivatives.
(XXV)
(XXVI)
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Unsym. 1,4-dihydropyridine with respect to carbamoyl group:
Symmetrical 1,4-DHPs derivatives with carbamoyl groups at 3 and
5 position displayed not only calcium channel blocking activity, but good
anti-inflammatory and analgesic profile also. Further investigation sugested
that phenyl carbamoyl moiety in dihydropyridine derivatives (XXVII) either
at 3 and 5 position have proved to be a good cadiovascular compound for
selective activity.
N
H
MeMe
O
N
H
O
N
Cl
O
Many more molecules is in the pipeline of the discovery programme
of different research agencies are doccumented. list of  molecules(XXVIII
& XXIX).
Compound BMY-20014, a1-adrenergic antagonist and UK-74,505
PAF antagonist are examples of unsym. 1,4-DHPs derivatives having sub-
stituted carbamoyl group at 3 position which exhibited diversed biological
activity.
BMY-20014
Bay-161133
N
H
MeMe
O
OO
NO2
NH
N
Bayer Molecules
N
H
MeMe
O
OO
NH
R2 N
R4
R3
O
R1
164481 R1=Me, R 2=R3=R4=H
164482 R1=H, R2=R3=CH3, R4=CH2Ph
164483 R1=R2=R3=R4=H
(XXVII)
(XXVIII)
(XXIX)
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SYNTHETIC ASPECTS:
The classical Hantzsch synthesis of 1,4-DHPs involving the conden-
sation of an aldehyde, ammonia and acetoacetic ester or other 1,3-
dicarbonyl compound was modified by Beyer et al.91 and later by
Knoevenagel et al.92 to allow the preparation of unsym. 1,4-dihydro pyridines
by condensation of an alkylidene or arylidene 1,3-dicarbonyl compound with
a b-amino-a, b-unsaturated carbonyl compound. Knoevenagel et al.91 also
prepared for the first time unsymmetrical 3-acetyl-1,4-DHPs by using acetyl
acetone instead of acetoacetic ester. There after Phillips et al.93 in 1951
and Courts et al.94  in 1952 have synthesized unsym.3-acetyl-1,4-DHPs of
type (XXX) and (XXXI) respectively.
In 1955, Berson and Brown et al.95 reported for the first time the syn-
thesis of a quinoline containing unsymmetrical compound 4-(4-quinolyl)-
2,6-dimethyl-3-carbethoxy-5-acetyl-1,4-dihydropyridine. Mosti et al. and co-
workers have synthesized little different kind of 5-acetyl-dihydropyridine
derivatives such as 2-substituted-5-acetyl-1,6-dihydro-6-oxo-3-pyridine car-
boxylic acids for its positive inotropic as well as cardiotonic activity and
structure activity relationship was also studied.
N
H
MeMe
O
OR
O
H3C
NO2
R= -alkyl N
H
MeMe
MeOOC
R1
NO2
R2
COCH3
R1= -H, -OCH3
R2= -H, OH
91. Bayer E., Ber., 24, 1662, 1891.
92. Knoevenagel E., and Ruschhaupt W., Ber., 31, 1025, 1898.
93. Philips A. P., J. Am. Chem. Soc., 73, 2248, 1951.
94. Courts A. and Petrow V., J. Chem. Soc., 1, 1952.
95. Berson J. A. and Brown E., J. Am. Chem. Soc., 77, 444, 1955.
(XXX) (XXXI)
 
23
Chapter-1
Study of some novel unsymmetrical...
Various methods for  generation of  various DHPs are given under accord-
ing to literature survey.
Method-1: Reaction of an aldehyde,  b-aminocrotonic ester and acylacetic
ester. Among the compounds obtained by this method are Nicardipine,
Nitrendipine and Felodipine96. The reaction is carried out in the presence
or absence of an alcohol such as methanol, ethanol, isopropanol etc., an
aromatic solvent such as benzene, toluene etc.,a halogenated hydrocar-
bon such as chloroform, carbon tetrachloride etc.,an ether such as tetrahy-
drofuran, dioxan etc.,an aprotic polar solvent such as acetonitrile,
dimethylformamide.,water or l ike at room temperature to 150OC,
preferabely 30 to 100OC. Seperation of the desired product from the reac-
tion mixture is effected by conventional operations like as concentration,
extration, column chromatography, recrystallization etc.
C
CH
NH2R1
R4OOC
CH2
R2O
CONHPh-R
+
CHO
Ar
N
H
H Ar
R2R1
COOR3COOR4
Method-2:  Reaction of ammonia with a benzylideneacyl acetic ester and
an acyl aceticester.  According to this method, Nimodipine has been ob-
tained97.
CH 2
R1
R4OOC
O R2O
CONHPh-RHC
+
N
H
H Ar
R2R1
COOR 3COOR 4
NH3
Ar
CHO
96. Herbert , H. et al  J.Org.Chem. 16, 1259 (1951).
97. Love B.et al, J.Med.Chem., 17,956 (1974).
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C
CH
NH2R1
R4OOC
+
N
H
H Ar
R2R1
COOR3COOR4
R2O
CONHPh-RHC
Ar
Method-3:  Reaction of b-aminocrotonic esters with benzylideneacylacetic
esters. Nisoldipine and Felodipine have been obtained by this method98.
Method-4: In this process reaction of ketone with benzylideneacylacetic
esters in presence of ammonia gas/solution. afforded to give the final prod-
uct98.
CH2
R1
R4OOC
O R2O
CONHPh-RHC
Ar
+
N
H
H Ar
R2R1
COOR3COOR4
NH3
Metrhod-5:  In this method98, reaction of respective alcohol with the con-
cern acid chloride of the 1,4-DHPs are reacted to obtain the ester func-
tionality.
R1N
CONHPh-R
Ar
ClOC
R2 N
H
H Ar
R1R2
CONHPh-RR3OOCR3-OH
In the present work, the 1,4-dihydropyrisdines are synthesized adopt-
ing above methods as per reaction schemes mentioned.
98. Iwanami,  M et al, Chem.Pharm.Bull., 27, 1426, (1979).
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NO2
O
NH
CH3 O
O
NO2
NH
O
CH3 O
H
Piperidine
R
R
+
Iso propyl alcohol
REACTION SCHEME:
NH
CH3 O
O
NH2
R +
CH3
CH3
O
O
Toluene
Step-1
Step-2
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NO2
NH
O
CH3 O
H
NH2 CH3
R'
+
NO2
N
O
CH3 N
H
CH3
H
H
R'
R
R
Toluene
Step-3
(DRC-1001 to DRC-7002)
REACTION SCHEME:
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NH CH3
O O
R1CHO
NH3
NH
O
O CH3
R1
O
O
H3C NH2
R'
R'
O
O
H3C NH2
NH
O
OH3C
R1
+..
R'
O
O
H3C NH2
NH
O
CH3OH
H
R1
R'
O CH3
O O
+
H3C NH2
O R1
NH
O
CH3O
O
R'
..
R
N
NH CH3
or
CH3
O
N
NH3
R
R R
R
R'
O
O
H3C N
H
OH
CH3
NH
OR1 R
R'
O
O
H3C N
H
CH3
NH
OR1
R
CH3N
H
H3C
NH
O R1
NR
(A)
(B)
(C)
or
or
REACTION MECHANISM:
The mechanism of the Hantzsch reaction was proposed very early.
It may be depicted as under.
Michael addition of enamine compound to benzylidene derivative re-
sults in the tautomeric system, which undergoes cyclization to the hydroxy
tetrahydropyridine, followed by loss of water to give unsymmetrical 1,4-
dihydropyridine.
The rate determining step is Michael addition.
-H2O
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Experimental:
All the melting points are uncorrected. IR specta were recorded (KBr)
on Shimadzu FT IR-8400 spectrophotometer. 1H NMR spectra were
recorded on Bruker AC 300 MHz FT-NMR spectrometer with DMSOD6 as a
solvent. Chemical shifts are expressed as d ppm. The purity of compounds
were monitored by TLC performed on silica gel plates purchased from
Merck. Mass spectra were recorded on JEOL SX 102/DA-6000.
(A) Preparaton of Acetoacetanilide:
Aniline (0.1 mole), ethylacetoacetate (0.1 mole) and caustic lye (2.0
gm NaOH + 0.5 ml Water) were heated at 110 OC in 50 ml toluene as solvent
for 9-10 hours. After completion of reaction, most of toluene was distilled
out. The reaction mass was cooled at room temperature and then taken in
an ice bath which formed light yellow crystals of crude acetoacetanilide. It
was then extracted with diethyl ether/ petroleum ether  and filtered. Etheral
solution was evaporated afforded to get pure acetoacetanilide. Yield 60-
70%. m.p. 80OC.
Similarly ,other acetoacetanilides were prepared by taking different amines
as starting materials.
(B) Preparation of 2-acetyl-N- (2-methylphenyl)-3-(3-nitrophenyl)
acrylamide:
A mixture of 3-nitrobenzaldehyde (0.01 mol, 1.51 gm) and 2-methyl
acetoacetanilide (0.01 mol,) was taken in conical flask (250 ml) containing
50 ml methyl alcohol,then it was stirred on stirring device for 30 min. and
pyridine was added (1.5 ml) in reaction mixture. After five hours solid product
was separated, the reaction was cooled the solid product was filtered and
washed with cold isopropyl alcohol to give free solid product, which was
crystallized in methanol. Yield 80%, m.p.: 210 oC.
[Calculated % C 66.66, H 4.97, N 8.64, O 19.73, Found % C 66.65, H 4.98,
N 8.65 O 19.74].
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(C) P r e p a r a t i o n  o f  2 , 6 - d i m e t h y l - 4 - ( 3 - n i t r o p h e n y l ) - 3 - ( 2 -
methylphenylcarbamoyl)-5-carbmethoxy-1,4-dihydropyridine
(DRC-2002):
A  mixture of 2-acetyl-N- (2-methylphenyl)-3-(3-nitrophenyl)
acrylamide (0.01 mol, 3.24 gm) and methyl-3-amino crotonate (0.01 mol,
1.15 gm) was taken in flat bottom flask and sufficient 1,4-Dioxane was
added, stirred and reflux on stirring device. After several hours, sticky mass
obtained in reaction flask which was treated by diethyl ether and solid
product was obtained, filtered and washed with tetrahydrofuran, Ity was then
further crystallized from DMSO, Yield 25%, m.p. 236 oC.
[Calculated % C 65.55, H 5.50, N 9.97  Found % C 65.58, H 5.48, N 9.91]
The other compounds of the series were prepared according to
above mentioned method and physical data of newly synthesized com-
pounds are recorded in Table: 1.4, Table:1.5 and Table: 1.6.
Experimental Observation:
All the substituted anilines and necessary chemicals were obtained
from Department of Chemistry, Saurashtra University under grant of UGC.
Melting points of all the synthesized compounds was taken in open capil-
lary bath on controlled temperature heating mental. The crystallization of
all the final compounds was carried out in DMF. TLC was carried out on
Silicagel-G as stationary phase and purchsed from MERCK India Ltd.
Ethylacetate: Hexane (4:6) was used as a mobile phase.
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Code No.
Substitution Molecular
Formula
Molecular
Weight
gm/mole
M.P O C
Elemental analysis %
R R' C H N
DRC-1001 2-Cl CN C21H17ClN4O3 408.83 177-178
61.69
(61.71)
4.19
(4.15)
13.70
(13.73)
DRC-1002 2-Cl COOCH3 C22H20ClN3O5 441.86 100-101
59.80
(59.88)
4.56
(4.51)
9.51
(9.54)
DRC-1003 2-Cl
COOC2H5 C23H22ClN3O5 455.89 220-221
60.59
(60.57)
4.86
(4.89)
9.22
(9.31)
DRC-1004 2-Cl COCH3 C22H20ClN3O4 425.86 195-196
62.05
(62.10)
4.73
(4.78)
9.87
(9.88)
DRC-2001 2-CH3 CN C22H20N4O3 388.41 180-182
68.03
(68.13)
5.19
(5.22)
14.42
(14.38)
NO2
N
O
CH3 N
H
CH3
H
H
R'
R
* Values in parenthesis denoted the theoretical percentage of composition.
Table:1.4 Physical constants of  2,6-dimethyl-3-(substituted phenylcarbamoyl)-5-substituted-4-(3-nitrophenyl)
-1,4-dihydropyridines.
 31
Code No.
Substitution Molecular
Formula
Molecular
Weight
gm/mole
M.P O C
Elemental analysis %
R R' C H N
DRC-2002 2-CH3 COOCH3 C23H23N3O5 421.44 201-202
65.55
(65.58)
5.50
(5.48)
9.97
(9.91)
DRC-3001 2-OCH3 CN C22H20N4O4 404.41 182-183
65.34
(65.31)
4.98
(4.94)
13.85
(13.89)
DRC-3002 2-OCH3 COOCH3 C23H23N3O6 437.44 153-154
63.15
(63.27)
5.30
(5.42)
9.61
(9.64)
DRC-3003 2-OCH3 COOC2H5 C24H25N3O6 451.47 218-219
63.85
(63.89)
5.58
(5.59)
9.31
(9.38)
DRC-3004 2-OCH3 COCH3 C23H23N3O5 421.44 231-232
65.55
(65.51)
5.50
(5.48)
9.97
(9.92)
NO2
N
O
CH3 N
H
CH3
H
H
R'
R
* Values in parenthesis denoted the theoretical percentage of composition.
Table:1.5 Physical constants of  2,6-dimethyl-3-(substituted phenylcarbamoyl)-5-substituted-4-(3-nitrophenyl)
       -1,4-dihydropyridine.
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Code No.
Substitution Molecular
Formula
Molecular
Weight
gm/mole
M.P O C
Elemental analysis %
R R' C H N
DRC-5002 2,4-diCH3 COOCH3 C24H25N3O5 435.473 264-265
66.19
(66.21)
5.79
(5.72)
9.65
(9.66)
DRC-6001 H COOCH3 C22H21N3O5 407.41 206-208
64.86
(64.78)
5.20
(5.17)
10.31
(10.36)
DRC-6002 H CN C21H18N4O3 374.39 209-210
67.37
(67.29)
4.85
(4.91)
14.96
(14.91)
DRC-7001 2,3-di CH3 COOCH3 C24H25N3O5 435.47 191-193
66.19
(66.11)
5.79
(5.78)
9.65
(9.64)
DRC-7002 2,3-di CH3 CN C23H22N4O3 402.44 217-218
68.64
(68.69)
5.51
(5.58)
13.92
(13.85)
NO2
N
O
CH3 N
H
CH3
H
H
R'
R
* Values in parenthesis denoted the theoretical percentage of composition.
Table:1.6 Physical constants of  2,6-dimethyl-3-(substituted phenylcarbamoyl)-5-substituted-4-(3-nitrophenyl)
-1,4-dihydropyridine.
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SPECTRAL STUDY :
The constitution of newly synthesized compound were supported by
IR, NMR, and Mass  spectral study and and X-ray crystallographic data.
The details are as under.
IR Spectral analysis:-
Instrument : Shimadzu FT-IR-8400
Sample technique :  KBr pellet
Frequency  range : 400-4000cm-1
Looking to the IR spectra of newly synthesized 1,4-dihydro pyridines,
the strong carbonyl (>C=O) stretching observed at ~1695-1715 cm-1 due to
the ester carbonyl  functionality. The other characteristics of ester group
i.e.C-O-C- stretching was observed between 1260-1280 cm-1.
In case of amide linkage, amide carbonyl (>CONH) was observed at
1635-1670 cm -1.
The stretching of secondary amine (>NH) appeared around ~3250-
3390 cm -1, it’s bending and C-N stretching appears at 1345-1370 cm -1
respectivley.
The C=N stretching of cyano group was observed as a strong peak
is the final identity of presence of cyano group in the compounds). observed
at 2185-2190 cm -1.
The C-H stretching of aromatic moiety was observed at ~3030 cm -1.
The other characterization were due to aromatic moieties, C-C multiple
bond stretching, C-H i.p. def. and  o.o.p. def. appears around at ~1641-
1450 cm-1, ~1085 cm-1 and ~830 cm-1 respectively.
The C-H stretching of methyl group observed at ~2850cm -1(asym.)
and ~2900cm-1 (sym.) and it’s bending observation at ~1384 cm-1 .
IR spectral data for  [DRC-1001 to DRC-7002] are given on page No.42-45.
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NMR Spectral Study :-
Instrument : BRUKER AC 300 MHz FT-NMR,
Internal reference : TMS
Solvent : CDCl3 or DMSO d6
 Looking to the NMR spectra, in the title compounds (DRC-
1002,DRC-2002, DRC-3002, DRC-5002,DRC-6001& DRC-7001), esteric
methyl protons(-COOCH3) was observed as a singlet at 3.60-3.66 d ppm.
In case of  C2 & C6  methyl protons (-CH3), they are observed as singlet at
2.0 to 2.5 d ppm. While assymetric (C4) carbon proton (>CH-) protons in all
compounds were   observed  at  4.70-5.10 d ppm.  The amide proton gave
signal at 8.50-9.50 d ppm. In most of derivatives -NH protons were ob-
served at 6.5-8.0 d ppm as a peak. The aromatic proton were observed at
around 6.60-8.30 d ppm. For spliting patterns of m-NO2 phenyl functional-
ity,  two triplets is clearly observed in the aromatic region due to ortho/di-
meta coupling of phenyl protos. For ortho substituted phenyl ring three
doublets is observed  due to di-ortho/meta coupling of phenyl protons.
The 1HNMR spectra of the compounds were given on page No.46-53.
Mass Spectral Study :
Instrument : JEOL SX 102/DA-6000 for FAB
In case of MASS spectral analysis the FAB (Fast atom
Bombardment) technique was used. The molecular ion peak (M+) of  the
compounds  were in total agreement  with it’s molecular  weight. In pres-
ence of Halogen (Cl, Br), Intensity of M+1 peak  was shown as per agree-
ment.
The MASS spectra of the compounds were given on page No.54-57.
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Table-1.7:  IR frequency of newly synthesized unsymmetrical 1,4-
dihydropyridines.
Compound
Code
IR Frequency (cm-1)
Amine Amide
(>C=O)
Cyano
(-C=N)
Ester
>C=O str.
Aromatic
>C=C<(>NH) >N-H of -CONH
DRC-1001 3244 3298 1676 2187 - 1483
DRC-1002 3203 ~3203 1676 - 1708 1483
DRC-1003 3209 3216 1679 - 1699 1478
DRC-1004 3216 3221 1671 - 1685 1486
DRC-2001 3209 3215 1669 2189 - 1497
DRC-2002 3210 3218 1670 - 1709 1485
DRC-3001 3246 3386 1685 2187 - 1434
DRC-3002 3268 3389 1681 - 1710 1485
DRC-3003 3247 3287 1679 - 1699 1478
DRC-3004 3268 3378 1680 - 1687 1489
DRC-5002 3269 3387 1686 - 1708 1489
DRC-6001 3266 3381 1681 - 1701 1482
DRC-6002 3245 3299 1676 2183 - 1444
DRC-7001 3247 3314 1667 - 1703 1499
DRC-7002 3244 3298 1676 2191 - 1483
Table:1.7
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Code No. Compound Code No. Charastristics d ppm value 
DRC-2002 
N
H
CH3 CH3
O
NH
H
NO2
CH3
O
O
CH3
 
2.115 (s, 3H ), 2.164 (s, 3H), 2.381 (s, 
3H), 3.622 (s, 3H), 5.876 (m, 1H ), 
6.69 (m, 2H), 7.00 (m, 1H), 7.11 (m, 
1H), 7.20 (m, 1H), 7.44 (m, 1H), 7.59 
(m, 1H), 7,89 (m, 1H), 7.99 (m, 1H), 
8.03 (m, 1H). 
DRC-5002 
N
H
CH3 CH3
O
NH
H
NO2
CH3
O
O
CH3
 
2.164 (s, 3H), 2.191 (s, 3H), 2.381 (s, 
3H),, 2.65 (s, 3H), 3.622 (s, 3H), 
5.876 (s, 1H), 6.696 (m, 1H), 6.742 
(m, 1H),  6.938 (m, 1H), 7.055 (m, 
1H), 7.445 (m, 1H), 7.595 (m, 1H), 
7.991 (m, 1H), 8.031 (m, 1H). 
DRC-6001 
N
H
CH3 CH3
O
NH
H
NO2
O
O
CH3
 
2.165  (s, 3H), 2.381 (s, 3H), 3.622 (s, 
3H),5.876 (s, 1H), 6.157 (s, 2H), 
6.159(s, 1H)7.16 (m, 1H), 7.309 (m, 
1H), 7.310 (m, 1H), 7.445 (m, 1H), 
7.517 (m, 1H), 7.520 (m, 1H), 7.595 
(m, 1H), 7.991 (m, 1H), 8.031 (s, 1H), 
DRC-6002 
N
H
CH3 CH3
O
NH
H
NO2
N
 
2.167  (s, 3H), 2.382 (s, 3H), 5.70 (s, 
1H), 6.158 (s, 2H), 6.16 (s, 1H)7.16 
(m, 1H), 7.309 (m, 1H), 7.310 (m, 
1H), 7.445 (m, 1H), 7.517 (m, 1H), 
7.520 (m, 1H), 7.595 (m, 1H), 7.991 
(m, 1H), 8.031 (s, 1H), 
DRC-7001 
N
H
CH3 CH3
O
NH
H
NO2
CH3
CH3
O
O
CH3
 
2.004 (s, 3H), 2.164 (s, 3H), 2.23 (s, 
3H), 2.381 (s, 3H),3.622 (s, 3H), 
5.876 (s, 1H), 6.647 (m, 1H), 6.66 (s, 
1H), 6.67 (s, 1H), 6.681 (m, 1H), 
7.445 (m, 1H), 7.595 (m, 1H), 7.728 
(m, 1H), 7.991 (m, 1H),  8.031 (m, 
1H), 
DRC-7002 
N
H
CH3 CH3
O
NH
H
NO2
N
CH3
CH3
 
2.101 (s, 3H), 2.171 (s, 3H), 2.31 (s, 
3H), 2.381 (s, 3H), 5.876 (s, 1H), 
6.649 (m, 1H), 6.69 (s, 1H), 6.68 (s, 
1H), 6.70 (m, 1H), 7.45 (m, 1H), 7.60 
(m, 1H), 7.73 (m, 1H), 7.98 (m, 1H),  
8.031 (m, 1H), 
 
 
Table-1.8: 1H NMR spectrosciopic data of some newly synthesized
unsymmetrical 1,4-dihydropyridines.
Table:1.8
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Single crystal X-rayDiffraction analysis:
Single crystal x-ray diffraction is the most common experimental
method of obtaining a detailed picture of a small molecule that allows
resolution of individual atoms. It is performed by analyzing the diffraction
of x-rays from an ordered array of many identical molecules. Many molecular
substances, including proteins, polymers, and others solidify into crystals
under the proper conditions. When solidifying into the crystalline state, these
individual molecules typically adapt one of only a few possible orientations.
A crystal is a three dimensional array of these molecules that are held
together by Van der Waals,  noncovalent bonding. The smal lest
representative unit of crystals is referred to as the unit cell. Understanding
the unit cell of these arrays simplifies the understanding of a crystal as a
whole.
The single crystal of the title compound was obtained by repeated
cystallisation and subsequently thin layer evaporation method.
The ability of the ring in 1,4-dihydropyridines to adopt a planar
conformation depends upon whether there is substitution at the 4-position.
The unsubstituted Hantzsch ester  is planar, while the corresponding
compound has a dihydropyridine ring that adopts what the authors term a
flat boat conformation. The spirodihydropyridine was also found to have a
nonplanar confirmation.
Method of Crystallization:
Compound 2 gm taken taken in 30 ml solvent mixture [Ethanol + DMF
(15ml: 7.5 ml)]. 4 gm Charcoal was added and heated on a heating device
for 8 minutes. The solution was filtered while hot through whatmann 42 filter
paper. The solution was kept in a stopper conical flask slightly opened.
The Crystals was grown up due to thin film evaporation technique.
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D
R
C
-2
0
0
2
ORTEP Diagram of DRC-2002
Packing of the molecules down b axis.
(Dashed lines represent the hydrogen bonds)
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Identification code DRC-2002 
Empirical formula C23 H23 N3 O5 
Formula weight 421.44 
Temperature 293(2) K 
Wavelength 0.71073 A 
Unit cell dimensions a = 11.201(2) A   alpha = 90 deg. 
b = 19.723(3) A    beta = 117.944(5) deg. 
c = 11.084(2) A   gamma = 90 deg. 
Volume 2163.1(7) A^3 
Z, Calculated density 4,  1.294 Mg/m^3 
Absorption coefficient 0.092 mm^-1 
F(000) 888 
Theta range for data collection 2.07 to 21.96 deg. 
Limiting indices -11<=h<=11, -20<=k<=20, -11<=l<=11 
Reflections collected / unique 4889 / 2632 [R(int) = 0.0396] 
Completeness to theta = 21.96 99.7 % 
Refinement method Full-matrix least-squares on F^2 
Data / restraints / parameters 2632 / 0 / 280 
Goodness-of-fit on F^2 1.464 
Final R indices [I>2sigma(I)] R1 = 0.0715, wR2 = 0.1820 
R indices (all data) R1 = 0.1152, wR2 = 0.2447 
Largest diff. peak and hole 0.452 and -0.455 e.A^-3 
 
Table:1.9 Crystal data and structure refinement for shelxl.
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O(22)-C(28) 1.344(6)
O(22)-C(30) 1.455(6)
O(27)-C(8) 1.225(6)
N(13)-C(12) 1.383(7)
N(13)-C(14) 1.395(6)
N(13)-H(13) 0.9602
N(7)-C(8) 1.355(6)
N(7)-C(4) 1.438(6)
N(7)-H(7) 0.9600
O(21)-C(28) 1.228(6)
C(28)-C(11) 1.459(7)
C(9)-C(14) 1.348(7)
C(9)-C(8) 1.484(7)
C(9)-C(10) 1.525(7)
C(11)-C(12) 1.355(7)
C(11)-C(10) 1.525(7)
C(10)-C(15) 1.532(7)
C(10)-H(10) 0.9600
C(12)-C(26) 1.508(7)
C(15)-C(20) 1.385(7)
C(15)-C(16) 1.397(8)
C(14)-C(25) 1.511(7)
C(5)-C(6)  1.360(9)
C(5)-C(4) 1.386(8)
C(5)-H(5) 0.9600
C(4)-C(3) 1.376(8)
C(25)-H(25A) 0.9599
C(25)-H(25B) 0.9601
C(25)-H(25C) 0.9599
C(19)-C(18) 1.373(10)
C(19)-C(20) 1.383(8)
C(19)-N(29) 1.473(9)
C(26)-H(26A) 0.9600
C(26)-H(26B) 0.9602
C(26)-H(26C) 0.9598
C(20)-H(20) 0.9602
O(23)-N(29) 1.228(8)
C(16)-C(17) 1.397(9)
C(16)-H(16) 0.9599
N(29)-O(24) 1.236(8)
C(3)-C(2) 1.414(9)
C(3)-C(31) 1.497(9)
C(6)-C(1) 1.346(10)
C(6)-H(6) 0.9599
C(1)-C(2) 1.369(10)
C(1)-H(1) 0.9600
C(18)-C(17) 1.359(10)
C(18)-H(18) 0.9600
C(2)-H(2) 0.9600
C(17)-H(17) 0.9599
C(30)-H(30A) 0.9600
C(30)-H(30B) 0.9600
C(30)-H(30C) 0.9601
C(28)-O(22)-C(30) 116.7(4)
C(12)-N(13)-C(14) 122.5(4)
C(12)-N(13)-H(13) 119.0
C(14)-N(13)-H(13) 118.5
C(8)-N(7)-C(4) 120.3(4)
C(8)-N(7)-H(7) 119.4
C(4)-N(7)-H(7) 120.3
O(21)-C(28)-O(22) 121.9(5)
O(21)-C(28)-C(11) 126.3(5)
O(22)-C(28)-C(11) 111.8(5)
C(14)-C(9)-C(8) 120.2(5)
C(14)-C(9)-C(10) 120.0(4)
C(8)-C(9)-C(10) 119.6(4)
C(12)-C(11)-C(28) 121.9(5)
C(12)-C(11)-C(10) 119.5(5)
C(28)-C(11)-C(10) 118.6(5)
O(27)-C(8)-N(7) 120.6(5)
O(27)-C(8)-C(9) 123.5(5)
N(7)-C(8)-C(9) 115.9(5)
C(11)-C(10)-C(9) 110.5(4)
C(11)-C(10)-C(15) 114.6(4)
C(9)-C(10)-C(15) 107.9(4)
C(11)-C(10)-H(10) 109.4
C(9)-C(10)-H(10) 108.5
C(15)-C(10)-H(10) 105.7
C(11)-C(12)-N(13) 119.5(4)
C(11)-C(12)-C(26) 126.9(5)
N(13)-C(12)-C(26) 113.6(5)
C(20)-C(15)-C(16) 117.7(5)
C(20)-C(15)-C(10) 119.3(5)
C(16)-C(15)-C(10) 122.9(5)
C(9)-C(14)-N(13) 119.2(5)
C(9)-C(14)-C(25) 126.9(5)
N(13)-C(14)-C(25) 113.8(4)
C(6)-C(5)-C(4) 120.7(6)
C(6)-C(5)-H(5) 120.5
C(4)-C(5)-H(5) 118.8
C(3)-C(4)-C(5) 120.9(5)
C(3)-C(4)-N(7) 120.2(5)
C(5)-C(4)-N(7) 118.8(5)
C(14)-C(25)-H(25A) 108.9
C(14)-C(25)-H(25B) 110.2
H(25A)-C(25)-H(25B) 109.5
C(14)-C(25)-H(25C) 109.4
H(25A)-C(25)-H(25C) 109.5
H(25B)-C(25)-H(25C) 109.5
C(18)-C(19)-C(20) 122.7(6)
C(18)-C(19)-N(29) 119.3(7)
C(20)-C(19)-N(29) 118.0(7)
C(12)-C(26)-H(26A) 108.8
C(12)-C(26)-H(26B) 110.3
H(26A)-C(26)-H(26B) 109.5
C(12)-C(26)-H(26C) 109.3
      Bond lengths Bond angle(deg)
Table:1.10  Bond length and bond angle between the atoms of DRC-2002
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C(31)-H(31A) 0.9601
C(31)-H(31B) 0.9599
C(31)-H(31C) 0.9598
C(19)-C(20)-H(20) 120.8
C(15)-C(20)-H(20) 119.5
C(17)-C(16)-C(15) 120.9(6)
C(17)-C(16)-H(16) 120.1
C(15)-C(16)-H(16) 119.0
O(23)-N(29)-O(24) 125.0(8)
O(23)-N(29)-C(19) 117.2(8)
O(24)-N(29)-C(19) 117.8(7)
C(4)-C(3)-C(2) 116.3(6)
C(4)-C(3)-C(31) 121.0(6)
C(2)-C(3)-C(31) 122.7(7)
C(1)-C(6)-C(5) 120.2(7)
C(1)-C(6)-H(6) 119.7
C(5)-C(6)-H(6) 120.1
C(6)-C(1)-C(2) 120.1(6)
C(6)-C(1)-H(1) 119.8
C(2)-C(1)-H(1) 120.0
C(17)-C(18)-C(19) 118.0(6)
C(17)-C(18)-H(18) 122.6
H(26A)-C(26)-H(26C) 109.5
H(26B)-C(26)-H(26C) 109.5
C(19)-C(20)-C(15) 119.8(6)
C(19)-C(18)-H(18) 119.5
C(1)-C(2)-C(3) 21.7(7)
C(1)-C(2)-H(2) 119.0
C(3)-C(2)-H(2) 119.2
C(18)-C(17)-C(16) 120.9(7)
C(18)-C(17)-H(17) 118.9
C(16)-C(17)-H(17) 120.2
O(22)-C(30)-H(30A) 109.6
O(22)-C(30)-H(30B) 108.9
H(30A)-C(30)-H(30B) 109.5
O(22)-C(30)-H(30C) 109.9
H(30A)-C(30)-H(30C) 109.5
H(30B)-C(30)-H(30C) 109.5
C(3)-C(31)-H(31A) 109.3
C(3)-C(31)-H(31B) 109.5
H(31A)-C(31)-H(31B) 109.5
C(3)-C(31)-H(31C) 109.6
H(31A)-C(31)-H(31C) 109.5
H(31B)-C(31)-H(31C) 109.5
      Bond lengths Bond angle(deg)
H(13) 10718 -2452 417 75
H(7) 7923 -459 -3385 71
H(10) 7892 -643 -1493 61
H(5) 4986 -615 -5431 84
H(25A) 9330 -2469 -3115 85
H(25B) 9799 -2975 -1886 85
H(25C) 10819 -2443 -1928 85
H(26A) 11402 -1187 2805 91
H(26B) 12273 -1596 2286 91
H(26C) 11292 -1980 2698 91
H(20) 5563 -941 -2878 77
H(16) 7800 -1917 700 94
H(6) 3691 -441 -7771 101
H(1) 4698 -445 -9163 117
H(18) 3708 -2146 -1289 113
H(2) 6996 -639 -8258 117
H(17) 5811 -2399 561 116
H(30A) 7485 833 731 95
H(30B) 9045 901 1257 95
H(30C) 8502 516 2139 95
H(31A) 9163 -892 -6348 142
H(31B) 9069 -1345 -5233 142
H(31C) 9404 -571 -4958 142
Table:1.11  Hydrogen coordinates ( x 10^4) and isotropic displacement param-
eters (A^2 x 10^3) for shelxl.
                        x                   y                 z               U(eq)
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N
H
CH3 CH3
O
NH
H
NO2
N
Cl
DRC-1001
Type Vibration mode
Frequency
Cm-1
Amine
>NH Str. 3244.0
-NH Str. of -CONH 3298 .0
Amide
>C=0 Str. 1676.0
C-N Str. 1517.9
Cyano >C=N Str. 2187.1
Aromatic
>C=C ring skeleton
vib.
1517.9
1483.2
1433.0
O.O.P. Bending
Vib.
752.2
792.7
Sample Technique: KBr Pallet
Instrument: Shimadzu FT-IR-8400
Frequency Range: 400-4000 cm-1
IR spectrum of  2 ,6-dimethyl -4- (3-ni t rophenyl ) -3- (2-
chlorophenylcarbamoyl)-5-cyano-1, 4-dihydropyridine.
.
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N
H
CH3 CH3
O
NH
H
NO2
Cl
O
O
CH3
DRC-1002
Type Vibration mode
Frequency
Cm-1
Amine
>NH Str. 3203.5
-NH Str. of -CONH ~3203.0
Amide
>C=0 Str. 1676.0
C-N Str. 1596.9
Carbonyl
>C=O Str.
(COOCH3)
1708.8
Alkyl C-H Str. (-CH3) 2896.9
Aromatic
>C=C ring skeleton
vib.
1591.0
1596.9
O.O.P. Bending
Vib.
761.8
835.1
Sample Technique: KBr Pallet
Instrument: Shimadzu FT-IR-8400
Frequency Range: 400-4000 cm-1
IR spectrum of  2 ,6-dimethyl -4- (3-ni t rophenyl ) -3- (2-chloro
phenylcarbamoyl)-5-carboxymethyl-1, 4-dihydropyridine.
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N
H
CH3 CH3
O
NH
H
NO2
O
CH3
N
DRC-3001
Type Vibration mode
Frequency
Cm-1
Amine
>NH Str. 3246.0
>NH Str. of CONH 3386.8
Amide
>C=O str. 1685.7
C-N Str. 1519.8
Cyano >C=N Str. 2187.1
Alkyl C-H Str. (CH3)
2900.0
3003.0
Aromatic
>C=C ring skeleton
vib.
1346.2
1384.8
1434.9
O.O.P. Bending
Vib.
744.5
802.3
Sample Technique: KBr Pallet
Instrument: Shimadzu FT-IR-8400
Frequency Range: 400-4000 cm-1
IR spectrum of  2 ,6-dimethyl-4- (3-ni trophenyl) -3- (2-methoxy
phenylcarbamoyl)-5-cyano-1, 4-dihydropyridine.
 
45
Study of some novel unsymmetrical...
Chapter-1
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmDRC-7001
 542.9
 632.6
 716.5
 737.7
 771.5
 786.9
 811.0
 896.8
1020.3
1070.4
1105.1
1120.6
1146.6
1185.2
1218.0
1292.2
1355.9
1383.8
1429.2
1499.6
1630.7
1667.3
1703.0
2945.1
3247.9
3314.4
N
H
CH3 CH3
O
NH
H
NO2
CH3
CH3
O
O
CH3
DRC-7001
Type Vibration mode
Frequency
Cm-1
Amine
>NH Str. 3247.9
-NH Str. of -CONH 3314.4
Amide
>C=0 Str. 1667.3
C-N Str. 1630.7
Carbonyl
>C=O Str.
(COOCH3)
1703.0
Alkyl C-H Str. (-CH3) 2945
Aromatic
>C=C ring skeleton
vib.
1429.2
1499.6
O.O.P. Bending
Vib.
786.9
811.0
896.8
Sample Technique: KBr Pallet
Instrument: Shimadzu FT-IR-8400
Frequency Range: 400-4000 cm-1
IR spectrum of 2,6-dimethyl-4-(3-nitrophenyl)-3-(2,3-di-methoxy
phenylcarbamoyl)-5-carboxymethyl-1, 4-dihydropyridine.
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DRC-1001
N
H
CH3 CH3
O
NH
H
NO2
N
Cl
DRC-1001
N
H
CH3 CH3
O
NH
H
NO2
N
Cl
300 MHz1H NMR spectrum of 2,6-dimethyl-4-(3-nitrophenyl)-3-(2-
chlorophenylcarbamoyl)-5-cyano-1, 4-dihydropyridine.
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Chapter-1
No.
Chemical
Shift in
(d ppm)
Multiplicity
No. of
protons
J value
Hz
1 2.064 s 3H(18) -
2 2.167 s 3H(7) -
3 4.979 s 1H(4a) -
4 7.136 t 1H(24) J= 6.9
5 7.184 t 1H (25) J= 7.5
6 7.251 d 1H(26) J= 7.8
7 7.396 t 1H(14) J= 7.8
8 7.647 d 1H (15) J= 7.5
9 7.745 m 1H(13) J= 7.2
11 8.114 d 1H (11) J= 9.0
12 9.011 s 1H (19) -
13 9.263 s 1H(1) -
12
11
13
10
14
15
4
35
26
N
H
1
CH3
18
16
CH3
7
O
17
NH
20
21
22
26
23
25
24 H
4a
NO2
19
8
N
9
Cl
27
DRC-1001
Assignment of proton values of each proton of DRC-1001 is car-
ried out as mentioned in Table-1.9
Table-1.9
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DRC-1002
DRC-1002
N
H
CH3 CH3
O
NH
H
NO2
Cl
O
O
CH3
300 MHz 1H NMR spectrum of 2,6-dimethyl-4- (3-nitrophenyl)-3-(2-
chloro phenylcarbamoyl)-5-carboxy methyl-1, 4-dihydropyridine.
 
49
Study of some novel unsymmetrical...
Chapter-1
12
11
13
10
14
15
4
35
26
N
H
1
CH3
18
16
CH3
7
O
17
NH
22
23
24
28
25
27
26 H
4a
NO2
21
Cl
29
8
O
9
O
19
CH3
20
No.
Chemical
Shift in
(d ppm)
Multiplicity
No. of
protons
J value
Hz
1 2.32 s 3H (18) -
2 2.37 s 3H (7) -
3 3.66 s 3H (20) -
4 5.08 s 1H (4a) -
5 7.00 t 1H (26) J= 9.0
6 7.20 t 1H (27) J= 7.5
7 7.30 d 1H (25) J= 14.1
8 7.47 t 1H (14) J= 8.1
9 7.76 d 1H (15) J= 0.9 & 6.6
10 7.91 s 1H (11) -
11 8.00 d 1H (28) J=8.1
12 8.11 d 1H (13) J= 7.5
13 8.18 s 1H (1) -
14 8.52 s 1H (22) -
DRC-1002
Assignment of proton values of each proton of DRC-1002 is carried
out as mentioned in Table-1.10
Table-1.10
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DRC-2002
DRC-2002
N
H
CH3 CH3
O
NH
H
NO2
CH3
O
O
CH3
DRC-2002
N
H
CH3 CH3
O
NH
H
NO2
CH3
O
O
CH3
300 MHz 1H NMR spectrum of 2,6-dimethyl-4- (3-nitrophenyl)-3-(2-me-
thyl phenylcarbamoyl)-5-carboxymethyl-1, 4-dihydropyridine.
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12
11
13
10
14
15
4
35
26
N
H
1
CH3
18
16
CH3
7
O
17
NH
22
23
24
28
25
27
26 H
4a
NO2
21
CH3
29
8
O
9
O
19
CH3
20
DRC-2002
No.
Chemical
Shift in
(d  ppm)
Multiplicity
No. of
protons
J value
(Hz)
1 1.94 s 3H (29) -
2 2.25 s 3H (18) -
3 2.32 s 3H (7) -
4 3.60 s 3H (20) -
5 5.13 s 1H (4a) -
6 6.99 m 1H (26) J= 9.3
7 7.07 m 1H (27) J= 6
8 7.12 m 1H (25) J= 7.2
9 7.30 d 1H (28) J= 7.5
10 7.45 t 1H(14) J= 7.8
11 7.70 d 1H(15) J= 7.8
12 7.98 d 1H (13) J= 14.1
13 8.17 s 1H (11) -
14 8.27 s
2H
(1 & 22)
-
Assignment of proton values of each proton of DRC-2002 is carried
out as mentioned in Table-1.11
Table-1.11
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DRC-3001
N
H
CH3 CH3
O
NH
H
NO2
O
CH3
N
DRC-3001
N
H
CH3 CH3
O
NH
H
NO2
O
CH3
N
DRC-3001
300 MHz 1H NMR spectrum of 2,6-dimethyl-4- (3-nitrophenyl)-3-(2-
methoxy phenylcarbamoyl)-5-cyano-1, 4-dihydropyridine.
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Chapter-1
12
11
13
10
14
15
4
35
26
N
H
1
CH3
18
16
CH3
7
O
17
NH
20
21
22
26
23
25
24 H
4a
NO2
19
O
27CH3
28
8
N
9
DRC-3001
No.
Chemical
Shift in
(d ppm)
Multiplicity
No. of
protons
J Value
Hz
1 2.07 s 3H (18) -
2 2.32 s 3H (7) -
3 3.70 s 3H (28) -
4 4.73 s 3H (4a) -
5 6.60 s 1H (20) -
6 6.77 d 1H (23) J= 7.8
7 6.89 t 1H (24) J= 7.8
8 7.02 t 1H (25) J= 0.9 & 7.5
9 7.53 d 1H (26) J= 7.8
10 7.56 t 1H (14) J= 8.1
11 7.70 d 1H (15) J= 7.5
12 6.15 s 1H (11) -
13 6.20 s 1H (1) -
Assignment of proton values of each proton of DRC-3001 is carried
out as mentioned in Table-1.12
Table-1.12
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DRC-1001
N
H
CH3 CH3
O
NH
H
NO2
N
Cl
M.Wt.=408.83gm/mol
FAB Mass spectrum of 2,6-dimethyl-4-(3-nitrophenyl)-3-(2-chlorophenylcarbamoyl)-5-cyano-1,
4-dihydropyridine (DRC-1001).
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DRC-1002
N
H
CH3 CH3
O
NH
H
NO2
Cl
O
O
CH3
M.Wt.=441.86 gm/mol
FAB Mass spectrum of  2,6-dimethyl-4- (3-nitrophenyl)-3-(2-chloro phenylcarbamoyl)-5-carboxy
methyl-1, 4-dihydropyridine (DRC-1002).
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N
H
CH3 CH3
O
NH
H
NO2
CH3
N
DRC-2001
M.Wt=388.41
FAB Mass spectrum of  2,6-dimethyl-4- (3-nitrophenyl)-3-(2-methyl phenylcarbamoyl)-5-cyano-
1, 4-dihydropyridine (DRC-2001).
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DRC-2002
M.Wt.=421.44
N
H
CH3 CH3
O
NH
H
NO2
CH3
O
O
CH3
FAB Mass spectrum of  2,6-dimethyl-4- (3-nitrophenyl)-3-(2-methyl phenylcarbamoyl)-5-carboxy
methyl-1, 4-dihydropyridine (DRC-2002).
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During the search for anti-coagulant compounds, various substituted
hemiacetals have been prepared by Michael addition of 4-hydroxy coumarin
with a,b-unsaturated ketones (or) a,b-unsaturated aldehydes and subse-
quent cyclisation of the Michael addition product under mild conditions.
The hemiacetals of the type (I) have been prepared by condensation of
a,b -unsaturated ketones l ike ethyl idene acetone, mesityl  oxide,
benzalacetone with 4-hydroxy coumarin in ethanol. The first condensation
product being a Michael addition product,  which was then isolated by treat-
ment with 4% hydrochloric acid in absolute methanol to give the correspond-
ing pyrano[3,2-c][1] benzopyran-5(2H)one1-6(I).
Introduction:
Coumarin constitute an important class of naturally occuring
compounds.  Synthetic coumarins are useful as anticoagulant1,  coronary
dialator2, antibacterial3,  antifungal and plant growth inhibitors. Recently
coumarin compounds are described as anti-HIV4-6 also. Among all the
coumarins, are most important of 4-Hydroxy substituted derivatives.
1. Sionae T. O.; J. Pharm. Sci., 53, 23, 1964.
2. Mathur, C. N., Mitra, C. R., Krishnaswamy, N. R., Kulshreshtha, R. K. and Arora,
R. B.; Arch. Int. Pharm., 153, 218 (1965); C.A., 63, 12154, 1965.
3. Cingolani. G. M., Gultieri, F. and  Pigini, M.; J. Med. Chem., 12, 531,1961.
4. Kasman, Y., Gustafson, K. R., Fuller, R. W., Cardellina, J. H., McMahon, J. B.,
Currens, Buckheif, R. W., Cragg, G. M. and Boyd, M. R.; J. Med.Chem., 35,
2735-2743, 1992.
5. Fuller, R. W., Bokesch, H. R., Gustafson, K. R., Mckee, T. C., Cardellina, J. ,
McMahon, J. B., Cragg, G . M., Soejarto, D. D.and Boyd, M. R.; Bioorg. Med.
Chem. Lett, 44, 1961-1964, 1994.
6. Patil, A. D., Freyer, A. J., Eggleston, D. S., Haltiwanger, R. C., Bean, M. F.,
Taylor, P. B., Coranfa, M. J., Breen, A. L., Bartus, H. R., Johnson, R. K, Hertzberg,
R. P. and  Westly, J. W.; J. Med. Chem., 36, 4131-4138, 1993.
7. Ikawa, M., Stahman, M.A. and Link, K.P. ; J. Am. Chem. Soc., 66, 902, 1994.
8 Seidmann, M. and Link, K.P.; J. Am. Chem. Soc., 74, 1885, 1952.
9. Weiner, C., Schroeder, C.H., West, B.D. and Link, K.P. ; J.Org.Chem., 27, 3086
, 1962.
 
59
Chapter-2
Synthesis of some pyrano[2,3-c]...
O
OH
O
+
R1
O
R2R3
C2H5OH
R1
O
R2
R3
O
OH
O
4% HCI
CH3OH
O
O
O
R3
R2
R1H3CO
10. Kudo, S. and Masabuchi, M., Japan Patent Application 8324 (1963); C.A., 59,
11437, 1993.
11. Hutchinson, D.W. and Tomlinson, J.A. ; Tet Lett.; 5027, 1968.
12. Covello, M., Dini, A. and Simone, F.D.; Ann.Chim (Rome), 58, 595 (1968); C.A.,
70, 47230, 1969.
13. Covello, M., Dini, A. and Simone, F.D.; C. Rend.Acad.Sci.Fis.Mat.Naples. 36,
361 (1669); C.A., 75, 48942, 1971.
14. Kudo, S. and Masabuchi, M.; Japan Kokai, 8324, 1955.; C.A. 59, 11437 (1963).
(I)
The condensation of 4-hydroxy coumarins have been successful with
unsaturated nitriles using pyridine afforded to give (II)
O
OH
O
+ R
CN
COOC 2H5
reflux 3-10 hrs
O
O
O
NH
R
COOC 2H5
(II)
Covello  and coworkers13  as well as Kudo and coworkers14 have syn-
thesized simillar series (III) from substituted 4-hydroxy coumarin and un-
saturated nitriles.
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O
OH
O
X +
Ar
CN
COOC2H5
O
O
O
O
Ar
COOC2H5
X
Where X=H, Ar=C6H5
X=H, Ar=2-NO2-C6H4
X=H, Ar=3-NO2-C6H4
X=H, Ar=4-NO2-C6H4
X=H, Ar=4-CI-C6H4
X=H, Ar=4-OCH3-C6H4
4-Phenylcoumarino-3,4-dihydro-a-pyrone (V) was obtaind by con-
densation of 4-hydroxy coumarin with benzylidenemalononitrile in presence
of piperidine (or) pyridine, the resulting intermediate (IV) was subsequently
hydrolysed with hydrochloric acid/acetic acid and finally cyclised with ace-
tic anhydride.
(III)
O O
OH
+
CNNC
C6H5 O
O
O
NH2
C6H5
AcOH/HCI
O O
OH
HOOC COOH
C6H5
Ac2O
O
O
O
O
C6H5
Pyridine
Trivedi and coworkers15 synthesized several pyranocoumarins from
4-hydroxy coumarins. They reported the synthesis of 3,4-dihydro-5-oxo-5H-
2,2-dimethyl pyrano[3,2-c]benzopyrans(V),3,4-dihydro-4H-5H-2,2-dimethyl
pyrano[3,2-c]benzopyrans-4,5-diones (VI) and 5-oxo-5H-2,2-dimethyl
pyrano[3,2-c]benzopyrans(VII).
(IV)
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O
O
O
R1
R2
R3
O
O
O
R1
R2
R3
O
O
O
O
R1
R2
R3
Where  (1)  R1=R2=R3=H   (3) R1=R3=H R2=CH3  (5) R1=R2=H, R3 = CH3
(2) R1=CH3, R2=R3=H     (4) R1=H, R2= OCH3, R3 = CH3
15a. Shah, R. R., and Trivedi, K.N.; Asian J. Pharmac Sci., 2, 45, 1980.
15b. Majmudar, K.C., Khan, A.T and Das, D.P.; Synth Commun, 19 (5&6),917. 1987.
15c. Majmudar, K.C., Khan, A.T and De, R.N., Synth Commun., 18, 1988.
Majumdar and coworkers reported15b a simple route to the
regeoselective synthesis of pyrano [2,3-c][1]bezopyran-5(3H)-one(VIII).
(V) (VI)   (VII)
O O
O
O O
O
(VIII) (IX)
The compound (IX) was prepared according to the published
method15c. by treatment of propenyl ether with N,N-dimethyl aniline at 130OC
for 3 hours or refluxing in pyridine for 20 hours. It gave 2-methyl-furo[2,3-
c][1]benzopyran-4-one (X), which is also obtained by the dehydrogenation
of the dihydrocoumarin (XI) by 10% paladized charcoal in refluxing diphe-
nyl ether.
O O
O
CH3
O O
O
CH3
(X)
(XI)
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Trivedi and coworkers16-17 have also synthesized 2-methyl-9-oxo-
furo[2,3-c]benzopyran  (X) from 3-hydroxy coumarin by allylation, claisen
migration, acetylation, bromonation and cyclization with alcoholic potas-
sium hydroxide. It is also prepared according to the method devloped by
Kaufmann18.
4-(1-phenylallyl)-3-hydroxy coumarin (XII) afforded a mixture of two
products; furano(XIII) and pyrano compounds  and (XIV). They were identi-
fied as 2-methyl-3-phenyl-9-oxo-9H-furo[2,3-c][1]benzopyran (XIV) and 4-
phenyl-4H-10-oxo-10H-pyrano[2,3-c][1] benzopyran (XIV).
16. Shaikh, Y.A. and Trivedi, K.N.; J.Ind.Chem.Soc. Vol. L.41, 1973.
17. Shaikh, Y.A. and Trivedi, K.N.; Curr.Sci, 38, 409, 1969.
18. Kaufmann, K.D. and Russey, E.E.; J.Org.Chem. 27, 670, 1962.
19. Ahluwalia, V.K., Bhat, K. and Chandraprakash; Heterocycles, 12, 1203, 1979.
20. Chatterjee, J.N. and Achari, K.C..; Tetrahedron Letters, 39, 3337, 1969.
O O
OH
Ph
PdCl2
CuCl2.O2
DMF.H2O
O O
O
CH3Ph
+
O O
O
Ph
(XII) (XIII) (XIV)
Ahluwalia and coworkers19 have reported that 3-hydroxy coumarin
reacted with chalcone in presence of pyridine-piperidine20, it afforded to
g ive 2-hydroxy-2 ,4-d ipheny l -10-oxo-3,4-d ihydropyrano[2 ,3-
c][1]benzopyrans (XIII) or 4-hydroxy derivatives (XIV) from substituted 3-
hydroxy coumarin(XII).
O
O
R O
R1O
OR2
Where,
(1) XVa = R=R1=H
(2) XVb=  R=H, R1=CH3
(3) XVc=  R=OMe, R1=CH3
(4) XVd=  R=OMe, R1=CH3
(5) XVe = R=OH, R1=CH3
(6) XVf =  R= OCOCH3, R1=CH3
(XVIII)
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O O
OHR1
+
O
O O
OR1
Ph
OR
Ph
O O
OR1
Ph
H
Ph
OH
3-hydroxy  coumarin Chalcone
(a)  R1=H
(b)  R2= OCH3
(XV) (XVI)Where,
(1) XV =R=H;R1=H
(2) XVI=R=H;R1=OCH3
Chatterjee and coworkers21 have found that Wanzlick22 oxidation
proceeds smoothly with 3-hydroxy coumarin. Thus, 3-hydroxy coumarin and
catechol gave 5,6-hydroxy coumarin (3’,4’-2,3)coumarone (XV & XVI)in the
presence of potassium ferricyanide.
21. Chaterjee, J.N. and Achari, K.C.; Tetrahedron Letters, 39, 3337, 1969.
22. Wanzlick, H.W., Gritzky, R. and Heideriem,H.; Chem.Ber., 96, 305, 1963.
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O
O
R O
CH3Ph
O O
O Ph
O
O
R O
PhCH3
(XIX) (XX)
(XXI)
23. Ahluwalia, V.K., Gupta, M.C. and Mehta, S.; Ind.J.Chem. 17B, 333, 1979.
24. Wolfrum,H. and Bolhman, F.; Justus Liebigs Ann.Chem., 1989.
Wolfrum and Bolhman24 synthesized naturally occuring pyrano[3,2-c]
coumarin (XXIV) by Diels-Alder trapping of 3-methylene-2,4-chromandione
(XIII). Thus a mixture of 5-methyl-4-hydroxy coumarin(XXIIa), paraformal-
dehyde and cyclopentadiene when   refluxed in dioxan for 4 hour gave
raconognaphalin (XXIVa) in 67% yield.
O
R OH
O
HCHO
O
R
O
O H
H
  a: R=CH3, b: R= H
O
R O
O
CH2
(XXII) (XXIII)
(XXIV)
It has been reported 23 that cinnamylation of 3-hydroxy coumarin with
cinnamyl bromide with acetone in presence of potassium carbonate gave
3-cinnamyloxy-coumarin (XXI) and upon Claisen rearrangement either it
gives 3-methyl-2-phenyl-furo[2,3-c]-benzopyran-9(H)-one (XX) or 2-methyl-
3-phenyl-furo[2,3-c]-benzopyran-9(H)-one (XIX).
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O O
O
R
O
R
O O
OH
R = -CH2-CH=C(CH3)2
+
25. Appendino, G., Cravotto, G., Tagliapietra, S., Ferraro, S. and Nano, G. M.; Helv.
Chim. Acta., 74, 1451, 1991.
26. Appendino, G., Cravotto, G., Toma, L., Annuziata, R. and Palmisano, G.;  J. Org.
Chem., 59, 5558, 1994.
27. Appendino, G., Cravotto, G., Tagliapietra, S., Ferraro, S. and Nano, G. M.,
Helv.  Chim. Acta., 73, 1865, 1990.
Appendino et al 25, 26 explored this method extensively for the synthe-
sis of substituted pyrano[3,2-c]coumarins. In which Diels -Alder trapping of
3-methylene -2,4-chromandione (XXIVb) was carried out, generated in situ
from (XXIIa) and paraformaldehyde with large number of dienes and
acetylenes. They also synthesized the natural product  ferprenin (XXVII)27
by the condensation of farnesal(V) with 4-hydroxy coumarin using ehtylene
diammonium diacetate as catalyst.
(XXV)
(XXVI)
(XXVII)
Reisch28 condensed  4-hydroxy coumarin with acetylene (XXIX) de-
rivative  in the presence of acetic acid and sulfuric acid and obtained (XXXI),
while the same condensation  when carried out in the presence of phos-
phorous oxychloride in chloroform gave (XXX).
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O O
O
C6H5
C6H5
O O
O
C6H5
C6H5
C6H5CH
OH
C6H5 CC
O O
OH
+
CHCl3
POCl3
In H2SO4
CH3COOH
Kappe and Mayer29 have synthesized at C3-C4 position of coumarin
e.g. (XXXII) and  (XXXIII) using  4-hydroxy coumarin, b-keto esters(b) or b-
enamino ester(a) and ammonium acetate.
(XXVIII) (XXIX)
(XXX) (XXXI)
O O
OH
COOC2H5NH2
R2R1
COOC2H5O
R1 R2
NH4OAc
NH4OAc
a :
b : or
O
O
O
O
NH2
COOC2H5
NH4OAc
R2  =H, CH2C6H5
R1 = CH3
O
O
O
O
R1
R2
(XXXII)
(XXXIII)
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Mario31 reported preparation of 2-amino-3-ethoxycarbonyl-4-phenyl-
5-oxo-7,9-diiodo-4H,5H-pyrano[3,2-c][1]benzopyran (XXXIV), 7,9-diiodo-
2,4-dioxo-3-carboxy-4-aryl-2,3-dihydro-4H,5H-pyrano[3,2-c][1]benzopyran
(XXXV) and 7,9 diiodo-2,4-dioxo-4-aryl-2,3-dihydro-4H,5H-pyrano[3,2-
c][1]benzopyran (XXXVI), by condensation of 6,8-diiodo-4-hydroxy coumarin
with arylidenecyanoacetate in presence of  piperidine.
O O
O
OO
I
O
H
Ar
I
O O
O
O
I
Ar
I
O O
O
ONH
I
OEt
H
Ar
I
28. Reisch, J.; Arch. Pharm., 299, 798, 1966.
29. Kappe, T., and Mayer, C.; Synthesis, 524, 1984.
30. Mario, c., Antonio, D. and De Simone, Francesco (Ist. Chim. Farm. Tossicol.,
Univ. Napoli, Naples, Italy); Redn. Accad. Sci. Fis. Mat., Naples, 36, 361-9
1969; C.A. 75 , 354, 1971.
During the synthesis for new anticoaglulant  compounds, various sub-
stituted pyrano[3,2-c][1]benzopyran-5(2H)one28-29 have been prepared. Out
of such compounds cyclocoumarol30(XXXVII) is found to be the most active
one.
O O
O
C6H5
CH3H3CO
(XXXIV) (XXXV) (XXXVI)
(XXXVII)
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31. Abd Ei-Nabi, H .A. ; Pharmazie, 52(1), 28-32, 1997.
32. Ikawa, M., Stahmann, M. A.and Link, K. P.; J. Am. Chem. Soc., 66, 902
1944.
33. Seidmann M. and  Link, K. P.; J. Am. Chem. Soc., 74, 1885, 1952.
34. Kudo, S. and Masabuchi, M.; Japan Patent Application, 8324 (1963); C.A. 59,
11437, 1963.
35. Hutchinson, D. W. and Tomlinson, J. A.; Tetrahedron Lett.,  5027, 1968.
36. Covello, M., Dini, A. and  Simone, F. D.; Ann. Chin (Rome),  58, 895,  1968.;
C.A. 70, 47230, 1969.
37. Overmann R. S. et. al. ; J. Biol. Chem., 7, 153, 1944.
38. Wiener, C., Schroeder, C. H., West, B. D. and  Link, K. P.; J. Org. Chem., 27,
3086, 1962.
Abd El-Nabi31 have prepared 2-amino-4-aryl-4H-pyrano[3,2-C] quino-
line-3-carbonitriles (XXXVIII) and ethyl 2-amino-4-aryl-4H-pyrano[3,2-
c]quinoline-3-carboxylates (XXXIX) by the reaction between 2,4-dihydroxy
quinoline and cinnamonitrile derivative in the  presence of triethyl amine.
Many other heterocyclic derivatives (XXXVIII) and  (XXXIX) were also pre-
pared by a similar route32-37.
N
H
O
O
NH2
NH2
CN
N
H
O
O
NH2
NH2
COOEt
Link and Wiener38 synthesized warfarin (XLIV), warfarin oxime (XLV)
and 2-oxo-3H-4-phenyl-5-oxo-g-pyrano[3,2-c][1]benzopyran (XLIII) from 2-
amino-3-cyano-4-phenyl-5-oxo-g-pyrano[3,2-C][1]benzopyran (XXXX).
(XXXVIII) (XXXIX)
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O O
CH
OMe
C6H5
CH2COR
O O
CH
OH
C6H5
CH2CO2H
O O
CH
OH
C6H5
CH2NHCOCH3
O O
CH
OH
C6H5
CH2COCH3
Hydrolysis H +
O O
O
NH2
C6H5
CN
O O
O
C6H5
O
R = CH3, Cl, OH
(XXXX)
(XLI) (XLII) (XLIII)
(XLIV) (XLV)
Shestopalov and coworkers39 synthesized the molecule and proved
the crystal structure of  2-amino-3-cyano-6-hydroxy-4-phenyl-4-H-benzo[ f
]chromene derivatives.
O
O
NH2
NH2
NH2
N
Ar
Ar
39. Shestopalov, A.M., Emelianova, Yu.,Nesterov, V.N.; Rss.Chem Bull, Vol. 51, No.
12, pp. 2238—2243,  2002.
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Yakaot and coworker40, 41have done the reaction of  of 4-hydroxycoumarin
and 4-hydroxyfurocoumarins with a,b-unsaturated nitr i les. Mass
Spectrometry of the new pyrano-pyran derivatives was also studied of the
same molecules42.
40. Yakout, E. M. A. Ibrahim,N. M., Ghoneimb,Kh. M.  and Mahran, M. R. H.;J.
Chem. Research (S), 652-653,1999.
41. Yakout, E. M. A. Ibrahim,N. M., Ghoneimb,Kh. M.  and Mahran, M. R. H.; J.
Chem. Research,  (M), 2818-2847, 1999.
42. Ahluvalia, V.K., Bhat, K and Chandraprakash,Heterocycles, 12 (9), 1203-1206,
1979..
43. Huang L.,  Kashiwada, Y.,  Cosentino L. M.,  Fan S.; Chen C., Mcphail A. T.,
Fujioka T., Mihashi K., Lee K. H.,  J.  Med. Chem. Lett., 37, 3947 (1994).
44. Huang L.,  Kashiwada, Y.,  Cosentino L. M.,  Fan S., Lee K. H., Bioorg. Med. Chem.Lett.,
4, 593  (1994).
DCK (3’, 4’-di-o-(-)-camphonyl-(+)-cis-Khellactone)43 is a structural
modifications of Suksdorfin44 ( It is a natural khellactone which  was iso-
lated from  the fruit of Lomatium suksdorfil). It demonstrated extremely po-
tent inhibitory activity against HIV-1 replication in H9 lymphocytic cells with
an EC50 value of 0.000256mM and therapeutic index of 136,719 and more
potent than AZT as an anti-HIV agent.
O OO
O
O
O
O
Suksdorfin
O OO
O
O
O
O
O
O
O
DCK
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SYNTHETIC ASPECTS :
The biological  act iv i ty of 2-amino-4-aryl  -3-cabonitr i le-4H-
naphtho[1,2-b]pyran45, 46 (XXXXVI) has  raised a renewed interest for these
molecules and analogues47, 48. Reactivity of polyfunctionalized  2-amino-
4H-pyran49  which prompted to synthesize some potential pharmacologi-
cally active analogues.
Shah and Dodia50 prepared many derivatives of 2-amino-4-aryl-3-
carbonitriles-4H,6H-pyrano[3,2-c]quinoline to study their anti-HIV activity
for  3’-Processing (IC50mm), Integration (IC50mm), against HIV strains like
HIV-1(IIIB) and HIV-2(ROD). The compounds (XLVII) and (XLVIII) showed
good anti-HIV activity against 3’-processing and Integration 22, 24 and
>100, >100(IC50mm) respectively.
45. Brunava, M.,  Dell, C. P., Gallagher, P. T. and Owton, W. M.; European Patent
Appl. 557075; C.A., 106768t, 1994.
46. Matrin, N., Martinez-Grau, Seoane, C. and Marco, J. L.; J. Heterocyclic
Chem., 32, 1225, 1995.
47. Bloxham, J., Dell, C. P. and Smith, C. W.; Heterocycles, 38, 399, 1994.
48. Elagamey, A. G. A. and El-Taweel F. M. A.; Indian J. Chem., 29B, 885, 1990.
49. Matrin, N., Martinez-Grau, Seoane, C., Marco, J. L., Albert, A. and Cano, F.
H.; Liebigs Ann. Chem., 801, 1993.
50. Dodia, N. and Shah, A.; Heterocyclic Communiation, 7, 3, 2001.
O
O
O
NH2 N
R
(XLVI)
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Another compounds (XLIX)  and (L) have also shown good activity against
HIV-I and HIV-2 (ROD) strains.
N
H
O
O
C6H5
NH2
CH3
CN
N
H
O
O
C6H5
NH2
CN
MeO
N
H
O
O
C6H5
NH2
CN
NO2
N
H
O
O
C6H5
NH2
CN
Cl
(XLVII) (XLVIII)
(XLIX) (L)
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Very recently new51(LY-290181) molecules is under preclinical trial
blocks which the cytokine-induced production, rather than the activity, of
neutral metalloproteases, and is potentially useful in preventing cartilage
destruction associated with degenerative disorders such as osteoarthritis.
This compound inhibited neutral protease stimulated by macrophage-
conditioned medium, IL-1 and IL-1 + basic fibroblast growth factor (bFGF)
in rabbit articular chondrocytes by 102, 104 and 79%, respectively, at a
concentration of 10 mcM. This lead compound is from a series of
naphthopyran derivatives of Lily (USA), a well known pharmaceutical
company.
LY-290181
51. Drug Data Report,; 18(3); 269,1996.
52. Drug Data Report,; 17(3); 255, 1995.
Another molecule is also reported for the treatment of restenosis and
diabetic complications with smooth muscle cell proliferation-inhibitory
activity, as demonstrated in vitro by measuring DNA synthesis in cultures
of rabbit aorta smooth muscle cells (IC50 = 0.5 mcM) and by inhibition of
bovine retinal capillary endothelial cell activation induced by phorbol esters
(plasminogen activator [PA] activity ED50 = 0.05 mcM). This is within this
series of 4H-naphthopyran derivatives from the same company52.
O
NH2 N
NO2
O
N
NH2
F
F F
(LI)
(LII)
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From this laboratory, Varu53 prepared 4-amino-3-carbonitrile-2-sub-
stituted-5-oxo-benzo [C]-4H-chromene (LIII) and reported that the conge-
ners a, b, c, d showed  anti-HIV activity showing more than 100 mm  values
against 3’-Processing and Integration ( IC50mm).
O
R
NH2
CN
O
      R=
     a.   3-Cl-phenyl
     b.   4-methylthio phenyl
     c.   2-hydroxy phenyl
     d.   2- nitro phenyl
In continuation of this study54, it was planned to prepare few drug
like molecules possessing fused benzopyran system, which may be within
the broad outline of Lipinsky’s rule. Further, the chemotherapeutic values
of pyrans have assumed new importance which also promted us to synthe-
size the new compounds mentioned in this chapter.
53. Varu, B.; Ph.D.Thesis, Saurashtra University, Rajkot, 2001.
54. Dodia N. M.; Ph.D.Thesis, Saurashtra University, Rajkot, 2000.
O
O
O
NH2
N
R
 
 
 
Code No. 
 
Structure 
Strain IIIB & 
ROD 
(CC50) 
Selectivity 
Index (SI) 
SHA/JP001 >125 >376 
SHA/JP014 
 
>125 - 
SHA/JP015 
 
>125 >117 
SHA/JP017 
 
>125 - 
SHA/JP026 
 
>67.70 8 
SHA/JP027 
 
>125 >3 
SHA/JP028 
 
 
>1255 >6 
3’ posessing 
IC50 (µm) 
Integration 
IC50 (µm) 
 
 
DN-80 
N
H
O
O
C6H5
NH2
CH3
CN
 
 
 
22 
 
 
24 
 
 
DN-81 
N
H
O
O
C6H5
NH2
CN
MeO
 
 
 
>100 
 
 
>100 
 
 
 
 
 
(LIII)
Table-2.1
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OH
CHO
Salicylaldehyde
Acetic anhydride Glycine
Sodium acetate
O O
NHCOCH3
3-Acetamido coumarin
O O
OH
3-Hydroxy coumarin
R
H X
CN
Methanol
Piperidine
O
O
O
NH2
X
R
3 N HCl
Methanol
O
O
O
NHCOCH3
X
R
acetylation
Where R= Different aromatic / heteroaromatic aldehydes
           X= CN, COOC2H5
(MOX-1 to14)
REACTION SCHEME-1:
MOX-15
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 Step-1 CHO
R +
NC
R'O
Piperidine
H
CN
R'
R
0-5O C
Step-2
R
+
O O
OH
Piperidine
reflux
O
O
O
NH2
R'
R
Acetylation
(CH3CO)2O
R
/TEA
H
CN
R'
O
O
O
NHCOCH3
R'
Where, R = Different aromatic / heteroaromatic aldehydes
            R’= CN, COOC2H5
(MOX-101 to 106)
REACTION SCHEME-2:
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O O
OH
+
H
X
CN
3-Hydroxy coumarin
Cinnamonitriles
O
X
OH
O
N
R 
R 
O
X
O
O
NH
HR 
O
X
O
O
NH2
R 
EtOH/TEA
Where R= Different aromatic / heteroaromatic aldehydes
           X= CN, COOC2H5
REACTION MECHANISM FOR PYRANO[2,3-C]CHROMENE
DERIVATIVES
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CH2
CN
CN
CH
CN
CN
-Base
H CN
CNAr
O O
OH
HR
OH
H
H
NC
NC
Ar
CH
NC
NC
-
Ar
O
H H
Ar
NC
NC
- H2O
        REACTION MECHANISM FOR PYRANO[3,2-C]CHROMENE
DERIVATIVES
(a) (b)
(c)(b) (d) (e)
(f) (e)
(g)
(h)(i)
O O
Ar
CN
H
H
R
:HO
N
C
Base
O O
O
Ar
NH
CN
H
HR
O O
O
Ar
NH2
CN
HR
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Experimental:
Protocols:
All the substituted anilines and necessary chemicals were obtained
from commercial sourses. Melting points of all the synthesized compounds
was taken in open capillary bath on controlled temperature heating mental.
The crystallization of all the compounds was carried out in DMF. TLC was
carried out on Silicagel-G as stationary phase and purchsed from MERCK
India Ltd. Ethylacetate: Hexane (2:8) was used as a mobile phase. The
other solvent system like acetone:benzene was also employed .
(A) Preparation of 3-acetamido coumarin
It was prepared accrding to method of Chakravarti et al55. An intimate
mixture of the salicylaldehyde (1 part, 10 ml), glycine (0.5 part, 5 gms),
fused sodium acetate (1.25 part, 12.5 gms) and freshly distilled acetic an-
hydride (5 part, 50 ml) was heated in an oil bath at 140OC for 1 hour. The
temperature was then gradually raised to 160OC . The reaction mixture was
allowed to cool to 100OC and poured it into water containing crushed ice.
The mass was kept overnight. The seperated solid was washed with dilute
sodium carbonate solution and with hot methanol and then crystallized from
acetic acid. Yield: 60-65 %, m.p. 207OC (Reported55  m.p.= 209OC)
(B) Preparation of 3- Hydroxy coumarin:
It was prepared according to the method of Chakravarti et al55, 56. 3-
acetamido coumarin (10 gms) in methanol (85 ml) and 3N HCl (120 ml)
was refluxed for 5 hours and filtered hot. The crystals seperated on cooling
were washed and crystallized from alcohol. Yield; 48-52 %, m.p.= 150OC
(Reported55, 56 m.p.=152OC).
55. Chakravarti, D and Das, R.; J. Ind.Chem.Soc., 48, 371, 1971.
56. Patel Jignesh , Ph.D.Thesis, Saurashtra University, Rajkot, 2002.
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C). Preparation of substituted  benzylidene malononitriles45.
Take  substituted aldehyde (0.01 mole) in 250 ml beaker, add 2-3
drops piperidine as basic catalyst and than add malononitrile (0.01 mole)
drop by drop  with stirring at 5-10oC. After  the addition,  liquid  mixture
become solid mass  which  was taken into cold  water. The free product
was filtered and washed with water and dried.The cinnamonitriles, thus
prepared was used without further purification.
D). Preparation of substituted  benzylidene malononitriles45.
Take  substituted aldehyde (0.01 mole) in 250 ml beaker, add 2-3
drops Triethylamine and than add ethyl cyano acetate (0.01 mole) drop by
drop  with stirring at 15-25OC. After  the addition,  liquid  mixture become
solid mass  which  was taken into cold  water. The free product was filtered
and washed with water and dried. It was further crystallized from methanol.
(E) Preparation of 3-Amino-5-oxo-1-(substituted phenyl)-3,5-
dihydropyrano[2,3-c]chromene-2-carbonitrile.
(General method)
A mixture of 3-hydroxy coumarin (0.01 mol) and cinnamonitriles (0.01 mol)
was refluxed in absolute ethanol (30 ml), containing a catalytic amount of
triethylamine(0.1ml) for 45 minute. The reaction mixture was cooled and
the product was collected by the filteration and recrystallized from N,N-
dimethylformamide (DMSO, 3-amino-5-oxo-1-(substituted phenyl)-3,5-
dihydropyrano[2,3-c]chromene-3-carbonitrile obtained in 65-70 % yield.
Similarly, other compounds of the series were prepared. For physical data
see page no.82-84.
(F) Preparation of Ethyl-3-amino-5-oxo-1-(substituted phenyl)-
3,5-dihydropyrano[2,3-c]chromene-2-carboxylate.
(General method)
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(G)  Preparat ion of  N-(2-cyano-5-oxo-1-phenyl -1 ,5-
dihydropyrano[2,3-c]chromene-3-yl) acetamide
Take 3-amino-5-oxo-1-(substituted phenyl)-3,5- dihydropyrano[2,3-
c]chromene-2-carbonitrile/carboxylate(0.1 mol) is placed on the stirring
appratus and acetic anhydride (0.5 mol)was added dropwise and then
heated on oilbath for 3-4 hour and solid product was seperated by filteration.
It was then recrystallized from N,N-dimethylform amide (DMF).
H). Preparation of  2-amino-3-carbonirile -4-phenyl-5-oxo-
4H,5H-pyrano[3,2-c]chromene.
A mixture of 4-hydroxy coumarin (0.01 mole) and benzylidene
malononitrile(cinnamonitrile) (0.01 mole) was refluxed in absolute ethanol
(30 ml) containing a catalytic amount of triethylamine (0.1 ml) for 1-2 hr.The
reaction mixture was cooled and the product was collected by  filtration.
Then it was washed with water followed by methanol for  remove unreacted
4-hydroxycoumarin and  recrystallized from N,N-dimethylformamide (DMF),
m.p. 269o C( Reported31 m.p. 273o C ),Yield 80%.
Similarly, other substituted  2-amino-3-carbonirile-4-phenyl-5-
oxo-4H,5H-pyrano-[3,2-c]chromene were prepared using different  4-hy-
droxy coumarins and cinnamonitriles.
The physical data tables of above compounds are given on page no. 85.
A mixture of 3-hydroxy coumarin (0.01 mol) and benzylidine cyano acetate
(0.01 mol) was refluxed in absolute ethanol (30 ml), containing a catalytic
amount of triethylamine (0.1ml) for 45 minute. The reaction mixture was
cooled and product was seperated by filteration and  recrystalized from
N,N-dimethylformamide (DMF), ethyl-3-amino-5-oxo-1-(substituted phenyl)-
3,5-dihydropyrano[2,3-c]chromene-2-carboxylate obtained in 65-70 % yield.
Similarly,  other compounds of the series were prepared.  For  phys ica l
data see page no.85.
82
Table:2.1  Physical constants of Ethyl-3-amino-1-(substituted phenyl)-5-oxo-1,5-dihydropyrano[2,3-c]-chromene-
       2-carboxylates.
O
O
O
H NH2
OO
CH3
R
* Values in parenthesis denoted the theoretical percentage of composition.
Code No.
Substitution Molecular
Formula
Molecular Weight
gm/mole M.P 
O C
% Composition
R C H N
MOX-1 4-F C21H16 FNO5 381.35 179-190
66.14
(66.11)
4.23
(4.26)
3.67
(3.71)
MOX-2 2-NO2 C21H16 N2O7 408.36 280
61.67
(61.71)
3.95
(3.91)
6.86
(6.81)
MOX-3 2-Cl C21H16  ClNO5 397.80 190
63.40
(63.52)
4.05
(4.23)
3.52
(3.66)
MOX-4 2-OH C21H17NO6 397.36 196
66.49
(66.59)
4.52
(4.63)
3.69
(3.79)
MOX-5 4-Cl C21H16ClNO5 397.80 192
63.40
(63.53)
4.05
(4.21)
3.52
(3.69)
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Table: 2.2  Physical constants of 3-amino-1,2-disubstituted pyrano[2,3-c]chromene-5(1H)one.
Code No.
Substitution Molecular
Formula
Molecular Weight
gm/mole
M.P O C
% Composition
R R' C H N
MOX-6 4-N,N-di CH3 phenyl COOC2H5 C21H16 FNO5 381.35 138-139
66.14
(66.25)
4.23
(4.09)
3.67
(3.69)
MOX-7 3,4-di OCH phenyl COOC2H5 C21H16 N2O7 408.36 154
61.67
(61.72)
3.95
(3.82)
6.86
(6.77)
MOX-8 2-Cl, 3-quinolyl COOC2H5 C21H16ClNO5 397.80 258
63.40
(63.31)
4.05
(4.23)
3.52
(3.69)
MOX-9 4-OCH3 phenyl CN C21H17NO6 397.36 190
66.49
(66.53)
4.52
(4.71)
3.69
(3.78)
MOX-10 4-SCH3 phenyl CN C21H16ClNO5 397.80 184
63.40
(63.63)
4.05
(4.25)
3.52
(3.62)
O
O
O
R
R'
NH2
* Values in parenthesis denoted the theoretical percentage of composition.
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Code No.
Substitution
Molecular
Formula
Molecular Weight
gm/mole
M.P O C
% Composition
R R' R'' C H N
MOX-11 3-NO2 phenyl CN NH2 C19H11N3O5 361.30 270
63.16
(63.21)
3.07
(3.14)
11.63
(11.58)
MOX-12
2-Cl,8-CH3
3-quinolyl
CN NH2 C23H14 ClN3O3
415.82 302 66.43(64.41)
3.39
(3.38)
10.11
(10.16)
MOX-13
2-Cl- 6,7-diCH3
3-quinolyl
CN NH2 C23H16 ClN3O3
429.85 280 67.06(67.14)
3.75
(3.71)
9.78
(9.80)
MOX-15 4-Cl phenyl COOC2H5 NHCOCH3 C23H18 ClNO6
439.84 276 64.21(64.25)
3.34
(3.31)
7.13
(7.12)
O
O
R
R'
R''
O
Table:2.3  Physical constants of 1,2,3 trisubstituted pyrano[2,3-c]chromene-5(1H)one.
* Values in parenthesis denoted the theoretical percentage of composition.
85
Table:2.4  Physical constants of N-(3,4-disubstituted-5-oxo-4H,5H-pyrano[3,2-c]chromene-2-yl)acetamide.
O
O
O
NHCOCH3
R'
R
H
Code No.
Substitution
Molecular Formula Molecular Weightgm/mole M.P 
O C
% Composition
R R' C H N
MOX-101 4-F COOC2H5 C23H18FNO6 423.29 230
65.25
(65.31)
4.29
(4.18)
3.31
(3.25)
MOX-102 4-OCH3 COOC2H5 C24H21NO7 4
35
.4
2
>310
66.20
(66.23)
4.86
(4.72)
3.22
(3.10)
MOX-103 3,4,5-triOCH3 COOC2H5 C26H25NO9 495.47 >310
63.03
(63.16)
5.09
(4.98)
2.83
(2.88)
MOX-104 3-Cl CN C21H13 ClN2O4 392.79 300
64.21
(64.36)
3.34
(3.42)
7.13
(7.25)
MOX-105 4-F CN C21H13FN2O4 376.33 217
67.02
(67.12)
3.48
(3.56)
7.44
(7.31)
MOx-106 4-OCH3 CN C22H16N2O5 388.37 269
68.04
(68.09)
4.15
(4.02)
7.21
(7.10)
* Values in parenthesis denoted the theoretical percentage of composition.
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SPECTRAL STUDY :
The constitution of newly synthesized compounds were supported
by  IR, NMR , Mass spectral study and X-ray crystallography. IR spectra
were recorded (KBr) on Shimadzu FTIR-8400 spectrophotometer. 1H NMR
spectra were recorded on BRUCKER AC 300 MHz FT NMR spectrom-
eter in DMSO as a solvent. Chemical shifts are expressed as d ppm.
Mass spectra were recorded on JEOL SX 102/DA-6000 spectrograph.
 IR Spectral Study :
Instrument : SHIMADZU FT IR-8400
Sample technique  : KBr pellet
Frequency range : 400-4000cm -1
 The different  frequencies of Infra red spectra of substituted 2-
amino-3-carbonitrile-4-(substitutedphenyl)-5-oxo-4H,5H-pyrano[2,3-
c]chromenes and 2-amino-3-carbonitrile-4-(substitutedphenyl)-5-oxo-
4H,5H-pyrano[3,2-c]chromenes are discussed here.
In the coumarin moiety, lactone carbonyl showed stretching vibra-
tion between 1665-1690 cm -1. The amino (-NH2)  group showed -NH
stretching  and bending at 3320-3415 cm -1 and 1580-1604        cm -1. It’s
C-N stretching was observed at  1380 cm -1. The nitrile group (-CN) was
observed in the range of 2190-2200 cm -1. The characteristic value of
cyano group is confirmed on basis of  IR data.
The other characterization of coumarin moiety (like C-C & C-O
stretching, C-C & C-O bending and C-O-C  asymmetrical-symmetrical
stretching) appeared at 1090, 765 and  1310, 1040 cm-1. The C-H stretch-
ing of aromatic moiety is observed at ~ 3020   cm -1. The aromatic moiety
and ring skeleton (like C-C multiple bond stretching, C-H i.p. def. and C-
H o.o.p. def.) were seen at 1620-1440cm -1, 1090 cm -1 and 740-850 cm -1
respectively.
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The nitro group present  on aromatinc ring skeleton is evidenced from
the two bands of N=O stretching vibration were observed at ~1534 cm -1
and ~1341 cm -1. The chloro group was confirmed due to their frequncies,
which appeared at 800-600cm -1 (C-Cl). Spectra on page no. 96-102.
1H NMR Study :
Instrument : BRUKER AC 300 MHz FT-NMR,
Internal reference : TMS
Solvent : CDCl3 or DMSO d6
 The aromatic protons were observed in the range of 6.5-7.80 d
ppm in almost all the cases. The -NH2  proton was observed at around
7.5 to 7.6 dppm (It was shifted according to the solvent used for the analy-
sis in some cases)  in most of the derivatives. In case of  MOX-3, MOX-
5 and MOX-16 the CH3-CH2 protons of ethyl group was shown the
charasteristic triplet-quartet (triplet(~1.2 dppm) and (quartet on~4.16))
in all the cases. The methyl protons are present in the compounds ap-
peared at 1.31dppm, as the methoxy protons on aromatic nucleus were
observed on 3.724 d ppm as singlet. The acetylation of the compounds
were confirmed by the methyl protons appeared at (~2.36-2.49 dppm) It
is the special charestristics of C4 proton (7a & 8a) which gave intense
singlet  in the range of 5.0 to 5.5 d ppm. Spectra on page no. 103-107.
Mass Spectral Study :
Instrument : JEOL SX 102/DA-6000 for FAB
 The molecular ion peaks (M+) of  the substituted  2-amino-3-
carbonirile -4-(4-substituted phenyl)-5-oxo-4H,5H-pyrano[3,2-c]chromene
in mass spectra total agreement  with it’s molecular  weight.  The mass
spectrum detailes of individual compounds are recorded on page 108-
109 . All the newly synthesized compound gives molecular ion(M+) and
(M+ 2)  peaks  as well with it’s relative intensity in the ratio of 1:3. This
led to confirmation of  chloro group present  in these compounds.
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X-ray Crystallography of the newly synthesized compounds:
Thirty six frames of data were collected by an oscillation method57.
Succesive  frames were scanned in steps of 5°/min with an oscillation
range of 5°. Image processing and data reduction were performed using
Denzo.4.
A single crystal of the title compound with dimensions of 0.2 × 0.25
×0.3 mm was chosen for X-ray diffraction studies. The measurements
were made on a  DIPLabo Imaging P la te  sys tem wi th  graph i te
monochromated radiation (Mo K).
The crystal and experimental data are given in Table 1.  The
structure  was  solved by direct methods and refined by full-matrix least
squares  methods with anisotropic temperature factors for the non-H at-
oms.  All H atoms were placed at chemically acceptable positions and
were  refined with isotropic temperature factors. The final coordinates
and equivalent thermalparameters of non-H atoms are listed in Table
2.               selected bond distances  and  angles are listed in Table-3. The
bond distances and bond angles  are in good agreement with  the stan-
dard values. Figure 1 represents an ORTEP diagram of the molecule
with thermal ellipsoids at 50% probability.
Table:2.5 Crystal data and structure refinement:
Identification code EX-57
Empirical formula C25 H16 N2 O4
Formula weight 408.40
Temperature 293(2) K
Wavelength 0.71073 A
Crystal system, space group triclinic, p-1
Volume 989.90(14) A^3 Z,
Calculated density 2,  1.370 Mg/m^3
Absorption coefficient 0.094 mm^-1
57. Otwinowski,  Z. and W. Minor,  Vol.276, Macromolecular Crystallography”, 1997,
Ed. C. W. Carter, Jr. and R.M. Sweet, Academic Press, New York, part A, 307-
326.
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F(000) 424
Crystal size 0.2 x 0.2 x 0.2 mm
Theta range for data collection 2.04 to 32.49 deg
Limiting indices -9<=h<=8, -17<=k<=17, -
18<=l<=18
Reflections collected / unique 9392 / 5807 [R(int) = 0.0310]
Completeness to theta 32.49     81.1 %
Refinement method Full-matrix least-squares on F^2
Data / restraints / parameters 5807 / 0 / 281
Goodness-of-fit on F^2 1.501
Final R indices [I>2sigma(I)] R1 = 0.0690, wR2 = 0.2059
R indices (all data) R1 = 0.0953, wR2 = 0.2361
Extinction coefficient 0.140(16)
Largest diff. peak and hole 0.447 and -0.312 e.A^-3
Unit cell dimensions:
a = 7.7940(5) A       alpha = 112.270(2) deg.
b = 11.7360(10) A   beta = 97.383(5) deg.
c = 12.4220(11) A   gamma = 103.876(5) deg.
 
90
Synthesis of some pyrano[2,3-c]...
Chapter-2
OO
O
NH2
H
O
N
E
X
-5
7
O
R
T
E
P
 D
ia
g
ra
m
 o
f 
E
X
-5
7
 
91
Synthesis of some pyrano[2,3-c]...
Chapter-2
Unit cell packing of EX-57
 
92
Synthesis of some pyrano[2,3-c]...
Chapter-2
O
O O
NH2
O
O H
O2N
M
D
J
P
-2
2
M
O
X
-2
O
O
O
NH2
O
O
CH3
O2N
O
R
T
E
P
 d
ia
g
ra
m
 o
f 
M
D
J
P
-2
2
O
R
T
E
P
 d
ia
g
ra
m
 o
f 
M
O
X
-2
 
93
Synthesis of some pyrano[2,3-c]...
Chapter-2
P
A
R
-3
OO
O
NH2
O
O
CH3
H
Cl
CH3
CH3
O
R
T
E
P
 d
ia
g
ra
m
 o
f 
P
A
R
-3
 
94
Synthesis of some pyrano[2,3-c]...
Chapter-2
OO
O
NH2
O
O H
O CH3
CH3
CH3
P
A
R
-1
5
O
R
T
E
P
 d
ia
g
ra
m
 o
f 
P
A
R
-1
5
 
95
Synthesis of some pyrano[2,3-c]...
Chapter-2
O
O
ONH2
O
O
H
S
CH3
CH3
CH3
CH3
P
A
R
-1
8
O
R
T
E
P
 d
ia
g
ra
m
 o
f 
P
A
R
-1
8
 
96
Chapter-2
Synthesis of some pyrano[2,3-c]...
O
O
O
H
OO
CH3
NH2
NO2 MOX-2
Type Vibration mode
Frequency
Cm-1
Amine -NH2 Str. 3417 (d)
Carbonyl
>C=O Str.
(COOC2H5)
1739.7
>C=O Str. ring 1679.9
alkyl C-O str.
1087
Alkyl C-H Str. (-CH3) 2925
Aromatic
>C=C ring skeleton
vib.
1452
1523
Aryl C-O str. 1222.8
O.O.P. Bending
Vib.
754
792
Sample Technique: KBr Pallet
Instrument: SHIMADZU FT-IR-8400
Frequency Range: 400-4000 cm-1
IR spectrum of  Ethyl -3-amino-1- (2-ni t rophenyl ) -5-oxo-1,5-
dihydropyrano[2,3-c]chromene-2-carboxylate.
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O
O
O
H
OO
CH3
NH2
Cl
MOX-5
Type Vibration mode
Frequency
Cm-1
Amine -NH2 Str. 3446 (d)
Carbonyl
>C=O Str.
(COOC2H5)
1739.7
>C=O Str. ring 1687.9
alkyl C-O str. 1097.4
Alkyl C-H Str. (-CH3) 2979.8
Aromatic
>C=C ring skeleton
vib.
1452
1490
Aryl C-O str. 1253.5
O.O.P. Bending
Vib.
750
763
825
IR spectrum of  Ethyl-3-amino-1-(4-chlorophenyl) -5-oxo-1,5-
dihydropyrano[2,3-c]chromene-2-carboxylate.
Sample Technique: KBr Pallet
Instrument: SHIMADZU FT-IR-8400
Frequency Range: 400-4000 cm-1
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O
O
O
H NH2
N
NO2 MOX-11
Type Vibration mode
Frequency
Cm-1
Amine -NH2 Str. 3334.7 (d)
Cyano -C=N 2189.1
Carbonyl
>C=O Str.
(COOC2H5)
1733.0
>C=O Str. ring 1685.6
alkyl C-O str. 1006.8
Alkyl C-H Str. (-CH3) 2979.8
Aromatic
>C=C ring skeleton
vib.
1413.7
1452.3
Aryl C-O str. 1271.0
O.O.P. Bending
Vib.
750.3
817.3
IR spectrum of  3-Amino-1- (3-ni t roophenyl ) -5-oxo-1,5-
dihydropyrano[2,3-c]chromene-2-carbonitrile.
Sample Technique: KBr Pallet
Instrument: SHIMADZU FT-IR-8400
Frequency Range: 400-4000 cm-1
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N
O
O
O
H NH2
NCl
CH3
MOX-12
Type Vibration mode
Frequency
Cm-1
Amine -NH2 Str. 3408.0(d)
Cyano -C=N 2196.8
Carbonyl
>C=O Str.
(COOC2H5)
1735.8
>C=O Str. ring 1662.5
Alkyl C-H Str. (-CH3) 2988
Aromatic
>C=C ring skeleton
vib.
1409.9
Aryl C-O str. 1174.6
O.O.P. Bending
Vib.
758.0
798.5
IR spectrum of 3-Amino-1-(2-chloro-4-methyl-3-quinolyl)-5-oxo-1,5-
dihydropyrano[2,3-c]chromene-2-carboxylate.
Sample Technique: KBr Pallet
Instrument: SHIMADZU FT-IR-8400
Frequency Range: 400-4000 cm-1
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0.0
20.0
40.0
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%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmMOX-16
 459.0
 509.2
 567.0
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 665.4
 732.9
 759.9
 831.3
 900.7
 964.3
1014.5
1085.81163.0
1211.21332.7
1373.2
1448.4
1490.9
1606.6
1633.6
1691.5
1739.7
2981.7
3404.1
MOX-15
O
O
O
H NH
O
CH3
Cl
OO
CH3
Type Vibration mode
Frequency
Cm-1
Carbonyl
>C=O Str.
(COOC2H5)
1739.7
>C=O Str. ring 1691.5
alkyl C-O str. 1085.8
Amide
>C=O Str. 1633.6
N-H str. 3404.1
Alkyl C-H Str. (-CH3) 2981.7
Aromatic
>C=C ring skeleton
vib.
1484.4
1490.9
Aryl C-O str. 1211.2
O.O.P. Bending
Vib.
759.9
831.3
IR spectrum of Ethyl-3-(acetylamino)-1-(4-chlorophenyl)-5-oxo-1,5-
dihydropyrano[2,3-c]chromene-2-carboxylate.
Sample Technique: KBr Pallet
Instrument: SHIMADZU FT-IR-8400
Frequency Range: 400-4000 cm-1
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O
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NH O
O
CH3CH3
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F
MOX-101
Type Vibration mode
Frequency
Cm-1
Carbonyl
>C=O Str.
(COOC2H5)
1730.0
>C=O Str. ring 1720.4
alkyl C-O str. 1070.4
Amide
>C=O Str. 1668.3
N-H str. 3427.3
Alkyl C-H Str. (-CH3) ~2980
Aromatic
>C=C ring skeleton
vib.
1419.5
1456.2
Aryl C-O str. 1222.8
O.O.P. Bending
Vib.
752.2
767.6
844.0
IR spectrum of Ethyl-2-(acetylamino)-4-(4-fluorophenyl)-5-oxo-4H5H-
1,5-dihydropyrano[3,2-c]chromene-3-carboxylate.
Sample Technique: KBr Pallet
Instrument: SHIMADZU FT-IR-8400
Frequency Range: 400-4000 cm-1
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O
O
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CH3CH3
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CH3
O
O
CH3
CH3
MOX-103
Type Vibration mode
Frequency
Cm-1
Carbonyl
>C=O Str.
(COOC2H5)
1720.4
>C=O Str. ring 1718.0
alkyl C-O str. 1128.3
Amide
>C=O Str. 1664.3
N-H str. 3421.5
Alkyl C-H Str. (-CH3) 2927.7
Aromatic
>C=C ring skeleton
vib.
1419.5
1456.2
Aryl C-O str. 1232.4
O.O.P. Bending
Vib.
775.3
IR spectrum of Ethyl-2-(acetylamino)-4-(3,4,5-trimethoxyphenyl)-5-
oxo-4H5H-1,5-dihydropyrano[3,2-c]chromene-3-carboxylate.
Sample Technique: KBr Pallet
Instrument: SHIMADZU FT-IR-8400
Frequency Range: 400-4000 cm-1
 
103
Chapter-2
Synthesis of some pyrano[2,3-c]...
MOX-3
O
O
O
H
OO
CH3
NH2
Cl
20
19
21
24
22
23
9
10
14
11
13
12
8
3
O
1
2
7
6
O
4
5
O
15
H
7a
17
O
18
O
25
26
CH3
27
NH2
16
Cl
28
No.
Chemical
Shift in
(d ppm)
Multiplicity
No. of
protons
1 1.31 t 2H (26)
2 4.17 q 3H (27)
3 5.17 s 1H (7a)
4 6.48 s (b) 2H (16)
5 7.213 m 1H (23)
6 7.233 m 1H (22)
7 7.241 m 1H (24)
8 7.25 m 1H (11)
9 7.28 m 1H (21)
10 7.31 m 1H(12)
11 7.43 t 1H(13)
12 7.56 d 1H (14)
MOX-3
300 MHz 1H NMR spectrum of Ethyl-3-amino-1-(2-chlorophenyl)-5-
oxo-1,5-dihydropyrano[2,3-c]chromene-2-carboxylate.
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MOX-5
O
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OO
CH3
NH2
Cl
24
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20
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21
9
10
14
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12
8
3
O
1
2
7
6
O
4
5
O
15
H
7a
17
O
18
O
25
26
CH3
27
NH2
16
Cl
28
No.
Chemical
Shift in
(d ppm)
Multiplicity
No. of
protons
1 1.31 t 2H (26)
2 4.17 q 3H (27)
3 5.179 s 1H (7a)
4 6.52 s (b) 2H (16)
5 7.20 m 1H (24)
6 7.210 m 1H (20)
7 7.238 m 1H (23)
8 7.270 m 1H (21)
9 7.288 m 1H (12)
10 7.321 m 1H(11)
11 7.432 t 1H(13)
12 7.562 d 1H (14)
MOX-5
300 MHz 1H NMR spectrum of Ethyl-3-amino-1-(4-chlorophenyl)-5-
oxo-1,5-dihydropyrano[2,3-c]chromene-2-carboxylate.
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MOX-15
O
O
O
H NH
O
CH3
Cl
OO
CH3
26
21
25
22
24
23
9
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14
11
13
12
8
3
O
1
2
7
6
O
4
5
O
15
H
7a NH
16 17
O
18
CH3
27
Cl
31
19
O
20
O
28
29
CH330
No.
Chemical
Shift in
(d ppm)
Multiplicity
No. of
protons
1 1.247 t 2H (29)
2 2.322 s 3H (27)
3 4.169 q 3H (30)
4 5.495 s 1H (7a)
5 7.23 m 1H (22)
6 7.26 s 1H (16)
7 7.287 m 1H (26)
8 7.308 m 1H (12)
9 7.360 m 1H (13)
10 7.38 m 1H (23)
11 7.42 m 1H(25)
12 7.46 t 1H(11)
13 7.528 d 1H (14)
MOX-15
300 MHz 1H NMR spectrum of Ethyl-3-(acetylamino)-1-(4-chlorophenyl)-
5-oxo-1,5-dihydropyrano[2,3-c]chromene-2-carboxylate.
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MOX-101
14
9
13
10
12
11
4
3
O
1
2
O
5
6
8
7
O
15
H
8a
25
24
26
23
21
22
NH
16
O
20
19
O
28
29
CH330
17
CH3 27
O
18
F
31
No.
Chemical
Shift in
(d ppm)
Multiplicity
No. of
protons
1 1.18 t 2H (29)
2 2.367 s 1H (27)
3 4.08 q 1H (30)
4 5.060 s 1H (8a)
5 6.933 m 1H (23)
6 6.96 m 1H (25)
7 7.00 m 1H (11)
8 7.33 m 1H (16)
9 7.41 m 1H (12)
10 7.47 m 1H(22)
11 7.53 m 1H(10)
12 7.67 d 1H (13)
13 7.83 d 1H (26)
O
O
O
H
NH O
O
CH3CH3
O
F
- 5
MOX-105
300 MHz 1H NMR spectrum of Ethyl-2-(acetylamino)-4-(4-fluorophenyl)-
5-oxo-4H5H-1,5-dihydropyrano[3,2-c]chromene-3-carboxylate.
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MOX-106
No.
Chemical
Shift in
(d ppm)
Multiplicity
No. of
protons
J value
Hz
1 2.417 s 3H (26)
2 3.726 s 3H (28)
3 5.023 s 1H (8a)
4 6.755 d 1H (25) J= 2.1
5 6.762 d 1H (24) J= 2.1
6 7.263 d 1H (22) J= 14.4
7 7.338 m 1H (21) J= 7.5
8 7.360 m 1H (11) J= 7.2
9 7.411 m 1H (13) J= 7.2
10 7.612 t 1H (12) J= 6
11 8.046 d 1H (10) J= 8.7
12 12.604 s(b) 1H (16)
MOX-106
14
9
13
10
12
11
4
3
O
1
2
O
5
6
8
7
O
15
H
8a
24
23
25
22
20
21
NH
16
CN
19
17
CH3 26
O
18
O
27
CH328
O
O
O
H
NHCH3
O
CN
O
CH3
300 MHz 1H NMR spectrum of Ethyl-3-(acetylamino)-1-(4-methoxyphenyl)-
5-oxo-1,5-dihydropyrano[3,2-c]chromene-2-carboxylate.
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CH3
MOX-12
M.Wt: 415.82
FAB Mass spectrum of 3-amino-1-(2-chloro-4-methyl-3-quinolyl)-5-oxo-1,5-dihydropyrano[2,3-c]chromene-2-car-
boxylate.
109
MOX-15
FAB Mass spectrum of ethyl-3-(acetylamino)-1-(4-chlorophenyl)-5-oxo-1,5-dihydropyrano[2,3-c]chromene-2-car-
boxylate.
M.Wt: 439.84
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“Synthesis of  some unsymmetrical 2,6-
dimethyl-4(substituted phenyl)-3-(substi-
tuted carbamoyl)-5-(substituted car-
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Introduction:
1,4-Dihydropyridine (DHPs) calcium antagonists1.2, nifedipine3 and
structurally related drugs (Chapter 1 table: 1.1), are a known subclass of
a wider class of calcium antagonists4-7, which are among the most commonly
used drugs for patients with cardiovascular diseases8. In particular, DHP-
CA are extensively used for the treatment of hypertension9, subarachnoid
hemorrhage, myocardial infarction  and stable and unstable angina even
though recently their therapeutic efficacy in myocardial infarction and angina
has been questioned10.
Interest in the synthesis of this class of compounds continues, both
to elucidate the molecular basis of  act ion and to improve their
pharmacological profile11. This class of compounds is also under clinical
evaluation for the treatment of heart failure12, ischemic brain damage13,
nephrapathies14 and atherosclerosis15.Thus Dihydropyridine type of
compouinds play a privotal role in a host of biological responses and particularly
those involved in muscle contraction16. By far the largest groups of calcium blocker
analogue series fall in to this class possibly because of their accessibility. The
great majority of the 1,4 DHPs are prepared by using the classical Hantzsch
synthesis17, 18 or one of its varients.
1. (a) Alex Gringauz, Introduction to medicinal chemistry, wiley-vch, 1997.
(b) Triggle, D. J.; Langs, D. A.; Janis, R. A. Med. Res. Rev. 9, 123-180, 1989.
(c) Janis, R. A.; Silver, P. J.; Triggle, D. J..Adv. Drug Res. 16, 309-591, 1987.
(d) Janis, R. A,; Triggle, D. J. J. Med. Chem. 26, 775, 1983.
2. Camille. G. Wermurth, The practice of Medicinal Chemistry, 2nd edition,
academic press, 2004.
3. Vater W., Kroneberg G., Hoffrneister F., Arzneim forsch/Drug Res., 22, 1-14,1972.
4. Chaykin S., Ann. Rev. Biochem.,  36, 149, 1967.
5. Triggle D. J., Mini Reviews in Medicinal chemistry, 3(3), 215-233,  2003.
6. Triggle D. J., Eur. J. of Pharmacology, 375(1), 311-325, 1999.
7. Proos R. Joseph, The year Drug News, 205-208, 1995.
8. Davis, R.; J. Am. Chem. Soc.110, 7873, 1988.
9. (a) Godfraind T., Miller R., Wimbo M., Pharmaco. Rev., 38, 321-416,  1986.
(b) Van Zwieten P., Am. J. Cardio.,  64, 1171-1211,  1989.
(c) Opie L. H., In: Clinical use of Calcium channel antagonist drugs (2nd Ed.)
     Kulwer Acad. Pub. London, 1990.
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The first dihydropyridine was in fact isolated back in 1882 as a stable
intermediate from this method17. In its simplest form of the synthesis
involves heating an aldehyde 1,3-diketone and ammonia. The reaction
almost certainly involves aldol condensation to form the benzylidene
derivative as the first step. Conjugated addition of a second mole of 1,3-
diketone would then afford the 1,5-diketone. Reaction of the carbonyl group
with ammonia will lead to the formation of the dihydropyridine ring to give
many drug molecules that has been used extensively for  treatment of
angina10 and hypertension19.
Many scientists studied usefulness of 1,4- DHPs for different phar-
macological activities such as  antitumor20, vasodilator21, coronary vasodi-
lator and cardiopathic22, antimayocardiac ischemic, antiulcer23, antialler-
gic24, antiinflammatory25 and antiarrhythmic26,  PAF antagonist27, Adenos-
ine A3 receptor antagonist
28and MDR reversal activity29-30.
d.) Van Zwieter P. A., Pafaffendorf M., J. Hypertension, 11S, 3-11, 1993.
10. Held, P. H., Yueuf, S., Furberg, C. D.  Br. Med. J.  299,1187,1989.
11. (a) Frigerio, M. Tetrahedron Lett, 29, 6335, 1989.
(b) Baldwin, J. J.; J. Med.Chem. 30, 690, 1987.
(c) Arrowsmith, J. E.; J. Med. Chem. 29, 1696,  1986.
12. Reicher-Reiss, H.; Baruch, E. Calcium Antagonista in Patients with Heart Failure.
Drugs, 42(3), 343-364, 1991.
13. Gelmere, H. J.; Henneric, N. Stroke,  1990.
14. Di Bona, G. F.; Epstein, M.; Mann, J.; Nordlander, M. R., Kidney Znt. 41, 1991,
(Suppl. 36).
15. Tiggle, D. J.,  Drugs Today, 27(3), 1991- 147-155 and references cited therein.
16. Krishana R. and Mayer L. D., Eur. J. Pharm. Sci., 11, 265-283, 2000.
17. Hantzsch, A., Justus Liebigs Ann.Chem., 1, 215, 1882.
18. Hantzsch, A., Ber., 17, 1515(1884); Ber., 18, 1774, 2579,  1885.
19. Haneeon, L.,Am. Heart J. 122, 308-311, 1991.
20. Zidermane, A., Duburs, G. and Zilbere, A.; . PSR Zinat. Akad. Vestic 4, 77
(1971); C.A., 75, 47266,  1991.
21. Wehinger, W. E., Horst, M., Andres, K. and  Yoshiharu; Ger. Offen; C.A., 107,
217482, 1987.
Synthesis of some unsymm....
 112
Chapter-3
22. Hachiro, S., Kunizo, H., Tadao, S., Hideyuki, A., Yoshihsru, D.; Eur. Patent
197,488, 1986.; Japan Patent 68,649,  1985.; C.A., 106, 328559, 1987.
23 Yan, Z. M., Dong, Y. M., Xuebao, Y.; Eur. Patent  220, 653, 1987.; Japan Patent
253,909, 1985.; C.A., 116, 173968, 1992.
24. Marco, F., Andrea, Z., Carmelo, G. and  Bermini, M.; Eur. Patent 272, 693; C.A.
109, 190259, 1988.
25. Johnson, R. C., Taylor, D. J., Hann Kenneth, V. and Sheng, S., U.S. Patent
4,758,669; C.A. 109, 149366, 1988.
26. Masakatu, H., Kenichi, K., Yasuhiko, S., Masakazu, H., Osamu, K. and
Hiroyoshi, H.; Eur. Patent  653, 1987; Japan Patent 235 909, 1985; C.A. 107,
134209, 1987.
27. Cooper K., Fray M. J., Parry M. J., Richardson K. and Steele J., J. Med. Chem.
35, 3115-3129, 1992.
28. Van Rhee A. M., Jiang J. L., Melman N., Olah M. E., Stiles G. L., Jacobson K.
A.,J. Med. Chem.,  39, 2980-2989, 1996.
Literature Survey & Biological profile of 1,4-DHPs:
1,4-Dihydropyridines are now established as heterocycles having tre-
mendous applications and still further scope for its pronounced drug activ-
ity like calcium channel antagonism and antihypertensive action. Many other
cardiovascular activities are associated with such compounds and they can
be presented in the structure  as 2,6-dimethyl-3,5-diacetyl or dicarboxylate
or dicarbamoyl or many other homoaryl or heteroaryl carbon chain having
C2 to C8 1,4-dihydropyridines substituted at 4-position.
1,4-DHPs possesses multidrug resistance (mdr) reversal activity. This
investigation further confirm ed by Hollt V. and co-workers31 in 1992.  The
development of multidrug resistance (mdr) of tumor  cells is a major prob-
lem in malignant tumor chemotherapy in tumor cells, by increasing drug
efflux, acquire cross-resistance to many structurally and functionally unre-
lated anticancer agents, which therefore never achieve effective intracellu-
lar concentrations32. Multidrug resistance (MDR) of cancer cells has often
been correlated with the over expression of P-glycoprotein (P-gp). An ABC
transporter ATP binding cassette act as a cellular pump membrane trans-
porter by extruding the anticancer agents and preventing their anti tumor
effect.
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Calcium Channel in DHP Binding
In the above figure, they propose a model for DHP binding which at-
tempts to reconcile some of the differences in the binding models discussed
above. Catterall’s photo affinity study using PN200-110 with the photolabile
group attachedtothe4-aryl moiety shows the major binding site to be III S6.
When the covalent affinity label was placed on the ester group, the major
binding site was the loop connectingIII S5 and IIIS6. In the primary sequence
of the R-1 subunit, there is a try porphan residue (Tryp1016) located mid-
way on this loop33. In thethe oretical study by Marrer et al34 a  strong inter
action was proposed between a tryptophan  and the portside ester of DHPs.
Solution-phase and  solid-state studies have shown the 1,4-dihydropyridine
ring to be in a flattened boat conformation with the ring to be in a flattened
boat conformation with the  4-aryl  group in the pseudoaxial  position. The
common nomenclature adopted for these compounds places the NH at the
stern of the boat and the 4-aryl moiety at the bow.
Figure 3.1 shows the edmundson helical wheel representation of the binding
model, based on covalent affinity labeling data of the hypothetical role of the IVS6 Portion
of the calcium channel in DHP binding.
Figure 3.1
29. Shah A., Gaveriya H., Motohashi N., Kawase M., Anticancer Res.,  20, 373,
2000.
30. Singer, T. P. and  Kearney, E. B.; Advan. Enzymol., 15, 79, 1964.
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Figure 3.2 indicates the Hypothetical binding interactions of a 4-isoxazolyl 1,4-
dihydropyridine to the IIIS6 membrane-bound strand of the calcium channel.
Langs & Triggle35a carried out modeling studies which indicated that
there may be important H-bond interactions between the ester groups and
argenine residues which are separated by two amino acids. This sequence
(Arg-X-X-Arg) is repeated 10 times in the S4 strands. However, Catterall’s
studies do not show binding on the S4 strand. The IIIS6 strand does have
the tryptophan residue and a glutamic acid residue (1040) positioned in
such a way that the dihydropyridine NH can hydrogen bond to the glutamic
acid and the port side ester to the tryptophan. This positions the DHP ring
down with respect to the transmembrane strand.
A correlation between the flatness of the DHP boat conformation in
the solid state and the binding affinity of the DHP derivatives was recognized
by Triggle35b. It has been postulated that this correlation relates to the forward
presentation of the 4-substituted moiety.
Figure 3.2
31. Hollt V., Kouba M., Dietel M., Biochem. Pharmacol., 43, 2601-2608, 1992.
32. Krishana R. and Mayer L. D., Eur. J. Pharm. Sci., 11, 265-283, 2000.
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33. Tanabe, T.; Takeshima, H.; Mikami, A.; Flockerzi, V.; Takahashi, H.;Kanagawa,
K.; Kajima, M.; Matsuo, H.; Hirase, T.; Numa, Nature , 328, 313-318.1987.
34. Hoeltje, H.-D.; Marrer, S. A  J. Comput.-Aided Mol. Des. 1, 23-30, 1987.
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Figure-3.3 1,4-DHP nucleus as “privileged” structure class
As per Figure 3.3, 1,4-DHPs is one of the class of the compounds
having the priviledge structure class and it has many potency to new mol-
ecule predict the “druglike”. There are many factors determine whether a
compound can become a lead molecule or not and only some of them are
structure dependent. That is why most general drug likeness classifiers
derives from  (Table 1.1 page No.10)  analysing known drug molecules.
Our effort to generate a large number of compounds for lead gen-
eration. Utilizing priviledged structure class35 to mimic known drugs has
the advantage of provided us to very specific suggestion about what mo-
lecular fragments to include in the synthesis of new class of the compounds
generated by our laboratory.
Synthesis of some unsymm....
 116
Chapter-3
Gaveria  and coworkers36 reported some unsymmetrical 1,4-dihy-
dropyridine derivatives (I) and (II) as potent antitubercular agents.
N
H
H
CH3 CH3
H3COOC
NO2
N
N
R
R
R = COCH3, H, C6H5
N
H
H
CO-CH=CH-R
CH3 CH3
H3COOC
NO2
35. (a)Langs, D. A.; Kwon, Y. W.; Strong, P. D., and Triggle, D. J.; J. Comput. Aided.
Mol.Des. 5, 95-106. 1991.
(b)Langs, D. A.; Strong, P. D. and Triggle, D. J. ; J. Comput. Aided Mol. Des.  4,
215-230. 1990.
36. Gaveria, H., Desai, B., Vora, V. and  Shah, A.; Heterocyclic Communication,
7(5), 481-482, 2001.
According to structural modification these drugs can be classified into four
categories:
(a) Symmetrical compounds having esteric linkage both at 3 and 5 position
of  dihyropyridine
(b) Structure having different ester linkage at 3 or 5 position or positional
variation at 2 or 3.
(c) Symmetrical compounds having atleast one ester group.
(d) Symmetrical structure without ester group or having two acyl group at 3
and 5 position respectively.
(I) (II)
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Christiaans and Timmerman38 studied new molecules like CV-159
(IV) and SM-6586 for possible variation at 3-position.
N
H
CH3 CH3
CH3
NO2
O N
N
N
CH3
37. Hernandez-Gallegos, Z., Lehmann, F., Hong, E., Posadas, F. and Ernandez-
Gallegos, E.; Eur. J. Med. Chem., 30, 355-364, 1995.
38. Christiaans, J.A.M.; Ph.D. Thesis, Vrie University, Amsterdam, The Netherlands,
1994.
N
H
R2 - OOC
H
COO-R1
CH3 CH3
Symmetrical & UnsymmetricalR = 3-NO2, 4-F, 3,5-di-F, 3-Br-4-F.
R1 = R2= Me, Et, -CH2-CF3, -CH2CH2-OPh, -(CH2)2-N(CH3)-CH3-Ph
Hernandez-Gallegos and coworkers37 have  synthesized new 1,4-
dihydropyridines(III) and evaluted their relaxant ability (rat aorta), antihy-
pertensive activity in spontaneously hypertensive rats and their microso-
mal oxidation rate (MOR) was determined.
CV-159
(III)
(IV)
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39. Carlos E. and Sunkel et al J . Med. Chem. 35, 2407-2414, 1992.
40. Schramm,M. and Towart, R.; Modulation of Calcicum channel by drugs Life Sci.,
37, 1843-60, 1985.
Carlos et al39 reported 1,4-DHPs derivatives with a 1,2-benzothiazol-
3-0ne 1-sulphoxide group (V), linked through an alkylene bridge to the C-3
carboxylate of the DHP ring, with both vasoconstricting and vasorelaxant
properties were obtained. In blocking Ca+2 evoked contractions of
K+depolarized rabbit aortic strips. Many compounds were 10 times more
potent than nifedipine. Their vascular versus cardiac selectivity was very
pronounced.
O
N
H
CH3 CH3
OH OH
OO
S
N
O
O
O
CH3
Schramm and cowroker40 have proved that phenyl carbamoyl moiety
in dihydorpyridine (VI) either cardiovascular selective activity.
N
H
O O
O NNH
Cl
CH3 CH3
(V)
(VI)
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41. Kelvin Cooper. et al,  US Patent 4,935,430. EP-A-258033, EP-A-266989.
42. Christiaans J.A.M., Timmerman, H., Eur. J. Pharm. Sci. 4 , 1-22, 1996.
43. Swamy, S.K., Reddy, T.M. and Reddy, V.M.; J. Pharm. Sci., 60(2), 102-106,
1998.
Reddy and coworkers43 synthesized 4-aryl hetroaryl-2,6-dimethyl-3,5-
bis-N-(2-methyl phenyl)carbamoyl-1,4-dihydropyridines (IX) through one-pot
synthesis using appropriate aromatic aldehydes and liquid ammonia.
Pharmacological screening of the new 1,4-dihyropyridines were also carried
out for CNS depresant (anticonvulsant and analgesic) and cardiovascular
(inotropic and blood pressure) activities by standard methods.
Similarly  Kelvin Cooper (Pfitzer , USA) et al41 found that DHP can
be highly selective as platlet activating factor (PAF) antagonist. They found
the potent results and prove that platlet aggregating activity (PAF) exhibit
a wide spectrum of biological activities elicited either directly or via the
release of other powerful mediator such as Thromboxane A2 or the
Leukotrienes. In vitro PAF  stimulates the movement and aggregationa and
the release there from of tissue damaging enzymes and oxygen redicals.
Accordingly following compounds UK-74505 (VIII) which antagonize
the action of  PAF and concequently also prevent mediator release by PAF,
will have clinical utilities in the treatment of the variety of the allergic,
inflamatory and hypersecretory conditions such as asthama, arthritis,
rhinitis, bronchitis and utricaria42.
N
H
O O
N
CH3
Z
R1
R2
Y
X
N
H
CH3
COOC 2H5
O
NH
N N
N
CH3
UK-74505General  structure
(VII) (VIII)
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Neamati and coworkers44 reported that 1,4-dihydorpyridine (X)
molecule NCS-372643 came out with its anti-HIV activity, which has opened
up the synthetic as well as pharmacological importance in antiviral area
also.
N
H
CH3 CH3
O O
NH NH
OH
OH
OH
OH
NO2
NSC-372643
44. Neamati, N., Hong, H., Mazumder, A. and Pommier, Y.; J. Med. Chem. 40(6),
942-951, 1997.
45. Tedjamylia, M.L., Srivastava, P.C. and Knapp, F.F.; J. Med. Chem. 28, 1574,
 1985.
Tedjamulia and coworkers45 reported that derivatives of 1,4-dihyd-
ropyridine (XI) may be used as carrier radiolabled barrier agent. The carrier
apparently helps to carry the radiolabled agent to the brain.
N CH3
NH
O
I
N
H
CH3 CH3
O O
NH NH
CH3 CH3
R
R = NO2, OH, diOCH3, N(CH3)2, etc….
(IX)
(X)
(XI)
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Shah and Parmar46 prepared many 3,5-dicyano-1,4-dihydro pyridines.
Out of many compounds, 3,5-dicyano-2,6-diethoxy -4-(2-hydroxyphenyl)-N-
(2-pyridyl)-1,4-dihydropyridine showed good antiinflammatory activity and
also showed moderate increase in blood pressure at 1mg/kg and 5mg/kg.
46. Parmar K., Ph. D. Thesis (1993), Saurashtra University , Rajkot, Gujarat (India).
47. Takenaka T., Maeno T., Jpn. J. pharmacol., 32, 132, 1992.
48. Sadanandam Y. S., Shetty M. M., Reddy Ram Mohan K., Leelavathi P., Eur. J.
Med. Chem., 29, 975-979, 1994.
In recent  years, chemistry of symmetrical 1,4-dihydropyridine hav-
ing carbamoyl groups at 3 and 5 position developed. It was observed that
the symmetric dihydropyridines, if incorporated with carbamoyl functional-
ity, some different pharmacological profile may be expected. In 1992, sym.
1,4-dihydropyridines having N-methyl or N-diethyl carbamoyl functional
group at 3 and 5 position in place of carboxylic ester group were synthe-
sized by Takenaka and Maeno et. al.47  and tested for potent calcium chan-
nel blocking activity. These derivatives possesses other pharmacological
activity.
Sadanandam  and coworkers48 reported antiinflammatory and anal-
gesic profile of sym. 1,4-DHP with certain structural modifications incor-
porating N-methyl and N,N-diethyl carbamoyl moieties at the 3 and 5 posi-
tions. The acute toxicology of these molecules (XII) were also investigated.
N
H
MeMe
O
N N
X
Y
X
Y
O
R
Where R= H, CH3, OH, OCH3, Br and di OCH3
          X= C2H5, Y= CH3, C2H5
(XII)
Synthetic Aspects:
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Glucowski, G and coworkers49  have proved the use of 1,4-DHPs in
the treatment of  benign prostatic hyperplasia, inhibition of cholesterol syn-
thes is .   The amidat ion  o f  carboxy l ic  ac id  (XIV)  w i th  3- (4 ,4-
diphenylpiperidino)propyl amine (XIII) in refluxing CH2Cl2 gave 58.8%. These
compounds showed reduction of uretheral pressure in vivo in dogs.
N
R1
R2 R4
X
Y
N
R8
R7
R3
O
R5
R6
N
H
H2NOC
R2 R4
O
OH
NO2
Where R1= linear or branched alkyl, alkoxy alkyl, aryl alkyl.
    R4 & R2= H, linearor branched alkyl
            R3= H, linearor branched alkyl
   R5 & R6=H, OH, Cl, Br, F,NO2, CF3, CH, NH2.
     R7, R8 = H, CN, CF3,OH, alkoxy etc...
             Y= C1-5 alkyleneC4-8 alkyleneetc..
            Z=O, NH, CH2
49. Glucowski, C., Weltsel, J., et al. US 5787131, WO appl, 94/453852 & US
166387. 1998.
50. Uneyama, Hisayuki. et al. PCT Int appl.WO 9849144, JP appl. 97/
10928325. 1997.
Uneyama and coworkers50  found activityof (XV) in vitro inhibited N-
type and L-type calcium channel in rat  and it shows a sympathetic ganalion
cell by 47.49% at 0.1 mm and 98% at 100 nm respectiely.
N
H
H2NOC
R2 R4
O
O
CN
(XIII) (XIV)
(XV)
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Shah and Naliapara51 have synthesized few series of 3,5-disubsti-
tuted carbamoyl derivatives and studied 2D QSAR of 4-substituted phenyl-
2,6-dimethyl-3,5-bis[(N-Substituted phenyl) carbamoyl]-1,4-dihydropyridine
(XVI) as potent antitubercular agents. These compound, show >90% inhi-
bition comparable to Rifampicin and MIC value <12.5mg.
N
H
MeMe
N
H
OO
N
H
R
R = -OC6H5, Cl, NO2, Br...
R1 = -NO2, OCH3, Cl...
R2R1
51. Naliapara Y. T., Desai B., Sureja D., Shah A., Saxena A. K., Bio. Org. & Med.
Chem., 9, 1993-98 , 2001.
N
H
MeMe
O
N
H
O
N
Cl
O
BMY-20014
Unsymmetrical 1,4-DHPs derivatives (XVII) with carbamoyl groups
at 3 position showed very good anti-inflammatory and analgesic profile in-
stead of cardiovascular effect.
(XVI)
(XVII)
Thus, in the present study a careful structural design of next gen-
eration of dicarbamoyl 1,4-DHPs were taken for their further study.
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NO2
O
NH
CH3 O
O
NO2
NH
O
CH3 O
H
Piperidine
R
R
+
Iso propyl alcohol
REACTION SCHEME:
NH
CH3 O
O
NH2
R +
CH3
CH3
O
O
Toluene
Step-1
Step-2
Reflux
15 hr.
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NO2
NH
O
CH3 O
H
+
NO2
N
O
CH3 N
H
CH3
H
H
NH
O
R
R
O CH3
O
NH
R'
Methanol
NH3
Reflux with stirring
R'
Step-3
(MDR-96 to MDR-125)
Where,
R  = 2-CH3,2-OCH3, 2-Cl, 4-Cl,  etc..
R’= 2,4-diCH3,3-CH3, 2,3-diCH3, 3,4-diCH3, ,2,5-diCH3
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Experimental:
All the melting points are uncorrected. IR specta were recorded (KBr)
on SHIMADZU FT-IR-8400 spectrophotometer. 1H NMR spectra were
recorded on BRUKER AC 300 MHz FT-NMR spectrometer in CDCl3 as a
solvent. Chemical shifts are expressed as d ppm. The purity of compounds
were monitored by TLC performed on silica gel-G plates purchased from
Merck. MASS spectra were recorded on JEOL SX 102/DA-6000.
(A) Preparaton of Acetoacetanilide:
Aniline (0.1 mole), ethylacetoacetate (0.1 mole) and caustic lye (2.0
gm NaOH + 0.5 ml water) were heated at 110 OC in 50 ml toluene as solvent
for 9-10 hours. After completion of reaction, most of toluene was distilled
out. The reaction mass was cooled at room temperature and then taken in
an ice bath which formed light yellow crystals of crude acetoacetanilide. It
was then extracted with diethyl ether/ petroleum ether  and filtered. Etheral
solution was evaporated afforded to get pure acetoacetanilide. Yield 60-
70%. m.p. 80OC.
Similarly ,other acetoacetanilides were prepared by taking different amines.
(B) Preparation of 2-acetyl-N- (2-methylphenyl)-3-(3-nitrophenyl)
acrylamide:
A mixture of 3-nitrobenzaldehyde (0.01 mol, 1.51 gm) and 2-methyl
acetoacetanilide (0.01 mol,) was taken in conical flask (250 ml) containing
50 ml methyl alcohol, stir it on stirring device for 30 min. and add pyridine
(1.5 ml) in reaction mixture. After five hour solid product was separated,
the reaction was cooled, solid product was filtered and washed with cold
isopropyl alcohol to give free solid product, This was crystallized in
methanol. Yield 80%, m.p. 210 oC.
[Calculated % C 66.66, H 4.97, N 8.64, O 19.73, Found % C 66.65, H 4.98,
N 8.65 O 19.74].
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(C)  Preparat ion of  2 ,6-dimethyl -4(3-ni t rophenyl ) -3- (2-
ch lorophenylcarbamoyl ) -5 - (2 -methy lphenylcarbamoyl ) -1 ,4 -
dihydropyridine.
A  mixture of 2-acetyl-N- (2-methylphenyl)-3-(3-nitrophenyl)
acrylamide (0.01 mol, 3.24 gm) and 2-chloro acetoacetanilide (0.01 mol,
2.13 gm) was taken in flat bottom flask and sufficient methanol was added,
stir and reflux it on stirring device then ammonia solution (2 ml) was added
dropwise.  After several hours solid produst was isolated in reaction flask
which was treated by diethyl ether and crude product obtained was filtered.
It was further washed with methanol several times and further crystallized
from DMF, Yield 25%, melting point: 238 oC.
[Calculated % C 65.05, H 4.87, N 10.84  Found % C 65.19, H 4.81, N 10.81]
The other compounds of the series were prepared according to
above mentioned method and physical data of three series of newly syn-
thesized compounds are recorded in Table-3.4, Table-3.5 and Table-3.6.
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Code No.
Substitution
Molecular Formula MolecularWeight M.P.
OC
% composition
R R' C H N
MDR-96 2-OCH3 2-Cl C28H25ClN4O5 523.97 198-199
63.10
(63.18)
4.73
(4.78)
10.51
(10.47)
MDR -97 2-CH3 2-Cl C28H25ClN4O4 516.97 238
65.05
(65.19)
4.87
(4.81)
10.84
(10.81)
MDR-98 2-OCH3 2,4-diCH3 C30H30N4O5 526.58 230-231
68.43
(68.43)
5.74
(5.71)
10.64
(10.62)
MDR-99 2-CH3 2,4-diCH3 C30H30N4O4 510.58 224
70.57
(70.69)
5.92
(5.88)
10.97
(10.89)
MDR-100 2-Cl 2,4-diCH3 C29H27ClN4O4 531.00 234
65.59
(65.72)
5.13
(5.19)
10.55
(10.59)
MDR-101 2-Cl 4-Cl C27H22 Cl2N4O4 537.39 228-229
60.34
(60.38)
4.13
(4.19)
10.43
(10.40)
MDR-102 4-Cl 2-OCH3 C28H25ClN4O5 532.97 203
63.10
(63.11)
4.73
(4.79)
10.51
(10.58)
Table-3.4 Physical constants of 2,6-dimethyl-3,5-disubstituted phenyl carbamoyl 4-(3-nitrophenyl)-1,4-
     dihydropyridines.
N
H
CH3 CH3
OO
NH
H
NH
NO2
R R'
* Values in parenthesis denoted the theoretical percentage of composition.
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Code No.
Substitution Molecular
Formula Molecular Weight M.P.
OC
% composition
R R' C H N
MDR-103 4-C l 2-C H3 C 28H25 C lN4O4 516.97 258-259
65.05
(65.09)
4.87
(4.88)
10.84
(10.96)
MDR-110 2-OC H3 3-C H3 C 29H28 N4O5 512.55 210
67.96
(67.48)
5.51
(5.59)
10.93
(10.91)
MDR-112 2-C l 3-C H3 C 28H25 C lN4O4 516.97 214
65.05
(65.21)
4.87
(4.89)
10.84
(10.77)
MDR-113 4-C l 3-C H3 C 28H25 C lN4O4 516.97 234-235
65.05
(65.09)
4.87
(4.86)
10.84
(10.82)
MDR-114 4-C l - C 27H23C lN4O4 502.94 220
64.48
(64.71)
4.61
(4.69)
11.14
(11.48)
MDR-116 2-OC H3 2-Cl C 28H25C lN4O5 523.97 218-220
63.10
(63.28)
4.73
(4.78)
10.51
(10.56)
MDR -118 2-C H3 2-Cl C 28H25C lN4O4 516.97 258-259
65.05
(65.19)
4.87
(4.79)
10.84
(10.77)
Table-3.5 Physical constants of 2,6-dimethyl-3,5-disubstituted phenyl carbamoyl 4-(3-nitrophenyl)-1,4-
     dihydropyridines.
N
H
CH3 CH3
OO
NH
H
NH
NO2
R R'
* Values in parenthesis denoted the theoretical percentage of composition.
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Code No.
Substitution
Molecular Formula Molecular Weight M.P.OC
% composition
R R' C H N
MDR-119 2-Cl 3,4-diCH3 C29H27ClN4O4 531.00 190-200
65.59
(65.57)
5.13
(5.11)
10.55
(10.58)
MDR-120 2-Cl 2,3-diCH3 C29H27ClN4O4 531.00 220-221
65.59
(65.54)
5.13
(5.11)
10.55
(10.58)
MDR-121 4-Cl 2,3-diCH3 C29H27ClN4O4 531.00 232-234
65.59
(65.57)
5.13
(5.17)
10.55
(10.59)
MDR-122 4-Cl 3,4-diCH3 C29H27ClN4O4 531.00 256
65.59
(65.67)
5.13
(5.21)
10.55
(10.68)
MDR-123 2-OCH3 2,3-diCH3 C30H30N4O5 526.58 208
68.43
(68.38)
5.74
(5.71)
10.64
(10.69)
MDR-124 2-OCH3 2,5-diCH3 C30H30N4O5 526.58 240-241
68.43
(68.43)
5.74
(5.78)
10.64
(10.62)
MDR-125 2-OCH3 3,4-diCH3 C30H30N4O5 526.58 214
68.43
(68.45)
5.74
(5.72)
10.64
(10.69)
Table-3.6 Physical constants of 2,6-dimethyl-3,5-disubstituted phenyl carbamoyl 4-(3-nitrophenyl)-1,4-
      dihydropyridines.
N
H
CH3 CH3
OO
NH
H
NH
NO2
R R'
* Values in parenthesis denoted the theoretical percentage of composition.
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Spectral Discussion:
Spectral data of only key intermediate and final compounds are in-
cluded. Elemental analysis of the compounds were in agreements (within
0.4% of theoretical value) with the strctures assigned. The constitution of
newly synthesized compounds were supported by   IR, NMR, and Mass
spectral study. The details are as under.
IR Spectral analysis:-
Instrument : SHIMADZU FT IR-8400
Sample technique :  KBr pellet
Frequency  range : 400-4000cm-1
As per spectral study of the newly synthesized 1,4-dihydro pyridine
molecules, most of the carbonyl (>C=O) stretching observed at ~1680-1690
cm -1 due to the amide carbonyl  functionality. The other confirmation of
amide group that it has shown >C-N stretching in range of 1501-1592. The
stretching of secondary amine (>NH) appears around ~3428-3432 cm -1,
it’s bending and C-N stretching appears at 1501-1592 cm -1 respectivley.
The C-H stretching of aromatic moiety was observed at ~3030 cm -1. The
other characterization due to aromatic moieties C-C multiple bond stretch-
ing, C-H inplane bending and out of plane bending appears around at
~1501-1592 cm-1, ~1085 cm-1 and ~680-790 cm-1 respectively.
The C-H stretching of methyl group observed at ~2920-2923cm -
1(asym.) and ~2831-2851cm -1 (sym.) and it’s bending was observed at
~1383 cm -1 .
IR spectral data for  [MDR 96 to MDR-125] are given in Table on135-140.
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Table:3.7:  IR frequency of newly synthesized unsymmetrical 1,4-
dihydropyridines.
Compound
Code
IR Frequency (cm-1)
Amine Amide
>C-N
str.
Methyl
(asym. str.)
Methyl
(sym. str.)
Amide
(>C=O)
Aromatic
>C=C<
ring skeleton
vibn.
>N-H   of
-CONH
MDR-96 3432 1501.5 2923 2851 1680 1457
MDR-97 3431 1515 2921 2850 1679 1452
MDR-98 3429 1498 2919 2848 1677 1450
MDR-99 3430 1514 2920 2847 1676 1468
MDR-100 3433 1518.8 2922 2852 1683 1494
MDR-101 3433 1505 2924 2850 1684 1464
MDR-102 3431 1517 2924 2850 1681 1447
MDR-103 3432 1497 2919 2848 1676 1454
MDR-110 3434 1498 2925 2854 1679 1471
MDR-112 3431 1592 2921 2853 1681.8 1495
MDR-113 3431 1591 2920 2856 1684 1488
MDR-114 3429 1590 2919 2852 1680 1491
MDR-116 3429 1589 2920 2856 1684 1493
MDR-118 3433 1519 2922 2853 1683 1496
MDR-119 3433 1520 2921 2851 1684 1498
MDR-120 3430 1585 2921 2855 1690 1474
MDR-121 3431 1586 2922 2855 1692 1481
MDR-122 3431 1586 2920 2851 1691 1483
MDR-123 3429 1498 2919 2847 1678 1459
MDR-124 3428 1519 2922 2831 1683 1494
MDR-125 3428 1520 2921 2830 1683 1489
Table-3.7
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NMR Spectral Study :-
Instrument : BRUKER AC 300 MHz FT-NMR,
Internal reference : TMS
Solvent : CDCl3 or DMSO d6
 Looking to the NMR spectra, the title compounds (MDR),  In case of
C2 & C6 methyl protons (-CH3) are observed as singlet at 2.100 -2.167 d
ppm .  While asymmetric (C4) carbon proton (>CH-) protons in all com-
pounds were   observed  at  5.0-5.8 d ppm.  The amide (-NH) protons gave
signals at 8.93-9.50 d ppm. In most of derivatives, -NH protons were ob-
served at 6.5-8.0 d ppm as a singlet. The aromatic protons were observed
at around 6.60-8.30 d ppm.
For splitting patterns of m-NO2 phenyl functionality, two triplets is clearly
observed in the aromatic region due to ortho/di-meta coupling of phenyl
protons. For ortho substituted phenyl ring,  three doublets is observed  due
to di-ortho/meta coupling of phenyl protons and for para substitution dou-
blet of doublet  was observed in the spectrum.
In case of MDR-100, all the methyl groups were seen in proper
assignment and the J value of meta coupling of the protons was also in
agreement with expected values.
In case of MDR-101, spectra was of non first order and so the J val-
ues was not given due to peak merging in each other,  while in case of
MDR-103, all the protons were seperated and due to 4-chloro substitution
in the phenyl moiety (1,4-substituted). The doublet of doublet (ortho/meta
coupling) in the range of 7.27 to 7.56 d ppm was clearly observed.
The 1H NMR spectra of the compounds were given on page no.141-150.
Mass Spectral Study :
Instrument : JEOL SX 102/DA-6000 for FAB
In case of mass spectral analysis the FAB (Fast atom
Bombardenment) technique was used. The molecular ion peaks (M+) of
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the compounds  in mass spectra  were in total agreement  with it’s molecu-
lar  weight. Halogen (Cl, Br) Intensity of M+1 peak  were observed as per
expected one.
The MASS spectra of the compounds were given on page no.151-156.
Table-3.8: Mass values for 2,6-dimethyl-3,5-disubstituted phenyl
carbamoyl 4-(3-nitrophenyl)-1,4-dihydropyridine.
Compounds
Code No.
m/z
(Relative intensity)
MDR-96 524(M+H)
+
(100 %)
MDR-97  517(M+H)
+
(100 %)
MDR-98  527(M+H)
+
(100 %)
MDR-99 510 (M+H)
+
(35 %)
MDR-100 531 (M+H)
+
(100 %)
MDR-101  (M+H)
+
(65 %)
MDR-102
 (M+H)+
(100 %)
MDR-103 516 (M+H)
+
(65 %)
MDR-110 512 (M+H)
+
(100 %)
MDR-112 516 (M+H)
+
(70%)
MDR-113 516 (M+H)
+
(70%)
MDR-114 503(M+H)
+
(65%)
MDR-116 503 (M+H)
+
(65%)
Table-3.8
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30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmMDR-96
 450.3
 526.5
 682.8
 747.4
 792.7
 903.6
1025.1
1097.4
1119.6
1219.9
1251.7
1290.3
1345.3
1383.8
1434.0
1457.1
1501.5
1601.8
1630.7
1680.8
2851.6
2923.9
3273.0
3432.1
N
H
OO
NH
H
NH
NO2
OCl CH3CH3 CH3
MDR-96
Type Vibration mode
Frequency
Cm-1
Amine -NH2 Str. 3432.1
Methyl
C-H Str. (asym.) 2923.9
C-H Str. (sym.) 2851.6
Amide
 >C=O str. 1680.8
>C-N str. 1501.5
Aromatic
>C=C ring skeleton
vib.
1434.0
1457.1
O.O.P. Bending
Vib. (1,2-di sub.)
747.4
Sample Technique: KBr Pallet
Instrument: SHIMASZU FT IR-8400
Frequency Range: 400-4000 cm-1
IR spectrum of 2,6-dimethyl-3-(2-chlorophenyl carbamoyl)5-(2-
methoxyphenyl carbamoyl)-4-(3-nitrophenyl)-1,4-dihydropyridine.
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0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmMDR-100
 438.8
 682.8
 743.5
 779.2
 795.6
 903.6
1004.8
1020.3
1083.9
1120.6
1220.9
1243.0
1316.3
1346.2
1383.8
1436.9
1494.7
1518.8
1585.4
1629.7
1683.7
2341.4
2852.5
2922.0
3256.6
3433.1
N
H
OO
NH
H
NH
NO2
Cl
CH3
CH3 CH3 CH3
MDR-100
Type Vibration mode
Frequency
Cm-1
Amine -NH2 Str. 3433.1
Methyl
C-H Str. (asym.) 2922.0
C-H Str. (sym.) 2852.5
Amide
 >C=O str. 1683.7
>C-N str. 1518.8
Aromatic
>C=C ring skeleton
vib.
1436.9
1494.7
O.O.P. Bending
Vib.
682.8
743.5
795.6
Sample Technique: KBr Pallet
Instrument: SHIMASZU FT IR-8400
Frequency Range: 400-4000 cm-1
IR spectrum of 2,6-dimethyl-3-(2-chlorophenyl carbamoyl)5-(2,3-
dimethylphenyl carbamoyl)-4-(3-nitrophenyl)-1,4-dihydropyridine.
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0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmMDR-112
 442.6
 534.2
 578.6
 679.9
 747.4
 774.4
 901.7
 938.3
1003.9
1021.2
1056.0
1083.9
1221.8
1314.4
1345.3
1383.8
1435.91474.
1495.7
1516.9
1592.1
1631.7
1681.8
2853.5
2921.0
3251.8
3431.1 N
H
OO
NH
H
NH
NO2
Cl
CH3
CH3 CH3
MDR-112
Sample Technique: KBr Pallet
Instrument: SHIMASZU FT IR-8400
Frequency Range: 400-4000 cm-1
Type Vibration mode
Frequency
Cm-1
Amine -NH2 Str. 3431.1
Methyl
C-H Str. (asym.) 2921.0
C-H Str. (sym.) 2853.5
Amide
 >C=O str. 1681.8
>C-N str. 1592.1
Aromatic
>C=C ring skeleton
vib.
1443.5
1495.7
O.O.P. Bending
Vib. (1,2-di sub.&
1,3-di sub.)
979.9
747.4
774.4
IR spectrum of 2,6-dimethyl-3-(2-chlorophenyl carbamoyl)-5-(3-
methylphenyl carbamoyl)-4-(3-nitrophenyl)-1,4-dihydropyridine.
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0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmMDR-113
 407.0
 444.6
 507.2
 688.5
 737.7
 776.3
 820.7
1013.5
1090.7
1226.6
1321.1
1348.1
1384.8
1396.4
1435.9
1488.9
1591.2
1609.5
1630.7
1684.7
2856.4
2920.0
3275.9
3431.1
N
H
OO
NH
H
NH
NO2
Cl
CH3
CH3 CH3
MDR-113
Sample Technique: KBr Pallet
Instrument: SHIMASZU FT IR-8400
Frequency Range: 400-4000 cm-1
Type Vibration mode
Frequency
Cm-1
Amine -NH2 Str. 3431.1
Methyl
C-H Str. (asym.) 2920.0
C-H Str. (sym.) 2856.4
Amide
 >C=O str. 1684.7
>C-N str. 1591.2
Aromatic
>C=C ring skeleton
vib.
1435.9
1488.9
O.O.P. Bending
Vib. (1,3-di sub.&
1,4-di sub.)
688.5
737.7
776.3
820.7
IR spectrum of 2,6-dimethyl-3-(4-chlorophenyl carbamoyl)-5-(3-
methyphenyl carbamoyl)-4-(3-nitrophenyl)-1,4-dihydropyridine.
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20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmMDR-120
 408.9
 443.6
 534.2
 749.3
 773.4
 791.7
 912.3
1004.8
1022.2
1056.0
1083.9
1221.8
1262.3
1294.1
1313.4
1345.3
1383.8
1436.9
1474.5
1496.7
1585.4
1631.7
1690.5
2855.4
2921.0
3080.1
3297.1
3430.2
N
H
OO
NH
H
NH
NO2
Cl
CH3
CH3 CH3 CH3
MDR-120
Sample Technique: KBr Pallet
Instrument: SHIMASZU FT IR-8400
Frequency Range: 400-4000 cm-1
Type Vibration mode
Frequency
Cm-1
Amine -NH2 Str. 3430.2
Methyl
C-H Str. (asym.) 2921.0
C-H Str. (sym.) 2855.4
Amide
 >C=O str. 1690.5
>C-N str. 1585.4
Aromatic
>C=C ring skeleton
vib.
1436.9
1474.5
O.O.P. Bending
Vib.
749.3
773.4
791.7
IR spectrum of 2,6-dimethyl-3-(2-chlorophenyl carbamoyl)-5-(2,3-
dimethylphenyl carbamoyl)-4-(3-nitrophenyl)-1,4-dihydropyridine
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10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmMDR-124
 420.5
 452.3
 471.6
 682.8
 744.5
 794.6
 898.8
1002.9
1027.0
1084.9
1119.6
1223.7
1260.4
1288.4
1316.3
1344.3
1383.8
1433.01457.1
1494.7
1519.8
1579.6
1630.7
1683.7
2831.3
2922.0
3244.0
3428.2
N
H
OO
NH
H
NH
NO2
O
CH3
CH3 CH3CH3 CH3
MDR-124
Sample Technique: KBr Pallet
Instrument: SHIMASZU FT IR-8400
Frequency Range: 400-4000 cm-1
Type Vibration mode
Frequency
Cm-1
Amine -NH2 Str. 3428.2
Methyl
C-H Str. (asym.) 2922.0
C-H Str. (sym.) 2831.3
Amide
 >C=O str. 1683.7
>C-N str. 1519.8
Aromatic
>C=C ring skeleton
vib.
1457.3
1494.7
O.O.P. Bending
Vib. (1,2-di sub.&
1,3-di sub.)
682.8
744.5
794.6
IR spectrum of 2,6-dimethyl-3-(2-methoxyphenyl carbamoyl)-5-(2,5-
dimethylphenyl carbamoyl)-4-(3-nitrophenyl)-1,4-dihydropyridine
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MDR-100
N
H
CH3 CH3
OO
NH
H
NH
NO2
CH3
CH3
Cl
N
H
CH3 CH3
OO
NH
H
NH
NO2
CH3
CH3
Cl
MDR-100
300 MHz 1H NMR spectrum of 2,6-dimethyl-3-(2-chlorophenyl carbam-
oyl)5-(2,3-d imethy lphenylcarbamoyl ) -4 - (3 -n i t rophenyl ) -1 ,4 -
dihydropyridine.
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12
11
13
10
14
15
4
35
26
N
H
1
CH3
18
16 8
CH3
7
O
9
O
17
NH
27
28
29
33
30
32
31 H
4a
NH
19
20
25
21
24
22
23
NO2
26
CH3
35
CH3
36
Cl
34
MDR-100
No.
Chemical Shift in
(d ppm)
Multiplicity No. of protons
J value
(Hz)
1 1.829 s 3H (36)
2 1.875 s 3H (35)
3 2.153 s 3H (18)
4 2.209 s 3H (7)
5 5.314 s 1H (4a)
6 6.887 m 1H (32) J= 8.1
7 6.933 m 1H (33) J= 7.5
8 6.958 m 1H (24) J= 3
9 6.985 m 1H (23) J= 3
10 7.021 m 1H (22) J= 3.3
11 7.043 m 1H (25) J= 3.3
12 7.064 m 1H (30) J= 3
13 7.602 t 1H (14) J= 7.8
14 7.749 d 1H (15) J= 7.5
15 8.045 d 1H (13) J= 0.9 & 8.1
16 8.072 m 1H (11) J= 8.1
17 8.178 m 1H (27) J= 1.8 & 8.1
18 8.829 s 1H (19)
19 8.902 s 1H (1)
Assignment of proton values of each proton of MDR-100 is carried
out as mentioned in Table-3.9.
Table-3.9
Chapter-3
Synthesis of some unsymm....
 143
MDR-101
N
H
CH3 CH3
OO
NH
H
NH
NO2
Cl
Cl
N
H
CH3 CH3
OO
NH
H
NH
NO2
Cl
Cl
MDR-101
300 MHz 1H NMR spectrum of 2,6-dimethyl-3-(2-chlorophenyl carbam-
oyl)-5-(4-chlorophenylcarbamoyl)-4-(3-nitrophenyl)-1,4-dihydropyridine.
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12
11
13
10
14
15
4
53
62
N
H
1
CH3
7
8 16
CH3
18
O
17
O
9
NH
19
20
21
25
22
24
23 H
4a
NH
27
28
33
29
32
30
31
NO2
26
Cl
34
Cl
35
MDR-101
No.
Chemical Shift in
(d ppm)
Multiplicity
No. of
protons
1 2.100 s 3H (18)
2 2.167 s 3H (7)
3 5.4 s 1H (4a)
4 7.047 m 1H (24)
5 7.063 m 1H (23)
6 7.108 m 1H (25)
7 7.134 m 1H (22)
8 7.273 m 1H (33)
9 7.301 m 1H (29)
10 7.559 m 1H (32)
11 7.584 m 1H(30)
12 7.717 m 1H(14)
13 8.011 m 1H (15)
14 8.129 d 1H (13)
15 8.265 s 1H (11)
Assignment of proton values of each proton of MDR-101 is carried
out as mentioned in Table-3.10
Table-3.10
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MDR-102
MDR-102
N
H
CH3 CH3
OO
NH
H
NH
NO2
O
CH3
Cl
N
H
CH3 CH3
OO
NH
H
NH
NO2
O
CH3
Cl
300 MHz 1H NMR spectrum of 2,6-dimethyl-3-(4-chlorophenyl carbamoyl)-
5-(2-methoxyphenylcarbamoyl)-4-(3-nitrophenyl)-1,4-dihydropyridine.
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No.
Chemical
Shift in
(dppm)
Multiplicity
No. of
protons
J Value
(Hz)
1 2.144 s 3H (7)
2 2.155 s 3H (18)
3 3.675 s 3H (35)
4 5.109 s 1H (4a)
5 6.883 d 1H (22) J= 11.4
6 6.933 t 1H (24) J= 6.6
7 7.716 t 1H (23) J= 7.8
8 7.259 m 1H (33)
9 7.270 m 1H (29)
10 7.282 m 1H (32)
11 7.335 m 1H (30)
12 7.346 m 1H (15)
13 7.501 t 1H (14) J= 7.8
14 7.638 d 1H (13) J= 7.8
15 7.926 s 1H (11)
16 7.993 m 1H (25)
17 8.111 m 1H (27)
18 8.170 m 1H (19)
19 8.476 s 1H (1)
12
11
13
10
14
15
4
53
62
N
H
1
CH3
7
8 16
CH3
18
O
17
O
9
NH
19
20
21
25
22
24
23 H
4a
NH
27
28
33
29
32
30
31
NO2
26
O
34CH3
35
Cl
36
MDR-102
Assignment of proton values of each proton of MDR-102 is carried
out as mentioned in Table-3.11
Table-3.11
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MDR-103
N
H
CH3 CH3
OO
NH
H
NH
NO2
CH3
Cl
N
H
CH3 CH3
OO
NH
H
NH
NO2
CH3
Cl
MDR-103
300 MHz 1H NMR spectrum of 2,6-dimethyl-3-(4-chlorophenyl carbam-
oyl)-5-(2-methylphenylcarbamoyl)-4-(3-nitrophenyl)-1,4-dihydropyridine.
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No.
Chemical
Shift in
(d ppm)
Multiplicity
No. of
protons
J Value
(Hz)
1 1.870 s 1H (34)
2 2.103 s 1H (7)
3 2.175 s 1H (18)
4 5.273 s 1H (4a)
5 7.010 m 1H (24)
6 7.031 m 1H (23)
7 7.044 m 1H (22)
8 7.063 m 1H (14)
9 7.270 d 1H (33) J= 9
10 7.300 d 1H (29) J= 9
11 7.536 m 1H (30) J= 5.7
12 7.555 m 1H (32) J= 1.8
13 7.561 m 1H (25) J= 6
14 7.695 d 1H (13) J= 7.8
15 8.009 d 1H (15) J= 7.8
16 8.133 s 1H (11)
17 8.250 s 1H (27)
18 8.913 s 1H (19)
19 9.585 s 1H (1)
12
11
13
10
14
15
4
53
62
N
H
1
CH3
7
8 16
CH3
18
O
17
O
9
NH
19
20
21
25
22
24
23 H
4a
NH
27
28
33
29
32
30
31
NO2
26
CH3
34
Cl
35
MDR-103
Assignment of proton values of each proton of MDR-103 is carried
out as mentioned in Table-3.12
Table-3.12
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N
H
CH3 CH3
OO
NH
H
NH
NO2
O
CH3
CH3
MDR-110
MDR-110
N
H
CH3 CH3
OO
NH
H
NH
NO2
O
CH3
CH3
300 MHz 1H NMR spectrum of 2,6-dimethyl-3-(2-methylphenyl carbam-
oy l ) -5 - (2 -meth o x ypheny lcarbamoy l ) -4 - (3 -n i t ropheny l ) -1 ,4 -
dihydropyridine.
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No.
Chemical Shift
in
(d ppm)
Multiplicity No. of protons
1 2.071 s 1H (36)
2 2.231 s 1H (18)
3 2.279 s 1H (7)
4 3.689 s 1H (35)
5 5.134 sm 1H (4a)
6 6.792 m 1H (31)
7 6.834 m 1H (32)
8 6.936 m 1H (24)
9 6.970 m 1H (23)
10 7.153 m 1H (25)
11 7.338 m 1H (22)
12 7.392 s 1H (30)
13 7.557 m 1H (33)
14 7.589 m 1H (14)
15 7.699 m 1H (13)
16 7.940 m 1H (15)
17 7.966 m 1H (11)
18 8.046 s 1H (27)
19 8.441 s 1H (19)
20 9.521 s 1H (1)
12
11
13
10
14
15
4
35
26
N
H
1
CH3
18
16 8
CH3
7
O
9
O
17
NH
27
28
29
33
30
32
31 H
4a
NH
19
20
25
21
24
22
23
NO2
26
O
34 CH3
35
CH3
36
MDR-110
Assignment of proton values of each proton of MDR-110 is carried
out as mentioned in Table-3.13
Table-3.13
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N
H
CH3 CH3
OO
NH
H
NH
NO2
OCl
CH3
MDR-96
M.Wt = 532.97
FAB Mass spectrum of 2,6-dimethyl-3-(2-chlorophenyl carbamoyl)-5-(2-methoxylphenyl carbamoyl)-4-(3-nitrophenyl)-
1,4-dihydropyridine.
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N
H
CH3 CH3
OO
NH
H
NH
NO2
CH3
CH3
CH3
MDR-99
M.wt: 510 gm/mol
FAB Mass spectrum of 2,6-dimethyl-3-(2,4-dimethylphenyl carbamoyl)-5-(2-methylphenyl carbamoyl)-4-(3-nitrophenyl)-
1,4-dihydropyridine
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N
H
CH3 CH3
OO
NH
H
NH
NO2
O
CH3
Cl
MDR-97
M.Wt = 516.97 gm/mol
FAB Mass spectrum of 2,6-dimethyl-3-(4-chlorophenyl carbamoyl)-5-(2-methoxylphenyl carbamoyl)-4-(3-nitrophenyl)-
1,4-dihydropyridine
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N
H
CH3 CH3
OO
NH
H
NH
NO2
O
CH3
CH3
MDR-110
M.wt: 512 gm/mol
FAB Mass spectrum of 2,6-dimethyl-3-(2-methoxyphenyl carbamoyl)-5-(2-methylphenyl carbamoyl)-4-(3-nitrophenyl)-
1,4-dihydropyridine
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N
H
CH3 CH3
OO
NH
H
NH
NO2
CH3
Cl
MDR-103
M.wt: 516 gm/mol
FAB Mass spectrum of 2,6-dimethyl-3-(4-chlorophenyl carbamoyl)-5-(2-methylphenyl carbamoyl)-4-(3-nitrophenyl)-
1,4-dihydropyridine
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MDR-113
M.Wt = 516.97 gm/mol
FAB Mass spectrum of 2,6-dimethyl-3-(4-chlorophenyl carbamoyl)-5-(3-methyllphenyl carbamoyl)-4-(3-nitrophenyl)-
1,4-dihydropyridine.
N
H
CH3 CH3
OO
NH
H
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Introduction:
As we have shown in Chapter-1 and Chapter-3,  4-phenyl
substituted-1,4-dihydropyridines of the nifedipine type analogs are the
most explored class of organic calcium channel modulators and since
their introduction into clinical medicine in 1975, have become almost
indispensable for the treatment of cardiovascular diseases. Many DHP
analogs have now been synthesized and numerous second-generation
commercial products have appeared on the market (II). In recent years
in terest  has a lso focused on aza-analogs such as 4-Ary l -1 ,4-
dihydropyrimidines of the nifedipine type (DHPMs) (III). The new aza clas
s of such drugs are also expected to have same pharmacological and
possible use in the treatment of cardiovascular diseases such as
hypertension, cardiac arrhythmias or angina1.
N
H
O
O
CH3
O
O
CH3
CH3 CH3
NO2
N
H
O
OO
MeO
NO2
R
CH3 CH3
1, Nitrendipine R= CH2CH3
2, Nicardipine R= CH2CH2N(CH3)C6H5
Nifedipine
1. Janis, R. A.; Silver, P. J., Triggle, D. J.; Adv. Drug Res. 16, 309, 1987.
(I)
(II)
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More than 20 years after the introduction of nifedipine(I), many
DHP analogs have now been synthesized and numerous second-
generation commercial products have appeared on the market (e.g. II &
III)2. In recent years interest has also focused on aza-analogs such as
d ihydropyr imid ines ( I I I )  (DHPMs)  which show a very  s imi lar
pharmacological profile to classical dihydropyridine calcium channel
modulators3-8. Over the past few years several lead-compounds have been
developed (e.g. SQ 32926 (III) and SQ 32547(IV)). Furthermore, several
marine alkaloids with interesting biological activities containing the
dihydropyrimidine-5-carboxylate core have been studied extensively to
expand the existing structureactivity relationships and to get further insight
into molecular interactions at the receptor level3-8.
2. Bossert, F., Vater, W. Med. Res. Rev. 9, 291, 1989.
3. Cho, H. Ueda, M.et al. J. Med. Chem. 32, 2399. 1989.
4. Atwal, K.S.et al,:  J. Med. Chem. 33, 1510, 1990.
5. Atwal, K. S.; J. et al,; Med. Chem. 33, 2629, 1990.
6. Atwal, K. S.; J. Med. Chem.34, 806, 1991.
7. Rovnyak, G. C.; . J. Med. Chem. 35, 3254, 1992, .
8. Grover, G. J.; J. Cardiovasc. Pharmacol. 26, 289, 1995.
N
N
H
S
O
O
N
CH3
O
O
i-Pr
F
SQ-32547(IV)
N
N
H
O
NH2
O
CH3
CH3 O
NO2
CH3
SQ-32926(III)
Many approches are devloped for the synthesis of pyrimidine class of
compounds but the pioneer work was carried out by the German scien-
tist who played a provital role in devloping multicomponent reactions
and few of them are known as Ugi four component reaction.
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Concept of Multicomponent reaction (MCRs) and it ‘s classes in brief.
In MCRs, “three or more reactants come together in a single
reaction vessel to form products that contain port ions of al l  the
components.”
9. Kappe, C. O. Acc. Chem. Res. 2000, 33, 879.
History of MCRs
First ‘ officially’ reported MCR was the Strecker synthesis of a-amino
crotononitrile in 1850.  A large portion of MCR chemistry has developed
from isocyanides Pioneering contribution was carried out by Ivar Ugi with
his discovery of the Ugi four component reaction.
Well known name reactions of MCRs:
They can be classified as under.
R H
O
+ NH3 + HCN
R CN
NH2
Strecker, A., Liebigs Ann.Chem. 75, 27, 1850
Arend, B. Westerman, N.; Risch, N; Angew. Chem. 110, 1096, 1998.
CH3
CH3 O
O
2 + NH3 +
CHO
N
H
CH3 CH3
COOCH3H3COOC
Hantzsch, A. Justus Liebegs Ann. Chem. 215, 1, 1882.
(2) Hantzsch Dihydropyridine synthesis (1882).
(1) Streker Synthesis (1838 first reported by laurent & gerhard,
1850 by streker).
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(3) Radziszewski Imidazole synthesis (1882).
(4) Hantzsch Pyrrole synthesis (1890).
CH3
CH3 + CH2O + MeNH2 + NH3
N
N
CH3
CH3
CH3
Radziszewski, B., Ber.Dtsch.Chem.Ges. 15, 1499, 1882.
OHC
COOC2H5+
NH2
+
H5C2OOC
Br
O
CH3
N
H5C2OOC COOC2H5
CH3CH3
Hantzsch, A., Ber. Dtsch. Chem.ges. 23, 1474, 1890.
NH2 NH2
O
COOC2H5
CH3
O +
CHO
NH
N
H
O
H5C2OOC
CH3
Biginelli, P., Gazz. Chim.Ital. 23, 360-413, (1893).
Kappe, O. Acc Chem Res. 33, 879, 2000.
(5) Biginelli reaction (1891).
(6) Mannich Reaction (1912).
CH3 CH3
O
+
CH2O
MeNH2 CH3
O
N
CH3
O
CH3CH3 CH3
Mannich, C.; Krosche, W. Arch Pharm. 250, 647, 1912.
Bur, S.K.; Martin, S.F. Tetrahedron, 57, 3221 (review).
martin, S.F., Acc. Chem. Res. 35, 895, 2002.
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(7) Bucherer-Bergs Hydantoin synthesis (1929).
N
N
H
O O
CH3
NHN
O
O
CH3
O
+ NH3 CO2+ +HCN N
H
NH
O
O
T T
T= Tiamine
Bucherer,T., ; Brasch,H; J.Prakt.Chem. 140, 151, 1934.
Kabik,S., Meisner,R.S., Rebek, J.; Tetrahedron Lett. 36, 6635, 1994.
(8) Robinsons synthesis of tropinone (1917).
OHC
CHO +
CH3NH2
H3COOC COOCH3
NCH3
O
COOCH3
COOCH3
Robinson, R.J.; J.Chem Soc. (London), 111, 876, 1917.
(8) Passerini Reaction (1921).
R1
OH
O
+ R2CHO+ R3NC R1 O NHR3
O
R2O
Passerini, M., Gazz. Chim.Ital. 53, 331, 1923.
(8) The Ugi reaction (1959).
R1 CHO+ R2-COOH + R3NC+ R4NH2
R2 N
R1
NH
R3
O
R4
O
Ugi, I., Horl,W., Hanusch, C., Schmid, T.; herdtweck, E. Heterocycles,
47, 985, 1998.
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Possible Synthetic Manipulation in Dihydropyrimidine moiety.
What is the possibilities of the modification in the ring of DHPM??
Looking forward to the structureof the DHPM ring, it require folowing
modification in it’s structure for generating new molecules for further
screening. So many, scientists have synthesized huge libraries for the
screening of new molecules.
(1) Partial of full oxidation (not trivial)
(2) Reduction of the ring to the hexahydropyrimidine
(3) Alkylation and acylation of the heteroatoms
(4) Manipulation of the ester at C(5)
(5) Manipulation of the methyl group at C(6) (halogenation, nitration,
sulphonation etc.)
(6) Ring condensing reactions to make bi, tri-cycles
NH
N
H
OCH3
OH
OCH3
1
2
3
45
6
(V)
10. Alexander,  Stadler and C. Oliver Kappe., J. Comb. Chem. 3, 624-630, 2001.
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Biological Profile of DHPM :-
Some calcium antagonists such as nifedipine and verapamil have
been used as antihypertensive agents. However, nifedipine and verapamil
have a serious disadvantage in the treatment of hypertension. Since their
plasma half-lives are relatively short, these drugs must be administered
repeatedly to achieve enough clinical efficacy, and the multiple dosages
lower compl iance. 11 Therefore, we approached the problems by
synthesizing new types of compounds that have long-lasting hypotensive
or antihypertensive activity.
Since 1967, variety of dihydropyridine derivatives have been
synthesized in the search for more potent vasodilating compounds with
longer duration of action. Recently, Bayer A. G. synthesized analogues
of the dihydropyridine skeleton itself, for instance, dihydropyran,
dihydrothiopyran, dihydropyridazine, and dihydropyrazine.,because of the
structural similarity between dihydro pyridine and dihydropyrimidine, we
became interested in the synthesis and pharmacological activities of
pyrimidine class12.
11. Buhler, F. R.; Hukthen, U. L.; Kiowski, W. J . Cardiouasc. Pharmacol. 4, 350,
1982, .
12. Belz, G. G.; Spies, G.; Excerpta Med. 177, 1986.
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DHP calcium channel antagonists (e.g. (VI), nifedipine) are flexible
molecules, in which the C4-aryl moiety and the C3/C5 ester substituents
can rotate, and the conformation of the 1,4-dihydropyridine ring can
change 14.   Besides th is ,  many s tud ies on the s t ructure-act iv i ty
relationships for DHPs and DHPMs with respect to calcium channel
antagonist-agonist modulation were carried out more recently.
N
H
O
O
CH3
O
O
CH3
CH3 CH3
NO2
Nifedipine
N
N
H
O
NH2
O
CH3
CH3 O
NO2
CH3
SQ-32926
There s t i l l  remains debate on the exact  s tereochemica l /
conformational requirements for activity13-16. It was recently proposed that
calcium channel modulation (antagonist vs. agonist activity) is dependent
on the absolute configuration at C4, whereby the orientation of the 4-aryl
group (R- versus S-enantiomer) acts as a “molecular switch” between
antagonist and agonist activity13. In the receptor-bound conformation, the
substituted aryl ring should be positioned axially, perpendicular to, and
bisecting the boat-like dihydropyridine ring, with the 4-aryl substituent
(X) prefering the synperiplanar (sp) orientation relative to C4-H (Figure
1)13.
(VI) (VII)
13. (a) Rovnyak, G. C.; Kimball, S. D.; Beyer, B.; Cucinotta, G.; DiMarco, J. D.;
Gougoutas, J.; Hedberg,A.; Malley, M.; McCarthy, J. P.; Zhang, R.; Moreland,
S. J. Med. Chem., 38, 119, 1995.
(b)Triggle, D. J.; Padmanabhan, S. Chemtracts: Org. Chem., 8, 191, 1995.
14. Review: Goldman, S.; Stoltefuss, J. Angew. Chem., Int. Ed. Engl., 103, 1587,
1991.
15.      Schleifer, K. J. J. Med. Chem., 42, 2204, 1999.
16. (a) Striessnig, J.; Grabner, M.; Mitterdorfer, J.; Hering, S.; Sinnegger, M.;
Glossmann, H. Trends Pharmacol. Sci., 19, 108, 1998 . (b) Review: Goldman,
S.; Stoltefuss, J. Angew. Chem. Int. Ed. Engl., 103, 1587, 1991.
Dihydropyrimidine derivative by Biginelli reaction..
 
165
Chapter-4
H
CH3
N
O
R O
H
..
XX = sp
hydrogen bond
(essential)
(non-essential)
Right-hand side
aryl down-agonist
aryl up-antagonist
Atwal  K. S. et al.17 worked in this area and have resulted  in the
discovery of dihydropyrimidines (VIII) and (IX) as potent adrenoreceptor
antagonists
N
N
R2
R3
CH3
R1COO
R4
N
NCl
CH3
EtOOC
CH3 CH3
NaOOC
Dhanapalan N. et al18  prepared dihydropyrimidinones such as
compound (X) which exhibited high binding affinity and subtype selectivity
for the cloned human a1a receptor. Systematic modifications of (X) led
to identification of highly potent and subtype-selective compounds such
as (XI) with high binding affinity (K1 ) 0.2 nM) for a1a receptor and greater
than 1500-fold selectivi ty over a1b and a1d adrenoceptors. The
compounds were found to be functional antagonists in human, rat, and
dog prostate tissues.
(Figure-1)
(VIII) (IX)
17. Karnail S. Atwal, Syed Z. Ahmed, J. Eileen Bird, Carol L. Delaney, Kenneth E.
Dickinson, Francis N. Ferrara, Aners Hedberg, Arthur V. Miller, Suzanne
Moreland, Brian C. O’Reilly, Thomas R. Schaeffer, Thomas L. Walddron, Harold
N. Weller. .  J. Med. Chem., 35, 4751-4763, 1992.
18. Dhanapalan, Nagarathnam.; J. Med. Chem., 2, 4764-4777, 1999.
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One compound exhibited excellent selectively to inhibit intraurethral
pressure (IUP) as compared to lowering diastolic blood pressure (DBP)
in mongrel dogs (Kb(DBP)/Kb(IUP) )= 40) suggesting uroselectivity for
a1a-selective compounds
18 (X & XI).
N
N
H
CH3
O
O
CH3 N
O
NO2
O
N
Ph
COOMe
H
H
N
N
H
O
H2N N
O
NO2
O
N
Ph
COOMe
CH3
H
H
Murali et al19  synthesised several DHPM-one analogues. Among
these many compounds give excellent selectivity (>880-fold) over a1b
and a1d, also showed good selectivity over several other recombinant
human G-protein coupled receptors. These compounds showed good
functional potency in isolated human prostate t issues, with Kbs
comparable to their in vitro a1a binding data. In addition, compound (+)-
(XII) also exhibited good uroselectivity (DBP Kb/ IUP Kb > 20-fold) in the
in vivo experiments in dogs.
N
N
H
O
H2N N
O
F
O
N
Ph
CN
CH3
F
H
(X)
(XI)
(XII)
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James and coworkers 20 repor ted the  DHPM wi th  4-
aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via
a C-5 amide as selective a1a receptor subtype antagonists.  Many of
these compounds were also  evaluated in vivo and found to be more
potent than terazosin in both a rat model of prostate tone and a dog
model of intra-urethral pressure without significantly affecting blood
pressure. While many of the compounds tested, displayed poor
pharmacokinetics, compound (XIII) was found to have adequate
bioavailability (>20%) and half-life (>6 h) in both rats and dogs.
NH
N
H
F
O
F
O
CH3
O
NN
F
(XIII)
19. T. G. Murali Dhar, ;   J. Med. Chem., 42, 4778-4793, 1999.
20. James, C. Barrow., P.;  J. Med. Chem., 43, 2703-2718, 2000.
21. Bharat, Lagu. ;  J. Med. Chem., 42, 4794-4803, 1999.
Bharat L. et al21 identify that compound (XIV) was a lead compound
with a binding and functional profile comparable to that of SI=103. The
putative  metabolite 2-carboxamidophenylpiperazine has negligible affinity
for the m-opioid receptor.
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N
N
H
MeOOC
N
O
F
O
N
N
CH3
F
CONH2
H H
Many natural alkloids were seperated by Frederickk C. et  al22   and
they found the nove l  s t ruc tures  o f  compounds which conta in
polyguanidine class of alkaloids isolated from the red Caribbean sponge
Batzella sp.23.  Structural feature of the batzelladines, with these tricyclic
units occurring with both the syn and anti stereorelationships of the
angular hydrogens that flank the pyrrolidine nitrogen.23,24. The compounds
shown activity against protein gp-120 to the human CD4 receptor23,25-31.
N
+
N N
H
HH
O
O
NNH2
NH2
H
CH3
CH3
H
N
+
N N
H
(CH2)8CH3
HH
O
O
( )6
CH3
NHN
NH2
H2NCNH(H2C)4O O
+
NH2
(XIV)
(XV)
(XVI)
22. Frederick Cohen, Larry E. Overman, Sylvie K. Ly Sakata.; Organic Letters, 1(13),
2169-2172, 1999.
23. (a) Patil, A. D.; Kumar, N. V.; Kokke, W. C.; Bean, M. F.; Freyer, A. J.; Debrosse,
C.; Mai, S.; Truneh, A.; Faulkner, D. J.; Carte, B.; Breen, A. L.; Hertzberg, R. P.;
Johnson, R. K.; Westley, J. W.; Potts, B. C. M. J.Org. Chem.,  60, 1182-1188,
1995. (b) Patil, A. D.; Freyer, A. J.; Taylor, P. B.; Carte, B.; Zuber, G.; Johnson,
R. K.; Faulkner, D. J. J. Org. Chem., 62, 1814-1819, 1997.
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24. Snider, B. B.; Chen, J.; Patil, A. D.; Freyer, A. J. Tetrahedron Lett., 37, 6977-
6980, 1996.
25. Gomes, R.; Berlinck, S. Prog. Chem. Org. Nat. Prod., 66, 119, 1995
26. Berlinck, R. G. S. Nat. Prod. Rep., 377 , 1996.
27. Greenhill, J. V.; Pharm, B.; Lue, P. Prog. Med. Chem., 30, 203,  1993.
28.      Sweet, R. W.; Truneh, A.; Hendrickson, W. A. Cum. Opin.Biotech., 2, 622-633,
1991.
29. Ryu, S. E.; Kwong, P. D.; Truneh, A.; Porter, T G.; Arthos, J.; Rosenberg, M.;
Dai, X.; Xuong, N.; Axel, R.; Sweet, R. W.; Hendrickson, W. A. Nature., 348,
418-426, 1991.
30. Culp, J. S.; Johansen, H.; Hellmig, B.; Beck, J.; Matthews, T. J.; Delers, A.;
Rosenberg, M. BiolTechnology., 9, 173-177, 1991.
31.  Dean, K. C.; MacDougal, J. S.; Inacker, R.; Folena-Wasserman, G.; Arthos, J.;
Rosenberg, J.; Maddon, T J.; Axel, R.; Sweet, R. W. Nature., 331, 82-84,  1988.
32. Duschinsky, R.; Gabriel, T.; Tautz, W.; Nussbaum, A. W.; Hoffer, M.; Grunberg,;
E. J. Med. Chem., 10, 47, 1967.
33. Bernardinelli, G.; Benhamza, R.; Tronchet, J. M. ; Acta. Cryst., C45, 1917, 1989.
34. (a) Chang, C.; Roth, B. In Some Pyrimidines of Biological and Medicinal Interest
II, Progress in Medical Chemistry; Butterworths: London, 7, 311, 1970.
In literature, 5,6-Dihydropyrimidine nucleosides have attracted
attention as the potential antitumor agents32,33 Antiviral and  physiological
dihydro nucleosides play an important role in nucleic acid metabolism
and appear frequently in the sequence of tRNA34.  It was also found that
5,6-dihydropyrimidine nucleosides (XVII & XVIII) serve as slow releasers
(prodrugs) of the parent nucleosides in vivo and were stable to glycosidic
bond cleavage.
NH
N
O
OH
R1
X
R
O
R2
OH
NH
N
O
OH
N3
X
R
O
OH
OH
(XVII) (XVIII)
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NH
N O
O
O CH3
CH3
CH3
MKC-442
NH
N O
O
CH3
O
S
OHHETP TNK-651
NH
N O
O
O
CH3
CH3
Rakesh Kumar and coworkers 34b synthesized, cytotoxic activities
and antiviral, and  of 5-substituted-6-azido-5,6-dihydro-2-deoxyuridine
(XIX) and thymidine (XX & XXI). Compounds (XIX) and (XX) exhibited a
broad spectrum of antiherpes activity against (HSV-1, HSV-2, HCMV, and
VZV).
(XIX) (XX)
(XXI)
34. (b)Kumar, R. Bioorganic & Medicinal Chemistry Letters, 12, 275–278, 2002.
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Despite the importance and current interest in dihydropyrimidines,
the mechanism of the classical three-component Biginelli condensation
has not been elucidated with certainty and remains disputed35. Early work
by Folkers and Johnson suggested that N,N- benzylidenebisurea, i.e.
the primary bimolecular condensation product of benzaldehyde and urea,
is the first intermediate in this reaction36. Later, Sweet and Fissekis have
proposed a different mechanism postulating that carbenium ion,  produced
by an acid-catalyzed aldol  react ion of  benzaldehyde with ethyl
acetoacetate, is the key intermediate and is formed in the first and limiting
step of the Biginelli reaction37.
To decide which of the two fundamentally different mechanistic
proposals is correct Kappe C. O.38 carried out a detailed reinvestigation
of the mechanism of the Biginelli  condensation using 1H and 13C NMR
spectroscopy to identify possible intermediates.
As already suggested by Folkers and Johnson,36 it is very likely
that this threecomponent condensation proceeds via one of the three
possible bimolecular reaction pathways from the urea/ aldehyde/
acetoacetate system.
History and background of Biginelli Mechanism:
35. Kappe C. O.Tetrahedron, 49, 6937-6963, 1993.
36. Folkers K.; Johnson T. B. J. Am. Chem. Soc., 55, 3784-3791, 1933.
37. Sweet F.; Fissekis J. D. J. Am. Chem. Soc., 95, 8741-8749, 1973.
38. Kappe C. O.  J. Org. Chem., 62, 7201-7204, 1997.
Dihydropyrimidine derivative by Biginelli reaction..
 
172
Chapter-4
The “carbenium ion mechanism” was proposed by Sweet and Fissekis,37
who investigated the reaction in 1973 and suggested that an acid-
catalyzed aldol condensation is the first and limiting step of the Biginelli
condensation. It was proposed that under acid catalysis benzaldehyde
and ethyl acetoacetate would react in an aldol-type fashion to produce
the corresponding aldol, which dehydrates in the presence of acid to the
resonance-stabilized carbenium ion 137-39.
Interception of cation 1 by urea or N-methylurea then produces
ureides 2, which ultimately cyclized to the Biginelli products 3. The main
argument for the proposed mechanism made by the authors relates to
the fact that acid-catalyzed treatment of independently prepared enone
4 with N-methylurea also produced pyrimidine albeit in moderate yield37.
CH3 O
EtOOC
Ph-CHO
H
+
CH3 O
EtOOC
OH
Ph
H2O
H
+
CH3 O
EtOOC C
H
Ph
+
-H
+
CH3 O
EtOOC
Ph
NH2
N OR
H
CH3 O
EtOOC
NH
Ph
O
NH
R
-H2ONH
N
R
Ph
EtOOC
CH3 O
-H
+
H
+
+
1
2a=H
2b=CH3
3a=H
3b=CH3
   4
According to Sweet and Fissekis, protonation of enone 4 regenerates
the carbenium ion intermediate 1,39which then can react with urea or
38. Folkers K.; Harwood H. J.; Johnson T. B. J. Am. Chem. Soc., 54, 3751-3758
1932.
39. Nielson A. T.; Houlihan W. Org. React. (N.Y.), 16, 1-438,  1968.
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N-methylurea. It was also considered important that in the reaction of
enone 4 with N-methylurea only the N1-methyl derivative 3b was produced
and not the N3-substituted isomer,which corresponds to the regiochemical
outcome observed in the three component Biginelli reaction of ethyl
acetoacetate, benzaldehyde, and N-methylurea 35,36 .
Kappe C. O. et al attempted to observe the acid-catalyzed aldol
reaction of benzaldehyde with ethyl acetoacetate proposed by Sweet and
Fissekis37 under typical Biginelli reaction conditions. Although aldol
reactions are most often catalyzed by base, the possibil i ty of an
acidcatalyzed aldol reaction of benzaldehyde with a 1,3-dicarbonyl
component such as ethyl acetoacetate can not be a prior excluded40.
However, it is well-known that in the case of acid catalysis, the reaction
products of the aldol reaction are in most cases the a,b-unsaturated
carbonyl compounds and not the b-hydroxycarbonyl (aldol) products40.
Upon monitoring the reaction of benzaldehyde and ethyl acetoacetate
in CD3OH/HCl by 
1H and 13C NMR spectroscopy, no evidence for an aldol
reaction or any other reaction between the two components at room
temperature could be obtained. The fact that benzaldehyde and ethyl
acetoacetate do not  react  under condi t ions where the Biginel l i
condensation itself proceeds smoothly rules out the carbenium ion
mechanism, where such a reaction is proposed to be the first step.
The so-ca l led  “ure idocro tonate  mechanism”  was a l ready
considered by Folkers and Johnson36, but was ruled out as a mechanistic
pathway since the bimolecular condensation product of ethyl acetoacetate
40.  Heathcock C. H.; Trost B.M.; Fleming I. Comprehensive Organic Synthesis,  2,
133-179, 1991.
41.  Donleavy J. J.; Kise M. A. Org. Synth., 2, 422-423, 1943.
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and urea, i.e. ureidocrotonate 5a,41 was shown to rapidly hydrolyze under
the typical Biginelli reaction conditions (EtOH, HCl)36. Since the fact that
ureidocrotonate 5a is sensitive to hydrolysis does not exclude this
intermediate for the Biginelli reaction. The independently prepared
enamides 5a,b were shown to rapidly hydrolize in CD3OH when catalytic
amounts of acid (and water) were present While ureidocrotonates can
be prepared from diketones and substitued urea under strictly anhydrous
conditions, i.e. by allowing a mixture of diketone and sub. urea to react
in a desiccator over concentrated H2SO4 for several days,
41,42 it is evident
that under Biginelli reaction conditions the equilibrium is far on the
acetoacetate/urea side.
CH3 O
EtOOC
H
+sub. urea
CH3 N
EtOOC
H
O
N
RH 2 N
N
H
Ph
EtOOC
CH3 O
R
//
5a, R=H
5b, R=CH3
6a, R=H
6b, R=CH3
Another argument against the involvment of an ureidocrotonate
intermediate relates to the fact that Nmethylurea reacts with ethyl
acetoacetate (1) to furnish exclusively regioisomer 5b bearing the N-
methyl substituent at the terminal amino group42. The formation of a
Biginelli dihydropyrimidine in a 5 + 1 cyclocondensation manner from 5b
and benzaldehyde would be expected to lead to the N3-substituted
Biginelli product 6b,43 which is observed neither in the three component
Big inel l i  react ion 35,37,38 nor  f rom the react ion of  ure ide 5b with
benzaldehyde under Biginelli conditions.
42. Senda S.; Suzui A. Chem. Pharm. Bull., 6, 476-479 (1958). Hlousek J.; Machacek
V.; Sterba V. Sb. Ved. Pr., Vys. Sk. Chemickotechnol. Pardubice, 39, 11-25
1978.  Chm. Abstr., 91, 174663n,1979.
43. Kappe C. O.; Roschger P. J. Heterocycl. Chem., 26, 55-64, 1989.
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In both cases, the isomeric dihydropyrimidine 3b is formed as the
exclusive regioisomer, which further supports Folkers and Johnson’s 36
proposition that the Biginelli reaction does not proceed through an
ureidocrotonate intermediate of type 5 and that immediate hydrolysis of
5 takes place, if the reaction is started from such ureidocrotonates.
Finally, Kappe C. O. considered the original mechanistic proposal
made by Folkers and Johnson,36 who suggested that the first step in the
three-component Biginelli condensation is the reaction of benzaldehyde
(2) with urea. When benzaldehyde and urea  were reacted under typical
Biginelli conditions (CH3OH/HCl) at room temperature, the anticipated
condensation product bisureide 7a44 started to precipitate from the
solution within 15-20 min. Bisureide 7a was also formed when equimolar
amounts of the two components were employed, and the analogous
condensation product (7b)45 was produced when N-methylurea was used
instead of urea.
Ph CHO CH
OH
N
H
C
O
N H
R
Ph
H
+
-H2O
H
N
+
H O
N H
R
Ph
H
+
O
N N
H
Ph
N
H
O
N
R
H
H
R
N
Ph
EtOOC
O
H
O NH
R
CH3
-H2O
NH
N
Ph
O
EtOOC
R
CH3
-H
+
sub. urea
sub. urea
7a, R=H
7b, R=CH3
8 9
10a, R=H
10b, R=CH3
11a, R=H
11b, R=CH3
44.  Schiff H. Ann. 151, 186-213,1869. Lu¨ dy, E. Monatsh. Chem., 10, 295-316
1889. Bakibaev A. A.; Tignibidina L. G.; Filimonov V.D.; Gorshkova V. K.;
Saratikov A. S. Khim. Farm. Zh., 25, 31-35,1991. Bakibaev, A. A. Zh. Org.
Khim., 11, 1686-1687,1994.
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However, when these reactions were carried out in the presence
of ethyl acetoacetate (1) under otherwise identical reaction conditions,
bisureides 7a,b were not formed, but dihydropyrimidines 3a,b started to
precipitate slowly from the reaction mixture within 1-2 h (complete
conversion took 2-3 days).
The add i t ion  o f  u reas to  benza ldehyde  leads to  N - (1 -
hydroxybenzyl)-ureas of type 8 via standard nucleophilic addition.
Although this is likely to be an equilibrium reaction, “hemiaminals” 8 are
expected to undergo rapid dehydration in the presence of acid to a
carbenium ion which may be formulated as a highly reactive N-acyliminium
species, i.e. 9. In the absence of the 1,3-dicarbonyl compound a second
equivalent of urea is added to furnish bisureides 7a,b, which due to their
low solubility44, 45 precipitate from the reaction mixture.
45. Schiff H. Ann., 291, 367-377, 1896. See also Koyano, K.; McArthur C. R. Can.
J. Chem., 51, 333-337,1973.
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46. Atwal, K.S.;  J.Org.Chem, 54, 5898, 1989.
The Atwal modification :
The synthesis of ethoxycarbonylated product is complicated not
only by the low yield for the preparation of pyrimidinethione using the
Biginelli condensation’ but also by the lack of regioselectivity in the
reaction of ethylchloroformate. Atwal and coworkers46 envisaged that use
of 2-hetero substituted 1,4-dihydropyrimidines could circumvent these
problems, anticipating the difference in reactivity between the pyrimidine
nitrogens would increase the selectivity of their reaction with an incoming
electrophile . Deprotection of the fully functionalized intermediates  would
lead to the desired products respectively.
R1OOC
CH3 O
H
R1
+ NH2
NH2 X
R2
NaHCO3
DMF
NH
N
H
CH3 H
R2
R1OOC
CH3
Deprotected 
Mostly 60-91% yield
NH
N
H
CH3 H
X
R1OOC
CH3
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Synthesis of DHPM via solid phase
With the help of solid phase synthesis, the acetoacetate building
block is linked to the solid support47. Thus, Biginelli condensation of Wang-
bound acetoacetate with excess aldehydes and ureas in NMP/HCl
provided the desired DHPMs on solid support. Subsequent cleavage with
50% Trifluoroaceticacid (TFA) furnished the free carboxylic acids .
CH3 O
O
O
P
+
O
Ar
H
NH
N
H
OCH3
O
OH
Ar
1. NMP, H
2. TFA, CH2CI2
NH2
NH2 O
+
The resulting polymer-bound urea was condensed with excess b-
ketoesters and aromatic aldehydes in THF at 55 °C in the presence of a
catalytic amount of HCl to afford the corresponding immobilized DHPMs.
Subsequent cleavage of product from the resin by 50% trifluoroacetic
acid  (TFA) provided DHPMs in high yields and excellent purity. The key
condensation step was further studied and optimized with the aid of an
automatic synthesizer demonstrating the solvent dependence of this
process48.
R2 O
O
O
R1 +
O
Ar
H NH
N OR2
O
O
R1
Ar
OH
O
NH2
NH O
O P
O
1. THF, HCI, 55
2. TFA, CH2CI2
oC
47.  Garcia-Valverde M.; Pernat T.; Kappe C. O. Unpublished results.
48.  Hamaker L. K.; Yang K.; Drane J. A.; Peterson, M. L. Proceedings of the Second
Lake Tahoe Symposium on Molecular Diversity,
(Table-4.6)
 (Table-4.7)
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Flours phase modification in Biginelli reaction:
In fluorous synthesis, the initial organic substrate is attached to a
“fluorous label”, which is of sufficient structure, size, and fluorine
content to render the attached organic molecule fluorous49. One or more
reactions are then conducted, and the fluorous components of the reaction
are subsequently separated from all non-fluorous (organic, inorganic,
solid, volatile) components by an appropriate phase separation technique.
R2 O
O
O
R1
+
O
Ar
H
NH2
NH O
O
O
Si(Rfh) 3
NH
N OR2
O
O
R1
Ar
O
O
1. HCl, THF/BTF, 50OC
2. Extraction with FC-72
3. TBAF, THF/GTF
Looking forward to involvement of the solid-phase synthesis
methods described above, libraries of compounds (DHPMs) can be
generated in a relatively straightforward fashion. Biginelli products are
therefore contained in many commercially available small molecule
libraries or compound collections and have undoubtely been subjected
to many high-throughput screening (HTS) processes. However, all of
these products would still be racemic49.
(XXII)
49. Hudlicky M. Chemistry of Organic Fluorine Compounds; Ellis Horwood:
Chichester, U.K., 1992.
(Table-4.8)
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Example of DHPMs with yield improvement by using catalyst.
NH2
NH2
O
R
O
O
R1
+
CHO
NH
N
H
OR
O
R181-95 % yield
Yb (Otf)3
Min Yang and coworkers50 have synthesized the different DHPMs
by using different inorganic salt as a catalyst and they found the yields
of the one-pot Biginelli reaction can be increased from 20 to 50% to 81-
99% while the reaction time was shortened from 18 to 48 h to 20 min. In
addition, the catalyst can be easily recovered and reused. It not only led
to economical automation, but also reduces hazardous pollution to
achieve environmentally friendly processes. This report discloses a new
and simple modification of the Biginelli dihydropyrimidinones synthesis.
By using Yb(OTf)3,  YbCl3, as a catalyst and under solvent free reaction
conditions,  one additional important feature of the present protocol is
the ability to tolerate the variation in all the three components. Besides
this a ketone ester, the aromatic, diketone and heterocyclic diketone  can
also be employed.
50. Yun, Ma., changtao, Quin., Limin, Wang., and Min, yang., J. Org. Chem. 65,
3864-3868, 2000.
51. Brindaban C. Ranu, Alakananda Hajra, and Umasish Jana J. Org. Chem. ,
65, 6270-6272, 2000.
Brindaban and coworkers51 have also synthesized various com-
pounds using the Inidium chloride (InCl3) as a catalyst and they found
the procedure of the synthesis of dihydropyrimidin-2(1H)-ones by
indium(III) chloride catalyzed condensation of 1,3-dicarbonyl compound,
(XXIII)
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 aldehyde, and urea provides an efficient and much improved modifica-
tion of Biginelli’s reaction.
NH2
NH2
O
R
O
O
R1
+
CHO
NH
N
H
OR
O
R1
InCl3 THF
81-95 % yield
CeCl3.7H2O
Ethanol or H2O
NH2
NH2
X
R
O
O
R1
+
CHO
NH
N
H
OR
O
R1
X=O or S
According to method of  Subhash Bose et al52 CeCl3  provides an
efficient and much improved modification of Biginelli’s reaction. In
addition, it is possible to apply the tenets of green chemistry to the
generation of biologically interesting Biginelli products using aqueous
medium approaches, which are less expensive and less toxic than those
with organic solvents. Moreover, this method offers several advantages
including high yields, short reaction times, and a simple work-up
procedure, and it also has the ability to tolerate a wide variety of
substitutions in all three components, which is lacking in existing
procedures. Furthermore, the present procedure is readily amenable to
para l le l  synthes is  and the genera t ion  o f  combinator ia l
dihydropyrimidinone libraries53.
52. D. Subhas Bose, Liyakat Fatima, and Hari Babu Mereyala, J. Org. Chem.
587, 68, 587-590, 2003.
53. Alexander, Stadler and Kappe, C.O. J.Combi.Chem, 3, 624-630, 2001.
(XXIV)
(XXV)
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Many more new catalysts was tried on the Biginelli reaction for the
yield improvement and reduce the reaction time and also for generating
libraries of new molecules. There are many new references on this topic.
As per Kappe they suggested all are related to the yield improvement
and publication point of view, but some of them are devloping new mol-
ecules and their screening against various disease.
NH2
NH2
O
O
R1
OR
CHO
NH
N
H
OR
O
R1+
54,55...75
FeCl3.6H2O
54
BiCl3.MeCN
55
LiCl4.MeCN
56
NiCl2.6H20
57
P-TsOH, EtOH58
CoCl2.6H2O-LaCl3.6H2O
59
Microwave(800W)60
NiCl2.6H2O-HCl
61
Bi(OTf)3.MeCN
62
NH4Cl
63
Ferrihydrate silicarogel64
Me3SiCl/NaI
65
Zn(OTf)2
66
MgBr2
67
Ag3PW 12O14
68
KHSO4
69
Con.HCl-ultrasound70
CdCl2, MeCN
71
CuCl-LiCl72
I2CH3CN
73
BiONO3
74
P-TSA-grinding75
54. Lu, J., Ma, H., Synlet, 1, 63-64, 2000.
55. K.Ramalinga., P.Vijayalakshmi., T.N.B.Kaimal; Synlett, 6, 863-865, 2001.
56. Yadav, J.S., Reddy, B.V.S., Srinivas, R., Venugopal, C., Ramalingam, T., Synthe
sis, 9,1341-1345, 2001.
57. Lu,J., Bai,Y.;Synthesis, 4, 466-470, 2002.
58. Jin, T., Zhang, S., Li, T.; Synth Comm.; 32 (12), 1847-1851, 2002.
59. Lu,J., Bai, J.,Guo, Y.H., Wang, J., Ma, H.R.; Chines J.Chem, 20(7), 681-687, 2002.
60. Kidwai, M.,Saxena, S., Mohan, R., Venkataramanan, R.; J.Chem.Soc. ;1, 16, 1845-
1846, 2002.
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61. Lu, J., Wang, F.L., Bai, Y.J., Li, W.H., Chines J. Chem., 22(10), 788-792, 2002.
62. Varala, M., Alam, M.M., Adapa, S.R.; Synlett.,1, 67-70, 2003.
63. Teimouri, F., Shaabani, A., Bazgir, A.; Tetrahedron Lett., 44(4), 857-859, 2003.
64. Martinez, S., Meseguer, M., Cases, L., Rodriguez, E., Molins, E., Vallribera, A.,
Tetrahedron, 59(9), 1553-1556, 2003.
65. Sabitha, g., Reddy,G.S.K.K., Reddy, C.S., Yadav, J.S.; Synlett,  6, 858-860, 2003.
66. Xu, H., Wang, Y.H., Chinese, J.Chem., 21 (3), 327-331, 2003.
67. Salehi, H., Guo, Q.X.; Synth. Comm., 34(1), 171-179, 2004.
68. Yadav, J.S.,Reddy, B.V.S., Sridhar, P., Reddy, J.S.S., Nagaih, K., Lingaiah, K.,
Saiprasad, P.S., Eur. J.Org. Chem. ;3, 552-557, 2004.
69. Tu, S., Fang, F., Zhu, S., Li, T., Zhang, X., Zhuang, Synlett,  3, 537-539, 2004.
70. Zhidovinova, M.S., Fedorova, O.V., Rusinov, G.L., Ovachinnikova, I.G.;
Rusian.Chem.Bull.; 52 (11), 2527-2528, 2003.
71. Narsaiah,A.V., Basak, A.K., Nagaiah.; Synthesis, 8, 1253-1256, 2004.
72. Manjula, A., Rao, B.V., Neelakant, p.; Synth. Comm., 34 (14), 2665-2671, 2004.
73. Srinivas, K.V.N.S., Das, B.; Synthesis, 13, 2091-2093, 2004.
74. Reddy, Y.T., Rajitha, B., Reddy, P.N., Kumar, B.S.,Rao, V.P.; Synthetic
Communications, 34 (20), 3821-3825, 2004.
75. Bose, a., Padnekar,S., Ganguli, S., Chakraborty, G., Manhas, M.; Tetrahedron
Lett. 45 (45), 8351-8353, 2004.
The recent literature on Biginelli reaction has covered very wide scope
and few most important reference are listed54-75.
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New drug molecules under clinical study:
Recently many new molecules which are under study from phase-
I to Phase-IV clinical trials for different pharmacological action have shown
that the basic characteristic of morpholine to behave as hidden amine
has attracted many medicinal chemists to incorporate this feature in drug
design. Pyrimidine also behaves to that of morpholine. Some interesting
compounds are as under .
N
H
N
CH3 CH3
O
O
CH3
N
H
NH
O CH3
O
CH3
NO2
Treatment of Hypertension54
Calcium Channel Blokers
Calcium Channel Blokers76
Company Name: Merck & Co.
Moreover Merck and Co developed77a compound whichis very active
as Non-nucleoside inhibitor of human hepatitis B virus (IC50 = 53 nM for
reduction of HBV DNA in human hepatoma HepG2.2.15 cells) with low
cytotoxicity in uninfected cells (CC50 = 7 mcM). This compound inhibited
both viral DNA and viral cores in HepG2.2.15 cells and HBV-transfected cell
lines, whereas it did not affect the activity of endopolymerase and had no
effect on other DNA or RNA viruses. In vivo,  in a transgenic mouse model,
oral doses of 3-100 mg/kg b.i.d. or t.i.d. for up to 28 days dose-dependently.
(XXVI)
(XXVII)
76. Drug Data Report; 8(1), 35, 1986.
77. Drug Data Report, 10(3), 200, 1988.
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decreased viral DNA in the liver and plasma with efficacy comparable to
lamivudine. However, unlike lamivudine, compound reduced cytoplasmic
HBV core antigen (HBcAg) in the liver of mice. Pharmacokinetic studies
in mice showed rapid absorpt ion, 30% bioavai labi l i ty and dose-
proportional plasma levels56.
N
H
NH
CH3
O
O
N
FF
CH3
Cl
F
compound code : Bay-41-4109
Anti Hepatitis B Virus Drugs78
Bayer
78. Drug Data Report, 24(2), 165, 2002.
(XXVIII)
N
N
O
OO
O
CH3 CH3
NO2
N
N
NH
OH
OO
O
CH3 CH3
N
N
O
OO
O
CH3
CH3 S
N
CH3
NO2
CH3
CH3
Calcium Channel Blocker
Drug Data Rep;8(5),465,1986,.
MAR-99
MAR-99
Leukotrine Antagonist
Drug data Rep; 10(10), 826, 1988.
(Known anti-asthmatic agent, now reported to pos-
sess anti-ulcerative and gastric antisecretory activi-
ties, which inhibits hydrochloric acid-ethanol-, stress-
and indomethacin-induced ulcers in rat.
Calcium Channel Blockers
Drug Data Rep; 10 (11), 899, 1988.
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N
NH
NH2
F
O
N
N
NH2
NH2
Cl
CH3
N
N
N
N
N
N
N
N
OH
OH
OH
OH
N
NHNH
NH
N
Cl
Cl
Cl
Cl
O CH3
O
N
H
N
O
OH
NH
CH3 CH3
O
N
NH
S
CH3
CH3O
O
O
CH3
Flucytosine
(fluorocytosine)
Antifungal Agent.
Clin Microbiol Infect 2003, 9, 1504.
In vitro susceptibility of Candida spe-
cies isolated from cancer patients
against some antifungal agents.
Primethamine
Antimalarial Agent.
lancet, 361 (9357), 577, 2003.
Dipyridamole
Acute Myocardial Infection
Treatment of Antiplatlet Therapy.
Immunosuppressants
(Oncolytic Drug)
Antibacterial Drugs
39th Intersci Conf Antimicrob Agents
Chemother  (Sept  26-29,  San
Francisco) 1999, Abst F1808
In vitro activity of novel 6-anilinouracils
targeted to DNA polymerase III of
Gram-positive bacteria
TNK-6123
TNK-6123
Anti HIV Agent
Reverse Transcripase Inhibitors.
Non-nucleoside HIV-1 reverse tran-
scriptase inhibitor
Compound was active not only against
wild-type HIV-1 strains (IC50 = 3 nM
against IIIB and NL4-3 HIV-1 strains)
but also showed nanomolar
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REACTION SCHEME
NH2
+
CH3
O
O
EtO
CH3
O
N
O
H
Toluene
Reflux
R'
R'
CH3
O
N
O
H
CHO
R
NH2
NH2 O
+
NH
N
H
CH3 O
NH
O H
R
R'
R'
STEP-1
STEP-2
RDC-1 to RDC-24
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Experimental Protocols:
All the substituted anilines and necessary chemicals were obtained
from commercial sourses. Melting points of all the synthesized compounds
was taken in open capillary bath on controlled temperature heating men-
tal. The crystallization of all the compounds was carried out in DMF. TLC
was carried out on Silicagel-G as stationary phase and purchsed from
MERCK India Ltd. Ethylacetate: Hexane (5:5) was used as a mobile
phase. The other solvent system like acetone:benzene was also employed.
Experimental:
(A) Preparation of Acetoacetanilide
It was prepared according to method mentioned in Chapter-1 on
page no.28.
(B) Preparation of 4-(3-nitrophenyl)-6-methyl-N-(2-methoxyphenyl)-
2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.
A mix ture  o f  2-methoxy acetoacetan i l ide  (0 .01mol ) ,  3 -
nitrobenzaldehyde (0.01mol), urea (0.2 mol),  containing conc. HCl (0.4
ml, ca. 4 drops) was heated under reflux for 24 h (after the first 6h, an
additional quantity of conc HCl (0.5 ml) was added). The mixture was
allowed to stand at room temperature for overnight, the precipitate was
filtered and recrystallized from DMF to give final DHPM compound. Iso-
lated as light yellow solid. Yield: 55 %. M.P. 270  OC.
[calculated C: 59.68 ;H:4.74 ;N;14.65]
[ Found C: 59.63 ;H:4.72 ;N:14.69]
The other compounds of the series were also prepared according
to above mentioned method. The physical data of newly synthesized com-
pounds are recorded. As per Table: 4.1, Table-4.2 and Table 4.3.
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Table-4.1 Physical  constants of  N - (subst i tutedphenyl) -6-methyl -4- (subst i tutedphenyl) -2-oxo-1,2 ,3 ,4-
       tetrahydropyrimidine-5-carboxamides.
Code No.
Substitution
Molecular Formula Molecular Weight M.P.OC
% composition
R R' C H N
RDC-1 3-NO2 2-OCH3 C19H18N4O5 382.87 270
59.68
(59.63)
4.74
(4.72)
14.65
(14.69)
RDC-2 3-NO2 2-CH3 C19H18N4O4 366.37 176
62.29
(62.35)
4.95
(4.92)
15.29
(15.27)
RDC-3 3-NO2 2,3-diCH3 C20H20N4O4 380.39 251-252
63.15
(63.17)
5.30
(5.36)
14.73
(14.72)
RDC-4 3-Cl 2-CH3 C19H18ClN3O2 355.81 208-209
64.13
(64.11)
5.10
(5.14)
11.81
(11.76)
RDC-5 4-OCH3 2,5-diCH3 C21H23N3O3 365.42 240-241
69.02
(69.09)
6.34
(6.39)
11.50
(11.47)
RDC-6 3-Cl 2,5-diCH3 C20H20ClN3O2 369.84 243
64.95
(64.91)
5.45
()5.48
11.36
(11.36)
RDC-7 3-NO2 2,5-diCH3 C20H20N4O4 380.39 245-246
63.15
(63.19)
5.30
(5.31)
14.73
(14.81)
NH
N
H
CH3
O
NH
O
H
R
R'
* Values in parenthesis denoted the theoretical percentage of composition.
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Code No.
Substitution
Molecular Formula MolecularWeight M.P.
OC
% composition
R R' C H N
RDC-8 3-Oph 2,5-diCH3 C26H25N3O3 427.49 258
73.05
(73.19)
5.89
(5.99)
9.83
(9.87)
RDC-9 3-Cl 2,3-diCH3 C20H20ClN3O2 369.84 260
64.95
(64.28)
5.45
(5.38)
11.36
(11.33)
RDC-11 3-NO2 2,3-diCH3 C20H20N4O4 380.39 256-257
63.15
(63.11)
5.30
(5.39)
14.73
(14.77)
RDC-12 3-Oph 2,3-diCH3 C26H25N3O3 427.49 220
73.05
(73.19)
5.89
(5.98)
9.83
(9.69)
RDC-13 4-Cl 2-Cl C18H15Cl2N3O2 376.23 208
57.46
(57.58)
4.02
(4.27)
11.17
(11.27)
RDC-14 4-Cl 2-CH3 C19H18ClN3O2 355.81 264-266
64.13
(64.28)
5.10
(5.06)
11.81
(11.97)
RDC-15 2-NO2 2-Cl C18H15ClN4O4 386.78 196
55.89
(55.87)
3.61
(3.67)
14.49
(14.53)
NH
N
H
CH3
O
NH
O
H
R
R'
* Values in parenthesis denoted the theoretical percentage of composition.
Table-4.2 Physica l  constants  of  N - (subst i tu tedphenyl ) -6 -methy l -4 - (subst i tu tedphenyl ) -2 -oxo-1 ,2 ,3 ,4 -
       tetrahydropyrimidine-5-carboxamides.
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Code No.
Substitution
Molecular Formula Molecular Weight M.P.OC
% composition
R R' C H N
RDC-16 4-NO2 2-Cl C18H15ClN4O4 386.78 224-225
55.89
(58.84)
3.91
(3.87)
14.49
(14.48)
RDC-17 4-NO2 2-CH3 C19H18N4O4 366.37 204-205
62.29
(62.37)
4.95
(4.96)
15.29
(15.38)
RDC-18 4-NO2 2,5-diCH3 C20H20N4O4 380.39 140
63.15
(63.27)
5.30
(5.28)
14.73
(14.78)
RDC-19 4-NO2 2-OCH3 C19H18N4O5 382.37 138
59.68
(59.66)
4.74
(4.89)
14.65
(14.59)
RDC-20 4-NO2 4-Cl C18H15ClN4O4 386.78 294
55.89
(55.72)
3.91
(3.83)
14.49
(14.46)
RDC-21 4-NO2 H C18H16N4O4 352.34 304-306
61.36
(61.25)
4.58
(4.59)
15.90
(15.83)
RDC-23 4-Cl H C18H16ClN3O2 341.79 157
63.25
(63.21)
4.72
(4.76)
12.29
(12.24)
RDC-24 3-Oph H C24H21N3O3 399.44 158
72.16
(72.23)
5.30
(5.39)
10.52
(10.53)
NH
N
H
CH3
O
NH
O
H
R
R'
* Values in parenthesis denoted the theoretical percentage of composition.
Table-4.3 Physica l  constants  of  N - (subst i tu tedphenyl ) -6 -methyl -4 - (subst i tu tedphenyl ) -2 -oxo-1 ,2 ,3 ,4 -
      tetrahydropyrimidine-5-carboxamides.
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Spectral Analysis:
Spectral data of only key intermediate and final compounds are
included. Elemental analysis of the compounds were in agreements
(within 0.2-0.4% of theoriticalvalue) with the strctures assigned.
The constitution of newly synthesized compound were supported
by   IR, NMR, and Mass  spectral study and x-ray crystallography is in-
cluded in this chapter. The details are as under.
IR Spectral analysis:-
Instrument : SHIMADZU FT IR-8400
Sample technique :  KBr pellet
Frequency  range : 400-4000cm -1
The infrared spectrum of all the compounds are taken in Shimadzu
FT-IR 8400. Looking to the spectral study of the newly synthesized (1,4-
dihydropyrimidines) molecules.   the carbonyl (>C=O) of the amidic  func-
tionality stretching was observed at 1660-1670 cm -1 and another ketonic
group was (NHCONHstr.) was observed at ~1700 cm -1 due to the amide
carbonyl  functionality of DHPM ring. The other confirmation of amide
group that it saw the >C-N stretching and it was founf in range of ~1520-
1530 cm -1.
Looking to the stretching of secondary amine (>NH) appears
around ~3400-3442 cm -1 and it was confirmed the N-H functionality in
the compound. The stretching C-N appears at 1501-1592 cm -1.
The C-H stretching of aromatic moiety was observed at
~3025 cm -1. The other characterization due to aromatic moieties C-C
multiple bond stretching, C-H inplane bending and out of plane bending
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appears around at ~1430-1500 cm -1 and ~746-806 cm -1.
The C-H stretching of methyl group observed at ~2920-2923cm -
1(asym.) and ~2831-2851cm-1 (sym.) and it’s bending observation at
~1383 cm -1 .
IR spectral data for  [RDC-1 to RDC-24] are given in table on page 196-
199.
Compound
Code
IR Frequency (cm-1)
Amine
>N-H
str.
Amide
(NH-C=O)
str.
Amide
NHCONH
str.
Amide
>C-N str.
Aromatic
>C=C<
ring skeleton
vibn.
RDC-1 3436.9 1662.5 1708.8 1530.4 1459.0
RDC-2 3449.8 1662.8 1707.8 1526.6 1455.0
RDC-3 3458.5 1665.3 1709.2 1541.5 1458.6
RDC-4 3404.1 1670.2 1705.0 1525.7 1454.2
RDC-5 3452.6 1678.6 1709.3 1529.6 1460.6
RDC-6 3406.6 1673.2 1702.0 1529.8 1458.6
RDC-7 3459.4 1666.2 1710.3 1542.5 1459.6
RDC-8 3460.5 1667.4 1710.5 1542.8 1463.8
RDC-9 3406.1 1673.2 1705.0 1526.7 1458.2
RDC-11 3459.8 1666.9 1709.5 1542.8 1459.9
RDC-16 3427.3 1660.6 1707.8 1518.8 1435.9
RDC-17 3432.3 1664.3 1708.9 1521.9 1442.3
RDC-18 3434.6 1665.6 1709.3 1524.3 1444.6
RDC-19 3432.4 1664.6 1708.9 1521.5 1440.6
IR frequencies of some important compounds(Table-4.4)
Table-4.4
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NMR Spectral Study :-
Instrument : BRUKER AC 300 MHz FT-NMR,
Internal reference : TMS
Solvent : CDCl3 or DMSO d6
 In the NMR spectra of the title compounds (RDC-1 to RDC-24)  In
case of   methyl protons (-CH3) are observed as singlet at 1.583 -2.814 d
ppm. Looking to the assymetric (C4) carbon proton (>CH-) protons in all
compounds were observed at 5.0-6.0 d ppm.  The amide proton gave
peak at 7.0-9.0 d ppm. In most of derivatives -NH protons were observed
at 6.5-8.0 d ppm as a singlet.
For (RDC-4), methyl proton of the DHPM ring was observed at
2.114 d ppm and the methyl proton of carabamoyl ring was observed at
1.918 d ppm and it is due to the amidic linkage of the phenyl ring in ortho
position and hence it moves towards the upfield. looking to the splitting
patterns of substituted  phenyl functionality, non first order spectra was
observed and all the aromatic protons were shown as multiplet and it
was seperated according to their J values. Three singlet was observed
in the upfield(7.6, 8.7 and 9.0)d ppm respectively for the -NH protons of
the compound.
Looking to NMR spectrum of (RDC-16) methyl proton of the DHPM
ring was observed at 2.167 d ppm. Asymetric proton (>CH-) protons was
observed at 5.503 d ppm. While amidic proton gave peak at 7.805, 8.958,
9.268 d ppm respectively as a broad peak and singlet. Looking to aro-
matic region of the spectra two triplet was observed due to the di-ortho/
meta coupling of protons present in the ring of 2-chloro phenyl (J value
of the protons is 7.5 Hz). One pair of doublet of doublet was observed
for the 4-nitro phenyl ring and it is the confirmative for the present of 4-
.
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substituted phenyl ring in the compound for the ortho/meta  coupling (J
value of the protons is 7.5 Hz) .
The 1HNMR spectra of the compounds were given on page no. 200-205.
In most of derivatives, -NH   protons were observed at 7.0-9.0 d
ppm as a singlet. All the aromatic proton observed at around 6.60-8.30 d
ppm.  Splitting pattern of the molecules was also remains same as the
above discussion.
Mass Spectral Study :
Instrument : JEOL SX 102/DA-6000 for FAB
In case of Mass spectral analysis of (RDC-1 to RDC-
22) the FAB (Fast atom Bombardenment) technique was used. The mo-
lecular ion peaks (M+) of  the compounds  in mass spectra  were in total
agreement  with it’s molecular  weight.
The Mass spectra of the compounds were given on page no.206-208.
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0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmRDC-1
 411.8
 510.1
 622.0
 662.5
 677.9
 694.3
 736.8
 750.3
 790.8
 806.2
 923.8
1022.2
1046.3
1090.7
1164.0
1223.7
1248.8
1286.4
1333.71376.1
1423.4
1459.0
1530.4
1604.71662.51708.8
3089.8
3337.6
3436.9
NH
N
H
CH3
O
NH
H
O
NO2
O
CH3
RDC-1
Type Vibration Mode
Frequency
Cm-1
Amine >N-H str. 3436.9
Methyl
C-H str. (asym.) 2900
C-H str. (sym.) 2850
Amide
>C=O str. 1662.5
C-N str. 1530.4
NH-CO-NH str. 1708.8
Aromatic
C=C ring skeleton vibn.
1423.4
1459.0
O.O.P bending vibn.
750.3
806.2
IR Spectrum of N-(2-methoxyphenyl)-6-methyl-4-(3-nitrophenyl)-2-
oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.
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0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmRDC-2
 445.5
 683.7
 731.0
 752.2
 902.6
 970.1
1097.4
1246.9
1273.9
1318.3
1353.0
1383.8
1434.0
1455.2
1526.6
1584.4
1627.81670.2
1707.8
3069.5
3249.8
3418.6
NH
N
H
CH3
O
NH
H
O
NO2
CH3
RDC-2
Type Vibration Mode
Frequency
Cm-1
Amine >N-H str.
3418.6(1)
3249.8(2)
Methyl
C-H str. (asym.) 3069.5
C-H str. (sym.) 2970
Amide
>C=O str. 1662.8
C-N str. 1526.6
NH-CO-NH str. 1707.8
Aromatic
C=C ring skeleton
vibn.
1434.0
1455.2
O.O.P bending vibn.
731.0
752.2
IR Spectrum of N-(2-methylphenyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide.
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 418.5
 443.6
 494.7
 589.2
 661.5
 688.5
 706.9
 749.3
1080.1
1147.6
1184.2
1245.0
1316.3
1383.8
1415.7
1454.2
1523.7
1586.3
1627.81670.2 1705.0
2922.0
3133.1
3250.8 3404.1
NH
N
H
CH3
O
NH
H
O
Cl
CH3
RDC-4
Type Vibration Mode
Frequency
Cm-1
Amine >N-H str. 3404.1
Methyl
C-H str. (asym.) 2922.0
C-H str. (sym.) 2850
Amide
>C=O str. 1627.8
C-N str. 1525.7
NH-CO-NH str. 1705.0
Aromatic
C=C ring skeleton
vibn.
1454.2
1523.7
O.O.P bending vibn.
706.9
749.3
IR Spectrum of N-(2-methylphenyl)-6-methyl-4-(3-chlorophenyl)-2-
oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.
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20.0
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90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmRDC-16
 492.8
 550.6
 650.9
 696.3
 741.6
 792.7
 856.3
1013.5
1035.7
1054.0
1105.1
1145.6
1186.1
1228.6
1276.8
1295.1
1314.4
1347.2
1382.9
1435.9
1465.8
1518.8
1591.2
1660.6
1707.8
2854.5
2926.8
3111.9
3244.0
3427.3 NH
N
H
CH3
O
NH
H
O
Cl
NO2
RDC-16
Type Vibration Mode
Frequency
Cm-1
Amine >N-H str. 3427.3
Methyl
C-H str. (asym.) 2926.8
C-H str. (sym.) 2854.5
Amide
>C=O str. 1660.6
C-N str. 1518.8
NH-CO-NH str. 1707.8
Aromatic
C=C ring skeleton
vibn.
1423.4
1459.0
O.O.P bending
vibn.
750.3
806.2
IR Spectrum of N-(2-chlorophenyl)-6-methyl-4-(4-nitrophenyl)-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide.
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RDC-1
NH
N
H
CH3
O
NH
H
O
NO2
O
CH3
RDC-1
NH
N
H
CH3
O
NH
H
O
NO2
O
CH3
300 MHz 1H NMR Spectrum of N-(2-methoxyphenyl)-6-methyl-4-(3-
nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.
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NH
3
2
4
N
H
1
5
6
8
13 9
12 10
11
14
CH3
16
O
15
NH
18
19
20
24
21
23
22
H
4a
O
7
NO2
17
O
25CH3
26
RDC-1
No.
Chemical
Shift in
(d ppm)
Multiplicity
No. of
Protons
Coupling
constant
(J Hz)
1 2.301 s 3H (16) -
2 3.775 s 3H (26) -
3 5.666 s 1H (4a) -
4 6.835 d 1H (21) J= 8.1
5 6.88 t 1H (22) J= 7.4
6 7.06 t 1H (23) J= 0.9
7 7.120 d 1H (24) J= 4.5
8 7.564 t 1H (12) J= 7.8
9 7.713 d 1H (11) J= 7.8
10 7.828 s 1H (1) -
11 7.993 s (b) 1H (3) -
12 8.170 d 1H (13) J= 8.1
13 8.237 s 1H (9) -
14 8.462 s 1H (18) -
Assignment of proton values of each proton of RDC-1 is carried out
as mentioned in Table-4.5
Table-4.5
Dihydropyrimidine derivative by Biginelli reaction..
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NH
N
H
CH3
O
NH
H
O
Cl
CH3
RDC-4
300 MHz 1H NMR Spectrum of N-(2-methylphenyl)-6-methyl-4-(3-
chlorophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.
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No.
Chemical
Shift in
(d  ppm)
Multiplicity No. ofProtons
Coupling
constant
(J Hz)
1 1.918 s 3H (25) -
2 2.114 s 3H (16) -
3 5.400 s 1H (4a) -
4 7.063 m 1H (22) J=12
5 7.103 m 1H (23) J=9.6
6 7.135 m 1H (21) J=6.3
7 7.157 m 1H (24) -
8 7.260 m 1H (12) J=7.2
9 7.284 m 1H (11) J=15.3
10 7.335 m 1H (13) J=7.5
11 7.397 m 1H (9) J=8.1
12 7.634 s 1H (18) -
13 8.784 s 1H (1) -
14 9.080 s 1H (3) -
NH
3
2
4
N
H
1
5
6
8
13 9
12 10
11
14
CH3
16
O
15
NH
18
19
20
24
21
23
22
H
4a
O
7
Cl
17
CH3
25
RDC-4
Assignment of proton values of each proton of RDC-4 is carried out
as mentioned in Table-4.6
Table-4.6
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NH
N
H
CH3
O
NH
H
O
Cl
NO2
RDC-16
300 MHz 1H NMR Spectrum of N-(2-chlorophenyl)-6-methyl-4-(4-
nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.
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NH
3
2
4
N
H
1
5
6
8
13 9
12 10
11
14
CH3 16
O
15
NH
18
19
20
24
21
23
22
H
4a
O
7
Cl
25
NO2
17
No.
Chemical
Shift in
(d  ppm)
Multiplicity No. ofProtons
Coupling
constant
(J Hz)
1 2.167 s 3H (16) -
2 5.503 s 1H (4a) -
3 7.155 t 1H (23)
J=7.5
J=7.5
4 7.205 t 1H (22)
J=14.4
J=7.5
5 7.407 m 1H (24) J=6.3
6 7.453 m 1H (21) J=7.5
7 7.566 d 1H (9) J=8.1
8 7.675 d 1H (10) J=8.1
9 7.805 s 1H (18) -
10 8.235 d 1H (13) J=7.5
11 8.260 d 1H (12) J=7.5
12 8.958 s 1H (3) -
13 9.268 s 1H (1) -
RDC-16
Assignment of proton values of each proton of RDC-4 is carried out
as mentioned in Table-4.7
Table-4.7
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NH
N
H
CH3
O
NH
H
O
NO2
O
CH3
RDC-104
M.wt = 382.370
FAB Mass spectrum of N-(2-methylphenyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-
carboxamide.
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NH
N
H
CH3
O
NH
H
O
Cl
CH3
RDC-4
          M.wt: 356 gm/mol
FAB Mass spectrum of N-(2-methylphenyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-
carboxamide.
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NH
N
H
CH3
O
NH
H
O
Cl
NO2
RDC-16
          M.wt: 386.78 gm/mol
FAB Mass spectrum of N-(2-chorophenyl)-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-
carboxamide.
“S y n t h e s i s  o f  s o m e  n o v e l
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             Quinolines are the most widely studied nucleus particularly in the
infectious diseases like antibacterial1, antifungal2, antimalaraial3, antitumor4
and also in antiinflammatory5. In past, the search for synthetic antimalarial
other than quinine derivatives initiated in Germany early in the twentieth
century. It was based on the observations of Guttman and Ehrlich6 made in
1891 that the dye methylene blue had some chemotherapeutic effect on
malaria in patients. These observations laid the stone for synthetic
antimalarials.In 1920’s the first synthetic antimalarial agent, pamaquine was
synthesized by Schulemann et al.7, which is 8-amino quinoline derivative.
After that many 8-amino quinoline derivatives such as pamaquine(I),
pentaquine(II)8 and primaquine(III)9 were synthesized.
N
MeO
NH
CH(CH2)3N(C2H5)2
CH3
Pamaquine
N
MeO
NH
(CH2)5NHCH(CH3)2
Pentaquine
N
MeO
NH
CH(CH2)3NH2
CH3
Primaquine
To get more effective and safe antimalarial compounds, a large
series of 4-amino quinolines investigated as a part of the extensive co-
operative program in the USA during world war II. In 1943, Chloroquine
eventually proved most promising drug.
Introduction and Literature Survey:
1. Parikh, A.K. and Bhatt, H.H., Ind.J.Het.Chem., 12, 61-64, 2002.
2. Ferrow,W, M., Hanna,C.and Schueler, F.W., J.Am.Pharm.Assoc. 43, 370, 1954.
3. Claret, P.A., Comprehensive Organic Chemistry, Pergamon, Oxford., 5, 537, 1979.
4. Joseph, B.,Darro, F., Guillaumet, G., Kiss, R.and  Frydman, A.,C.A., 134, 193378, 2001.
5. Doshi, H.A., Bhalla, H.L., Indian Drugs, 37, 190-195, 2000.
6. Guttman P. and Ehrlich P., Berli. Klin. Wochenschr.,  28, 953, 1891.
7. Schulemann W., Proc. Roy. Soc. Med., 25, 897, 1932.
8. Drake N. L., Vanhook J., Garman J. A., Hayer R., Johnson R., Melamea S., and
(I) (II) (III)
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Chloroquine
CH(CH2)3N(C2H5)2
CH3
N
NH
Cl
12 Quinacrine
CH(CH2)3N(C2H5)2
CH3
N
MeO
NH
13
Research on the structure activity relationships of chloroquine and
related alkaloid compounds continues in an effort to find new effective
antimalarials with improved safety profiles that can be used successfully
replacing chloroquine and multidrug resistant strains of P. falciparum. The
following quinoline derivatives were synthesized(IV, V, VI, VII).
Amodiaquine
N
NH
Cl
OH
CH2N(C2H5)2
14 Hydroxychloroquine
CH3
N
NH
Cl
(CH2)3 N
CH2CH2OH
C2H5H
15
Glafenine
N
NH
Cl
O
OH
OH
O
16 Mefloquine
N
H
NCl
OH H
17
Peck R. M., J. Am. Chem. Soc., 68, 1529, 1946.
9. Elderfield R. C., J. Am. Chem. Soc., 68, 1525, 1946.
12. Magidson O. Y., and Grigorowsky, Chem. Ber.,  69, 396, 1936.
13. Magidson O. Y., and Rubtsov M. V., J. Gen. Chem. USSR,  7, 1896, 1937.
14. Burckhalter J. H., and Tendick F. H., J. Am. Chem. Soc., 70, 1363, 1945.
15. Surrey A. R., and Hammer H. F., J. Am. Chem. Soc., 72, 1814,  1950.
16. Allais A. and Meier J., Fr. Pat. M2413 (1964); US Pat. 3,232,944, 1966.
17. Ohnmacht C. J., J. Med. Chem. 14, 926, 1971.
(IV) (V)
(VI) (VII)
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Amodiaquine is no longer recommended for t reat ing
falciparum malaria because its use is associated with hepatic toxicity.
Hydroxychloroquine is equivalent to chloroquine against falciparum ma-
laria.
Mefloquine is a product of the malaria research program estab-
lished in 1963 by the Walter Reed institute for Medical research to de-
velop promising new compounds to combat emerging strains of drug re-
sistant P. falciparum. It is safe and most effective against drug resistant
strains of P. falciparum16.
Another class of derivatives developed early in the 20 th century of
quinoline was hydroxy derivatives. 8-hydroxyquinoline (Oxyquinoline) and
Nitroxoline were used as an antiseptic, which were prepared by Skraup
et al.17 in late 18 th century . Chiniofon, 8-hydroxy-7-iodo quinoline deriva-
tive was used for many years as an antiseptic before its amebicidal prop-
erties were discovered18. Subsequently,  other iodinated hydroxyquinolines
were synthesized namely Diiodohydroxy quinoline19 (Embequin) and
Iodochlorohydroxyquinoline20 (Clioquin,Vioform).
16. Schmidt L. H. and Crosby R., Antimicrob. Agents Chemother.,  13, 1011-
1030, 1978.
19. a). Skraup Z. H., Montash, 1, 316, 1880.; b). Kostanecki st. V., Ber., 24, 154
1891.
18. (a). Kuster A., Klin., Wochenschr., 41, 1125,1909. (b). Miihlens P. and Menk
W., Munch. Med. Wochenschr., 68, 802, 1921.
19. Papech Burtner, J. Am. Chem. Soc., 58, 1314, 1936.
20. a). Ger. Pat. 117,767 (1899). b). U. S. Pat. 641,491, 1900. c). Das A. and
Mukherji S. L., J. Org. Chem.,  22, 1111, 1957.
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Additionally many non-iodinated 8-hydroxyquinolines were found to be ac-
tive against E. histolytica in vitro and in experimental amaebiasis in rats and
dogs21,22 such as Chloroquinadol(XI)23,   Broxyquinol ine(XII)24 and
Halquinol(X)25. They are also effective in humans. As a consequence, a
wide range of Mannich bases derived from 8-hydroxy- quinoline were
prepared(IX)26
Chinifon
NCl
OH
SO3Na
R= Cl, Clioquinol
NI
OH
R
R=I, Embequin
Halquinol
N
OH
Cl
Chloroquinaldol
NCl
OH
Cl
CH3
Broxyquinoline
NBr
OH
Br
21. Thompson P. E., Reinertson J. W., Bayles A and Mccarty D. A., Am. J. Trop.
Med. Hyg., 4, 224-228, 1955.
22. Anderson H. H., and Hanson A., Pharmacol. Rev., 2, 399-439, 1950.
23. Senn, U. S. Pat. 2,411,670, 1946.
24. (a) Bedall K., and Fischer O., Ber. Dtsch. Chem. Ges. 14, 1367, 1881. (b)
Zinnei Fiedler, Arch. Pharm. Ber. Dtsch. Pharm. Ges. 291, 493, 1958.
25. Olin Mathieson, Fr. Pat. FR 1,372,414, 1961.
26. (a) Helin A. F. and Vander C. A., J. Org. Chem., 17, 229-232, 1952. (b)
Edgerton W. H. and Burckhalter J. H., J. Am. Chem. Soc., 74, 5209-5210,
1952. (c) Burckhalter J. H., Bringar W. S. and Thompson, J. Org. Chem., 26,
4070-4078 1961.
and investigated as amaebicides. Those series of compounds having general
structure as below with best activity being observed in compounds like 5-
chloro-7-(diethylaminopropyl amino) methyl-8-hydroxyquinoline  hydrochlo-
ride29 (n=3).
(VIII) (IX) (X)
(XI) (XII)
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(Clamoxyquin.HCl)  was effective and well tolerated in clinical trials
against various forms of humans intestinal amebiasis27,28.
The mode of action of the 8-hydroxyquinoline (XIII) has been in-
vestigated32 and the antiamaebic effect appears to be exerted by chelation
of ferrous iron necessary for amaebial growth.
This early  research of 8-amino, 4-aminoquinoline derivatives as
an antimalarial and 8-hydroxy quinoline derivatives as an antiamaebic drew
attention of many researchers to prepare different types of quinolines
derivatives specially quinolones derivatives in subsequent years.
Clamoxyquin,
NR
OH
Cl
R= CH2NH(CH2)3N(C2H5)2
27. Cavier R., and Gandon F., Therapie, 81, 1153,  1963.
28. Grant L. S., Belle E. A., and Ramprashad W., Indian Med. J., 17, 31, 1968.
(XIII)
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Table 5.1: Some important 4-quinolone drugs in use:
Norfloxacin
NH N N
O
C2H5
CO2HF
N N
O
C2H5
CO2H
CH3
Nalidixic acid
Lomefloxacin
NH N N
O
C2H5
CO2HF
CH3
F
Pefloxacin
N N N
O
C2H5
CO2HF
CH3
Ciprofloxacin
NH N N
O
CO2HF
Ofloxacin
N N
O
CO2HF
CH3
O
N
CH3
Sparfloxacin
NH N N
O
CO2HFCH3
CH3
NH2
F
Clinafloxacin
N N
O
CO2HF
Cl
NH2
Gatifloxacin
NH N N
O
CO2HF
CH3
OMe
Grepafloxacin
NH N N
O
CO2HF
CH3
CH3
Moxifloxacin
N
N
H
N
O
CO2HF
OMe
Sitafloxacin
N N
O
CO2HF
Cl
NH2
F
Table: 5.1
Pyrano[3,2-c]quinolone nucleus...
Chapter-5
 
215
In quest to search antibacterial and antimalarial compounds, re-
searchers have synthesized many 2-quinolone compounds particularly 4-
hydroxy carbostyryls or 4-hydroxy-2-quinolone. Its derivatives are available
in natural products in abudance. The potential application of hydroxyquino-
line, quinones in certain malaria and cancer chemotherapy encouraged
Pettit R. George29  to extend his studies on 8-hydroxy carbostyryls deriva-
tives. In 1962, 4-substituted-2-quinolones derivatives (XIV to XVII) were
patented by Imperial Chemicals Ltd.30, which were tested for b-adrenergic
blocking agents and found to be effective. Chodnekar M. S. et al.31 had
synthesized several 4-hydroxy quinoline, quinolone derivatives as b-adr-
energic blocking agents.
N
OH
N
H
CH3
CH3
OH
N
O
N
H
CH3
CH3
OH
CH3
N
N
H
CH3
CH3
OHO
CH3
N
H
CH3
CH3
OH
N
CH3
O
Research on this type of derivatives gave the useful compounds
like Procaterol32, Careteolol etc. Procaterol is a selective b-adrenergic
agonist. It is useful as a bronchodilator, a peripheral vasodilator, an an-
tihypertensive agent and for treating bronchial asthma.
29. Pettit Geroge R., J. Org. Chem. 25, 1365, 1960; ibid,  33, 1089, 1968.
30. Japanese pat. JP 38789/1971 and JP 1182/1967 (C. A. 62, 16212e)
31. Chodnekar M. S., J. Med. Chem. 15, 49-57, 1972.
32. Yoshizaki S., J. Med. Chem., 19, 1138, 1976.
(XIV) (XV)
(XVI) (XVII)
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N
H
Cl
Cl
CO2H
NH
O
N
H
L-689,560
Mcquaid et al. and his team33 have been succeeded to improve in
vivo properties by replacing the carboxylic acid group with alternative acidic
bioisoster i.e. 4-hydroxy-2-quinolone chromophore. The compound
7-chloro-4-hydroxy-3-phenyl-2-quinolone(XVIII), L-698,532 (IC50=170nM;
ED50=4.5mg/kg i. p. and 7.6mg/kg p. o.)  was identified after extensive
structure activity studies as non-carboxylic, high affinity antagonist. Les-
son and coworkers34 reported prototype compounds (XXI) having 3-alkoxy
carbonyl and 3-benzoyl group at 3-position of 4-hydroxy-2 quinolones
with a small electron withdrawing group at position 7. These compounds
have shown better anticonvulsant activity than Kyuneric acid derivatives. It
was assumed  that the enolic b-dicarbonyl moiety in the 4-hydroxy-2-
quinolones was suggested to be a vinylogous carboxylic acid possessing
improved oral absorption and penetration in the blood-brain barrier.
Cl
CO2Et
NCO Cl
CO2Et
N
H
R
OO
O R
RCOCH2COR/NaH NaOCH3
N
H
Cl
OH
O
R
O
R = Me, Ph, cyclopropyl, cyclohexyl, benzyl, heteroaryl
33. (a) Mcquaid L.A., Smith E. C., Lodge D., Pralong E., Wikel J. H., Calligaro D.
O., Malley P. J.; J. Med. Chem., 35, 3423-3425, 1992. (b) Petrkocis, Drugs of
the future, 20(2), 173-183, 1995.
(XVIII)
(XIX) (XX) (XXI)
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Further optimization of 3-phenyl ring substituents provided a series of
highly potent, orally active compounds (XXII), exemplified by L-701,324
(IC50=2.0nM; ED50=0.9mg/kg i. p. and 0.9mg/kg). Recently, Bristow and
coworkers35 have found that compound L-701,324 , a full antagonist at
glycine modulatory site of the NMDA receptor, exhibited an atypical neu-
roleptic profile in rodents. The position isomer of the type (XXIV)36 is
virtually devoid of antagonist activity at the glycine site.
N
H
Cl
OH
O
OR
N
H
Cl
OH
O
N
H
Cl
OH
O
O
N
H
Cl
OH
O
O
                                                                          L-698,532
34. Rowley Michael, Lesson Paul D., Stevenson Graeme I., Moseley Angela M.,
Stansfield Ian, Sanderson Ian, Robinson Lesley, Baker Raymond, Kemp John
 A., Marshall George R.,  Foster Alan C., Grimwood Sarah, Tricklebank Mark
D., and Saywell Kay L., J. Med. Chem., 36, 3386-3396, 1993.
35. Bristow L. J., Flatmann K. L., Huston P. H., Kulagowski J.J., Leeson P. D., J.
Pharmacol. Exp. Ther., 277, 578, 1996.
36. Kulagowski J. J., Baker R., Curtis N. R., Leeson P. D., Rowley M., J. Med.
Chem., 37, 1402,1994.
(XXII) (XXIII)
(XXIV) (XXV)
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Some natural alkaloids having quinolone moiety (Table-5.2):
The chemistry of 4-hydroxy-2(1H)-quinolone was developed origi-
nally to synthesize natural compounds which were found in various chin-
chona alkaloids and furoquinoline alkaloids of such few examples, alka-
loids are Orixine, Orixinone, Preskimmianine, Edulitrine, Casimiroin,
Lunidine, Lunidonine, Hydroxylunidine, Lunacridine, Ravenoline and
Ravenine. (Table 5.2). Some of the quinolone alkaloids exhibit antimicro-
bial activity and marked cytotoxicity against animal and plant tumors.
NO
O
OM e
C H 3
Cas imiro in
N
H
O M e
O M e
R
M e O
P res kimm i an in e
R=  -C H2 C HC (C H 3 )2
Lu nid oni ne
NO
O
OM e
C H 3
O
CH3
O H
C H3
N
H
C H2 CH2 R
OMe
R= -CH 2C H (O H ):C (O H)(C H3)2
O rixi ne
R
N
HO
O
O Me
O M e
R= - C H2 COC H (C H3 )2
Orix i none
N
O Me
C H3O Me
E dul it r ine
NO
O
OM e
C H3
O
C H3
O H
C H3
Lunid ine
NO
O
O M e
C H3
O
C H 3
OH
OH
C H3
Hy d roxyl un id in e
N
CH3
O
CH3
CH2
C H3O H
R avenol ine
N
C H3
O
O
R a ven in e
Table-5.2
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LITERATURE PREVIEW OF QUINOLONES:
A perusal of literature reveals that various 4-hydroxy-2-quinolone de-
rivatives possess different kind of therapeutic activity. A brief review of
work reported by different scientists is as follows.
Hasegawa et al.37 had prepared 2-quinolones platinium complexes,
(XXVI) which are useful for treating a malignant tumor.
N
O
R1
O
R2
O
 OH
Pt
+
R1= -H, alkyl
R2= -alkyl, NR3R4
R3, R4= alkyl, Ph
-
N
H
OH
O
R
O
R= C2-C11 alkyl
Tomita K. et al.38 synthesized 3-benzoyl-4-hydroxy-2-quinolone.
Other 3-substituted derivatives (XXVII) like, 3-propenyl, butyryl, isovaleryl,
caproyl, octanoyl and decanoyl were also prepared by Friedel-Craft re-
action and studied their antitubercular activity.
Mohamed and coworkers39 studied 3-heterocyclic-4-hydroxy-6-me-
thyl-2(1H)-quinolones for its antibacterial and antifungal activity. The start-
ing compounds,3-aryliminomethyl-4-hydroxy-6-methyl-2(1H)-quinolones
were synthesized by the reaction of 4-hydroxy-6-methyl-2(1H)-quinolone
wi th  t r ie thy lor tho formate  and the  appropr ia te  amines l i ke  4-
aminoantipyrine and p-toluidine
37. Hasegawa, S., Matsunaga,K., Muto Masoto, Handa satoru, Japanese Pat. JP
0232,086; C. A. 114, 34897K, 1991.
38. Tomita K., Yakugaku Zasshi,  71, 1100-1112, 1951.
(XXVI)
(XXVII)
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These Schiff bases were also obtained by reacting 3-formyl-4-hydroxy-6-
methyl-2(1H)-quinolone with above amines. The systems like thiazolidinone,
pyrazole, triazine and triazole were introduced at 3-position.
Shah  and coworkers40 have studied antitubercular activity of substi-
tuted 4-hydroxy-2-quinolones.
Ukrainets I. V. and coworkers41 synthesized antiinflammatory com-
pounds like N-(2-thiazolyl)amides and N-(2-pyridyl)amides of 4-hydroxy-
2-quinolone-3-carboxylic acid. Some of the molecules have high
antiexudative activity (carrageenin edema) than the activity of Sudoxicam.
Kappe Thomas and Faber Kurt68 reported (4-hydroxy-1-methyl-2-oxo-1,2-
dihydroquinoline-3-yl) (Tetrazol-5-yl) ketone and 5-methyl-2,4-dioxo-2,3,4,5-
tetrahydrofuro[3,2-C]quinoline as an antiinflammatory agent. Alfonso et al.69
had synthesized alkyl and acyl substituted quinolones (XXX)  which shows
antiviral activities against herpes group viruses. In particular, the compounds
are useful against HSV-1 and HSV-2 (Herpes simplex virus).
N
H
N
NN
N
OH
O
O
CH3
O
N O
O
CH3
N O
R1
OCOCH3
OCOCH3
OCOCH3
R
R1= -CH2Ph, Ph, CH3 etc.(XXX)
39. Mohamed E. A., Ismail M. M., Gabr Y., Abass M., and Farrag H. A., Ind. J.
Chem., 34B, 21-26, 1995.
40. Shah Anamik, and Dodia Narsinh; Ind. J. Het. Chem.,  9(2), 139-142 (1999).
41. (a) Ukrainets I. V., Taran S. G., Evtifeeva O. A., Turov A. V., Chem. Het. Compd.(Engl.
Transl.), EN, 29, 8, 938-940, 1993. (b) ibid, 30, 10, 1211-1213, 1994.
(XXVIII)
(XXIX)
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Uchida e t  a l . 42 in  1983 synthes ized some carbostyr i l
derivatives(XXXI), which are useful for curing peptic ulcer of stomach
and duodenum. The compound named Rebamipide particularly has pro-
phylaxis and curing effects for treating chronic ulcers.
Dereck Buckle and coworkers43 exploited many 4-hydroxy-2-
quinolones analogs (XXXII) substituted at 3-position with nitro group and
they compared antiallergic activity with their related hetero aromatic ana-
logs.
N
H
O
N
H
O
Cl
COOH
Rebamipide
N O
R
OH
NO2
R = alkyl
Thus , 2-quinolone compounds having different substituents dis-
plays interesting and promising pharmacological activities. To enhance
its activity by making fused 2-quinolone derivatives  with pyrazole, thiaz-
ole, pyran, pyrone, pyridine , morpholine number of compounds were
synthesized. Particularly  Pyranoquinolone compounds are of recent inter-
est because of it’s structural similarity with many lead compounds recently
identified from calanolide.
42. Uchida M., Chem. Pharm. Bull., 33, 3775,  1985.
43. Buckle D. R., Morgan N. J., Ross J. W., Smith H., and Spicer B. A., J. Med.
Chem., 16, 1334, 1973.
(XXXI)
(XXXII)
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IMPORTANCE OF PYRANOQUINOLONE DERIVATIVES IN
DRUG RESEARCH.
It can be seen that 4-hydroxy-2-quinolones are important com-
pounds, not only because this moiety is present in a number of natural
products but also because quite a few derivatives exhibit variety of inter-
esting pharmacological properties. Further, pyrano quinolinones shows
good pharmacological activities such as, antibacterial, antimicrobial, an-
tiviral, anti-HIV and antitumor. The derivatives of fused 2-quinolones
(XXXIII) are useful as cardiovascular agents also.
N
H
O
O
CH3CH3
N
H
O
O CH3
CH3
COOH
COOH
N
H
O
O CH3
CH3
CHO
CHO
N
H
O
O
CH3CH3 OH
OH
N
H
O
O
CH3CH3
O
N
H
O
O
CH3CH3
N
H
Cl
O
CH3CH3
44. Brown R. F. C., Hughes G. K., and Ritchie E., Aust. J. Chem. 9, 227, 1956.
45. Brown R. F. C.,  Hughes G. K., and Ritchie E., Aust. J. Chem. 7, 348, 1954.
Findersine(XXXIII)
(XXXIV)
(XXXV) (XXXVI)
(XXXVII) (XXXVIII) (XXXIX)
Findersine44 an alkaloid isolated from Flindersia australis has been found
to be a fused pyrano-2-quinolone skeleton. Some derivatives of Findersine45
(XXXIV to XXXIX) were obtained by oxidation, halogenation, dehydration from
4-hydroxy-2-quinolones with the formation of 3,4-fused system.
Pyrano[3,2-c]quinolone nucleus...
Chapter-5
 
223
Knierzinger and Wolfbeis46 reported 2H, 5H-pyrano[3,2-c]quinoline
diones(XL)
Kappe and Mayer47 studied formation of heterocycles at C3-C4 po-
s i t ion  by  var ious  b -ke to  es ters .  They prepared many
pyranoquinolines(XLI) as under,
They also reported modified Pechmann condensation75 (XLII)  with re-
spect to different condensates in presence of ammonium acetate.
46. Knierzinger A. and Wolfbeis O. S., J. Het. Chem., 17, 225, 1980.
47. Kappe T., and Mayer C., Synthesis, 524, 1981.
N O
OH
R1
R
R1 NH2
N O
O
O
R2
R
N O
O
R1
R
CH
N C6H5
Where R= -H, CH3
R1= -H, OCH3, N(CH3)2
R2= -SO2C6H5, COOEt, CN
N O
OH
R
NH4OAc N O
O
O
R
COOC2H5
O
N O
OH
R
R1 COOC2H5(R4)2N
R2 R3
NH4OAc N O
O
O
R2
R
R1
R3
Where, R= -H, CH3, CH2COOC2H5   R1, R2, R3= -H, CH3
 (XL)
(XLI)
(XLII)
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Vladimir and coworkers48 have synthesized some fused derivative
from pyrano-2-ones as well as 4-hydroxy-2-quinolones (XLIII). It pos-
sesses an unsymmetrically substituted diactivated methylene group and
might exist in two or more tautomeric forms.
Karemmerer and coworkers49 prepared substituted N-alkyl-3-nitro
-pyrano[3,2-c]quinoline-2-ones (XLIV) that were tested as antiallergic
agents .  Thus,  N-e thy l -m-ch loroan i l ine   was reacted wi th  2 ,4-
dichlorodiphenyl malonate in tetralin and the product was nitrated to ob-
tain above compounds. Many compounds were prepared by Trkovnik50 and
coworkers.
48. Vladimir Kepe, Marijan Kocevar, and Slovenko Polanc, Heterocycles,  41(6),
1995.
49. Karemmerer F. J., Ulrich G., Alpermann H. G., Ger. Offen 2,836,470, 1980.
50. Trkovnik Mladen, Iveric Z., Kelneric Z.,  EP 820, 998, 1998.
N
H
O
OH
R N
H
O
COOH
N
H
O
O
NHCOR
CH(OEt)3
CH3COOCH(OEt)2
(CH3)2NCH(OCH3)2
AC2O
OR
OR
+
R = Me, Ph, 2-pyrazinyl, 
      3-pyridinyl
N
H
Cl
C2H5
CH2
O
O
O
O
Cl
Cl
Cl
Cl N O
O
O
R
OH
Cl
N O
O
O
R
OH
Cl
NO2
Where R = -H, alkyl
R1 = -H, alkyl, alkoxy, haloalkyl
tetralin
nitration
+
(XLIII)
(XLIV)
Pyrano[3,2-c]quinolone nucleus...
Chapter-5
 
225
Atwal Karnail51 in 1991 have prepared pyrano[3,2-c]quinolin-5-ones
as ca lc ium channel  b lockers .  The 4-hydroxy-2-qu ino lone was
cyclocondensed with 3-methyl-2-butenal and the product N-benzylated
to give after bromination pyranoquinolinone(XLV), which was aminated
to give (R2= -OH, R7= -NH2). It was condensed with 4-chlorobutanoyl chlo-
ride to give (XLVI).
Kyotani and coworkers52 have reported pyranoquinolines (XLVII) as
cardiovascular agents. The general structure of the compound is as
under,
51. Karnail Atwal, US 5,070,088, 1991.
52. Kyotani Y., Tsutomu T., Juji K., JP 05, 310,744, 1993.
N
H
O
OH
N
H
O
O
O
(H3C)2C:CHCHO
N O
O
NH2
OH
CH2Ph
N O
O
NH
OH
CH2Ph
(CH2)3Cl
O
Cl(CH2)3COCl
i. N-benzylation
ii. bromination
iii. amination
N
H
O
R4
R2
R3
R1
O
Where R1 = -alkyl, R2 = -H, OH, alkoxy etc.
R3 = -H, alkyl  R4 = -H, alkyl
(dotted line indicates optional double bond)
(XLV)(XLVI)
(XLVII)
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Morinaka et.al53 had synthesized several ester derivatives of
quinolopyran-4-one-2-carboxylic acid(XLVIII). These novel compounds
are especially useful as antiallergic and for treatment of asthma.
Gurjar and coworkers54 have reported calanolide A analogs(XLIX)
as an anti-HIV agents, these analogs have pyranoquinolone skeleton.
53. Morinaka, Y., Takahashi K., US 4,298,610, 1981.
54. Gurjar, M. K., Sharma G. V. M., Illangovan A., Narayanan V., US 6,191,279 ,
2001.
55. (a) Yang Zheng-Yu., Xia Yi, Xia Peng, Yoko Tachibana, Kenneth F. Bastow and
Lee Kuo-Hsiung, Bioorg. Med.Chem. Lett., 9, 713-716, 1999. (b) Kuo, Hsiung,
Bioorg. Med. Chem.Lett, 9, 713-716, 1999.
N
H
O
O
COOR
R1
R2
R3
O
Where R = alkyl, sub. alkyl
R1, R2, R3 = H, alkyl, Sub. alkyl
alkoxy, benzyloxy, aryl, halo
N
R
OO
R2
R3
O
CH3 CH3
R4
R7 R1
R6
R5
Where R = Me, R1 = H or sub. alkyl
R2 - R5 = H or Me
R6, R7 = H, OH, aryloxy
(XLVIII)
(XLIX)
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Dimers of 4-hydroxycoumarin56, 57 derivatives and 4-hydroxy-2(1H)-
quinolone exhibit anti-HIV and other pharmacological activities. In last
ten years Pommier and other researchers58, 59 established the role of
dimeric as well as tetrameric 4-hydroxycoumarin (L) as HIV-1 integrase
inhibitor. The tetrameric 4-hydroxycoumarin compound NSC-158393 was
found to exhibit maximum antiviral activity against HIV-1 integrase
(IC50=1.5mM) and protease.
Later onwards Zaho and co-workers60 studied the structure activity
relationship study to determine the essential components of NSC-
158393.Their study revealed that;
1). Minimum active pharmacophore is consisted of a coumarin dimer
containing an aryl substituent on the central linker methylene.
2). By removing two of the original four coumarin units potency of the
56. Links K. P., Federation Proc., 4, 176, 1945.;Harvey Lectures, 39, 162, 1943-44
57. Stahmann M. H., Huebher C. F. and Links K. P., J. Biol. Chem., 138, 518, 1941.
58. Burke Terrence R., Fersen M., Mazumder Abhijit, Yung J., Wang J., Carothers,
A. M.,Grunberger D.,Driscoll J., Kohn K. and Pommier Vyes, J. Med. Chem., 38,
4171-4178, 1996.
59. Mazumder Abhijit, Wang Shaomeng, Neamati Nouri, Nicklaus Maer, Sunder
Sanjay, Sulie chem., Milne W. A. , Rice G. William, Burke Terrence R. and
Pommier Vyes, J. Med.Chem., 39, 2472-2481, 1996.
60. Zaho H., Neamati Nouri, Womg H., Mazumder Abhijit, Wang G., Sunder Sanjay,
Milne W. A. , Burke Terrence R. and Pommier Vyes, J. Med. Chem., 40, 242-
249, 1996..
SYNTHETIC ASPECTS:
O O
OH
O
O
OH
O OO
OH
OH
O
(L)
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      resulted compound,  reduced(IC50=43mM) significantly.
3). Replacement of the central phenyl ring by bulky aromatic systems
     having higher lipophilicity  enhanced affinity and improved potency.
4). By introducing -O H  group at 7th position of coumarin ring increased
     inhibitory potency across a wide range of analogues.
This study resulted 3,3’-(2-napthalnemethylene) bis (4, 7-dihydroxycoumarin
(IC50=4.2 mM, LI).   In another study
61, it was further observed that a cou-
marin dimer was sufficient for activity and a hydrophobic moiety on methyl-
ene linker was required for potent inhibitory activity.
To explore the other structural modification, Dodia62 synthesized
bioisosters of 4-hydroxy coumarin dimers where the Oxygen atom of the
coumarin nucleus has been replaced by a Nitrogen atom. These compounds
are dimers of 4-hydroxy quinolones or dimers of 4-hydroxy carbostyrils.
The compounds of  this series (LII) have shown moderate activity as
anti HIV agents.
O
OH
OH O OO OH
OH
N
H
N
H
O O
CH3 CH3
R' R'
R
(LI)
(LII)
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Recently,  Kuo-Hsing Lee and coworkers had synthesized bioisosters
of Seselin65 i.e. 8,8-Dimethyl-2H,8H-pyrano[6,5-h]quinoline-2-ones (LV)
(DMPQ compounds) and bioisosters of DCK lactam analogs(LIV)66 as an
anti-HIV and were very potent against H9 lymphocytes with an EC50 value
of 0.00024mM and a therapeutic index of 119333 and the compounds was
about 225 fold more active then AZT.
61. Mao Pili Chin-Min, Mouscadet Jean-Francois, Leh herve, Auclair Christian and
Hsu, Lingyih, Chem. Pharm. Bull., 50(12), 1634-1637, 2002.
62. Dodia N. M., Ph. D. Thesis, 2000. Saurashtra University, Rajkot, Gujarat (India).
63. Parecha, A., Ph.D.Thesis, Saurashtra University, 2002.
64. Narodia, V., Ph.D.Thesis, Saurashtra University, 2002.
65. Yang Zheng-Yu, Xia Yi, Xia Peng, Yoko Tachibana, Kenneth F. Bastow  and
LeeKuo-Hsiung, Bioorg. Med.Chem. Lett., 9, 713-716, 1999.
66. Yang Zheng-Yu, Xia Yi, Xia Peng, Brossi Arnold, Cosentino L. M. and Lee Kuo-
Hsiung, Bioorg. Med. Chem. Lett., 10, 1003-1005, 2000.
Very recently from our laboratory Parecha63, Narodiya64 have synthe-
sized 4-hydroxy-3-[(subst i tuted-4-hydroxy-2-oxo-2H-chromene-3-
yl)(substituted-2-chloroquinoline-3-yl)]-2H-chromene-2-ones (LIII) and other
derivatives of quinoline moiety. and they found moderate active against HIV
strains (III-B and ROD) and their IC50, CC50 and SI profiles were interesting,
for further study on structural aspects.
N
O OO O
OH OH
Cl
R' R'
R
(LIII)
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 agents67  where the Oxygen atom of the pyranocoumarin nucleus has been
replaced by Nitrogen atom. They are angular pyranocoumarin derivatives.
DCK (3’, 4’-di-o-(-)-camphonyl-(+)-cis-Khellactone)68 is a structural
modifications of Suksdorfin69 (LVI) .  It is a natural khellactone which  was
isolated from the fruit of Lomatium suksdorfil). It demonstrated extremely
potent inhibitory activity against HIV-1 replication in H9 lymphocytic cells
with an EC50 value of 0.000256mM and therapeutic index of 136,719 and
more potent than AZT as an anti-HIV agent.
67. Huang L.,  Kashiwada, Y.,  Cosentino L. M.,  Fan S.; Chen C., Mcphail A. T.,
Fujioka T., Mihashi K., Lee K. H.,  J.  Med. Chem. Lett., 37, 3947, 1994.
68. Huang L.,  Kashiwada, Y.,  Cosentino L. M.,  Fan S., Lee K. H., Bioorg. Med.
Chem.Lett.,  4, 593, 1994.
69. Lee T. T.,  Kashiwada, Y., Huang L., Snider J., Cosentino L. M.,  Lee K. H.,
Bioorg. Med. Chem., 2,1051, 1994.
O OO
Seselin
N
H
OO
R4
R3 R2
R1
DMPQ
O OO
O
O
O
O
Suksdorfin
(LIV) (LV)
(LVI)
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O OO
O
O
O
O
O
O
O
DCK
70. Chavada Mausami ; Ph. D. Thesis, Saurashtra University, Rajkot, (India).2000.
71. (a) Trivedi J. M., and Mehta C. M., J. M. S. Uni., Baroda, 13(3), 82-7, 1964;
 C.A.,64, 12719, 1966. (b).  J. Ind. Chem. Soc., 50(3), 231-2, 1973; C.A., 79,
78563, 1973.
In our laboratory,  Mausami and co-workers70  has synthesized angu-
lar 4-hydroxy coumarin derivatives i.e. 3,3’-arylidene bis (7,8-Benzo-4-
hydroxycoumarin) (LVIII). These compounds have shown promising anti-HIV
activity with IC 50=>10 mM.
These facts have prompted us to design compounds having pyran
ring attached with heteroaromatic ring of 4-hydroxy-2-quinolones,  thus mak-
ing angular pyrano[3,2-C]quinolines. To synthesize these derivatives sev-
eral dimerization of methods for the preparation of dimer of 4-hydroxy-
2(1H)-quinolones. All reported 4-hydroxy-2-quinolone (LIX) were first re-
ported by Trivedi and  Mehta71 in 1966.
O
OH
O OO
OH
R
(LVII)
(LVIII)
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Where R = 8-Cl, 6-Cl, 7-CH3, 6-CH3, 6,7-(CH3)2,
                 7,8-benzo, 5,6-benzo
N
H
OH
O N
H
O
OH
R R
Dodia72 and co-workers had synthesized dimers of 4-hydroxy-2(1H)-
quinolone by condensing two moles of 4-hydroxy-2(1H)-quinolone with one
mole of an aldehyde in alcohol in presence of basic catalyst such as pyri-
dine. Similarly dimers of  pyrano[3,2-C]quinolones can be prepared from
pyrano[3,2-C]quinolones by reacting it with an aldehyde in  a  suitable  sol-
vent in presence of basic catalyst like pyridine, piperidine.
Recently, one molecule (LX) is in Phase-II clinical trial which bears
the quinoline moiety with the N-phenyl substitution.and effect on the anti-
allergic and antiasthamatic area.
72. Dodia N. M., Ph. D. Thesis, 2000, Saurashtra University, Rajkot, Gujarat (India).
(LIX)
N N O
N
OH
(LX)
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The key  intermediate pyrano[3,2-C]quinolone can be prepared  by
the action of diethyl malonate on N-methylaniline at elevated temperature.
This compound was previously prepared by Bowman et al.73and Bosson et
al74. in only 41 % and 29 % yield by using excess diethyl malonate. Later on
Kappe Thomas et al.75 has done the modification in the procedure and able
to increase the yield upto 55 % but still it was unsatisfactory. Another sci-
entist76 from the same institute has developed the process and increase
the yield upto 80-85% by performing reaction in diphenyl ether at 250 oC.
73. Bowman R.E., Campbell  A., and Tanner E., J. Chem. Soc., 444 (1959). C. A.,
53, 18041d (1959).
74. Bosson J., Rasmussen M., Ritchie E., Taylor  W. C., Aust. J. Chem., 16,
480, 1963.
75. Kappe Thomas, and Faber Kurt, J. Het. Chem., 21, 1881-83, 1984.
76. Blytthin, D.J. and Gala, D.; Drugs Fut, 16(12), 1099, 1991.
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Thaker77 and Sureja78  synthesized substiuted-2,3,4 -cromantrione-
3-(phenylhydrazones) by diazocoupling of substituted 4-hydroxy coumarin
with various  arylamines. The compound were tested for antitubercular ac-
tivity and the   result  were very promising. In few cases MIC were observed
<12.5 ug/ml bearing >90% inhibition against H37Rv strain when compared
to rifampicin (0.125 ug/ml).
Elnagdi and coworkers79 established  the structure as 3-phenylazo-
4-hydroxycoumarin (LXI), while  Shawli and coworkers80 confirmed the struc-
ture as 2,3,4-chronatione-phenyl hydrazone.
R = H, CH3, dICH3, Benzo
R’ = H,CH3, NO2, Halogen,etc.
Dodia81 synthesized 3-phenylazo-4-hydroxy-2- quinolone by
diazocoupling of substituted  4-hydroxy-2-quinolone with various
arylamines. From these series some effective compounds were  studied
for antitubercular activity,  some of the structures are mentioned  in
table 5.3.
O
O
O
N N
H
R'
R
77. Thaker , D. ;  Ph. D. Thesis, Surashatra Uni., Rajkot, India, 1996.
78. Sureja, D. ;  Ph. D. Thesis, Surashatra Uni., Rajkot, India,  1997.
79. Elanagdi, N. H., Fahmy, H. M., Morsi, M. A. and El-Ees, S. K. ; Ind.J. Chem.,
16B, 295,  1978.
80. Shawli, A.S. , Nagwa, M. S.,and Badahdah, K. O.; J. Heterocyclic Chem.,  22,
1937,  1985.
81. Dodia, N. ; Ph. D. Thesis, Surashatra University.,Rajkot, India, 2000.
(LXI)
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N
H
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N N
H
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N
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N N
H
NO2
CH3
N
H
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O
N N
H
NO2
Cl
N
H
O
O
N N
H
Cl
        No.      Structure Assay     MIC         %
( ug/ml)  Inhibition
a. BACTEC       >6.25          99
b. BACTEC       >6.25          95
c. BACTEC       >6.25          82
d. BACTEC       >6.25          76
Antitubercular activity of these compounds (Table-5.3) was deter-
mined against rifampicin (0.25 ug/ml as 98% inhibition). Preliminary
screening results suggest that thesecompounds are showing  99%, 95%,
82% and 76% activity respectively, against H37Rvstrain, Which were
further studied for level-II screening.
All these fact  has led us to synthesize some new Quinolone 2,3,4-
(1H)-trion-3-(phenylhydrazones) derivatives having some design of the
previous structure with  a, b, c,  and d  for the possible structure-activity
relationship study for development of new chemical entities having po-
tential antitubercular activities.
TABLE-5.3
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REACTION SCHEME-1:
N
O
O
O
OH
NH H2C
COOC2H5
COOC2H5
+
diethylmalonate
diphenylether
240OC, 4 hr.
diphenylamine
5,6-dihydro-4-hydro-2,5-dioxo-6-phenyl-2H-pyrano[3,2-c]quinoline
Pyrano[3,2-c]quinolone nucleus...
Chapter-5
 
237
N
O
O
O
NH
R
N
O
O
O
OH
+
NH2
R
Microwave
5-8 min
REACTION SCHEME-2:
MDS-1 to 17
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N
O
O
O
OH
+
Microwave
5-8 min
N
O
O
O
O NH2
R'
R
R'
NC
H
R
REACTION SCHEME-3:
MDQ-1 to 10
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N
O
O
O
OH +
N
O
O
O
OH
CHO
N
O
O
O
OH
N
O
O
O
OH
R
R
Ethanol, piperidine
stirring with reflux
6-7 h
REACTION SCHEME-4:
MD-1001 to 1008
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MECHANISIM FOR PYRANO[3,2-C]QUINOLINE RING FROM
DIPHENYL AMINE :
The Pyrano[3,2-C]quinoline ring formation ocuured in two steps.In
the first step, 3-unsubstituted -4-hydroxy-2(1H)-quinolone ring formedby
condensetion of one mole of aniline and one moleof diethyl malonate with
loss of two mole of ethanol.In second step, cyclocondensation of 3-
unsubstituted -4-hydroxy-2(1H)-quinolone with another  mole of diethyl
malonate at higher temperature give Pyrano[3,2-C]quinoline-2,5(6H)-
diones.
NH
Ph
..
CH2
COOEt
COOEt
N
O
O
OEt
H H
Ph
N
OH
O
Ph
N O
O OEt
Ph
..
N
OH
O
Ph
CH2
COOEt
COOEt N
OH
O
O
O
OEt
OEt
H
Ph
N O
HO
O OEt
OH
Ph
N O
O
OH
O
Ph
+
-
-EtOH
+
-EtOH
-EtOH
+
-
-
-EtOH
+
+
-H+
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MECHANISM FOR DIMERIZATION OF PYRANO[3,2-C]QUINOLINE-2,5-
(6H)-DIONES:
W. R. Sullivan82 has proposed the following 3 step mechanism.
According to the proposed mechanism, first step is aldol condensa-
tion between aldehyde and pyrano[3,2-c]quinoline-2,5(6H)-dione which
yielded the aldol, followed by dehydration into an a,b-unstaturated ke-
tone and in final step reaction of intermediate with another molecule of
pyrano[3,2-c]quinoline-2,5(6H)-dione afforded the pyrano[3,2-c]quinoline-
2,5(6H) diones.
82. Sullivan W. R., Huebner C. F., Stahmann M. A., and Link K. P., J. Am. Chem.
Soc., 65, 2288, 1943.
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EXPERIMENTAL:
All the melting points are uncorrected. IR specta were recorded (KBr)
on SHIMADZU FT-IR-8400 spectrophotometer. 1H NMR spectra were
recorded on BRUKER AC 300 MHz FT-NMR spectrometer in CDCl3 as a
solvent. Chemical shifts are expressed as d ppm. The purity of compounds
were monitored by TLC performed on silica gel-G plates purchased from
Merck. MASS spectra were recorded on JEOL SX 102/DA-6000.
(A) Preparation of 5,6-dihydro-4-hydro-2,5-dioxo-6-phenyl-2H-
pyrano[3,2- c]quinoline
A mixture of N-phenylaniline (10 gm) and diethyl malonate (24 mL)
was mixed with diphenyl ether (40 mL) in a 250 mL round bottom flask
which was equipped with distillation apparatus. Reaction mixture was
heated in an oil-bath at 220-250oC with stirring. At about 150 oC libera-
tion of ethanol was started. During 3-5 hours, the liberated ethanol (about
55 mL) was distilled out until no more ethanol was formed. Then the
mixture was allowed to cool to 100OC. To the reaction mixture acetone
(25 mL) was added and further stirred for 12 hours at 95-100 oC. It was
cooled to 25-30 oC. The precipitated solid was filtered by suction and
washed with 1, 4-dioxane (10 mL) and diethyl ether (3x10 mL) to remove
diphenyl ether. The product was recrystallized in  DMF-ethanol to yield
41.5 g (60.0 %), m. p. 304
O
C [Literature
83
 m.p.303-5
O
C] confirmed by IR
(six membered ring lactone 1735cm
-1
, quinolone 1675 cm
-1
).
(B) Preparation of 3-amino-1(substitutedphenyl)-6-phenyl-5,12-
dioxo-6,12-dihydro-1H,5H-pyrano[2’,3’:4,5]pyrano[3,2-c] quino
line-2-carbonitrile.
4-hydroxy-6-methyl-2H pyrano[3,2-c]quinoline-2,5(6H)-dione
(0.01mol ) and a-cyano cinnamate (0.01 mol), absolute ethanol (45 ml)
83. Indian Journal of Chemistry, 107-108, 1971.
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and catalytic amount of piperidine (0.1 ml) was taken in round bottom flask,
refluxed in water bath for 6-8 hrs. The reaction mixture was cooled and the
product was collected by filteration. The crude product was crystallized from
DMF.
Similarly, other compounds were prepared. For physical data see table-
5.4 and page no.244.
(C) Preparation of 4-anilino-6-phenyl-2H-pyrano[3,2-c]quinoline-
2,5(6H)-diones. (General Method).
4-hydroxy-6-methyl-2H pyrano[3,2-c]quinoline-2,5(6H)-dione
(0.01mol ) was mixed with substituted aniline (0.01 mol) and put it in the
microwave oven for 4-10 minutes. The resultant mas was treated with
(20mLx3) methanol and product was filtered.The product was dried in
hot air oven and recrystallized from DMF. The yield recorded between 10-
25%. Light-yellow amorphous product was obtained after crystallization.
Similarly all the other compounds were prepared for data tavle see Table-
5.5 on page no.245.
(D) Preparation of 3,3’-arylidine bis [4-hydroxy-6-phenyl-6H-
pyrano[3,2-c]quinoline-2,5-dione]. (General method)
In a 100 mL three neck round bottom flask 4-hydroxy-6-phenyl-2H-
pyrano[3,2-c] quinoline-2,5(6H)-dione (0.062 mol), absolute alcohol (15 mL)
and  dry piperidine (0.3 g) was taken. It was mixed well to the reaction
mixture. substituted aldehyde (0.034 mol, 0.55 eq.) was added. It was
heated to reflux temperature i.e. 85-88 oC and stirred for 3 h. Solid product
was separated. It was cooled to 25-30 oC. Solid product was filtered,
washed with ethanol (3x3 mL). It  was dried at  80
O
C. The product was
obtained in 50-70 % yield.
Similarly other compounds were synthesized. The physical data are given
in Table 5.6 on page no. 247.
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Code No.
Substitution
Molecular Formula Molecular Weight M.P.OC
% composition
R
R' C H N
MDQ-1 4-OCH3 CN C29H19N3O5 489.47 >315
71.16
(71.25)
3.91
(3.96)
8.58
(8.61)
MDQ-2 4-F CN C28H16FN3O4 477.44 294-296
70.44
(70.58)
3.38
(3.31)
8.80
(8.96)
MDQ-3 4-SCH3 CN C29H19N3O4S 505.54 >315
68.90
(68.88)
3.79
(3.86)
8.31
(8.42)
MDQ-5 3-Cl COOC2H5 C30H21ClN2O6 540.95 218-222
66.61
(66.63)
3.91
(3.95)
5.18
(5.14)
MDQ-6 2-NO2 COOC2H5 C30H21N3O8 551.50 259-260
65.33
(65.32)
3.84
(3.78)
7.62
(7.75)
MDQ-7 3-NO2 COOC2H5 C30H21N3O8 551.50 252-254
65.33
(65.39)
3.84
(3.76)
7.62
(7.66)
MDQ-8 3,4-di OCH3 COOC2H5 C32H26N2O8 566.55 260-262
67.84
(67.95)
4.63
(4.75)
4.94
(4.86)
MDQ-9 4-SCH3 COOC2H5 C34H24N2O6S 552.59 290-292
67.38
(67.42)
4.38
(4.45)
5.07
(5.09)
MDQ-10 4-OCH3 COOC2H5 C31H24N2O7 536.53 264-266
69.40
(69.56)
4.51
(4.55)
5.22
(5.19)
N
O
O
O
O
H
NH2
R'
R
Table-5.4 physical constant of 3-amino-2-substituted-1(substitutedphenyl)-6-phenyl-5,12-dioxo-6,12-dihydro-1H,5H-
     pyrano[2’,3’:4,5]pyrano[3,2-c]quinolines.
* Values in parenthesis denoted the theoretical percentage of composition.
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Table-5.5  Physical constant of 4-[substitutedphenylamino]-6-phenyl-2H-pyrano[3,2-c]quinoline-2,5(6H)-diones.
* Values in parenthesis denoted the theoretical percentage of composition.
Code No.
Substitution Molecular
Formula
Molecular Weight M.P.OC
% composition
R C H N
MDS-1 2,3-di CH3 phenyl C26H20N2O3 408.44 >310
76.45
(76.51)
4.94
(4.86)
6.86
(6.79)
MDS-2 2-Cl Phenyl C24H15ClN2O3 414.84 262
69.49
(69.51)
3.64
(3.74)
6.75
(6.82)
MDS-3 3-Cl Phenyl C24H15ClN2O3 414.84 292
69.49
(69.52)
3.64
(3.65)
6.75
(6.69)
MDS-4 Phenyl C24H16N2O3 380.39 279-281
75.78
(75.86)
4.24
(4.35)
7.36
(7.29)
MDS-5 2,5-di CH3 Phenyl C26H20N2O3 408.44 >300
76.45
(76.52)
4.94
(4.99)
6.86
(6.80)
MDS-6 2-CH3 Phenyl C25H18N2O3 3
94
.4
2
19
0 76.13
(76.10)
4.60
(4.69)
7.10
(7.06)
MDS-7
4-OCH3 Phenyl C25H18N2O4 4
10
.4
2
21
8-
22
0
73.16
(73.11)
4.42
(4.49)
6.83
(6.80)
MDS-8 3-CF3 Phenyl C25H15F3N2O3 448.39 264-266
66.97
(66.90)
3.37
(3.36)
6.25
(6.20)
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Table-5.5  Physical constant of 4-[substitutedphenylamino]-6-phenyl-2H-pyrano[3,2-c]quinoline-2,5(6H)-diones.
Code No.
Substitution Molecular
Formula Molecular Weight M.P.
OC
% composition
R C H N
MDS-9 Cyclo hexyl C24H22N2O3 386.44 245
74.59
(74.58)
5.74
(5.89)
7.25
(7.36)
MDS-10 3-NO2 Phenyl C24H15N3O5 425.39 176-178
67.76
(67.85)
3.55
(3.62)
9.88
(9.72)
MDS-11 2-NO2 Phenyl C24H15N3O5 425.39 293-295
67.76
(67.72)
3.55
(3.52)
9.88
(9.82)
MDS-12 4-NO2 Phenyl C24H15N3O5 425.39 222
67.76
(67.82)
3.55
(3.46)
9.88
(9.82)
MDS-13 2-CF3 Phenyl C25H15F3N2O3 448.39 213
66.97
(66.82)
3.37
(3.29)
6.25
(6.39)
MDS-14 Benzyl C25H18N2O3 394.42 192
76.13
(76.21)
4.60
(4.71)
7.10
(7.12)
MDS-15 4-Cl Phenyl C24H15ClN2O3 414.84 240
69.49
(69.53)
3.64
(3.59)
6.75
(6.69)
MDS-16 2,4-di CH3 Phenyl C26H20N2O3 408.44 210
76.45
(76.58)
4.94
(4.99)
6.86
(6.82)
MDS-17 2,6-di Cl phenyl C26H20N2O3 408.44 298
64.16
(64.23)
3.14
(3.25)
6.24
(6.36)
* Values in parenthesis denoted the theoretical percentage of composition.
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Code No.
Substitution Molecular
Formula
Molecular Weight M.P.OC
% composition
R C H N
MD-1001 3-NO2 C43H25N3O10 743.67 288
69.45
(68.51)
3.39
(3.41)
5.65
(5.69)
MD-1002 4-Cl C43H25ClN2O8 733.12 240
70.45
(70.56)
3.44
(3.56)
3.82
(3.89)
MD-1004 3-Cl C43H25ClN2O8 733.12 186
70.45
(70.51)
3.44
(3.59)
3.82
(3.91)
MD-1005 4-OCH3 C44H28N2O9 728.70 208
72.52
(72.61)
3.87
(3.82)
3.84
(3.89)
MD-1006 4-NO2 C43H25N3O10 743.67 270
69.45
(69.47)
3.39
(3.49)
5.65
(5.69)
Table-5.6  Physical constant of 6-phenyl-3-((6-phenyl-2,4,5-trioxo-3,4,5,6-tetrahydro-2H-pyrano[3,2-c]quinoline-3yl)-
      (substitutedphenyl)methyl)-3H-pyrano[3,2-c]quinoline-2,4-5(6H)-triones.
* Values in parenthesis denoted the theoretical percentage of composition.
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Code No.
Substitution
Molecular Formula Molecular Weight M.P.OC
% composition
R C H N
MD-1007 H C43H26N2O8 698.67 196-197
73.92
(73.89)
3.75
(3.69)
4.01
(4.11)
MD-1008 2-Cl C43H25ClN2O8 733.12 211
70.45
(70.51)
3.44
(3.51)
3.82
(3.83)
MD-1011 2-OH C43H26N2O9 714.67 228-229
72.27
(72.26)
3.67
(3.69)
3.92
(3.99)
MD-1012 3-OCH3 C44H28N2O9 728.70 202
72.52
(72.56)
3.87
(3.81)
3.84
(3.89)
MD-1013 2-OCH3 C44H28N2O9 728.70 208
72.52
(72.51)
3.87
(3.81)
3.84
(3.80)
MD-1018 4-OH C43H26N2O9 714.67 224-225
72.27
(72.30)
3.67
(3.69)
3.92
(3.99)
Table-5.6  Physical constant of 6-phenyl-3-((6-phenyl-2,4,5-trioxo-3,4,5,6-tetrahydro-2H-pyrano[3,2-c]quinoline-
      3yl)(substitutedphenyl)methyl)-3H-pyrano[3,2-c]quinoline-2,4-5(6H)-triones.
* Values in parenthesis denoted the theoretical percentage of composition.
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Spectral discussion:
Spectral data of only key intermediate and final compounds are in-
cluded. Elemental analysis of the compounds were in agreements (within
0.4% of theoritical value) with the structures assigned.
The constitution of newly synthesized compounds were supported
by   IR, NMR, and Mass  spectral study and x-ray crystallography is included
in this chapter. The details are as under.
IR Spectral analysis:-
Instrument : SHIMADZU FT IR-8400
Sample technique :  KBr pellet
Frequency  range : 400-4000cm-1
As per spectral study of the newly synthesized compounds. The car-
bonyl compounds in the MDQ series it appears on ~1735 cm -1. NH2 (>N-
H)and CN was appeared on ~3408 and ~2196 cm -1 respectively. The C-H
stretching of the aromatic moiety was observed at ~3030 cm -1. The other
characterization due to aromatic moieties C-C multiple bond stretching,
C-H inplane bending and out of plane bending appears around at ~1501-
1592 cm -1 and ~740-800 cm -1 respectively. For IR spectra see page no.
251.
Looking to MDS series >N-H str. was observed at 3410-3420 cm -1.carbo-
nyl stretching was observed at 1710 to 1645 cm-1. Looking to O.O.P bend-
ing of the phenyl ring was observed on 700-800 cm -1.For IR spectra see
page no.252.
As per the characterization of MD series bothe the C=O groups was
appeared on 1714 and 1666 respectively. Lookig to the OH group in the
molecule it appeares on the 3250-3300 cm -1.For IR spectra see page no.
253-255.
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NMR Spectral Study :-
Instrument : BRUKER AC 300 MHz FT-NMR,
Internal reference : TMS
Solvent : CDCl3 or DMSO d6
 The 1H NMR of the title compounds (MDQ-1) shows  singlet at 5.40
d ppm. The amide protons appeared at 8.50-9.50 d ppm as  In most of
derivatives -NH protons were observed between 6.5-8.0  d ppm as a sin-
glet. The aromatic protons are observed between around 6.60-8.30 d ppm.In
case of MDQ-1 methoxy group was observed at 3.35  dppm.
In case of NMR spectrum of MDS series methylene protons was
observed on 4.6 to 5.0 dppm. While amidic proton gave peak at 8.00-9.50
d ppm as a broad peak. In all the compounds spectra was shown as the the
non first order spectra.
In case of MD series  assymetric proton was observed on 5.0 to 6.0
dppm and other all the protons was observed in proper agreement.
The 1HNMR spectra of the compounds were given on page no.256-258.
Mass Spectral Study :
Instrument : JEOL SX 102/DA-6000 for FAB
In case of MASS spectral analysis the FAB (Fast atom
Bombardenment) technique was used. The molecular ion peak (M+) of  the
compounds  in mass spectra  were in total agreement  with it’s molecular
weight.  In case of  MDQ-8 M+1 peak (~30%) was found. In case of MDS
series equal intensity of M+1 and M+2 peak was observed. While in case
of MD-1007 peak was observed in the intensity of the 75% and it was shown
~75% intensity of the peak.
The MASS spectra of the compounds were given on page no.259-264.
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MDQ-1
N
O
O
O
O
H
NH2
O
CH3
N
Type Vibration mode
Frequency
Cm-1
Amine -NH2 Str. 3408.0
Cyano -C=N 2196.8
Carbonyl
O-C=O Str. 1735.8
N-C=O Str. ring 1662.5
Aromatic
>C=C ring skeleton
vib.
1409.9
Aryl C-O str. 1174.6
O.O.P. Bending
Vib.
758.0
798.5
IR spectrum of 3-amino-1(4-methoxyphenyl)-6-phenyl-5,12-dioxo-
6,12-dihydro-1H,5H-pyrano[2’,3’:4,5]pyrano[3,2-c]quinoline-2-
carbonitrile.
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1/cmMDS-15
 434.0
 503.4
 622.0
 654.8
 699.1
 766.7
 801.4
 823.5
 866.9
1010.6
1073.3
1089.7
1153.4
1216.0
1236.31296.1
1318.3
1343.3
1384.8
1452.3
1471.6
1489.9
1534.3
1648.1
1714.6
3091.7
3415.7
MDS-3
N
O
O
O
NH
Cl
Type Vibration mode
Frequency
Cm-1
Amine -NH Str. 3415.7
Carbonyl
O-C=O Str. 1714.6
N-C=O Str. ring 1648.1
Aromatic
>C=C ring skeleton
vib.
1452.3
1489.9
Aryl C-O str. 1236.3
O.O.P. Bending
Vib.
766.7
801.4
Single bond C-Cl str. 699.1
IR Spectrum of 4-[3-chlorophenylamino]-6-phenyl-2H-pyrano[3,2-
c]quinoline-2,5(6H)-dione.
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 745.4
 764.7
 800.4
 937.3
1039.6
1113.8
1160.1
1251.7
1294.1
1322.1
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1434.0
1451.3
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1524.6
1592.1
1666.4
1714.6
2857.3
3248.9
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MD-1008
Type Vibration mode
Frequency
Cm-1
Hydroxyl -OH Str. ~3255
Carbonyl
O-C=O Str. 1714.6
N-C=O Str. ring 1666.4
Aromatic
>C=C ring skeleton
vib.
1451.3
1492.8
Aryl C-O str. 1294.1
O.O.P. Bending
Vib.
764.7
800.4
Single bond
C-Cl str. 759.4
C-N str. 1160
IR Spectrum of 6-phenyl-3-((6-phenyl-2,4,5-trioxo-3,4,5,6-tetrahydro-
2H-pyrano[3,2-c]quinol ine-3yl ) (2-chlorophenyl ) -methyl ) -3H-
pyrano[3,2-c]quinoline-2,4-5(6H)-trione.
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 596.9 635.5
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 760.9
 809.1
1112.9
1164.9
1251.7
1294.1
1324.0
1384.8
1421.4
1451.31488.0
1544.9
1606.6
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1705.9
1718.5
3064.7
3402.2 N
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CH3
MD-1012
Type Vibration mode
Frequency
Cm-1
Hydroxyl -OH Str. 3402.2
Carbonyl
O-C=O Str. 1718.5
N-C=O Str. ring 1656.7
Aromatic
>C=C ring skeleton
vib.
1480.5
1492.8
Aryl C-O str. 1294.1
O.O.P. Bending
Vib.
760.9
809.1
Single bond C-N str. 1164.9
IR Spectrum of 6-phenyl-3-((6-phenyl-2,4,5-trioxo-3,4,5,6-tetrahydro-
2H-pyrano[3,2-c]quinoline-3yl)(3-methoxyphenyl)-methyl)-3H-
pyrano[3,2-c]quinoline-2,4-5(6H)-trione.
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 497.6
 550.6
 594.0 631.6
 703.0
 755.1
 812.01016.4
1111.9
1158.2
1246.9
1295.1
1324.0
1384.8
1438.8
1490.9
1545.8
1656.7
1716.5
2865.1
3030.9
3435.0
N
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N
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OCH3
MD-1013
Type Vibration mode
Frequency
Cm-1
Hydroxyl -OH Str. 3435.0
Carbonyl
O-C=O Str. 1710.5
N-C=O Str. ring 1656.7
Aromatic
>C=C ring skeleton
vib.
1490.9
Aryl C-O str. 1295.1
O.O.P. Bending
Vib.
755.1
812.0
Single bond C-N str. 1158.2
IR Spectrum of 6-phenyl-3-((6-phenyl-2,4,5-trioxo-3,4,5,6-tetrahydro-
2H-pyrano[3,2-c]quinoline-3yl)(2-methoxyphenyl)-methyl)-3H-
pyrano[3,2-c]quinoline-2,4-5(6H)-trione.
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MDQ-1
N
O
O
O
O
H
NH2
O
CH3
N
17
12
16
13
15
14
8
9
N
11
10
O
7
6
18
5
O
1
2
4
3
30
3531
3432
33
O
29
O
28
22
27 23
26 24
25
H
4a
NH219
O
36
CH337
20
N
21
No.
Chemical
Shift in
(d  ppm)
Multiplicity
No. of
Protons
1 3.35 s 3H(37)
2 5.40 s 1H(4a)
3 6.69 s 1H(24)
4 7.16 m 3H(23, 26, 27)
5 7.45 m 3H(14, 16, 32)
6 7.56 m
6H(13, 15, 33,
34, 35, 31)
7 9.39 s 2H(19)
300 MHz 1H NMR Spectrum of 3-amino-1(4-methoxyphenyl)-6-phenyl-
5 ,12-d ioxo-6 ,12-d ihydro-1H,5H-pyrano[2 ’ ,3 ’ :4 ,5 ]pyrano[3 ,2-
c]quinoline-2-carbonitrile.
 Pyrano[3,2-c]quinolone nucleus...
Chapter-5
257
MDS-3
N
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O
NH
Cl
13
8
12
9
11
10
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5
N
7
6
24
29 25
28 26
27
O
1
2
4
3
O
23
O
15
NH
16
17
22
18
21
19
20
Cl
30
No.
Chemical
Shift in
(d  ppm)
Multiplicity
No. of
Protons
1 4.69 s 1H(3)
2 6.72 d 2H(18, 22)
3 7.00 m 2H(21, 27)
4 7.22 m 1H(20)
5 7.31 m 2H(26, 28)
6 8.04 m 3H(10, 11, 12)
7 8.11 m 3H(9, 29, 25)
8 8.96 s(b) 1H(16)
300 MHz 1H NMR Spectrum of  4-[3-chlorophenylamino]-6-phenyl-2H-
pyrano[3,2-c]quinoline-2,5(6H)-dione.
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O
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13
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3026
2927
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O
1
2
4
3
O
24
O
15
OH
23
H
16a
NO2
45
No.
Chemical
Shift in
(d  ppm)
Multiplicity
No. of
Protons
1 5.305 s 1H(16a)
2 6.30 d 2H(20, 21)
3 7.00 t 2H(18, 22)
4 7.18 m 3H(50, 51, 28)
5 7.25 m
4H(27, 29, 52,
53)
6 7.35 m 2H(49, 26)
7 7.53 m
5H(10, 11, 12,
41, 42)
8 7.80 d 2H(39, 40)
9 8.00 d 2H(9, 30)
10 8.80 s (b) 2H(23, 54)
300 MHz 1H NMR Spectrum of 6-phenyl-3-((6-phenyl-2,4,5-trioxo-
3 , 4 , 5 , 6 - t e t r a h y d r o - 2 H - p y r a n o [ 3 , 2 - c ] q u i n o l i n e - 3 y l ) ( 3 -
nitrophenyl)methyl)-3H-pyrano[3,2-c]quinoline-2,4-5(6H)-trione.
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Introduction:
The utility of  4-aryl-1,4-dihydropyridines as therapeutic agents in
cardiovascular disorder 1-3 has stimulated studies to investigate the geo-
metrical  requirements  at  the dihydropyridine binding site4. Numerous
drugw were reported in earlier chapters.
A variety of compounds5,6 have been shown to inhibit P-gp mediated
drug efflux such as Verapamil7, dihydropyridines (Ca2+ channel blockers),
Propafenone,  Acridone, Carboxamide 209 and stipiamide, surfactants,
antibodies. Among them 1,4-DHPs without  Calcium antagonist activity pos-
sess MDR reversal activity
8
. However, these agents were not accepted clini-
cally due to their unwanted cardiovascular side effects and sometimes life
threatening cardiovascular toxicity such as atria-ventricular block and
hypotension.So, it is desirable to have compounds that are not cardiotoxic
and devoid of cardiovascular effects at the doses effective for reverting
MDR8.
1. Van Houtte, P. M. and Cohen, R. A.;  Am. J. Cardiol, 99A, 52, 1983.
2. Godfraind, T., Albertini, A., Paoletti, R., (eds.); Elsevier Biomedical; New York,
1982.
3. Cupka, P.; Czech. CS 243,591(1987); C.A., 110, 8051 (1989).
4. A. M. Triggle, E. Shefter, and D. J. Triggle.; J. Med. Chem. ,23, 1442-1445,
1980.
5. Krishana R. and Mayer L. D., Eur. J. Pharm. Sci., 11, 265-283 (2000).
6. Kawase M. and Motohashi N., Curr. Drug Targets, 4, 31-43 (2003).
7. Tanabe H.,Tasaka S., Ohmori H., Gomi N., Sasaki Y., Machida T., Lino M.,
Kiue  A., Naito S., Kuwano M., Bioorg. Med. Chem.,  6, 2219 (1998).
8. Shah A., Gaveriya H., Motohashi N., Kawase M., Anticancer Res.,  20, 373,
2000.
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 As a consequence, much attention has been focused on the devel-
opment of safer MDR inhibitors characterized by proper potency, selectiv-
ity and pharmacokinetics. Structure activity relationship of DHP suggests
that calcium channel antagonist activity is reduced by replacement of ester
substituents at the 3 and 5 positions with acetyl group. Recently a series of
3,5-diacetyl-1,4-dihydropyridne derivatives9,10 synthesized and preliminar-
ily assessed for their ability to reverse MDR in in vitro assay systems. They
have showed remarkable P-gp inhibitory activity in L5178 Y mouse T- lym-
phoma cells transfected with MDR1 gene. Among the possible resistance
modifiers the Dihydropyriines (DHPs), calcium channel antagonists have
been studied extensively as the analog of verapamil11. In a combination
treatment with antitumor agents, such as vinca alkaloids or anthracyclines,
and verapamil, cardiovascular side effects were found12. It is very impor-
tant finding that DHPs without calcium channel antagonistic activity pos-
sess MDR reversal activity11. structure activity relationship of DHP calcium
channel antagonist suggests that two acyl substitution at the 3 and 5 posi-
tion in DHP might afect the activity of DHP calcium channel antagonists13.
Further to that 1,4-dihydropyridines which are identified privileged
structure class have the diversified chemotherapeutic activity with antitu-
bercular as evidenced by recent work done in this class of compounds.
9. Kawase M., Shah A. Gaveriya H., Motohashi N., Sakagami H., Varga A. and
Molnar J. , Bioorg. Med. Chem., 10, 1051-1055, 2002.
10. Triggle D. J., Compr. Med. Chem.,  3, 1047, 1990.
11. Tanabe, H., Tasaka, S., Ohmori, H., Gomi, N., Sasaki, Y.,Machida, T., Lino, M.,
Kiue, A., Naito, s., Kuwano, M., Bioorg. Med. Chem, 6, 2219 and references
sited therein, 1998.
12. Tsuro, T., Iida, H., Tsukagoshi, S., Sakurai, Y., Cancer Res. 41, 1967, 1992.
13. Triggle, D.J., Compr.Med.Chem, 3, 1047, 1990.
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Shah et al 14 synthesized  4-substituted phenyl-2,6-dimethyl-3,5-bis-
(N-substitutedphenyl)- carbamoyl-1,4-dihydropyridine(I) and studied their
2D QSAR  as well as  antitubercular activity aganist M.tuberculosis H37Rv ,
among them some derivatives show >90% inhibition comparable to rifampi-
cin.
N
H
H
CONH
CH3 CH3
HNOC
R
R' R'
R = OC6H5, Cl, NO2, Br......      R' = NO2, OCH3, Cl.....
Literature Survey and Biological profile of symmetrical
1,4-DHPs
Another class of 1,4-DHPS having a cyano group at 3 and 5 posi-
tion was prepared by  Court and Petrow15 in 1952. They have  prepared
3,5-dicyano-2,6-diphenyl-4-(2-nitrophenyl) -1,4-dihydropyridine(II) as well
as 3,5-dicyano-2,6-dimethyl-4-(2-nitrophenyl) 1,4-dihydropyridine (III) and
other similar compounds. Recently  X-Ray crystallography studied of this
structure was reported by Shah et al.16-
N
H
CN
MeMe
NC
R
R = aryl/sub. aryl
N
H
CN
PhPh
NC
R
R = aryl/sub. aryl
(I)
(II) (III)
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Josef et. al.22 synthesized by condensing of acetone/cyclopentanone/
cyclohexanone with benzoyl acetonitrile 3,5-dicyano 1,4-DHPs of general
structure (IV). In this reaction, 2,4,6-triphenyl-2-cyano-methyl-2H-pyran was
also obtained in small amounts.
14. Desai, B., Sureja, D., Naliapara, Y., Shah, A. and Saxena, A. K.; Bioorg. Med.
Chem. 9, 1993-1998, 2001.
15. Courts A. and Petrow V., J. Chem. Soc.,1, 1952.
16. Madegowda M.,  Doreswamy B.H., Priti Adlakha, Kena Raval, Bharat Varu,  Shah,
A., Sridhar M. and Prasad J., Analytical Sciences , 19, x55-56, 2003.
17. Doreswamy, B.H., Mahendra, M., Shah, A., Anandlawar, S, M. and Prasad,  J.S.;
Analytical Sciences, 20, x13, 2004.
18 Devaru, V.B., Devrajgowda, H.C., Doreswamy, B.H., mahendra, M., Shah,
A.,Anandalawar, A.M. and Prasad, J.S., Analytical Sciences, 20, x47, 2004.
19. Lakshmi, S., Sridhar, M.A., Prasad, J.S., Manvar, D., Loriya, R., Patel, G.
and Shah, A.; communicated to Journal of Molecular Structure.
20. Lakshmi, S., Sridhar, M.A., Prasad, J.S., Manvar, D., Parecha, A., Patel, G.
and Shah, A.; communicated to Analytical Sciences.
21. Pattan, S.R., Parathe, A.N., Ind. J.Het.Chem, 12, 387-388, 2003.
22. Josef K., Jaroslav P., Lubos V., Collect. Czech. Chem. Commun.,  39(3),
854-60, 1974 ; C. A.,  81, 13360q, 1974.
23. Stefan M. and Josef K., Collect. Czech. Chem. Commun., 48(11), 3112-22
1983; C. A., 100, 85559v,  1984.
Similarly many symmetrical and unsymmetrical 1,4-dihydropyridines23
having cyano group at 3 and 5 position and para biphenyl group at 2 and 6
pos i t ion  were  prepared.  When acetophenone reac ted w i th  3-
aminocrotonitrile gave Symmetrical 3,5-dicyano-2,4,6-trimethyl-4-phenyl-
1 ,4-d ihydropyr id ine 24 (V I )  and a ldehyde condensat ion  w i th  3-
aminocrotonitrile in suitable acidic medium like acetic acid or hydrochloric
acid gave sym. 3,5-dicyano-2,6-dimethyl-4-substituted phenyl-1,4-
dihydropyridine25, 26.
R = CH 3, R 1 = (CH 2)4, (CH 2)5
N
H
CN
PhPh
NC
R R1
O
CN
PhPh
NC
CN
(IV)
(V)
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On basis of work done by Shah ans coworkers Pattan and cowork-
ers21 have synthesized molecules having the carbamoyl group in the posi-
tion of 3 and 5 in DHP ring (VIb) but they were screened against C.Albicans
and A.Nizer by cup method and were studied microbial activity against
E.Coli and S.Ayrens.
N
H
CH3
O
NH
H
CH3
O
NH
R1
O
R R
(VIb)
COCH3
+
H3C
C
NH2
CH
CN
N
H
CN
MeMe
NC
CH3
(VIa)
24. James W. T., U. S. Pat. 3,973,025; C. A., 85, 177262t, 1976.
25. Roman B., Marian M., Pawl N., Pol. 86, 477,  1977.; C. A., 87, 135104d,
1977.
26. Josef K., Anotonin K., Zdenek P., Jaroslav P., Collect. Czech. Chem. Commun.,
43(4), 1068-79 (1978); C. A.,  89, 10891u, 1978.
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Cozzi et al.27 studied anticancer activity especially as an aromatase
inhibitory activity of dicyano and cyanoester derivatives of 1,4-DHP con-
taining an imidazol-1-yl or 1,2,4-triazol-1-yl ring (VII) at C4 position of phe-
nyl ring. Aromatase inhibitory activity recorded in vitro near to 10-9M con-
centration. Moreover compound was tested for TXA2-synthase inhibition
in which it was found inactive upto 1.0 x 10-5M concentration.
27. Cozzi P., Briatico G., Giudici D., Rossi A.,Salle E. D., Med. Chem. Res.,  69,
611-17, 1996.
28. Parmar K., Ph. D. Thesis , Saurashtra University , Rajkot, India,1993.
N MeMe
R1NC
N
X
N
R2
 R1 = CN, R2 = H, CH3
 X = CH
Shah and Parmar28  prepared many 3,5-dicyano-1,4-dihydro py-
ridines. Out of many compounds, 3,5-dicyano-2,6-diethoxy -4-(2-
hydroxyphenyl)-N-(2-pyridyl)-1,4-dihydropyridine showed good antiinflam-
matory activity and also showed moderate increase in blood pressure at
1mg/kg and 5mg/kg.
(VII)
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Pharmacological screening of the new 1,4-dihydropyridines were
carried out for CNS depressant (anticonvulsant and analgesic) and car-
diovascular (inotropic and blood pressure) activities by standard methods.
Recently Pommeir and co-workers29 have identified 3,5-dicarbamoyl de-
rivative NSC-372643 as an anti-HIV agent.
N
H
MeMe
NO2
N
H
OO
N
H
OH
OH
OH
OH
NSC - 372643
Thus looking to interesting chemotherapeutic profile as anti HIV, anti
Cancer and antitubercular, the 1,4-dihydropyridine having carbamoyl groups
at 3 and 5 position  are still subject of intensive studyThis recent findings
were contribution from this laboratory, details of its chemistry, pharmaco-
logical activity  is given in next few pages.
Kametani and co-workers30 prepared symmetrical DHPs (IX) with
respect to C3 and C5 position.
N
H
NN
O
O
NN
(VIII)
(IX)
29. Neamati N.,Hong  Huixia, Mazumder A.,Pommier  Z., J. Med. chem. , 40(6),
942- 51, 1997.
30. Kametani, T., Ogasawara, K., Kozuka, A.,; yakugaku Zasshi, 89 (9), 815-22v
,1966 ; C.A., 65, 20092h, 1996.
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Shah et al31 have synthesized many symmetrical DHPs with 3,5-
diacetyl-1,4-dihydropyridine and they studied the interaction between ampi-
cillin, erythromycin and synthesized molecules (XI) on different strains of
E.Coli.
They also studied and investigated the (XII)cytotoxic and mdr rever-
sal activities against the mouse lymphoma cells transfected with mdr21.
Moreover the same author group32 synthesized many compounds
with dibenzoyl functionality and concluded that new series of mdr modula-
tors can be derived from the BzDHPs (XII) and they found that mdr reversal
was dependant on the nature of substituentsand their position at the C4
phenyl ring of BzDHPs.  Among them one compound have shown high mdr
modulating potency and the tumor specific cytotoxicity including a new drug
candidate for mdr cancer therapy.
R= 3-CF3, 3-NO2, 3-Cl, 2-NO2, 2-Cl, 3-Br, 3-OCH3, 3-OPh etc...
N
H
CH3CH3
COCH3H3COC
R
N
H
CH3CH3
COCH3H3COC
NO2
N
H
CH3CH3
COPhPhOC
NO2
(X) (XI)
(XII)
31. Gyorgiyi, G., Sandor, F., Noboru, M., Shah, A., Gevariya, H., Masami, K.,
Joseph, M.; Int.J. Antimicrobial Agent. 20, 227- 229, (2002).
32. Masami,K., Shah,A., gevariya,H., Motohashi, N., sakagami, H., Varga, A., and
Molnar, J.; Bioorg. Med. Chem. 10 , 1051- 1055 (2002).
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N
H
O O
CH3 CH3
R
R= 3-CF3, 3-NO2, 3-Cl, 2-NO2, 2-Cl, 3-Br, 3-OCH3, 3-OPh etc...
33. Saponara, S., Masama,K., Shah, A., Motohashi, M., Molnar, J., Ugoscai, K.,
Sgargali, G. and Fusi, F.; British Journal of Pharmacology, 141, 415-422
(2004).
Shah et al33 was pioneer in the invstigation of the 3,5-diacetyl and
3,5-dienzoyl-1,4-DHPs (DP1-11) (XIII) on vascular function in vitro, by com-
paring their mechanical and electrophysiological actions in rat arota rings
and single rat tail artery myocytes respectively, To quantify their multidrug
resistance (mdr) reversing activity in L5178 Y mouse T-lymphoma cells
transfacted with mdr1 gene and they suggest that DP7 may represent a
lead compound  fo r  the  des ign,  nove l ,  sa fe  and potent  MDR
chemosensitizers needed for the chemotherapy of the cancer and other
disease.
(XIII)
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Structural requirement for antitubercular activity  in 1,4-
DHPs form QSAR study:
N
H
CH3 CH3
NHNH
O O
R
R'R'
R= Cl, NO2, Br, OC6H5 etc..
R’= NO2, OCH3, Cl etc..
Many derivatives of the type (XIV) were screened for their antituber-
cular activity against M.Tuberculosis H37 RV out of which, among them some
molecules showed >90% inhibition comparable to rifampicin32.
The QSAR study of all these derivatives indicates that the presence
of  bulk ier  subst i tuents in the phenyl  r ing at  C 4 posi t ion of  the
dihydropyridines positively contributes for the antitubercular activity34. The
electronic influence of the substitutions at the carbamoyl phenyl ring present
at 3 and 5 position of dihydropyridine are importnat for antitubercular ac-
tivity. The presence of the electron withdrawing  group(EWG) at meta and
para position increases activity.  This electronic influence the enzymatic
hydrolysis of the amide bond present at 3 and 5 position of substituted
dihydropyridines to corresponding acids insidethe M. Tuberculosis.
34. P. S. Kharkar, B. Desai, H. Gaveria, B. Varu, R. Loriya, Y. Naliapara,   A. Shah
and V. M. Kulkarni, . J. med. chem. 45(22) 4858-4867(2002).
(XIV)
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The authors earlier reported 2D and 3D QSAR studies of 1,4-
dihydropyridines class of  compound showing antitubercular activity
stressed the need for dicarbamoyl moiety at position C3 and C5.
Three-dimensional quantitative structure-activity relationship (3D
QSAR) methods, comparative molecular field analysis (CoMFA) and com-
parative molecular similarity indices analysis (CoMSIA), were applied on
a series of 1,4-dihydropyridines possessing antitubercular activity. The study
was performed using 33 compounds, in which 22 molecules were used for
the derivation of the 3D QSAR models (training set) and 11 molecules were
used to evaluate the predictive ability of the derived models (test set). Su-
perimpositions were performed using three alignment rules: atom-based
fitting, SYBYL QSAR rigid body field fit of the steric andelectrostatic fields
of the molecules, and flexible fitting (multifit). Both methods were analyzed
in terms of their predictive abilities and produced comparable results with
high internal as well as external predictivities. Steric and electrostatic fields
of the inhibitors were found to be relevant descriptors for SAR. Use of low-
est unoccupied molecular orbital energies or ClogP as additional descrip-
tors in the QSAR table did not improve the significance of the 3D QSAR
models. Both CoMFA35 and CoMSIA36 models based on multifit alignment
showed better correlative and predictive properties than other models. A
QSAR study using genetic function approximation was also performed for
the same set of molecules using different types of physicochemical de-
scriptors to deal with cell-based activity data. The QSAR models revealed
the importance of spatial properties and conformational flexibility of side.
35. Cremer, R.D. et al, J. Am. Chem. Soc. 110, 5959-5967, 1988.
36. Kleb, g. Abhram, U., Mietzner, T., J. Med. Chem., 37, 4130-4146, 1994.
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During course of our study it was discovered that through there is
presence of dicarbamoyl functionality at C3 and C5 position the results
werefound to be not so promising because of the design of compounds of
the type(XV) , where we are removing phenyl ring at C4 position of DHP.
the removal of phenyl ring is detrimental to antitubercular activity. The ac-
tivity data of these  compounds shows that the  range of   inhibition against
H37RV is comparatively less 0-37%. Thus the phenyl substitution at C4 po-
sition is  ineviatable  for the better potential. In literature37, C4 phenyl 1,4-
dihydropyridines  have  shown inhibition  up to 90% against  H37RV.
Conclusion:
The phenyl ring at 4-position may  be involved in binding of  these mol-
ecules with the receptor site  and therefore the  presence  of  phenyl ring at C4
position of  DHP is  essential   for higher  antitubercular activity (i.e. >90%),
Thus it’s absence is detrimental to anti TB profile of  above  mentioned DHP
series.
N
H
CH3 CH3
R R'
H H
R = COOC2H5, COOCH3, COCH3 , COC6H5, CONHC6H5R”
R’ = COOC2H5, COOCH3, COCH3, COC6H5, CONHC6H5R”
Requirement of C4 phenyl ring in 1,4-DHPs for antitubercular activ-
ity.
RFD Series
37. Kinnari Dholaria, Ph.D. thesis, Saurashtra University, 2002.
(XV)
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X-ray Crystallography study:
Earlier Ravikumar38 and coworkers carried out crystallographic char-
acterization of the following three types of dicarbamoyl dihydropyridine.
As per crystallographic characterization16-20 of these calcium chan-
nel analogs (XVI). dihydropyridine ring is in shallow boat confirmation in all
the compounds studied. The carbamoyl groups at 3 and 5 are oriented
anticlinical in (i) and (ii) but in case of (iii), they are anticlinical and
synperiplanner, Intra and intermolecular interaction may be influencing the
positioning and orientation of the aryl group and the confirmationof the novel
C3 and C5 carbamoyl group.
N
H
CH3 CH3
N
CH3
CH3
N
CH3
CH3
O O
R
 (i)  R= 2-NO2
(ii)  R= 4-methoxy
(iii) R= 3,4-dichloro
They a lso 39so lved the crys ta l  s t ruc ture  o f  fo l lowing two
dihydropyridines by direct methods and refined by full matrix least square
procedure.
Both compounds crystallized with two molecules in the asymmetric
unit. In compounds (XVI & XVII), there are two molecules from a hydrate,
thus they can be regarded as a monohydrated dimer yielding Z=4 in the
unit cell. The dihydropyridine rings are in shallow boat confirmation with
C4 substitutions are oriented closely towards the ideal direction of the
dihydropyridine ring.
38. Sagar, M.B., Ravikumar, K., Sadanandam, Y.S.; Zeitschrift Fur Kristallographie
3, 213 , 1998.
39. Sagar, M.B., Ravikumar, K., Sadanandam, Y.S.; Zeitschrift Fur Kristallographie
12, 214, (1999).
(XVI)
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N
H
CH3 CH3
NH
CH3NH
CH3
O O
O
O
CH3
CH3
N
H
CH3 CH3
NH
CH3NH
CH3
O O
O
The orientatin of carbamoyl groups at C3 and C5 are synperiplanar and
anticlinical in  (XVI) and are anticlinical in (XVII). The presence of the furan ring
in (XVII), instead of the aryl ring affects the orientation of its molecules. In com-
pound (XVI) participation of the carbamoyl N atom has significantly changed
the hydrogen bonding network.
Triggle and coworkers4 proved that the DHP skeleton is with the flat
boat form and they proved In all X-ray structure analysis of 4-aryl-1,4-dihydro-
pyridine-3,5-dicarboxylates (Nifedipine type analog) known to date. The
dihydropyridine skeleton is present in the conformation of a flat boat, the
4-aryl residue holding the pseudoaxial position, i.e., standing virtually per-
pendicular on the plane of the dihydropyridine, and the hydrogen assuming
a pseudoe quatorial position (XVIII). The reason for this is probably steric
repulsion of the aryl residue and the two ester groups.
(XVI) (XVII)
(XVIII)
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REACTION SCHEMES:
Step-1
DRCA-9 to 89
DRCJ-1 to 21
NH
CH3 O
O
NH2
+
CH3
CH3
O
O
Toluene
R'
R'
CH3
N
O
H
O
OH
R
CH3
N
O
H
O
+
R' R'
R'
R
N
H
CH3 CH3
NN
O O
H H
H R'
NH3
Step-2
Hantzsch synthesis
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(f) (e)
R'CO
O
CHR"
CHCOR'
R"
R O
R"
R O
N
H
H R''
COR'
R
R'OC
OH
R
H
N
H
H R''
COR'
R
R'OC
R
(a) (b)
(c)
(d)
H2NNH2 :
Michael type
addition C-R
-
H
COR'
C-COR'
C-R
H transfer
H
- H2O
C
CR C R
+
CH
C
C
R'CO
CH
C
C
R'CO
NH2
. .
+
C
+
REACTION MECHANISM
R
R'
O
O
R''-CHO
NH3
R
R'
O
O
R''
R
R'
O
NH2
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Experimental:
Experimental protocols:
The original Hantzsch pyridine synthesis, which consists of conden-
sation of acetoacetic ester with aldehyde and ammonia is now extended
and substituted acetoacetanilide was used instead of acetoacetic ester.
All the chemicals obtained from industrial sourses. The crystallization of all
the compounds was carried out in mixture of DMF and ethanol. TLC was
carried out on SilicaGel-G as stationary phase and purchsed from MERCK
India Ltd.Ethylacetate: Hexane (4:6) was used as a mobile phase. the other
solvent system like acetone:benzene, methanol:chloroform was also em-
ployed but the best results were obtained in mixture of ethylacetate and
hexane(4:6).
(A) Preparation of Acetoacenalide
It was prepared according to method in Chapter-1, page no.28
(B) Preparation of  2,6-dimethyl-3,5-di-(2-chlorolphenyl carbamoyl)-
4-(2-methoxyphenyl)-1,4-dihydropyridine.
2-methoxy acetoacetanilide(0.02 mole) was dissolved in 25 ml of
methanol then added into 2-chlorobenzaldehyde(0.01 mole) and heated on
waterbath till the reaction mixture was dissolved. Add about 2 ml of liq.
ammonia solution and reflux the reaction mixture for 6-7 hours. The crude
solid product was obtained which was filtered and washed with methanol.
It was crystallized from DMF-ethanol mixture.
Yield 35%, m.p.128-129OC.
[calculated C: 56.68 ;H:4.74 ; N;14.65]
[Found C: 56.40;H:4.72 ;N:8.14]
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The other compounds of the series was prepared according to above men-
tioned method and physical data of newly synthesized compounds are
recordd in Table-6.1 and 6.2.
(c) Preparation of  2,6-dimethyl-3,5-di-(2,5-dimethylphenyl carbam
oyl)-4-(4-nitro phenyl)-1,4-dihydropyridine.
A mixture of 2,5-dimethyl acetoacetanilide (0.02 mol) and 4-nitro
benzaldehyde (0.01 mol) was refluxed with continuous heating with stirring
using 40 ml methanol as solvent on a stirring apparatus for 5 minutes Mean-
while Ammonia (4 ml) was added in the reaction mass. After 4 hrs. Light
yellow product was separated in the flask. The resulting product was
filtered and washed twice with methanol and finally dried in the hot air oven.
It was recrystallized from (DMF) yield 53-54%, m.p >3000C.
[Calculated % C (70.90%)H (6.15%) N (10.68%)]
[Obtained % C (70.93%)H (6.14%) N (10.65%)].
The other compounds of the series were prepared according to
above mentioned method and physical data of newly synthesized com-
pounds are recordd in Table-6.3, 6.4 and 6.5.
283
N
H
CH3CH3
NH
OO
NH
H
CH3
CH3
CH3
CH3 R
Code No.
Substitution
Molecular Formula Molecular Weightgm/mole M.P 
O C
% Composition
R C H N
DRCJ-1 3-NO2 C31H32N4O4 524.61 > 300
70.90
(70.93)
6.15
(6.14)
10.68
(10.65)
DRCJ-2 4-Cl C31H32ClN3O2 514.05 260-262
72.43
(72.48)
6.27
(6.25)
8.17
(8.12)
DRCJ-3 3,4-diOCH3 C33H37N3O4 539.66 193
73.44
(73.40)
6.91
(6.88)
7.79
(7.77)
DRCJ-4 4-NO2 C31H32N4O4 524.61 271-273
70.90
(70.88)
6.15
(6.21)
10.68
(10.71)
DRCJ-5 3-Br C31H32BrN3O2 558.50 220-221
66.67
(66.51)
5.78
(5.71)
7.52
(7.56)
DRCJ-6 3-Cl C31H32ClN3O2 514.05 236-239
72.43
(72.48)
6.27
(6.28)
8.17
(8.17)
DRCJ-7 3-OPh C37H37N3O3 571.70 201-202
77.73
(77.71)
6.52
(6.48)
7.35
(7.32)
DRCJ-8 4-OH C31H33N3O3 495.61 > 300
75.13
(75.10)
6.71
(6.77)
8.48
(8.40)
Table: 6.1 Physical constants of  2,6-dimethyl-3,5-di-(2,5-dimethylphenyl carbamoyl)-4-(substituted phenyl)-
      1,4-dihydropyridines.
* Values in parenthesis denoted the theoretical percentage of composition.
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Code No.
Substitution
Molecular Formula Molecular Weightgm/mole M.P 
O C
% Composition
R C H N
D
R
C
J-
9
2-OH C31H33N3O3 495.61 240-243
75.13
(75.21)
6.71
(6.68)
8.48
(8.39)
D
R
C
J-
10
H C31H33N3O2 479.61 225
77.63
(77.60)
6.94
(6.99)
8.76
(8.79)
D
R
C
J-
11
2-Cl C31H32ClN3O2 514.05 283-285
72.43
(72.44)
6.27
(6.24)
8.17
(8.14)
D
R
C
J-
12
2-NO2 C31H32N4O4 524.61 260-262
70.97
(70.93)
6.15
(6.18)
10.68
(10.64)
D
R
C
J-
13
2-OCH3 C32H35N3O3 509.63 280-282
75.41
(75.36)
6.92
(6.95)
8.25
(8.21)
D
R
C
J-
15
4-OCH3 C32H35N3O3 509.63 > 300
75.41
(75.40)
6.92
(6.89)
8.25
(8.29)
D
R
C
J-
21
4-N,N-di CH3 C33H38N4O2 522.68 264-265
75.83
(75.89)
7.33
(7.33)
10.72
(10.76)
Table:  6.2 Physical constants of  2,6-dimethyl-3,5-di-(2,5-dimethylphenyl carbamoyl)-4-(substituted
                 phenyl)-1,4-dihydropyridines.
R
N
H
CH3 CH3
NH NH
O O
H R'R'
* Values in parenthesis denoted the theoretical percentage of composition.
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R
N
H
CH3 CH3
NH NH
O O
H R'R'
Code No.
Substitution
Molecular Formula Molecular Weightgm/mole M.P 
O C
% Composition
R R' C H N
DRCA-8 2-Cl phenyl 2-OCH3 C29H28ClN3O4 518.00 128-129
67.24
(67.31)
5.45
(5.46)
8.11
(8.14)
DRCA-9 4-OH,3-OCH3phenyl 2-Cl C28H25Cl2N3O4 538.42 189
62.46
(62.45)
4.68
(4.56)
7.80
(7.89)
DRCA-10 4-Cl phenyl 2-Cl C27H22Cl3N3O2 526.84 235
61.55
(61.55)
4.21
(4.35)
7.98
(7.91)
DRCA-11 4-OCH3 phenyl 2-Cl C28H25Cl2N3O3 522.42 199
64.37
(64.31)
4.82
(4.80)
8.04
(8.16)
DRCA-12 3-OH phenyl 2-Cl C27H23Cl2N3O3 508.39 200-201
63.79
(63.84)
4.56
(4.68)
8.27
(8.35)
DRCA-15 4-Cl phenyl 2-CH3 C29H28ClN3O2 486.00 242
71.67
(71.69)
5.81
(5.82)
8.65
(8.69)
DRCA-17 4-Cl phenyl 2,4-di Cl C27H20Cl5N3O2 595.73 289-291
54.44
(54.36)
3.38
(3.31)
7.05
(6.98)
DRCA-18 2-NO2 phenyl 2-Cl C27H22Cl2N4O4 537.39 164
60.34
(60.39)
4.13
(4.12)
10.43
(10.41)
* Values in parenthesis denoted the theoretical percentage of composition.
Table:6.3 Physical constants of 2,6-dimethyl-3,5-di-(substitutedphenyl carbamoyl)-4-(substitutedphenyl)-1,4-
     dihydropyridines.
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Code No.
Substitution
Molecular Formula Molecular Weightgm/mole M.P 
O C
% Composition
R R' C H N
DRCA-19 3,4,5-tri OCH3phenyl 2-Cl C30H29Cl2N3O5 582.47 192
61.86
(61.85)
5.02
(5.00)
7.21
(7.19)
DRCA-20 3,4-di-OCH3phenyl 2-Cl C29H27Cl2N3O4 552.44 182
63.05
(63.15)
4.93
(5.01)
7.61
(7.74)
DRCA-21 CH3 2-CH3 C24H27N3O2 389.49 100-101
74.01
(73.98)
6.99
(7.01)
10.79
(10.82)
DRCA-22 CH2CH2phenyl 2-CH3 C31H33N3O2 479.61 177
77.63
(77.71)
6.94
(6.95)
8.64
(8.63)
DRCA-23 4-OH phenyl 2-CH3 C29H29N3O3 467.55 213
74.50
(74.58)
6.25
(6.25)
8.99
(8.91)
DRCA-29 3-Cl phenyl 2-Cl C27H22Cl3N3O2 526.84 226
61.55
(61.50)
4.21
(4.20)
7.98
(7.99)
DRCA-34 4-OH phenyl 2-Cl C27H23 Cl2N3O3 508.39 196-198
63.79
(63.81)
4.56
(4.50)
8.27
(8.27)
DRCA-36 3-NO2 phenyl 2-OCH3 C29H28N4O6 528.55 245
65.90
(63.88)
5.34
(5.36)
10.60
(10.58)
R
N
H
CH3 CH3
NH NH
O O
H R'R'
* Values in parenthesis denoted the theoretical percentage of composition.
Table:6.4 Physical constants of 2,6-dimethyl-3,5-di-(substitutedphenyl carbamoyl)-4-(substitutedphenyl)-1,4-
    dihydropyridines.
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Code No.
Substitution
Molecular Formula
Molecular
Weight
gm/mole
M.P O C
% Composition
R R' C H N
DRCA-73 4-F Phenyl 4-Cl C27H22 Cl2FN3O2 510.38 215 65.54 4.34 8.23
DRCA-76 3-PhO Phenyl 4-Cl C33H27Cl2N3O3 584.49 196 67.81 4.66 7.19
DRCA-79 4-OH, 3-OCH3Phenyl 4-Cl C28H25Cl2N3O4 538.421 264
62.46 4.68 7.80
DRCA-83 4-Cl Phenyl 2-CH3 C29H28ClN3O2 486.00 260-262 71.67 5.81 8.65
DRCA-85 2-OCH3Phenyl 2-CH3 C29H28N4O6 481.58 226
67.24 5.45 8.11
DRCA-87 3,4-diOCH3Phenyl 2-CH3 C31H33N3O4 511.61 238-240
68.49 6.12 7.73
DRCA-88 4-F Phenyl 2-CH3 C29H28FN3O2 469.55 210 69.45 5.63 8.38
DRCA-89 H 2-CH3 C23H25N3O2 375.46 280-281 77.13 6.47 9.31
R
N
H
CH3 CH3
NH NH
O O
H R'R'
* Values in parenthesis denoted the theoretical percentage of composition.
Table: 6.5 Physical constants of 2,6-dimethyl-3,5-di-(substitutedphenyl carbamoyl)-4-(substitutedphenyl)-
       1,4-dihydropyridines.
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SPECTRAL INTERPRETATION:
Spectral data of only key intermediate and final compounds are in-
cluded. Elemental analysis of the compounds were in agreements (within
0.4% of theoritical value) with the structures assigned.
The constitution of newly synthesized compounds were supported
by   IR, NMR, and Mass  spectral study and x-ray crystallography is included
in this chapter. The details are as under.
IR Spectral analysis:-
Instrument : SHIMADZU FT IR-8400
Sample technique :  KBr pellet
Frequency  range : 400-4000cm-1
As per spectral study of the newly synthesized (1,4-dihydropyridines)
molecules, The carbonyl (>C=O) stretching is observed at ~1670-1685 cm-
1 due to the amide carbonyl  functionality. The other confirmation of amide
group that it saw the >C-N stretching in range of ~1580cm-1. Looking to the
stretching of secondary amine (>NH) appears around ~3412-3442 cm -1,
it’s bending and C-N stretching appears at 1501-1592 cm-1 respectivley.
The C-H stretching of aromatic moiety was observed at ~3030
cm-1. The other characterization due to aromatic moieties C-C multiple bond
stretching, C-H inplane bending and out of plane bending appears around
at ~1501-1592 cm-1, ~1085 cm-1 and ~746-806 cm-1 respectively.
The C-H stretching of methyl group observed at ~2920-2923cm -
1(asym.) and ~2831-2851cm-1 (sym.) and it’s bending observation at ~1383
cm -1 . In case of DRCA-34 broad band (3268.2) was found due to pres-
ence of -OH group. IR spectra of the compounds on 295-303.
IR spectral data for  [DRCJ-1 to 21] are given tabular form on page no.289
IR spectral data for  [DRCA-10 to 79] are given tabular form on page no. 290.
Synthesis and X-ray crystallographic...
 
Chapter-6
289
Compound
Code
IR Frequency (cm-1)
Amine
>N-H   of
-CONH
Amide
(>C=O)
Amide
>C-N str.
Methyl
(asym. str.)
Methyl
(sym. str.)
Aromatic
>C=C<
ring skeleton
vibn.
DRCJ-1 3428 1686 1579 2921 2853 1416
DRCJ-2 3430 1670 1578 2918 2855 1413
DRCJ-3 3432 1672 1581 2921 2860 1456
DRCJ-4 3428 1685 1579 2921 2853 1414
DRCJ-5 3430 1670 1579 2917 2856 1415
DRCJ-6 3430 1670 1578 2918 2855 1413
DRCJ-7 3426 1668 1580 2921 2856 1417
DRCJ-8 3427 1684 1580 2922 2854 1416
DRCJ-9 3427 1683 1580 2923 2854 1413
DRCJ-10 3432 1672 1581 2921 2860 1456
DRCJ-11 3430 1670 1578 2918 2855 1413
DRCJ-12 3427 1685 1578 2920 2852 1418
DRCJ-13 3435 1672 1581 2921 2860 1456
DRCJ-15 3438 1676 1580 2925 2864 1458
DRCJ-21 3425 1668 1580 2921 2856 1417
N
H
CH3CH3
NH
OO
NH
CH3
CH3
CH3
CH3 R
DRCJ-1 to 21
Table-6.6: IR frequencies of some important compounds
Table-6.6
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Compound
Code
IR Frequency (cm-1)
Amine
>N-H of
-CONH
Amide
(>C=O)
Amide
>C-N str.
Methyl
(asym. str.)
Methyl
(sym. str.)
Aromatic
>C=C<
ring skeleton
vibn.
DRCA-10 3442 1665 1589 2930 2835 1434
DRCA-11 3442 1660 1589 2925 2837 1433
DRCA-12 3441 1660 1588 2924 2838 1434
DRCA-15 3425 1662 1528 2925 2844 1431
DRCA-17 3421 1683 1579 2920 2856 1434
DRCA-18 3443 1666 1589 2930 2836 1436
DRCA-19 3444 1664 1595 2929 2840 1438
DRCA-20 3443 1664 1594 2930 2839 1437
DRCA-29 3442 1665 1589 2930 2835 1434
DRCA-34 3400 1664 1590 2922 2830 1435
DRCA-36 3412 1670 1598 2933 2834 1451
DRCA-73 3430 1660 1581 2922 2830 1430
DRCA-76 3428 1686 1580 2920 2856 1434
DRCA-79 3435 1662 1588 2923 2833 1431
N
H
CH3CH3
NH
OO
NH
R
R' R'
 Table-6.7: IR frequencies of some important compounds
DRCA-10 to 79
Table-6.7
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NMR Spectral Study :-
Instrument : BRUKER AC 300 MHz FT-NMR,
Internal reference : TMS
Solvent : CDCl3 or DMSO d6
 The 1H NMR of the title compounds (DRCJ-1 to 21)  shows  C2 & C6
methyl protons which are observed as singlet at 1.583 -2.814 d ppm. More-
over signals of both the protons are at same d ppm value and merged each
other. While assymetric (C4) >CH protons appeared were   observed  be-
tween  5.0-6.0 d ppm.  The amide protons appeared at 8.93-9.50 d ppm as
In most of derivatives -NH protons were observed between 6.5-8.0  d ppm
as a singlet. The aromatic protons are observed between around 6.60-8.30
d ppm.
For (DRCJ-1 to 21) splitting patterns of substituted  phenyl function-
ality doublet of doublet was clearly observed in the aromatic region due to
ortho/meta coupling of phenylic protons. In case of 2,5-di methyl substitu-
tion ortho/meta coupling of phenylic protons.
The 1HNMR spectra of the compounds were given on page no.306.
In case of NMR spectrum of DRCA-8 to 89 both C2 & C6 methyl pro-
tons (-CH3) are observed as singlet at 2.2-2.4 d ppm and observed as
asinglet due to symmetry of the molecule. C4 carbon proton (>CH-) protons
in all compounds were observed at 4.6-5.2 d ppm. While amidic proton
gave peak at 8.00-9.50 d ppm as a broad peak. In most of derivatives -
NH(1) protons were observed at 6.5-8.0 d ppm as a singlet. All the aromatic
proton observed at around 6.60-8.30 d ppm. In case of  AKSA-34 due to 2-
substituted phenyl part triplet was observed due to diortho/meta coupling.
The 1HNMR spectra of the compounds were given on page no.308-313.
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Mass Spectral Study :
Instrument : JEOL SX 102/DA-6000 for FAB
In case of MASS spectral analysis of (DRCJ-1 to 21)
the FAB (Fast atom Bombardenment) technique was used. The molecular
ion peak (M+) of  the compounds  in mass spectra  were in total agreement
with it’s molecular  weight.  In case of  DRCA-11, M+1 peak (76%)was
found due to presence of chlorine group in the molecule and and in case of
DRCA-17 equal intensity of M+1 and M+2 peak was observed due to the
presece of four chlorine presence in the molecule.
The MASS spectra of the compounds were given on page no.313-318.
X-ray crystallographic study of DRCA-10:
Table 6.8  Crystal data and structure refinement for shelxl.
       Identification code AKSA-10 (DRCA-10)
       Empirical formula C27 H22 Cl3 N3 O2
       Formula weight 526.83
       Temperature 293(2) K
       Wavelength 0.71073 A
       Unit cell dimensions a = 20.5660(17) A alpha = 90 deg.
b = 10.6980(4) A beta = 104.300(2) deg.
c = 22.7890(18) A gamma = 90 deg.
       Volume 4858.6(6) A^3
       Z, Calculated density 8, 1.440 Mg/m^3
       Absorption coefficient 0.409 mm^-1
       F(000) 2176
      Theta range for data collection    2.16 to 32.54 deg.
       Limiting indices -29<=h<=29, -11<=k<=11, -34<=l<=34
       Reflections collected / unique 11135 / 6045 [R(int) = 0.0201]
       Completeness to theta =32.54   68.4 %
       Refinement method Full-matrix least-squares on F^2
       Data / restraints / parameters 6045 / 0 / 317
       Goodness-of-fit on F^2 1.049
       Final R indices [I>2sigma(I)] R1 = 0.0593, wR2 = 0.1769
       R indices (all data) R1 = 0.0910, wR2 = 0.2190
       Extinction coefficient 0.0017(4)
       Largest diff. peak and hole 0.659 and -0.499 e.A^-3
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1/cmDRCA-10
 443.6
 506.3
 528.5
 660.6
 746.4
 778.2
 815.8
 837.0 88 .2
 936.4
1018.3
1055.0
1085.8
1115.7
1186.1
1216.0
1289.3
1382.9
1404.1
1434.0
1462.9
1497.6
1589.2
1622.0
1649.0
1665.4
2341.4
3248.9
3405.1
3442.7
DRCA-10
N
H
CH3 CH3
NH NH
O O
H
ClCl
Cl
IR spectrum of 2,6-dimethyl-3,5-di-(2,-chlorolphenyl carbamoyl)-4-(4-
chlorophenyl)-1,4-dihydropyridine.
Type of
Functional
group
Mode of
vibration
Frequency
Cm-1
Amine -N-H str. 3442.7
Methyl
C-H str. (asym) 2930.0
C-H str. (sym) 2835.0
Amide
>C=O str. 1665.4
>C-N str. 1589.2
Aromatic
>C=C< ring
streching vibn.
1434.0
1462.9
O.O.P. Bending
vibn.
746.4
778.2
815.8
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1215.11288.4
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2837.1
2925.8
3244.0
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3402.23442.7
N
H
CH3 CH3
NH NH
O O
H
ClCl
O
CH3
DRCA-11
IR spectrum of 2,6-dimethyl-3,5-di-(2,-chlorolphenyl carbamoyl)-4-(4-
methoxyphenyl)-1,4-dihydropyridine.
Type of
Functional
group
Mode of
vibration
Frequency
Cm-1
Amine -N-H str. 3442.2
Methyl
C-H str. (asym) 2925.8
C-H str. (sym) 2837.1
Amide
>C=O str. 1660.6
>C-N str. 1589.2
Aromatic
>C=C< ring
streching vibn.
1494.7
1433.0
O.O.P. Bending
vibn.
744.5
777.3
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DRCA-15
N
H
CH3 CH3
NH NH
O O
H
CH3CH3
Cl
IR spectrum of 2,6-dimethyl-3,5-di-(2-methylphenyl carbamoyl)-4-(4-
chlorophenyl)-1,4-dihydropyridine.
Type of
Functional
group
Mode of
vibration
Frequency
Cm-1
Amine -N-H str. 3425.3
Methyl
C-H str. (asym) 2925.8
C-H str. (sym) 2844.8
Amide
>C=O str. 1662.5
>C-N str. 1528.7
Aromatic
>C=C< ring
streching vibn.
1431.1
1458.1
1490.9
O.O.P. Bending
vibn.
742.5
779.2
833.2
Synthesis and X-ray crystallographic...
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N
H
CH3 CH3
NH NH
O O
H
ClCl
Cl
ClCl
DRCA-17
IR spectrum of 2,6-dimethyl-3,5-di-(2,4-di-chlorolphenyl carbamoyl)-4-
(4-chlorophenyl)-1,4-dihydropyridine.
Type of
Functional
group
Mode of
vibration
Frequency
Cm-1
Amine -N-H str. 3421.5
Methyl
C-H str. (asym) 2920.0
C-H str. (sym) 2856.4
Amide
>C=O str. 1683.7
>C-N str. 1579.6
Aromatic
>C=C< ring
streching vibn.
1434.9
1471.6
O.O.P. Bending
vibn.
690.5
786.9
810.0 (strong)
Synthesis and X-ray crystallographic...
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CH3 CH3
NH NH
O O
ClCl
H
OH
DRCA-34
IR spectrum of 2,6-dimethyl-3,5-di-(2-chlorolphenyl carbamoyl)-4-(4-
hydroxyphenyl)-1,4-dihydropyridine.
Type of
Functional
group
Mode of
vibration
Frequency
Cm-1
Amine -N-H str. 3400.1
Methyl
C-H str. (asym) 2922.0
C-H str. (sym) 2830.5
Amide
>C=O str. 1664.0
>C-N str. 1590.2
Aromatic
>C=C< ring
streching vibn.
1435.9
1465.8
1496.7
O.O.P. Bending
vibn.
755.1(strong)
845.7
-OH group 3268.2
Synthesis and X-ray crystallographic...
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1259.41290.3
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1345.3
1384.8
1414.7
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1495.7
1519.8
1579.6
1616.2
1629.7
1685.7
2853.5
2921.0
3255.6
3428.2
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H
CH3CH3
NH
OO
NH
H
CH3
CH3
CH3
CH3
NO2
DRCJ-4
IR spectrum of 2,6-dimethyl-3,5-di-(2,5-di-methylphenyl carbamoyl)-4-
(4-nitrophenyl)-1,4-dihydropyridine.
Type of
Functional
group
Mode of
vibration
Frequency
Cm-1
Amine -N-H str. 3428.2
Methyl
C-H str. (asym) 2921.0
C-H str. (sym) 2853.5
Amide
>C=O str. 1685.7
>C-N str. 1579.6
Aromatic
>C=C< ring
streching vibn.
1414.7
1495.7
O.O.P. Bending
vibn.
683.7
741.6
797.5 (strong)
Synthesis and X-ray crystallographic...
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DRCJ-5
IR spectrum of 2,6-dimethyl-3,5-di-(2,5-di-methylphenyl carbamoyl)-4-
(3-bromophenyl)-1,4-dihydropyridine.
Type of
Functional
group
Mode of
vibration
Frequency
Cm-1
Amine -N-H str. 3430.2
Methyl
C-H str. (asym) 2917.1
C-H str. (sym) 2856.4
Amide
>C=O str. 1670.2
>C-N str. 1579.6
Aromatic
>C=C< ring
streching vibn.
1415.7
1456.2
O.O.P. Bending
vibn.
754.1
805.2 (strong)
Synthesis and X-ray crystallographic...
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DRCJ-6
IR spectrum of 2,6-dimethyl-3,5-di-(2,5-di-methylphenyl carbamoyl)-4-
(3-chlorophenyl)-1,4-dihydropyridine.
Type of
Functional
group
Mode of
vibration
Frequency
Cm-1
Amine -N-H str. 3430.2
Methyl
C-H str. (asym) 2918.1
C-H str. (sym) 2855.4
Amide
>C=O str. 1670.2
>C-N str. 1578.6
Aromatic
>C=C< ring
streching vibn.
1413.7
1456.2
O.O.P. Bending
vibn.
754.1
806.2 (strong)
Synthesis and X-ray crystallographic...
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DRCJ-7
IR spectrum of 2,6-dimethyl-3,5-di-(2,5-di-methylphenyl carbamoyl)-4-
(3-phenoxyphenyl)-1,4-dihydropyridine.
Type of
Functional
group
Mode of
vibration
Frequency
Cm-1
Amine -N-H str. 3426.3
Methyl
C-H str. (asym) 2921.0
C-H str. (sym) 2856.4
Amide
>C=O str. 1668.3
>C-N str. 1580.6
Aromatic
>C=C< ring
streching vibn.
1417.6
1491.8
O.O.P. Bending
vibn.
753.2 (strong)
795.6
Synthesis and X-ray crystallographic...
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N
H
CH3 CH3
NH NH
O O
ClCl
H
OH
DRCA-34
300 MHz 1H NMR spectrum of 2,6-dimethyl-3,5-di-(2-chlorolphenyl car-
bamoyl)-4-(4-hydroxyphenyl)-1,4-dihydropyridine.
Synthesis and X-ray crystallographic...
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4
35
26
N
H
1
CH3 18
CH37
16 8
NH
27
NH
19
20
25
21
24
22
23
28
29
33
30
32
31 O
17
O
9
Cl
34
Cl
35
10
15 11
14 12
13
H
4a
OH
26
No.
Chemical Shift
in d  ppm
Multiplicity
No. of
Protons
1 2.279 s 6H (18,7)
2 4.690 s 1H (4a)
3 6.721 d 1H(14)
4 6.349 d 1H(12)
5 6.976 t 1H(24)
6 7.004 t 1H(23)
7 7.164 m 1H(31)
8 7.166 m 1H(32)
9 7.223 m 1H(25)
10 7.240 m 1H(22)
11 7.291 d 1H(33)
12 7.316 d 1H(30)
13 8.044 d 1H(13)
14 8.073 d 1H(11)
15 8.118 m 1H(15)
16 8.141 m 1H(19)
17 8.141 m 1H(27)
18 8.969 s (b) 1H(1)
DRCA-34
Assignment of proton values of each proton of DRCA-34 is carried
out as mentioned in Table-6.9
Table-6.9
Synthesis and X-ray crystallographic...
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N
H
CH3CH3
NH
OO
NH
H
CH3
CH3
CH3
CH3
NO2
DRCJ-4
300 MHz1H NMR spectrum of 2,6-dimethyl-3,5-di-(2,5-di-methylphenyl
carbamoyl)-4-(4-nitrophenyl)-1,4-dihydropyridine.
12
11
13
10
14
15
4
35
26
N
H
1
16 8
CH37
CH3 18
NH
19
O
9
O
17
NH
27
20
25
21
24
22
23
28
29
33
30
32
31 H
4a
CH334
CH335
CH336
CH337
NO2
26 No.
Chemical
Shift in
d  ppm
Multiplicity
No. of
Protons
1 1.814 s 6H (18,7)
2 2.153 s 12 H
(34,35,36,
37)3 2.199 s
4 5.305 s 1H(4a)
5 6.843 m 1H(31)
6 6.867 m 1H(23)
7 6.930 m 1H(33)
8 6.983 m 1H(30)
9 7.008 m 1H(22)
10 7.008 m 1H(25)
11 8.150 d 1H(12)
12 8.150 d 1H(14)
13 8.172 d 1H(15)
14 8.172 d 1H(11)
15 8.852 s 1H(19,27)
Assignment of proton values of
each proton of DRCA-34 is carried
out as mentioned in Table-6.10
DRCJ-4
Table-6.10
Synthesis and X-ray crystallographic...
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N
H
CH3CH3
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OO
NH
H
CH3
CH3
CH3
CH3
O
DRCJ-7
300 MHz1H NMR spectrum of  2,6-dimethyl-3,5-di-(2,5-di-methylphenyl
carbamoyl)-4-(3-phenoxyphenyl)-1,4-dihydropyridine.
12
11
13
10
14
15
4
35
26
N
H
1
16 8
CH37
CH3 18
NH
19
O
9
O
17
NH
33
20
25
21
24
22
23
34
35
39
36
38
37 H
4a
CH340
CH341
CH342
CH343
O
26
27
32 28
31 29
30
No.
Chemical Shift
in d  ppm
Multiplicity No. of Protons
1 1.583 s 6H (18,7)
2 2.118 s 6H (41,43)
3 2.210 s 6H(40,42)
4 5.2 s 1H(4a)
5 6.5 m 1H (30)
6 6.84 m 4H(28,29,31,32)
7 6.90 m 5H(22,23,36,37,14)
8 7.00 m 2H(13,15)
9 7.20 m 3H(25,39,11)
10 8.05 s 1H(1)
11 8.661 s 2H(19,33)
Assignment of proton values of
each proton of DRCA-34 is carried
out as mentioned in Table-6.11
DRCJ-7
Table-6.11
Synthesis and X-ray crystallographic...
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DRCA-15
N
H
CH3 CH3
NH NH
O O
H
CH3CH3
Cl
300 MHz1H NMR spectrum of 2,6-dimethyl-3,5-di-(2-methylphenyl car-
bamoyl)-4-(4-chlorophenyl)-1,4-dihydropyridine.
Synthesis and X-ray crystallographic...
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35
26
N
H
1
CH3 18
CH37
16 8
NH
27
NH
19
20
25
21
24
22
23
28
29
33
30
32
31 O
17
O
9
10
15 11
14 12
13
H
4a
CH334
CH335
Cl
26
No.
Chemical Shift
in d  ppm
Multiplicity
No. of
Protons
1 2.292 s 6H (18,7)
2 3.726 s 6H (34,35)
3 4.822 s 1H(4a)
4 6.807 t 1H(23)
5 6.836 t 1H(24)
6 6.884 t 1H(31)
7 6.909 t 1H(32)
8 6.948 t 1H(33)
9 6.994 m 1H(25)
10 7.271 d 1H(30)
11 7.299 d 1H(22)
12 7.393 d 1H(11)
13 7.421 d 1H(15)
14 7.709 s 1H(1)
15 7.765 s 2H(19,17)
16 8.249 d 1H(14)
17 8.276 d 1H(12)
DRCA-15
Assignment of proton values of each proton of DRCA-34 is carried
out as mentioned in Table-6.12
Table-6.12
Synthesis and X-ray crystallographic...
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N
H
CH3 CH3
NH NH
O O
H
ClCl
Cl
ClCl
DRCA-17
300 MHz1H NMR spectrum of  2,6-dimethyl-3,5-di-(2,4-di-chlorolphenyl
carbamoyl)-4-(4-chlorophenyl)-1,4-dihydropyridine.
Synthesis and X-ray crystallographic...
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4
35
26
N
H
1
CH3 18
CH37
16 8
NH
27
NH
19
20
25
21
24
22
23
28
29
33
30
32
31 O
17
O
9
10
15 11
14 12
13
H
4a
Cl
34
Cl
36
Cl
26
Cl
35
Cl
37
DRCA-17
No.
Chemical
shift in d
ppm
Multiplicity
No. of
protons
1 2.204 s 6H (18,7)
2 5.066 s 1H (4a)
3 7.175 m 1H (12)
4 7.203 m 1H (14)
5 7.226 m 1H (15)
6 7.254 m 1H (11)
7 7.287 m 1H (25)
8 7.302 m 1H (33)
9 7.417 d 1H (24)
10 7.459 d 1H (32)
11 7.941 m 3H (22,30,1)
12 8.030 s (b) 2H (19, 27)
Assignment of proton values of each proton of DRCA-34 is carried
out as mentioned in Table-6.13
Table-6.13
Synthesis and X-ray crystallographic...
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H
CH3 CH3
NH NH
O O
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ClCl
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CH3
CH3
DRCA-20
300 MHz1H NMR spectrum of 2,6-dimethyl-3,5-di-(2-chlorophenyl car-
bamoyl)-4-(3,4-di-methoxyphenyl)-1,4-dihydropyridine.
Synthesis and X-ray crystallographic...
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N
H
1
CH3 18
CH37
16 8
NH
30
NH
19
20
25
21
24
22
23
31
32
36
33
35
34 O
17
O
9
10
15 11
14 12
13
H
4a
Cl
37
Cl
38
O
28
O
26
CH329
CH327
DRCA-20
No.
Chemical
shift in d
ppm
Multiplicity No. of protons
1 2.307 s 6H (18,7)
2 3.717 s 3H (29)
3 3.756 s 3H (27)
4 4.951 s 1H (4a)
5 6.62 d 1H (11)
6 6.964 m 1H (23)
7 6.970 m 1H (24)
8 6.998 m 1H (34)
9 7.02 m 1H (35)
10 7.189 m 1H (25)
11 7.24 m 1H (36)
12 7.316 d 1H (15)
13 8.033 s(b) 4H (1,19,30,14)
14 8.124 d 1H (22)
15 8.151 d 1H (33)
Assignment of proton values of each proton of DRCA-34 is carried
out as mentioned in Table-6.14
Table-6.14
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CH3CH3
NH
OO
NH
H
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CH3
CH3
CH3
NO2
DRCJ-4
M.wt= 524.61 gm/mole
FAB Mass spectrum of 2,6-dimethyl-3,5-di-(2,5-dimethylphenyl carbamoyl)-4-(4-nitrophenyl)-1,4-dihydropyridine.
315
DRCJ-7
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O
M.wt= 571.70 gm/mole
FAB Mass spectrum of 2,6-dimethyl-3,5-di-(2,5-dimethylphenyl carbamoyl)-4-(3-phenoxyphenyl)-1,4-dihydropyridine.
316
M.wt= 522.42 gm/mole
N
H
CH3 CH3
NH NH
O O
H
ClCl
O
CH3
DRCA-11
FAB Mass spectrum of 2,6-dimethyl-3,5-di-(2-chlorophenyl carbamoyl)-4-(4-methoxyphenyl)-1,4-dihydropyridine.
317
M.wt= 595.73 gm/mole
N
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CH3 CH3
NH NH
O O
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ClCl
Cl
ClCl
DRCA-17
FAB Mass spectrum of 2,6-dimethyl-3,5-di-(2,4-dichlorophenyl carbamoyl)-4-(4-chlorophenyl)-1,4-dihydropyridine.
318
M.wt=552.44 gm/mole
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CH3 CH3
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CH3
DRCA-20
FAB Mass spectrum of 2,6-dimethyl-3,5-di-(2-chlorophenyl carbamoyl)-4-(3,4-dimethoxyphenyl)-1,4-dihydropyridine.
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Introduction of Polymorphism:
Definition:
“Ability of a molecule to crystallise in to more than one different crystal
structure”.
Drugs which form crystalline solids often exist in more than one
crystal form, each of which may have distinct properties in terms of solu-
bility, melting point etc.  Invariably, one of the crystal forms may be more
stable or easier to handle than another although the conditions under
which the various crystal forms appears may be so close as to be very
difficult to control on the large scale.  This effect can create differences
in the bioavailability of the drug which leads to inconsistencies in effi-
cacy.  In some cases, one crystal form can be transformed into another
during storage and this called as polymorphism.
One view of polymorphism is that every compound may exists in
different polymorphic forms and the number of polymorphs known for a
given compound is in proportion to the amount of research spent on  this
aspect.
Polymorphs have different arrangements in the unit cell containing
the same single entity.
One polymorph of carbon provides black and slippery graphite,
another is hard, transparent diamond. A blue pigment used in ink-jet
printers has either a red or green tint, depending on the pigment’s crystal
structure. Even crystallized cocoa butter has different polymorphs; some
cause the chocolate to melt in your mouth more quickly than others.
In recent years, the pharmaceutical industry has increasingly fo-
cused its attention on polymorphs. There’s plenty of incentive. The pre-
cise arrangement of molecules within the crystal of a drug determines
how fast it dissolves in the body and how much enters the bloodstream.
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Polymorphs of a drug differ in properties that affect its shelf life or ease
of manufacture. A newly discovered polymorph may turn out to be a more
effective and convenient than the original product.
The Food and Drug Administration requires all companies to reg-
ister the precise polymorph of any drug that they produce. Pharmaceuti-
cal manufacturers also have to demonstrate that each polymorph is stable
and can be reproduced reliably. Otherwise, it would be hard to set a
drug’s effective dosage.
Looking to the regulatory affair,  drug companies are becoming
increasingly aware that different polymorphs can translate into more or
less profit. Because each polymorph is legally defined as a unique, pat-
entable composition of matter, a company that develops a new drug will
patent all the polymorphs that it has discovered and produced1-3.
That, however, affords the patent holder only limited business pro-
tection4. Because the science behind polymorphs remains murky, there’s
no guarantee that a competitor won’t discover a new polymorph of the
drug that’s better than the patented ones5.
The world of polymorphs also opens up complicated business strat-
egies. For example, when a patent is set to expire, a company might
have other patents related to a drug’s polymorphs that make it difficult
for competitors to produce generic versions.
It also comes down to fundamental chemistry. Polymorphism has
elicited enough excitement and fear in the drug business that a growing
number of researchers in academia and in private companies are taking
a closer look at how crystals grow, and what these scientists discover
could shape an entire industry6,7.
1. N.Hall, Predicting Polymorphism. Pharmaceutical formulation & quality,
February/March-2000.
2. Bernstein, J. Polymorphism in Molecular Crystals; IUCR Monographs on
Crystallography 14; Oxford Science Publications: OUP, Oxford, U.K., 2002.
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Physical and chemical properties of polymorphs:
Polymorphs differ greatly in physical & chemical properties like
melting point, solubility, dissolution, bulk density, flow rate, wettability
etc. . Polymorphs may have different chemical sensitivities due to
occluded solvents or mother liquors. Polymorphs may have different light
absorption property. Generally the higher melting polymorphs is usually
the stable one and has the least solubility. If two polymorphs have the
close melting points both are stable and both can be obtained easily by
crystallization. polymorphs may vary in stability to heat and polymorphs
can exhibit chromisomerism (different colour) of the two polymorphs of
Telmisartan(antihypertensive) one is very prone to devloping static
electricity while the other has no such tendency and is free flowing8-9.
3. Byrne, S. R.; Pfeiffer, R. R.; Stowell, J. G. Solid State Chemistry of Drugs, 2nd
ed.; SSCI Inc.: West Lafayette, IN, pp 489-498.1999.
4. Halablian J. et al. J.Pharm.Sci, 64, 1269-1288, 1975.
5. Brittain et al. Physical characterization of pharmaceutical solids , Marcel
Dekker Inc., New york, pp. 1-36.
6. Threfall, T. L. Analyst, 120, 2435-2460, 1995,
7. Brittain, H. G. J. Pharm. Sci. , 86, 405-412.1997,
8. Grant et al. Polymorphism in pharmaceutical solids, Marcel Dekker Inc. New
York. pp-1-34.
9. Yu, L.; Reutzel, S. M.; Stephenson, G. A. Pharm. Sci. Technol. Today, ,1, 118-
127.1998.
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Techniques for producing/generating new polymorphs:
The conventional approach to finding polymorphs begins with old-
fashioned crystallization experiments10-11. First, dissolve the drug in a
solvent. Next, cool the solution or evaporate the solvent, coercing the
drug molecules to stick together to form crystals. Varying the temperature
of the solution and using different solvents are among the long-used tricks
for getting the molecules to stack in different geometries. It was also
found that intense pulses of near- infrared l ight could affect the
crystallization of the amino acid glycine. When the light was linearly
polarized, so that its electric field vibrated in one direction, the crystal
grew as one polymorph; when the light was circularly polarized, so that
the electric field rotated, it induced a second polymorph.
As per literature various other general methods are as under12-13.
(1) Crystallization from a solvent. (polar, non-polar, mixed)
(2) Rapid or gradual quenching of hot solutions (to precipitate acid or
base) in presence or absence of additives.
(3) Aging of suspension.
(4) Desolvaton of solvates.
(5) Seeding with pure polymorphs.
All the above techniques are used for generating new polymprphs but to
playing with solvent/solvents is easy methods are widely used.
10. Kitaigorodsky, A. I. Molecular Crystals and Molecules; Academic Press: New
York, 1973. (b) Yu, L. J. Pharm. Sci., 84, 966-974.1995.
11. Staab, E.; Addadi, L.; Leiserowitz, L.; Lahav, M. AdV. Mater. 2, 40-43, 1990.
12. Weissbuch, I.; Lahav, M.; Leiserowitz, L. AdV. Mater. 6, 952-956, 1994,
13. Davey, R. J.; Blagden, N.; Potts, G. D.; Docherty, R. J. Am. Chem. Soc.
119, 1767-1772, 1997.
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Different Techniques/methods for prediction/identifying new poly-
morphs:
Different polymorphic structures can only be found by creating them
in the lab. Different polymorphs may be produced under different
conditions, and the chemist must try to vary conditions in order to achieve
as many different polymorphs as possible14.
The resulting crystalline structures can then be analyzed using X-
ray diffraction. If a pure single crystal can be grown, then single crystal
X-ray diffraction is the best way to get high quality data about the
crystalline structure. However, it is often difficult and time-consuming to
grow crystals large enough to be examined using single crystal X-ray
diffraction. In such cases, only a powder can be crystallised, and the
resulting X-ray powder diffraction pattern is difficult to interpret.
The whole process is difficult and time-consuming. Success
depends not only on the skill of the chemists in interpreting the X-ray
diffraction patterns, but also on whether they have happened to crystallise
all of the polymorphic forms of the molecule. There is no guarantee that
they have found every polymorph.
Polymorphism, the ability of a molecule to crystallise into more
than one different crystal structure and can determine whether a com-
petitor can steal your new product - yet experimental polymorph predic-
tion is painstaking and always leaves scientists wondering whether they
have found all of the possibilities. Now new polymorph prediction and
powder diffraction software offer chemists a helping hand in determining
the possible polymorphs of organic compounds15.
The most widely used physical methods for identification and other
features of polymorphs are physical methods for identification of poly-
morphs: Microscopy, Melting Point Determination, IR Spectra, X-ray Dif
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fraction (XRD), DTA & DSC. Microscopy  gives definite leads quickly on
small scale. IR spectra useful for qualitative & quantitative work. DTA &
DSC are used to find out most stable polymorph. XRD data are confir-
matory in case of doubt. All this above methods (DTA, DSC, TGA, XRD,
Microscopy) GC is also a useful method for solvate identification.
Biopharmaceutical aspects of polymorphism:
Most of the classes of the drugs exhibit polymorphism for ex-
ample16, antibiotic, antibacterial, steroids, antihistamines, hypnotic, non-
sterodial, antiinflamatory, tranquilizers etc. Different H-bonding arrange-
ments in the unit cell seem to be the main reason for polymorphism in
drugs17.
Polymorphism has an important role to play in formulation and
preparatoin of dosage forms of drug substances. It can affect the tabletting
behaviour, chemical stability, absorption characteristics, particle size dis-
tribution in suspension and alternatively it changes the bioavailability of
the drug molecules18.
14. Byrn, S. R.; Pfeiffer, R.; Ganey, M.; Hoiberg, C.; Poochikian, G. Pharm. Res.
12, 945-954,1995.
15. Rodrý´guez-Hornedo, N.; Murphy, D. J. Pharm. Sci., 88, 651-660.1999.
16. Habelian, J.; McCrone, W. J. Pharm. Sci., 58, 911-929, 1969.
17. McCrone, W. Polymorphism. In Physics and Chemistry of the Solid State;
Fox, D., Labes, M. M., Weissburger, A., Eds.; Interscience: New York, Vol. II,
Chapter 8, 1965.
18. Polymorphism in Pharmaceutical Solids; Brittain, H. G., Ed.; Marcel Dekker
Inc.: New York, 660, 1999.
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Experimental:
Looking to above literature, we started our work on polymorphism
study in the Diloxanide furoate which is widely used as antiamoebic and
antiprotozoal.  All the material and neccessary solvents were obtained
from Department of Chemistry. Diloxanide Furoate was directly obtained
from Parth Laboratories Pvt. Ltd. as a gift material.
Selection of solvents for crystallization:
We have selected 5 different solvents for crystallization depend-
ing the boiling point range and the polarity (Table-7.1). It is known that
the formation of new polymorphs will depend on the choice of solvent for
crystallization and process of crystallization, when the crystallization is
adopting as a method for generating new polymorphs. We used the sol-
vents methanol, Isopropyl alcohol, 1,4-ioxane, ethanol and chlorform.
Compound
Code
solvent used
for
crystallization
Brand name of
solvents
Polymorph
find
GOD-1 Methanol (LR) Allied Chemicals NO
GOD-2
Isopropylalcohol
(LR)
Allied Chemicals NO
GOD-3
1,4-Dioxane
(LR)
(Polypharm
laboratory
reagents)
NO
GOD-4 Ethanol (LR)
(Baroda Chem.
Ind. Ltd.)
NO
GOD-5 Chloroform (AR) Thomas Baker NO
Table: 7.1
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There are various methods of growing single crystals:
For x-ray crystallography, it is necessary to grow crystals with edges
around 0.1-0.3 mm. Crystals are formed as the condit ions in a
supersaturated solution slowly change. There are three degrees of
saturation in solution, and crystallographers take advantage of these when
growing crystals:
Unsaturated - where no crystals will form or grow.
Low supersaturated - where crystals will grow but no new ones will form.
High supersaturated - where crystals will both form and grow.
One theory of crystal growth is to start by getting a few crystals to
grow in the highly supersaturated solution. Then the crystals are exposed
to a less saturated solution so they can grow. This is done either by
moving the crystals or changing the saturation of the solution.
For small molecules, growing large enough crystals is relatively
simple then other molecules. By taking a supersaturated solution and
gradually changing the conditions, crystals will begin to grow. If left
undisturbed for a few days ideally a few large crystals will grow.
Some known techniques for growing single crystals:
Batch crystallization :  A saturated solution left in a sealed container to
let the crystals grow.
Microbatch crystallization:  A drop of solution is put in inert oil and left
to grow. Here there probably is some diffusion of proteins into the oil,
lowering the saturation over time.
Macroseeding: A crystal is grown in a highly saturated solution and
placed in a less saturated one where only growth of the crystal will occur.
Microseeding: A few crystals are grown, then crushed, and put into a
final solution that combines them into a few nice crystals. This involves
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quite a bit of experimentation with solutions’ concentrations to get the
desired number of crystals.
Free interface diffusion: A container has levels of varying saturation.
Crystals form initially in the highly saturated part, but as the solution
mixes, it eventually only supports crystal growth.
Dialysis: Similar to the previous, but with a semipermeable membrane
separating the layers.
Method of Crystallization in GOD Series:
GOD-1: Diloxanide Furoate 1.5 gm taken in 30 ml methanol(LR), 3.5 gm
charcoal was added and  stirreed on 1150 rpm with heating on a Deepali
Stirrer (model MS-4) for 5 min 30 sec.. The solution was filtered while
hot through whatmann 42 filter paper. The solution was kept in a stoppered
conical flask slightly opened. The crystals rectangular shape was grown
up in 16 days by thin film evaporation of the methanol.
GOD-2: Diloxanide Furoate 2.0 gm taken in 30 ml Isopropylalcohol(LR),
3.0 gm charcoal was added and  stirred on 1300 rpm with heating on a
Deepali Stirrer (model MS-4) for 4 min. The solution was filtered while
hot through whatmann 42 filter paper. The solution was kept in a stoppered
conical flask slightly opened. The rectangular shape and transperent
crystals  was grown up in 13 days by thin film evaporation of the
isopropylalcohol.
GOD-3: Diloxanide furoate 1.5 gm taken in 25 ml 1,4-dioxane(LR), 2.5
gm charcoal was added and  stirreed on 1450 rpm with heating on a
Deepali stirrer (model MS-4) for 5 min. The solution was filtered while
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Analysis of the crystals:
All the analysis work was carried out at Laboratory of Physics,
University of Mysore, Manasgangothri, Mysore(India) The work was
coverd under a part of collaborative research programme.
Conclusion:
We found that the celline and all the crystallographic parameter of
all the crystals exhibit the same cell parameter and they are crystallized
in same space group and hence the crystals have no different packing or
having the same molecular design(bond distance, bond angle etc..). so
we were observed that all the crystals were not polymrph of the eachother
hot through whatmann 42 filter paper. The solution was kept in a stoppered
conical flask slightly opened. The crystals rectangular shape was grown
up in 28 days by thin film evaporation of the isopropylalcohol.
GOD-4: Diloxanide furoate 2.0 gm taken in 25 ml ethanol(LR), 3.5 gm
charcoal was added and  stirreed on 1500 rpm with heating on a Deepali
stirrer (model MS-4) for 6 min. The solution was filtered while hot through
whatmann 42 filter paper. The solution was kept in a stoppered conical
flask slightly opened. The big rectangular shape and transperent crystals
was grown up in 31 days by thin film evaporation of the ethanol.
GOD-5: Diloxanide furoate 2.5 gm taken in 25 ml chloroform(LR), 3.5
gm charcoal was added and  stirreed on 1250 rpm with heating on a
Deepali stirrer (model MS-4) for 6 min. The solution was filtered while
hot through whatmann 42 filter paper. The solution was kept in a stopper
conical flask slightly opened. The small rectangular shape crystals   was
grown up in 23 days by thin film evaporation of the chloroform.
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as they are crystallographically identical.
ORTEP DIAGRAM OF GOD-1AND GOD-4:
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X-ray Crystallography of some important molecules:
Looking to the importance of our earlier molecules which were very
very important research molecule in various pharmacological study. We
planned to get the molecular structure and some information about the
skeleton of the molecules. The work of X-ray crystalography of molecules
synthesized by our research group was undertaken. This includes defining
molecular structure, identifying all the atoms present along with their
space patterns, and establishing correlation with physical and chemical
properties of the substances, arrangement of ions, atoms, and  molecules
in a crystal. The symmetry and geometry exhibited  by  their arrangement
are part of the structural  properties.
We s tud ied the  d i f fe rent  molecu les  espec ia l l y  the  1 ,4-
dihydropyridines class. Moreover we have proved the crystal structure of
N-substituted 1,4-DHPs, The crystal structure of the same class was first
time reported by our reseach group.
We undertake the work for following three molecules.
(1) N-(Phenyl) -3,5-d icarbethoxy-2,6-dimethyl - (4-phenyl) -1,4-
dihydropyridine(MDAND-1).
(2) N-(3-chloro phenyl)-3,5-dicarbethoxy-2,6-dimethyl-4-(4’-thio
methyl) phenyl-1, 4- dihydropyridine(MDAND-7).
(3) 3,5-d icarbethoxy-2,6-d imethyl -4-(4 ’ -methoxy phenyl) -1,4-
dihydropyridine(DHP-1).
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(1) N-(Phenyl)-3,5-dicarbethoxy-2,6-dimethyl-(4-phenyl)-1,4-
dihydropyridine(MDAND-1).
Introduction & importance:
1,4-dihydropyridine contributes majority of calcium channel
blockers and also for other cardiovascular disease19,20. Out of many
cardiovascular 1,4-DHP drugs, only Flordipine is N-substituted derivative,
While N-methyl Nimodipine has shown antidepressive characteristics.
The flourdipine was developed due to prodrug concept entered in late
80s. Earlier Bossert21 and coworkers studied using same method for
preparation of N-substituted-1,4-dihydropyridines by the condensation
of an aldehyde, acetoacetic ester with an amine in presence of acid
acceptor like pyridine. They also employed Hantzsch reaction by using
ethyl alcohol instead of pyridine22.
Mannich reaction at N1 of DHP gave new N-substituted DHP’s as hybrid
molecule but no desired activity of this product was established. Various
approaches for N-alkylation are reported by sodium hydride in dimethyl
formamide. Many new DHPs having N-alkyl or N-aryl 1,4-DHPs were prepared.
Wehinger and coworkers (WO8402123) prepared DHP molecule
having antihypertensive and antischemic activity Moreover, same type
of compounds were prepared by Schroff and Desai (US4500527) by
adopting method using NaH. The replacement of hydrogen at NH was
believed to be detrimental to cardiovascular activity. Huang23 and
coworkers were successful in synthesizing antihypertensive model of
flourdipine, contrary to the structural requirement proposed by Triggle24.
In  recent  years,  the d ihydropyr id ines are s tud ied for  d i f ferent
pharmacological profiles especially other then cardiovascular use. The
approach is to study their possible use as immunomodulators.
19. Love, B., Goodman, M., Sender, K., Tedeschi, r., Macow, E., ;
J.Med.Chem. 17, 956-1165, 1974..
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During discovery of nifedipine, Loev and Coworkers1 reported that
the N- phenyl- 1, 4-dihydropyridine was also formed by reaction of aniline
and acetoacetic ester under present conditions. The dihydropyridines
(product-A) obtained in small yields while another substances (Product
B & C) were obtained as the major products25,26 which had previously
been assigned the incorrect structure (Figure-7.1). This compound was
also obtained when the usual Hantzsch condition were employed.
While In our synthetic approach, all three components (aldehyde,
acetoacetic ester and aniline) were heated together under specified
condition in 1;2;1 proportion and water was eliminated to get the direct
N-substituted 1,4-DHP product in good yield (Product-A). The earlier
reported14 yield of such compound was only 3%, while in present case it
is approximately 38%.
Product-A
Product-B
Product-C
Figure-7.1
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Reaction scheme for MDAND-1(Scheme-1):
Experimental:
Preparation of N- (Phenyl) 3,5-dicarbethoxy- 2, 6-dimethyl-4- (phenyl-
1, 4- dihydropyridine (Scheme-1):
A mixture of benzaldehyde (0.01 mol) ethyl aceto acatate (0.02
mol) and aniline (0.01 mol) was heated (without solvent) on steam bath
for 2-3 hours. Produced water was removed constantly by using Dean
Stark apparatus. Methanol (25 ml) was added directly to the reaction
mixture and refluxed for 15 hours. The reaction mixture was poured into
ice water, the solid mass separated was extracted with diethyl ether (50
ml) and dried over magnesium sulphate and concentrated. The solid
MDAND-1
Reflux
under specified
condition
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product separated out was treated with chilled methanol. The product
was filtered and recrystallised from ethyl acetate. Yield 35%, m.p. 1480 C.
Experimental Observation and protocols:
It was observed during TLC monitoring of the reaction that five or six
products were obtained. After completing the reaction, the reaction mixture
was poured in to ice water. The product mixture was extracted with diethyl
ether and was dried over, magnesium sulphate. The solid mass was obtained
was treated with chilled methanol and many side products were getting
dissolved but the N-substituted-1,4-dihydropyridine was not soluble in chilled
methanol and therefore this treatment provided an easy and excellent method
for separation of pure product. The reaction conditions employed thus
provides an excellent single step synthesis of comparative better yields of
N-substituted-1,4-dihydropyridines in very pure isolated form.
Conclusion:
This method gave an easy isolation of Product-A, better yield and
single spot TLC,1,4-DHP compounds having N-substitution  can be isolated
without any chromatographic or column separation. Thus it provides a facile
method to get such DHP compounds17,18.The earlier reported methods were
giving different reaction products which were difficult to isolate and the
reaction steps involved were two or more involving expensive reagent like
NaH and under strict anhydrous condition, while the method employed
can be a widely applicable general method.
20. Mayer and Stout; Chem Rev., 82 (2), 226, 1982.
21. Sugiyama, Y., Kubota, K., Omote, Y., Sugiyama, N.; Nippon Kagaku Zasshi,
86(1), 106-7, 1965; C.A., 62, 16185, 1965.
22. Loriya, R,; Ph.D. Thesis, Saurashtra University,  2002.
23. Inoue,G; Nippon Kagaku Zassi, 79, 1243-6(1958); C.A.., 54, 24716, 1960.
24. Varu, B.; Ph.D. Thesis, Saurashtra University, 2001.
25. M.G.Rimoli, L..Avallone, S. Zanarone, E.Abignente, A. Mangoni,; Heterocyclic
Chem. 39, 1117, 2002.
26. Oshimu, K., Ohishi, K.,Morinaga. Y., Nakagava. R., Suga, Y., Ekiyama, T.,
Akiyama, Y., Tsuji, T.; Chem.Pharm.Bull., 43 (5), 818-828, 1995.
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Method for obtaining single crystal:
N- (Pheny l )3 ,5 -d i ca rbe thoxy -2 ,6 -d ime thy l -4 - (pheny l -1 ,4 -
dihydropyridine (2.5 gm) was taken in 30 ml solvent mixture [Ethanol +
DMF (7.5:2.5)]. 3 gm Charcoal was added and heated on a heating device
for 6 minutes. The solution was filtered while hot through whatmann 41
filter paper. The solution was kept in a stopper conical flask slightly
opened. The Crystals was grown up due to thin film evaporation.
N
CH3
CH3
OO
O
O
CH3
CH3
MDAND-1
Figure-7.2
ORTEP diagram of MDAND-1
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Reaction scheme for MDAND-7 (Scheme-2):
MDAND-1
Reflux
under specified
condition
Experimental:
Preparation of N-(3-methyl Phenyl)-3,5-dicarbethoxy- 2, 6-dimethyl-4-
(4-thio methyl)-phenyl-1, 4- dihydropyridine. (Scheme-2):
A mixture of 4-thiomethyl benzaldehyde (0.01 mol) ethyl aceto
acatate (0.02 mol) and m-toluidine (0.01 mol) was heated (without solvent)
on steam bath for 2-3 hours. Produced water was removed constantly by
using Dean Stark apparatus. Methanol (25 ml) was added directly to the
reaction mixture and refluxed for 15 hours. Then the reaction mixture
was poured into ice water, the solid mass separated was extracted with
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diethy l  e ther  (50 ml)  and dr ied over  magnesium sulphate and
concentrated. The solid product separated out was treated with chilled
methanol. The product was filtered and recrystallised from ethyl acetate.
Yield 39%, m.p. 1140 C.
Experimental Observation:
TLC was carried out on Silica Gel-G (stationary phase) and ethyl
acetate: hexane (mobile phase). The other systems like acetone:
benzene, methanol: chloroform, methanol: benzene, dichloromethane:
methanol etc. were also employed, but the best results obtained in mixture
of ethyl acetate: hexane (2:8).
Spectral Data for MDAND-7:
IR Spectral study:
The infrared spectrum was recorded on Shimadzu FT-IR-8400 on KBr
pellet. The frequency range is 400-4000cm -1
1693(>C=O), 1380 (C-N str.), 3040(C-H atom. str,), 1490(C-H ben., alk.),
1282,1081 (C-O-C str. asy. sym.)
NMR spectral Data:
The 1H NMR spectrum was analyzed on Bruker AC (300 MHz) FT-NMR
and deuterated chloroform (CDCl3) was used as solvent, TMS being
internal standard. [1.24 (t, 6H, 2xCH3), 2.05 (s, 6H,2x-CH3), 2.38 (s,
3H,CH3), 2.47 (s, 3H,SCH3),4.13(q, 4H,2x-CH2), 5.09 (s, 1H,C4H), 6.92(m,
1H Ar-H),7.21 (m, 3H,Ar-H), 7.32 (m, 4H,Ar-H)].
MASS Spectral Data:
The FAB MASS was recorded on JEOL SX 102/DA-6000.
Mwt.465 [m/e (%)]:M+ 466 (47), 420 (84), 392 (Base peak), 342 (90), 314
(10), 286 (20), 242 (10), 154 (7), 132 (12).
Elemental Analysis:
[Calculated % C (69.65%)H (6.71%) N (3.01%)]
[Obtained  % C (69.68%)H (6.78%) N (3.06%)]
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Method for obtaining single crystal:
N-(3-methyl Phenyl)-3,5-dicarbethoxy- 2, 6-dimethyl-4- (4-thio
methyl)-phenyl-1, 4- dihydropyridine (2 gm) taken in 30 ml solvent mixture
[Ethanol + DMF (7.5:2.5)]. 3 gm Charcoal was added and heated on a
heating device for 6 minutes. The solution was filtered while hot through
whatmann 42 filter paper. The solution was kept in a stopper conical
flask slightly opened. The crystals were grown up due to thin film
evaporation.
X-ray Crystallographic data of MDAND-7:
Single crystal of dimensions 0.3x0.3x0.4 mm was chosen for x-ray
structure analysis. 36 frames of data were collected on DIPLabo image
plate system, with each frame being exposed for 300 seconds. The data
were processed using Denzo27 and merged using Scalepack28. The
structure was solved with SHELXS-9729 in the triclinic crystal class. The
details of crystal structure are given in Table 1.
The CCDC ref No. is : 247508. ORTEP of  the molecule is shown
in Fig-3. The thermal parameters of the terminal carbon atoms, C1, C20
and C25 are relatively high indicating greater vibrations of these atoms
about the mean position. Table 2 shows the atomic coordinates of the
atoms and their equivalent thermal parameters (Ueq). Bond lengths and
angles have been provided in tables 4 and 5 respectively.
27. Z. Otwinowski and W. Minor, Macromolecular Crystallography, 1997, 276: part
A, p.307-326,  C.M. Carter, Jr. and R. M. Sweet, Eds., Academic Press.
28. S. Mackay, C. J. Gilmore, C. Edwards, N. Stewart and K. Shankland,  maXus
Computer Program for the Solution and Refinement of Crystal Structures.,
Bruker Nonius, The Netherlands, MacScience, Japan and The University of
Glasgow, 1999.
29. G. M. Sheldrick, (SHELXS-97, SHELXL-97), University of Göttingen, Germany,
1997.
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Figure-7.3
ORTEP diagram for MDAND-7
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Figure-7.4
Packing of Molecule (MDAND-7) down a
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Figure-7.5
Packing of Molecule (MDAND-7) down b
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Figure-7.6
Packing of Molecule (MDAND-7) down c
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X-ray crystallographic study of 3,5-dicarbethoxy-2,6-dimethyl -4-(4’-
methoxy) Phenyl -1,4-dihydropyridine (DHP-1).
Introduction:
Very recent ly,  we have prepared many symmetr ica l  and
unsymmetrical 1,4-dihydropyridine bearing different groups at C3 and C5
position and studied their various pharmacological potentiality30 in the
chemotherapy of tuberculosis31,32, cancer33,34 and mdr reversal activity in
tumor cells35.
The 1,4-dihydropyridines are known for their action as calcium
channel  b lockers  and are used for  t reatment  o f  var ious other
cardiovascular diseases36,37. Most of the 1,4-dihydropyridine compounds
possess various functional groups on C4 phenyl ring
38.
X-ray crystallography study is carried out very recently for few drug
molecules of dihydropyridines and it is now an established fact that
majority of 1,4-dihydropuyridine rings has a boat type confirmation with
varying degree of puckering at C4 position
39.
30. Meyer, H., Bossert, F., Vater, W., Stoepel,K.;U.S.Publ.Appl.13 503,345 ; C.A,
84, 164639a, 1976.
31. Kharkar. P. S., Desai.B., Gaveria. H., Varu. B., Loriya. R., Naliapara.  Y.,     Shah.
A. and Kulkarni. V. M.,  J. med. chem. 45(22) 4858-4867, 2002.
32. Desai. B., Sureja. D., Naliapara.  Y., Shah. A. and Saxena. A.;  Bioorganic &
medicinal chemistry.,9,1993-1998, 2001.
33. Anamik Shah, Harsukh Gaveriya, Noboru Motohashi, Masami Kawase, Setso
Saito, Hiroshi sakagami, Kazue Satoh, Yukio Tada Agnes Solymosi, Kristina
Walfard, and   Joseph Molnar,.  Anticancer Research., 20: 373-378, 2000.
34. Gyongi Gunics, Noboru Motohashi, Joseph Molnar, Sandor Farkas,  Masami
Kawase, Setso Saito and Anamik Shah.. Anticancer Research.,21: 269-274
2001.
35. Saponara.S., Kawase.M., Shah.,A. Motohashi. N. Molnar.J., Ugocsai. K., Sgargli.
G. & Fusi.F.,  Br. J. Pharmacology. 141 (3), 415-22, 2004.
36. Triggle D. J., Cellular and Molecular Neurobiology, Vol. 23, No.3 June 2003.
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37. Triggle D. J. The 1,4- Dihydropyridine nucleus: A pharmacophoric  Template,
Mini Rev. Med. Chem. 3,137-147, 2003
38. Mahendra. M., Beeranahally. D., Parecha. A., Patel. J., Shah. A., and Prasad
J.S. . Analytical Sciences.,  x19-20. Vol.20, 2004.
39. G.Rovnyak, N.Anderson, J.Gougoutas, A.Hedberg, S.D.Kimball, M.Malley,
S.Moreland,M.Porubcan,A.Pudzianowski., J.Med.Chem.,34, 2521-2524, 1991.
40. Devarajegowda H., Prasad J. S., Sridhar M. A., Gaveria H.C. and  Shah.A.,
Mol.Cryst.Liq.Cryst. Vol. 348., pp.301-316.2004
41. Devaru.V., Devarajegowda.H., Doreswamy, B., Mahendra .M., Shah. A.,
Anandalwar.S.,and Prasad.J.S., Analytical Sciences., (x47)Vol.20, 2004.
42. Mahendra.M., Doreswamy.B.,Shridhar.M.,Prasad.J.S.,Patel.G.R., Patel.J.A., and
Shah.A., Journal of chemical crystallography,  7,  Vol.34, 2004.
43. Hantzsch, A. Justus Liebig; Synthesis of dihydropyridine; Ann. 215, 1, 72
 1882 ; Ber. 18, 1744, 1885; 19, 289, 1886.
Modification to The C4 part of 1,4 dihydropyridine moiety carried
out and we preferred to synthesize such analogs similar to known drugs
like Flordipine, Felodipine, Darodipine. Thus in continuation of our earlier
work on 1,4-DHP’s40,41, we synthesized42 some DHP molecules with
introduction of methoxy group at C4 position with different electron
donating groups (EDG). In this case, the title compound was prepared
by Hantzsch (Dihydro) pyridine synthesis43.
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Reaction scheme for DHP-1:
Preparation of  3,5-dicarbethoxy-4-(4’-methoxy)-phenyl-2,6-dimethyl-
1, 4-dihydropyridine:
A mixture of 4-methoxy benzaldehyde (1.2gm; 0.01 mole) and ethyl
aceto acetate (3.18 gm, 0.025 mole) in methanol (40 ml) was stirred
effected at refluxed for 5 to 10 minutes then add ammonia solution (4
ml) in it, further it was stirred for 15 to 16 hrs. The solid product separated
out was filtered. The yield was 58%. The purity of the compounds was
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checked by TLC (Acetone: Benzene 4:6). Compound was recrystallized
from DMF + Methanol. m.p.,1160 C.
[Require C (66.85%) H (6.96%)  N (3.89%)]
[Found C (66.82%) H (6.94%)  N (3.85%)]
Method of Crystallization:
Compound 2.0 gm taken in 15 ml of DMF, Charcoal 1.5 gm was
added and heated on a heating apparatus for 2 minutes. The solution
was filtered while hot through whatmann 42 filter paper. The solution
was kept in a stopper conical flask slightly opened for 25 days. The
Crystals was grown up due to thin film evaporation of solvent.
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Fogure-7.7         ORTEP diagram of DHP-1
D
H
P
-1
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X-ray Crystallographic data of DHP-1:
A single crystal of the title compound with dimensions of 0.2 × 0.3
× 0.3 mm was chosen for Xray diraction studies. The data were collected
on DIPLabo Image Plate system with graphite monochromated radiation
(MoK). Thirty six frames of data were collected in oscillation mode with
an oscillation range of 5and processed using Denzo5. The reflections
were merged with Scalepack. The crystal and experimental details are
given in Table 1.
The structure was solved by direct methods using SHELXS-976.
The structure was refined by fullmatrix least squares method with
anisotropic temperature factors for non-hydrogen atoms using SHELXL-
976. Table-2 gives the atomic coordinates and equivalent thermal
parameters of the nonhydrogen atoms. The hydrogen atoms were fixed
at chemically acceptable positions and were refined with isotropic
temperature factors. Tables-3 and 4 give the bond lengths and angles.
SUMMARY
The work presented in the thesis is entit led “Synthesis and
Characterization of Some Bioactive Compounds”. The study is related to
three areas which are divided in to seven chapters. First chapter cosists of
study of  unsymmetrical 1,4-DHPs was undertaken. In 2nd chapter,  study of
pyrano chromene derivatives. In 3rd chapter study of some unsymmetrical
dicarbamoyl 1,4-DHPs was carried out. The synthesis of dihydropyrimidine
derivatives were undertaken by modified Biginelli reaction in 4 th chapter.
Study of  some important quinolones is given In 5 th chapter. The
antitubercular study of some symmetrical 3,5-di (substituted phenyl
carbamoyl)1,4-DHPs is described in 6th chapter. Chapter 7th deals with the
polymorphism study of diloxanide furoate and x-ray crystallography of some
important compounds which was synthesized for exploration of structural
requirement and skeletal study.
Chapter-1:
This chapter deals with unsymmetrical 1,4-dihydropyridines which are known
for their cardiovascular activity known as Amlodipine, Darodipine,
Felodipine and Manidipine. Over and above these compounds are
promising agents as a-adrenergic antagonist, antitubercular, thromboxane
A2 inhibitors(TXA2), antitumor and in use for specific cardiovascular
disorders. 15 compounds were prepared by two step reaction. The spectral
data of IR, NMR and Mass were collected. The elemental analysis values
and x-ray crystallography are in good agreement with structures.
Chapter-2
Second chapter addresses the synthesis of 21 pyrano[3,2-c] chromene and
pyrano[2,3-c]chromene derivatives. The compounds were prepared from
condensation of  3-hydroxy coumarin or 4-hydroxy coumarin with a-cyano
cinnamate. Thus by treating substituted coumarin with a-cyano cinnamate
in presence of pyperidine/Triethylamine as a catalyst in refluxing condition.
 The desired product were obtained.The structures were confirmed on basis
of  IR, NMR, MASS and X-ray crystallographic data.
Chapter-3
In this chapter, 21 unsymmetrical 1,4-DHPs compounds were designed by
considering the previous results screened by former team members. We
have synthesized the compounds by Aldol condensation of aldehydehyde
with acetoacetanilide and then Micheal addition of enamine compound to
benzylidine derivatives afforded to give the unsymmetrical 1,4-DHPs. This
methods were adopted because of the isolation of pure and single spot
product. The structures were confirmed on the basis of IR, NMR, MASS
and CHN analysis.
Chapter-4
In the present chapter, 22 compounds were synthesized by well known and
classical Biginelli reaction modification. We have studied the reaction of
MCRs and all the recent literature related to Biginelli reaction was studied
and the problems related to reaction mechanism in this reaction and
modif icat ions were shown in l i terature.  React ion of  subst i tuted
acetoacetanilide with aldehyde and urea in the presence of few drops of
conc.HCl gives the title compounds. The synthesized compounds were well
characterized by the IR, NMR and MASS spectral study.
Chapter-5
In this chapter, synthesis of 37 novel heterocyclic compounds containing
pyrano[3,2-c]quinolone derivative were synthesized as quinolones are the
important class of compounds in the antiinfectious disease. It gives
information of natural 2-quinolones, on different methods of synthesis and
of  various pharmacological activities. A brief review about fused 2-
quinolones is given which covers literature preview, different synthetic
methods, and biological activities of various derivatives. These fused
quinolones are well associated with various biological activities like
antibacterial, biological activities like antibacterial, antiallergic, anticancer
and anti-HIV. All the compounds were synthesized from diphenyl amine as
a raw material and using various multistep reaction. These compounds are
fully characterized by IR, NMR and MS spectra values and spectra are given
of each compound. Its physical data like, m. p. and % of C, H, and N are
given.
Chapter-6
This chapter gives synthesis of 39 compounds with brief review of various
symmetrical 1,4-dihydropyridines. Many 1,4-dihydropyridines l ike,
Nifedipine, Nitrendipine, Nimodipine are well established as Calcium
channel blockers, which are useful in antiaginal and antihypertensive
therapy. Many different pharmacological activities are exhibited by 1,4-
dihydropyridines, such as antitumor, antiinflammatory, PAF antagonist,
antituberculosis and  multi drug reversal (MDR). 1,4-dihydropyridines were
synthesized by condensation of substituted acetoacetanilide, ammonia and
various aldehydes in refluxing methanol (Hantzsch synthesis). IR, NMR,
Mass and elemental analysis values are in good agreement with structures.
and x-ray crystallography was also carried out for some important
compounds which was proved potent against various Tubercular strains.
Chapter-7
The present chapter deals with  X-ray crystalography of three importnat molecules
which have been synthesized. This includes defining molecular structure, identifying
all the atoms present along with their space patterns, and establishing correlation
with physical and chemical properties of the substances, atoms, and molecules in a
crystal. The symmetry and geometry exhibited  by  their arrangement are part of
the structural  properties. we recently started to some work on polymorph study and
hence we prompted to study the polymorphism study of the known antisysentric
drug Diloxanide furoate and to have some information of the molecular packing
etc.. and we were not able to get new polymorph in the mentioned condition.
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